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Abstract 
This thesis aimed to investigate the clinical problem of the initial management of febrile 
neutropenia (FN) in children and young people undergoing treatment for malignant disease, 
to thoroughly evaluate the existing research, and to collect and synthesise this to quantify 
the risk of adverse clinical outcomes, through development of develop a new risk prediction 
model, using individual participant data (IPD). A further aim was to develop methodological 
approaches to IPD analysis in the development of predictive models, including the graphical 
display and communication of such information.  
 
The research helped create a global collaboration of 19 research groups (PICNICC) which has 
shared data on over 5000 episodes of FN. This individual patient data was synthesised using 
hierarchical logistic regression meta-analysis to develop a new predictive model for MDI, 
which is robust to internal validation techniques (bootstrapping and leave-one-out cross-
validation). The multivariable predictive model derived has six components: Tumour type, 
temperature, clinical description of being “severely unwell”, and measurements of three 
elements of the full blood count: haemoglobin concentration, total white cell count and 
absolute monocyte count. It showed good overall fit (Brier[scaled] 4.5% discordancy), 
moderate discrimination (AU-ROC 0.736) and good calibration between predicted and actual 
estimates of the risk of MDI (calibration slope 0.95). A basic implementation of the 
predictive model has been made ‘live’ at: http://tinyurl.com/PICNICC1 
 
The content of this thesis has directly generated five systematic reviews published in 
academic journals [1-5], along with a further six peer reviewed papers [6-11]. Further papers 
are in preparation. This has influenced national [12] and international guidelines [13] on the 
management of FN in children and young people. We have demonstrated that such a data 
sharing project is feasible across many different jurisdictions and eras of study; we now need 
to undertake a series of further projects to evaluate the model and improve the 
management of paediatric FN worldwide. 
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Chapter 1: Introduction to the problem of fever in the
immunocompromised host
The treatment of childhood cancer is one of the great success stories of healthcare in the
late 20
th
century.[1] In Europe, children with a malignant disease have an excellent chance of
survival, with overall survival rates approaching 75%.[2] Of those who do not survive, the
cause of death is most often directly related to the malignancy, but one in twenty-five
children with cancer will die due to complications of therapy: one in six of all deaths.[3-4]
One important cause of death is infection, frequently presenting as the occurrence of fever
with neutropenia.[5-6]
Clinical background
In the mid-1960s, it was noted that adults with a severe reduction in numbers of neutrophils
(neutropenia) following chemotherapy were at very high risk of serious infection, and that
early aggressive treatment with broad spectrum antibiotics could save lives.[7-8] The clinical
phenomenon of neutropenia with fever is known by a variety of synonymous phrases, but
frequently as ‘febrile neutropenia’ or ‘neutropenic sepsis’.
The pathophysiology of infection in a child following the administration of chemotherapy or
radiotherapy is complex. Deficiencies occur in innate and adaptive immunity, with changes
in cellular and non-cellular elements of the defences against infection. There are also
marked differences between individuals [9-10] in their response to infection.
Anatomical defences are compromised by the effects of chemotherapy and radiotherapy
disrupting the mucous membranes of the gut and integrity of the skin; side effects are
experienced as mucositis and dermatitis. This enables colonisation and invasion of bacteria
into the blood stream or local infection of the tissue. Foreign bodies such as central venous
catheters are frequently inserted, which provide a potential site for bacterial colonisation.
The use of cytotoxic agents alters the host intestinal flora, and chemical barriers (such as
gastric acidity) can be reduced by supportive care medications.
The production of inflammatory and antimicrobial proteins can be reduced by anti-cancer
treatments [9], dampening any coordinated antibacterial response of the complement
cascade and inflammatory pathway. Cellular components of the innate phagocytic system
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are reduced in number and may be impaired in function. These include the identifiable levels
of circulating neutrophils in peripheral blood and the less visible tissue macrophages and
natural killer cells.
Chemotherapy also affects adaptive, acquired B- and T-cell mediated immunity. The
proliferation rate of these cells is reduced by chemotherapy, depleting circulating cells and
humoral antibody levels. Some malignancies (leukaemia and lymphoma) are of white cell
origin, and while the absolute numbers of cells may be high, they are functionally
incompetent and this increases the risk of infection.[11]
Clinically based risk stratification
The identification of recipients of chemotherapy at high risk of infection, and definition of
the entity of febrile neutropenia, led to the rapid use of early assessment and aggressive
treatment with broad spectrum intravenous antibiotics until the neutrophil count had
recovered. Though no randomised trials evaluated this, the dramatic fall in mortality rates
(from 30% to around 1% in Western Europe) was convincing.[5] The next logical step was to
explore whether the duration of antibiotics could be safely shortened, and antibiotics
discontinued despite neutropenia. This was shown to be possible.[12] From here, the next
milestone in refining therapy is to define a subset of patients at low risk of infection, to
reduce the intensity of treatment in that group, and facilitate rational intensification of anti-
infective treatment in the high-risk group.
In adult oncology practice, a large international prospective study of 1,139 patients was
undertaken and produced a scoring system to identify patients at low risk of serious medical
complications during febrile neutropenia.[13] The factors included: an outpatient
presentation; a solid (compared with haematological) malignancy; “young age” (defined in
this setting as <60 years); no chronic obstructive airways disease; mild or absent symptoms
of infection; normal blood pressure; and absence of dehydration. This system supported
earlier work which identified many of the factors as important predictors and has been used
as the basis for outpatient management of fever in low-risk neutropenic adult patients.[14]
Despite this, there is evidence of minimal uptake of this approach in routine adult practice in
the UK.[15]
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The adult system did not include children in its derivation, and is of very limited applicability
in this group: age is not a discriminator, and chronic airways disease is extremely rare. It is
frequently said in paediatric medicine that “Children are not little adults”; when it relates to
the use of this scoring system, it appears to be very relevant. [16]
Assessing the risk of adverse outcome of each episode of febrile neutropenia has been
undertaken by different groups, with many creating a clinical decision rule (CDR) which
purports to allow clinicians to accurately judge risk and treat appropriately. A clinical
decision rule is a clinical tool designed to be used at the bedside to assist clinical decision
making [17]; the methods used in creating and assessing such rules are explored further
later in this chapter.
The existing CDRs in paediatric oncology patients have proposed varied criteria for risk
stratification, involving various combinations of bone marrow suppression indicators [18-
22], maximum body temperature[18-19], cancer type[23] and the presence of clinically
severe illness.[11, 19, 21, 24-25] However, the currently published models differ in
describing different numbers of important predictor variables (e.g. Baorto [12] identified
one, Klaassen [26] described two, Ammann [19] used five), and different specific variables
(bone marrow suppression may be indicated by monocyte count [12], leukocyte count [19]
or platelet count [22]).
Biomarker based approaches
Another element of initial risk stratification of significant interest is the use of serum
markers of inflammation and infection derived from blood tests taken on admission to
predict similar outcomes.
Studies have been undertaken which explore the predictive ability of specific serum markers,
for example C-reactive protein (CRP), procalcitonin (PCT), Interleukin-6 (IL6) or Interleukin-8
(IL8).[27-30] These markers have been demonstrated to have some discriminatory ability in
other fields of paediatrics (e.g. CRP has been used in septic arthritis, PCT in neonatal sepsis
and IL6 in meningitis). In paediatric febrile neutropenia (FNP), the reports have had few
patients, episodes and definite outcomes. Drawing these reports together, and synthesising
their results, could add greatly to our understanding of their potential clinical usefulness,
indicating which markers may be pertinent to examine in newly developed clinical decision
rules.
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C-reactive protein (CRP) is a substance that was initially discovered in the 1930s by Tillett
and Francis [31], its name arising from the observation of a reaction between an
unidentified protein and the C-polysaccharide from Streptococcus pneumoniae. It was soon
discovered to be endogenously generated from within the liver, and its ubiquity in
inflammatory conditions recognised soon after. CRP is generated with other acute-phase
reactants between four and six hours following tissue damage, and seems to reach a peak
around one to three days following injury.[32] Routine measurement of CRP within one hour
of admission is possible in most technologically advanced countries, and in some places
near-patient testing (for example, in a primary care centre) is possible.
The more recently discovered procalcitonin (PCT) is a pro-hormone of calcitonin, a hormone
associated with calcium homeostasis. Pathophysiological studies have shown PCT has a rapid
rise in new-onset sepsis, and falls rapidly with the administration of antibiotics and mirrors
the clinical course of critically ill patients. Commercial assays are available in many hospitals,
and can produce results within two hours.
Interleukin 6 (IL6) is one of a series of cytokines which are released by immune system cells
and drive the active and organised process of inflammation. IL6 is released from
macrophages and monocyte-lineage cells, and can be measured in the blood rapidly after
tissue damage. Interleukin 8 (IL8) is a related protein, first identified in the early 1980s as a
neutrophil chemoattractant. It too is produced by a wide range of inflammatory cells, and is
rapidly produced following tissue damage.
Although all these markers have a sensible pathophysiological basis for their ability to
distinguish between people who do and do not have an incipient severe infection, many
other factors are involved with their production. Some factors may reduce the production of
these markers. In malignancy, the generative potential of the liver may be compromised, the
immune system is suppressed and functions inadequately, potentially reducing the number
of cells which could produce cytokines. In contrast, the tissue damage of malignant
infiltration may produce an inflammatory response, triggering release of the marker
proteins. The toxic effects of chemotherapy may reduce the ability of the kidneys and liver
to clear metabolites including these markers. Therefore, just detecting the presence of an
inflammatory response, for example to a mild rhinovirus (common cold) infection, does not
equate with severe septic shock. The effect of how these elements alter with age, and how
the range of different malignancies that affect children as compared with adults vary also
need to be taken into account.
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Reduced intensity treatment
Based on the identification of a low-risk group, small randomized controlled trials (RCTs) [33-
37] of the use of reduced intensity and/or duration of antibiotic therapy have been
undertaken in children. The intention is to improve quality of life by reducing hospitalisation,
and reducing unnecessary health care costs. These trials have been too small to produce
definitive conclusions about the efficacy or safety of the approaches undertaken. The
underlying assumption (that parents would prefer an outpatient or home-based approach)
has also been called into question.[38]
Preventing febrile neutropenia
Reducing unnecessary hospitalisation, exposure to antibiotics and costs associated with
febrile neutropenia has been one approach to improving the management of children who
present with infectious complications during cancer therapy. Another strand of research has
been attempting to reduce the risk of febrile neutropenia occurring.
An ideal approach to reducing the risk of adverse outcomes of febrile neutropenia would be
to prevent neutropenia secondary to chemotherapy and/or to prevent infection in
neutropenic patients. Colony-stimulating factors (CSFs) were introduced into clinical trials 20
years ago and are now used widely in both adults and children. They expand the pool of
circulating neutrophils by stimulating proliferation and hastening maturation of myeloid
progenitor cells in bone marrow, and are used successfully in the treatment of chronic and
cyclical neutropenia.[39] Clinical experience suggests that the prescription of granulocyte-
CSF (G-CSF) in the oncology setting does not have the same dramatic benefits. An extensive
systematic review of 148 RCTs (19 were exclusively in paediatric populations and 12 included
both adults and children) with a total of 16,839 cycles of treatment assessed the effects of
G-CSF.[40] The synthesis demonstrated no effect of G-CSF on mortality (relative risk 0.95,
95% CI 0.84 to 1.08). There was a small reduction in the number of episodes of febrile
neutropenia (relative risk 0.71 95% CI 0.63 to 0.80) and a small effect of duration of
hospitalisation (mean difference -2.4 days, 95% CI -3.3 to -1.1) and use of parenteral
antibiotics (mean difference -1.8 days, 95% CI -2.5 to -1.1). Subgroup and meta-regression
analyses, and the use of Baysian approaches incorporating further data [41] showed these
results to be consistent regardless of the type of malignancy or age of patients. If CSFs were
oral, cheap and had no side effects then these moderate benefits might be considered
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useful: unfortunately, none of these attributes are true for CSFs and their use is not
routinely recommended.
An alternative approach to prevention would be to use antibiotic prophylaxis. While this has
been losing favour in a number of areas (e.g. urinary tract infection [42], recurrent tonsillitis
[43], dental procedures in those with cardiac defects [44]) there is convincing evidence for
their use in preventing surgical site infections. [45] A systematic review published in 2005
[46] examined 109 RCTs that evaluated the use of prophylactic antibacterial drugs in cancer
patients. This showed that across a broad spectrum of ages, malignancies and methods of
administration, prophylactic antibacterials given through periods of neutropenia conferred a
survival advantage. The use of quinolone antibiotics reduced overall mortality with a relative
risk 0.66 (95% CI 0.55 to 0.81).[46] However, direct clinical application of these data is
hindered by substantial variation in the protocols for administration of prophylaxis, making
selection of a particular approach difficult.
There is a significant concern that the widespread use of antibiotics may engender
resistance, but data from these trials do not suggest the emergence of this problem.[47-48]
Cohort studies of the routine use of prophylaxis do suggest an increase in rates of resistance
of colonising organisms, and that these rates fall with discontinuing prophylaxis. However,
these same data show higher mortality rates in patients when prophylactic antibiotics are
not used, despite that fact that there are lower rates of ‘resistant’ organisms cultured. The
balance of community resistance against individual protection is clearly difficult, but seems
to favour the use of prophylaxis. These factors probably account for the caution about
current widespread use of prophylactic antibiotics: the ongoing challenge is to support their
judicious introduction, perhaps in selected patient groups, with close microbiological
surveillance.
Vaccination is the most effective anti-infective prophylaxis that is used in the world today
[49] and high levels of herd immunity against vaccine-preventable diseases are the best
protection for children with cancer. In the setting of acute treatment for malignancy, there is
limited evidence for the use of vaccination since most of the serious infections that occur are
not vaccine-preventable. Influenza vaccination while on low-intensity therapy (e.g.
maintenance treatment for acute lymphoblastic leukaemia)[50] is probably effective, and
conjugate Haemophilus influenzae type B (Hib) and pneumococcal vaccines may reduce the
risk of invasive infection.[51] Live vaccines remain potentially lethal if given during
immunosuppressive therapy, but the use of attenuated varicella vaccine has been
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extensively studied during Acute Lymphoblastic Leukemia (ALL) maintenance therapy by
groups in Japan and the USA with few adverse events and apparent protective responses.
[52]
Environmental prevention, for example the use of face masks and gowns, ‘clean’ diets and
water supplies, and excluding patients from large public gatherings (such as football
matches, shopping centres and cinemas) had very limited evidence for efficacy.
Conclusion
Despite the generally good success in treating children with cancer, with overall survival
rates approaching 75% [2], one in twenty-five children with cancer will die due to the
complications of therapy: this is one in six of all deaths.[3-4] One important cause of death
remains infection, frequently presenting as the occurrence of fever with neutropenia.[5-6]
The traditional approach to such patients is to admit them to hospital and treat with
prolonged courses of intravenous antibiotics until both fever and neutropenia have resolved.
Current practice in paediatric oncology with respect to the risk stratified approaches in
febrile neutropenia is variable, both nationally [53] and internationally.[51, 54-55] Some
centres use a risk-stratified, reduced intensity approach, others treat all children with
aggressive antibiotic therapy Calls for collaborative trials have been made [56-58] but little
progress made. The essential problems with research in this area are common in much of
paediatric practice, rare conditions with small numbers of cases, and limited collaboration in
primary studies. This clinical decision problem is the classic area where systematic review,
with meta-analysis, may be able to draw together numerous studies and reach more
powerful conclusions than any single study could. The output of clear risk stratification
product of this work will inform practice and future therapeutic RCTs.
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Chapter 2: Introduction to the methodologies employed in
prognostic and diagnostic predictions in medical decision
making
Background
Clinical decision rules (CDR) are clinical tools designed to be used at the bedside to assist
decision making [17] and are generally either diagnostic or prognostic. Well known examples
from adult medicine include the Ottawa ankle rules [59] and Wells DVT rule [60], both using
clinical features to predict in particular the absence of an ankle fracture (and so avoid the
need for radiography) or the absence of a DVT (and so avoid unnecessary anticoagulation).
In paediatrics, such rules have been developed for the prediction of good outcomes from
septic arthritis in the limping child [61], the identification of infants at low risk of serious
bacterial infection [62], meningitis [63] or radiographic pneumonia [64], but are not
generally or widely used.
Clinical decision rules are developed by an initial derivation study that creates the rule. This
should be followed by further studies determining their discriminatory validity (do they
actually tell the difference between the groups of affected and unaffected) and predictive
accuracy (do they predict at the same sorts of proportions of individuals as they were
created to do). Such validations can occur at different times, but within the same institution
(temporal validation), in different physical locations but with similar clinical settings
(geographical validation) and across different clinical settings (domain validation), for
example in both tertiary specialised paediatric oncology centres and secondary care
hospitals [65]. The final step should be to demonstrate their efficacy in routine practice with
multi-site randomised controlled trials [66].
An ideal CDR for the management of febrile neutropenia would predict the risk of adverse
outcomes from data collected at or soon after presentation. To this extent, it is ‘prognostic’
as a prediction of the course of disease [67]. However, this data may well be practically used
in two different ways: to decide if the risk was ‘low enough’ to allow outpatient
management, and at the opposite end of the risk scale, to consider the need for increasingly
close observation and more aggressive management. The ‘low risk’ decision collapses into a
dichotomy that can be considered ‘diagnostic’ (“is this a low-risk episode or not?”) and such
patients discharged for out-patient therapy. The patients at higher risk do not have such a
clear difference in potential management options. There are no effective truly prophylactic
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measures to prevent septic shock in this group, so the degree of risk generates a heightened
degree of concern and observation, but does not require a dichotomous decision to be
made. This ‘high risk’ information is not clearly a ‘decision problem’ and continuous,
‘prognostic’ information may be more useful. Such hypotheses about the nature and use of
the information are ripe for testing.
It is worth noting that the description and decision of what constitutes ‘low risk’ is a matter
of debate. It reflects both a desire to know if a patient has a significant infection which
needs a specific therapy, and an understanding of the likelihood of a fatal or near-fatal
outcome. In some settings this may collapse into the same information: the diagnosis of a
systemic fungal infection is associated with an extremely high chance of death [68], and the
diagnosis needs little further by way of prognostic information. With other infections, for
example infection with coagulase-negative Staphylococci [69], serious adverse outcomes are
rare. The setting of this threshold of ‘low enough’ risk appears to vary between healthcare
professionals and families, and between healthcare professionals themselves [38] , and
requires further study.
Taking all of these factors into account, the clinical use of a rule can only be countenanced if
it is valid (truthful) and accurate (meaningful). In the setting of managing febrile
neutropenia, the ideal output for a CDR is to use data available at the start of the episode to
diagnose the patient as either seriously infected or not, and accurately predict their
subsequent chance of important morbidity.
CDR and other predictive models - Derivation
A study of risk prediction, including the derivation and validation of clinical decision rules as
a subset of risk prediction, requires that precise, accurate and unbiased information is
collected so that any relationships discovered between predictors and outcomes are likely to
be valid.
The prototype of a study that aims to create a clinical decision rules is one which
prospectively collects information about a cohort of patients that present with a given
problem (for example, fever in the neutropenic child). This cohort should be from
consecutive patients, or a random sample of everyone who had been affected with the
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condition. To collect patients by a different method may introduce a significant bias
between those collected and those excluded. For example, if only patients who present
‘during office hours’ are included, this group could be more generally more ‘well’ than those
who are sufficiently unwell to be taken for assessment in the middle of the night [70]. Using
all patients obviously avoids this problem. Random selection is less intuitive, but derived
from the principle that a truly random selection will accurately reflect the total population
sampled.
The information collected for each patient should be the same. Gathering information
prospectively appears to improve the likelihood of complete data capture and reduce biases
arising from outcome reporting. For example, avoiding cases with a negative outcome (such
as death) being more accurately captured and recorded than those with a better outcome
[71]. The way that missing data is handled could reduce the efficiency of a study if it doesn’t
use as much information as it could, leading to unnecessarily wide confidence intervals, or
could introduce biases and so incorrect predictive estimates if handled inappropriately.
A further consideration is that patients involved in the study need to be similar to the
patients that the studies’ results will be applied to. This is necessary because different
groups may have different outcomes. For example, patients treated in tertiary clinics at
super-specialised hospitals may have different outcomes than those from local hospitals,
general practice or the community [72-73]. These differences should not be interpreted as
meaning one sample location is ‘wrong’; they indicate that the truth varies according to the
population or case-mix under consideration, and needs to be made specific for the question
asked.
In addition to the test data being collected in the same way for each patient, the outcomes
should be assessed similarly, regardless of how the patient has presented (rather than
patients who have been assessed at high risk of a problem undergoing a different outcome
assessment than those at low risk). An example might be to only undertake chest X-rays
(CXR) on children who have crackles or reduced air entry on physical examination when
developing CDR for the detection of pneumonia. In this way, the study will tautologically
prove the absence of these signs is perfect at ruling-out CXR positive pneumonia as they will
never have been diagnostically tested. Such “differential verification” procedures have been
shown quantitatively to overestimate the ability of the test to accurately diagnose a disease
[74]. Another variation in this theme is a contamination of the reference standard with the
test result: if the definition of pneumonia is “radiographic findings of pneumonia with an
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appropriate clinical pattern”, then children without classic signs or symptoms of pneumonia
can’t have the diagnosis, and therefore signs and symptoms of pneumonia cannot have
anything less than near-perfect sensitivity.
The need for outcomes to be assessed blind to (without knowledge of) prognostic or
diagnostic data is theoretically important, as there may be a tendency among clinicians to
attribute different outcomes on the basis of ‘clinical likelihood’. The exaggeration of effect
has been demonstrated in studies of therapeutics [75], but has not been clearly
demonstrated in studies of diagnosis [74] and prognosis [76]. This may reflect a true
difference, or merely that there are fewer data available from prognostic and diagnostic
studies.
Any good CDR should be based on outcomes which are important to patients and clinicians,
and studies should be of sufficient duration for the outcome to become apparent. Some
studies report outcomes too early; if new events are still likely to occur, this poorly reflects
the true predictive value of a potential marker[77]
Data analysis presents a further series of challenges. There are various approaches to
creating a CDR including the use of regression models, classification and regression trees
(CART), neural networks and Bayesian networks. No clear superiority for one technique has
been demonstrated [78], but it has been shown that different approaches can produce
different results from the same data set [79]. This highlights an acknowledged difficulty with
model building – that differing techniques may reach different conclusions from the same
information.
The assumptions underlying these models are that the data collected is a true
representation of the population of interest, that data have been collected accurately and
that the various predictors can be combined simply, with different weightings of different
elements.
The functional form of the predictors needs to be accurately assessed. For most model
building techniques, the initial assumption is that the predictors and outcome have a linear
relationship. If this is not the case, a transformation or non-linear form should be used. For
example, temperature in the prediction of serious bacterial infection (SBI) in neonates is a
‘U’ shape, with both very low and very high temperatures being associated with SBI [62].
Other relationships have different forms, with ‘floor and ceiling effects’ such as the S-shaped
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curve of oxygen dissociation from haemoglobin, or the J-shaped associations of body-mass
index and mortality. If these are modelled by assuming only a linear relationship can exist,
the variable may be discounted (e.g. U-shaped), over predicted at low values and under
predicted at high ones (S-shape) or a complex failure of accurate estimation found in the
lower portion of a J-shaped curve.
Related issues include multicollinearity, where variables are highly related, will lead to
unstable models and inaccurate predictions. An example of co-linearity may be total white
cell count and neutrophil counts in the setting of chemotherapy-induced marrow
suppression. When faced with this situation, the most clinically sensible variable of the co-
linear group should be chosen. A further assumption in simple models is that the
observations are independent of one another. One relevant situation when the observations
are not independent is when multiple ‘cases’ actually reflect multiple admissions from the
same individual; this ‘relatedness’ needs to be built into the data analysis method.
Continuous variables (age, blood pressure, absolute neutrophil count) will have their
maximum predictive accuracy in a model if used as their actual value, rather than
categorised in bands of values. Clinicians seem to find the use of continuous variables in this
setting unhelpful, and prefer to use categories. To build the most clinically effective CDR, a
sensible approach would be to combine these approaches, exploring the association with a
continuous value and making a clinically usable CDR with a categorical one. Undertaking this
adds further challenges. Repeated studies examining prognostic model building have shown
that the collapsing of continuous variables into ordinal (ordered) categories or dichotomies
is often undertaken using methods which are highly likely to give spurious results [78, 80].
The problem arises from analyses where a particular set of data is examined to find the cut-
point at which the greatest differentiation between the diagnostic or prognostic categories
is achieved. In doing so, effectively multiple tests are being undertaken and the reported p-
value associated with the final choice is likely to be a gross exaggeration of the true
‘significance’ of the value. Approaches using clinically or pathophysiologically meaningful
values, or ones previously described in the literature, reduce these problems.
Selection of explanatory variables for a short and usable CDR is a further area of potential
problems. The best approaches are to think carefully about what relationships are expected
to exist in advance of data analysis. This approach will reduce the chance of spurious, data-
driven associations slipping into a CDR. More apparently ‘rigorous’ and ‘statistical’
techniques can be undertaken. Such selections can be performed by taking all possible
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explanatory variables, and excluding those which are not statistically significant (backwards
elimination), or by taking in the most statistically significant individual factors (forwards
selection) or a combination of the two, adding and removing to build the statistically best
fitting model (stepwise). These techniques, when driven by a ‘p-value’ are seriously at risk of
choosing variable with chance relationships and making unstable models [81]. These
techniques will also exclude variables that confound each other from entering a
multivariable analysis [82]. In essence, selecting variables only by looking at how significantly
they are associated with outcomes in the dataset being examined produces highly effective
descriptions of that dataset; it doesn’t improve the ability of the model to describe the real
population from which those data were drawn [83].
Building stable predictive models requires a minimum of 10 to 20 events per variable
considered [84], with more being better. Small numbers of events increase the possibility of
finding spurious associations that existing only in that dataset, and not in the general
population [83]. There are a range of techniques that have been developed to try to reduce
the chance of such problems occurring, described as ways of ‘shrinking’ the overinflated
estimates from the model, or ‘penalising’ the model as it tries to build in too many overly
optimistic variables [85]. Such modifications may lead to models where the predictive values
are retained in future studies [86].
To make things usable in a clinical environment, it is often far more sensible to present
clinicians with a simple table of signs and symptoms with a numerical score than a complex
equation. Remarkably, the use of very simple versions of the weights from regression
equations often work in practice as well as the mathematically precise numbers [87], and it
may even be worth ignoring weights all together and just calling each ‘one point’ [88].
CDR and other predictive models - Validation
Given the issues off over optimism and generalisability described above, a newly developed
CDR should be validated before use. In this context, validation means that the CDR has been
shown to accurately discriminate between those with and without disease, or accurately
estimate the proportion of patients with the disease. This is analogous to the clinical trial
testing of a drug which has shown positive results in cell cultures or mice; inaccurate
predictive information both as false positive [89] or false negative test results [90] can be as
harmful as an untested therapy.
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As previously noted, various levels of validation are described, including temporal validation
(the rule is tested again by the same clinical team), geographical validation (testing the rule
in a different location, but similar clinical setting) and domain validation (testing the rule in
an alternative clinical setting, such as secondary rather than tertiary care). This last stage
may be irrelevant if it is to be applied in the same setting as rule development occurred. The
use of these various steps is important to demonstrate there is a practical ability of the rule
to be used widely and effectively.
The final step should be to demonstrate the efficacy of a CDR in routine practice with multi-
site randomised controlled trials [66]. The trial doesn’t seek to examine if the CDR is
accurate, but instead to randomise between application of the CDR and no application
measuring key patient-important, or health-system- important outcome such as length of
hospital stay, invasive testing, or improved quality of life. This stage is rarely undertaken, but
can be a very powerful way of demonstrating improved care through the use of a diagnostic
intervention [91].
CDR and other predictive models - Implementation
Understanding how clinicians use a clinical decision rule, or any diagnostic information,
involves understanding how medical professionals ‘think’. A number of researchers from a
range of backgrounds have examined the diagnostic practices of physicians. There is a
wealth of research that demonstrates the common clinical myth of diagnosis following the
doctors actions of ‘take a history and do a physical examination’ is inaccurate [92-93], and
that instead health professionals apply an array of mental shortcuts (heuristics) [93-94]
which both speed up working practice and at the same time can lead to dangerously wrong
conclusions. In fitting a CDR into the practice of managing a clinical problem, it can be useful
to take a straightforward model as to how doctors make a diagnosis and move on to treat
the disease.
The diagnostic process can be thought of in three stages: initiation, refinement and
conclusion [95]. The initiation stage is where a differential diagnosis begins to be considered.
The refinement is a working through of these differentials, and the conclusion is a point
where a decision to act has been made.
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In some situations, such as seeing a toddler with Down’s syndrome, initiation is the only
step. While this is clear to many lay people, there is research to suggest that the more expert
a physician is in a particular area, the more rapidly they come to a diagnosis, and that this in
part is because of pattern recognition or fitting new cases to a mental ‘categorisation’ [94].
For most situations, initiation is truly the first idea that undergoes a process of refinement. It
is in this process that CDR can help guide clinicians, and lead to a diagnostic conclusion.
Other approaches include a formal Bayesian analysis, pattern fitting, or a stepwise rule-out
of significant serious diagnoses.
The conclusion part of the process may be an actual pathological diagnosis (e.g. pneumonia),
or a rule-out (e.g. no evidence of bacterial meningitis) or an admission of remaining
diagnostic uncertainty.
The CDR should help in refinement by providing good quality guidance to avoid diagnostic
errors and minimise unnecessary tests. Commonly diagnostic errors occur because of both
systems and cognitive errors [96-97]. Such errors can include: a failure to syntheses
diagnostic information correctly and come to a premature diagnostic conclusion; a lack of
appreciation of the value of a sign or symptom in making a diagnosis; or exaggeration of the
accuracy of a test finding. Other reasons for misdiagnosis would not be helped by the use of
CDRs, such as the true diagnosis being rare, or failure in the technical skill of the individual
doctor, for example in reading an x-ray or eliciting a physical sign.
However, there remains an almost emotional difficulty in turning to a CDR when instead
clinicians should be like House [98], Holmes [99] or Thorndyke [100] in making diagnoses
from skill and knowledge. This is despite the widely publicised data which suggest that in
many cases a CDR performs better than ‘expert opinions’ [101-104]. Why healthcare
professionals do not follow where the best evidence should steer is a matter of ongoing
debate and research.
The most effective uses of CDR seem to have been where the rule has a clear clinical utility,
has been championed by well-respected local clinicians, and clearly improves outcomes for
patients and clinicians [105-106]. Implementation of any well-derived and validated rule will
require skilled advice and a multi-factorial approach to maximise real clinical gains. This
should highlight that CDR are potentially a way of making predictions more accurate, and/or
quicker and less unpleasant to achieve. They don’t necessarily do this [107] and so each rule
requires clear sighted critical appraisal before implementation.
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Systematic reviews of CDRs
In exactly the same way that therapeutic studies should be viewed and reviewed within the
context of all the unbiased information, preferably in the form of a systematic review with
meta-analysis, CDR and prognostic studies should be seen within the same context. The
rationale behind these studies is identical to that which drives therapeutic reviews: by
pooling information chance associations can be minimised and a more precise and accurate
estimate of effect can be obtained. The nature of the numerical outputs from these studies
is explored in the next sections.
It is notable that reviews of predictive studies, in keeping with reviews of therapeutic
interventions, can sometimes produce useful new results [60]. They can also confirm the
inadequacy of the current studies to derive a clinically applicable result [108], or highlight
the poor quality of underlying studies and the need for higher quality primary research [109-
110]. Even more prevalent in predictive studies than in therapeutics are the difficulties
produced by the poor quality of reporting of studies [111], and marked publication bias [78].
In many areas, these lead to the need to undertake research which pools the raw individual
patient data (IPD) from high quality studies. Undertaking an IPD meta-analysis would
increase the number of events studied, which allows more confidence to be placed in the
estimates of association between predictive variables and outcome and allow for more
consistent handling continuous outcome data, which may well have been categorized
differently in differing datasets. It would also permit the independent assessment of
episodes (e.g. using only the first episode for each patient) and then analyze the degree to
which episodes, patients and outcomes are interdependent.
Simple numerical descriptions of test accuracy
In order to describe accuracy of a test result is it is usually necessary to produce a numerical
estimation. Many tests give results as continuous values (for example biomarkers ), yet for
simplicity these are reported as being positive (e.g. above a certain value) or negative (below
the cutoff value). The group under study, in this case children presenting with febrile
neutropenia, can be thought of as coming from two populations: those with the ‘disease’,
for example pneumonia, and those without it. The values of “lung injury protein” (LIP) are
distributed differently in the two groups. (See Figure 1, over)
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Figure 1: “Lung injury protein” diagnostic test distribution
The threshold then has part of both populations on each side; the proportion of people with
pneumonia who have a positive test is the sensitivity. The proportion of people without
pneumonia who have a negative test is the specificity. Shifting where the threshold is drawn
alters both these proportions. As Figure 2 shows, pushing the line for ‘positivity’ upwards
makes the test more specific (captures fewer people without the disease in the definition)
but becomes less sensitive (fails to diagnose a greater number with the disease). The reverse
is true when the level for positive results is reduced.
Figure 2: “Lung injury protein” diagnostic test: different cutoffs
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Meta-analysis of diagnostic test accuracy
Meta-analysis is the statistical combination of results from more than one study. In the
setting of a systematic review, this process should produce the most precise values which
represent the sensitivity and specificity for a diagnostic test and explore the limits of our
certainty.
When such a meta-analysis is undertaken, there are three elements in combining the test
results that may vary. The first is that the group under study are a (random) selection of the
‘true’ population of children with and without pneumonia. Any single estimate of test
effectiveness is only an estimate of the ‘true’ test accuracy, and each study reports this
chance uncertainty be providing estimates of the variance of sensitivity and specificity.
The next aspect of variation is that the ‘true’ population from which the sample was drawn
may actually be a mixture of slightly different populations. For example, it may be that
slightly different LIP values are present in Scottish children who have higher normal values
than children in London, through genetic polymorphisms, or less variation between them
(see Figure 3). This aspect of variation can be evaluated by the use of a random effects
meta-analysis procedure. This examines variability between study populations and provides
an estimate of the ‘average’ sensitivity and specificity in an ‘average’ population, and also
provides a numerical range in which the truly different values may lie in different
populations.
Figure 3: “Lung injury protein” diagnostic test: different mean and SD
The third aspect of variability may be that a different threshold is used between studies. In
studies that report ‘hard’ laboratory findings, this should be easily assessed (although
different assay techniques mean this is not necessarily the case). In those using clinical
criteria, for example “looked clinically unwell”, this is much more difficult to judge. One way
to assess this is to examine
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capped lines display the 95% confidence intervals associated with the sensitivity or
specificity values.
This same graphical display can be used to show the relationship between the varying
threshold of a continuous or multiple-layer diagnostic test as a curved line (see Figure 5,
example of a single study).
Figure 5: ROC plot showing the results of one continuous scale diagnostic test to determine the presence or
absence of disease.
Using test accuracy estimates in clinical practice
For clinical application, the important values are generally not the proportion of people with
a disease (e.g. pneumonia) who have a positive test (sensitivity) and proportion of people
without pneumonia who have a negative test (specificity) but rather the proportion of
people with a negative test result who truly didn’t have disease (negative predictive value,
NPV) and the converse, the proportion of people with a positive test who did have
pneumonia (positive predictive value, PPV). These values are the compilation of both the
diagnostic accuracy and prevalence of the disease in the population.
A clear illustration of this comes from an analysis of the different NPV and PPV of testing for
Clostridium difficile infection with commercially available stool toxin test kits [112]. As Figure
6 demonstrates, the ‘truth’ of a positive result varies from 50% correct to 92% correct,
depending on how prevalent C. difficile is in the population under study. (This Figure shows
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a theoretical Clostridium difficile toxin assay with a sensitivity of 92% and a specificity of
97%. NPV=negative predictive value. PPV=positive predictive value. [112])
Figure 6: Effect of varying prevalence on the PPV and NPV
The practical implication of this is that the direct translation of sensitivity and specificity
values from a single study or meta-analysis into practically meaningful PPV and NPV can only
be undertaken if the prevalence of the condition is known, or can reasonably be estimated.
An alternative expression of the sensitivity and specificity of a test is the use of likelihood
ratios (LR). These values compare the proportion of patients with the disease and without
the disease for a given test result. In the LIP example (Figure 1, specificity 74.8% and
sensitivity 72.0%) these values would be LR+ (likelihood ratio for a positive test) = sensitivity
/ (100% - specificity) = 74.8/28.0=2.67 and the LR- = (100% - sensitivity) / specificity = 0.35.
Such values can be calculated for each level of a test result, and so are useful for multi-level
as well as dichotomous tests (compare Tables 1 and 2 for LIP).
Table 1: Sensitivity & specificity for Lung injury protein values to detect pneumonia
Test cutoff Sensitivity Specificity
73 98.8 15.9
93 72.0 74.8
109 22.7 97.7
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Table 2: Likelihood ratios for Lung injury protein values to detect pneumonia
Test cutoff LR+ LR-
73 1.17 0.11
93 2.99 0.38
109 9.87 0.79
These likelihood ratios can then be used in formal Bayesian analysis converting pre-test odds
of disease into post test-odds of disease, or informally interpreted as how far the diagnostic
pendulum is pushed towards a disease (e.g. LIP value of 110 makes it about 10-times more
likely the child has pneumonia, and LIP of 70 makes it about one-tenth as likely).
Conclusion
Defining a subset of patients as low risk of infection reduces the intensity of treatment in
that group, and facilitates rational intensification of anti-infective treatment in the high-risk
group. To make this decision rational and repeatable, a logical approach is to use a clinical
decision rule. This rule needs to be developed in a robust manner, to reduce the effects of
chance, confounding and bias obscuring the true relationships between proposed predictor
variables and the outcome of each episode of febrile neutropenia. Furthermore, a rule
needs to be tested, to make sure it works effectively and is practically useful.
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Chapter 3: Methods of Systematic reviews of Clinical Decision
Rules and Serum Biomarkers
Two linked systematic reviews [113-114] were undertaken of existing rules and the value of
serum biomarkers, in order to determine whether an IPD meta-analysis was necessary; to
identify suitable data sets; and to guide such a study in collecting appropriate variables
between 2008 and 2010. These reviews were later updated [115-116], and as a by-product a
further review related to a specific aspect of early assessment was also produced: do all
children presenting with fever and neutropenia require a chest radiograph to exclude
pneumonia [117]? These reviews provided the evidence on which to propose the key
predictor variables to be used in the following IPD analysis.
This chapter described the methods generic to both groups of reviews; the clinical decision
rule studies [113, 115] and the biomarkers papers [114, 116]. The results of the reviews are
then described in Chapter 4, and a discussion and conclusions to the extensive background
work for this thesis are presented in Chapter 5.
Methods
The reviews were conducted in accordance with “Systematic reviews: CRD's guidance for
undertaking reviews in health care” [118] Protocols were written for each review and in
advance of starting the review were registered with the HTA Registry of systematic reviews,
CRD32009100453 and CRD42011001684.
Search & retrieval strategy
Electronic search strategies (See Appendix 1 and Appendix 2) were developed which
examined the following databases: MEDLINE, MEDLINE(R) In-Process & Other Non-Indexed
Citations, EMBASE, CINAHL, Cochrane Database of Systematic Reviews (CDSR), Database of
Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTA),
Cochrane Central Register of Controlled Trials (CENTRAL), Conference Proceedings Citation
Index - Science (CPCI-S), Literatura Latinoamericana y del Caribe en Ciencias de la Salud
(LILACS)
Reference lists of relevant systematic reviews and included articles were reviewed for
further relevant articles. Published and unpublished studies were sought and no language
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restrictions applied. Non-English language studies were translated. Searches were
conducted on date for the initial review published in 2008 and on for the update published
in 2012.
Inclusion and exclusion criteria
Studies were included in the review if they met the following criteria.
Methodology Studies which aimed to derive or validate a CDR in either all or a defined
subset of patients were included. Both prospective and retrospective cohorts were included,
but those using a case-control (“two-gate”) approach were excluded as these have been
previously shown to exaggerate diagnostic accuracy estimates [119].
Population Children or young people (aged 0 – 18y) who were receiving treatment for cancer
or leukaemia (including extra-cranial and intra-cranial tumours) presenting with febrile
neutropenia. Studies which examined children and adults were included if the paediatric
data were available separately.
Predictor variables for CDR reviews Clinical decision rules (CDR) using clinical and
haematological or biochemical variables used to predict outcome for the particular episode
of febrile neutropenia
Predictor variables for Biomarkers reviews Serum inflammatory/infectious markers (for
example including, but not limited to, C-reactive protein (CRP), procalcitonin or interleukin
levels) measured within the first 12 hours where timing of samples was reported.
Outcomes (At least one of) Survival, need for intensive care, need for high-dependency care,
single organ impairment (oxygen requirement, renal impairment, hepatic impairment),
invasive bacterial or fungal infection, any documented infection (including radiologically
confirmed pneumonia), duration of admission.
Study selection
Two reviewers independently screened the title and abstract of studies for inclusion, and
then the full text of retrieved articles. Disagreements were resolved by consensus.
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Validity assessment
The validity of each study was assessed using 11 of the 14 questions from the QUADAS
assessment tool for diagnostic accuracy studies [120]. The QUADAS tool was adapted
specifically for the review, as suggested by “Systematic reviews: CRD's guidance for
undertaking reviews in health care” [121], omitting questions on “time between index and
reference test”, “intermediate results” and “explanation of withdrawals”. (See Appendix 3.)
The CDR and reference tests are necessarily related, and the design of a CDR and the
reporting of the biomarkers studies meant that “intermediate” results are included in any
analysis. The issue of incomplete data was addressed in the analysis of the method of
derivation or validation, and as such was not included as a quality criterion.
Data extraction
Data were extracted by one researcher using a standardised data extraction form and
checked by a second. The data extracted included participant demographic details such as
age and sex, geographical location of the study, the participant inclusion/exclusion criteria,
antibiotics used, and the performance of the CDR as a 2*k table (where k refers to the
number of strata described). Information was extracted on the methods used to derive the
CDR (where applicable), including the variables considered, methods of statistical analysis,
and methods of dealing with multiple episodes in individual patients and missing data. An
example of the form used for the biomarkers review is given in Appendix 4. Authors were
not contacted for clarification in the event of ‘unclear’ risk of bias assessments or to seek
additional information.
Methods of data synthesis
The studies were reviewed using both narrative and quantitative synthesis.
Quantitative synthesis was undertaken for studies which tested the same CDR or biomarker,
and investigated for sources for heterogeneity.
For dichotomous test data in this review, where possible analyses used a bivariate model
(using the ‘metandi’ command for STATA10 [122]). The bivariate approach, when possible,
accounts for the paired nature of dichotomous test characteristics as described in chapter 2.
For tests that included very small numbers of studies (n≤ 4) fitting a bivariate model is
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problematic as the procedure frequently fails to converge. In these cases, a univariate
approach was used (pooling sensitivity and specificity separately).
For tests where three-level (low, mid- and high-risk) results were produced, an innovative
approach adapted from a previous method used to pool three-level results for the diagnosis
of deep venous thrombosis was developed in [60]. The initial method used random-effects
meta-analysis was undertaken using WinBUGS 1.4.3 [123] to estimate the proportions of
individuals classified as low, medium or high risk in the ‘diseased’ (e.g. bacteraemic) and
non-diseased groups. The extension developed to this method allowed multivariate random
effects were applied to the calculation of each cutoff value. Data from studies which used a
similar rule but provided only two of the risk categories were also included in this analysis
[124]. These proportions were used to calculate likelihood ratios for each risk category and
corresponding 95% credible intervals. In such cases, where cutoff thresholds are fixed
between studies, not using a multinomial approach which accounts for variability of
threshold is less likely to introduce biases.
Two main types of analysis were used for the biomarkers meta-analysis, one using classical
statistical methods and one based upon Bayesian analysis. For the maximum likelihood
estimate approach, the data were pooled from studies reporting the same marker and
similar outcomes using a single cutoff from each study using the STATA routines metandi
and midas for analyses of HSROC curves and bivariate analyses with >3 studies, for those
with <4 studies a random effects linear regression was fitted using xmelogit. Where possible,
the most common cutoff value was chosen for greatest precision of estimate.
Analysis using out innovative Bayesian multinomial random effects method was undertaken
to derive proportions of the population with/without the outcome at each cut-off level of
the serum markers using monte-carlo markov chain modelling via WinBUGS 1.4.3 [123] with
non-informative priors. These results were then used to derive likelihood ratios for each
level with corresponding 95% credible intervals.
Where data for continuous variables were presented as mean and standard deviation, rather
than 2*2 tables, conversion was undertaken using the assumption of Normality (or log-
Normal in the case of serum proteins) and deriving the assumed 2*2 table for cutoffs
reported by other studies [Anzures, Cochrane Colloquium Freiburg 2008].
Heterogeneity between study results was explored through consideration of study
populations, study design, predictor variables assessed and outcomes chosen. Sensitivity
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analysis was undertaken by comparing results with the original (derivation) data set
included and excluded. The sparse nature of the data rendered statistical approaches such
as consideration of the I
2
statistic inappropriate.
Where quantitative synthesis was not possible, a hypothesis generating narrative approach
was used. The narrative synthesis was undertaken according to the framework described in
“Systematic reviews: CRD's guidance for undertaking reviews in health care” [125]. This
proposes an iterative approach to developing a theory underpinning the data, using this to
structure a preliminary synthesis of the findings of the included studies, and exploring how
relationships within and between studies support or refute the hypothesis, with an
assessment of the robustness of the synthesis.
Methods of data display
Results of dichotomous meta-analyses are displayed using ‘cross-hairs’ plots. We developed
this innovative graphical augmentation of ROC space plotting to assist disseminating the
concepts of diagnostic meta-analysis to clinicians, and published this in a descriptive
methodological article [126].
Traditional approaches to displaying information from diagnostic meta-analysis have been to
use side-by-side forest plots of sensitivity and specificity, which allow the reader to view the
univariate heterogeneity of sensitivity and specificity, but are difficult to appreciate a
biaviate relationship. An alternative has been to open circles of the point estimate of each
study in ROC space, with a larger marker indicating a larger study. While this shows the
bivariate relationship, physically this plotting inverts the relationship most clinical readers
are familiar with from forest plots.
The cross-hairs plot combines the clinically familiar idea of a forest plot, with box of point
estimate and whiskers of individual study 95% confidence intervals, with the enabling the
bivariate relationship of sensitivity and specificity to be assessed easily and maintaining the
relationship between size-of-arms and uncertainty.
The basic plot uses a single colour or tone to identify the individual studies, with an
identified marker icon, and a distinct icon and colour/tone to display the meta-analytic
summary. This can be displayed as paired univariate meta-analyses (see Figure 7), or as a
confidence ellipse (see Figu
type of graph.
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example, the rainbow sequence) by demonstrating how different thresholds affect the
sensitivity and specificity of a test (see Figure 9).
Figure 9: Multicolour cross-hair plot with explicit different test thresholds
Code is available for STATA in Appendix 5, and for users of the R statistical environment, the
package mada [127] has been adapted to include this display format after discussion with
the author.
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Chapter 4: Results of Systematic reviews of Clinical Decision
Rules and Serum Biomarkers
This chapter presents the results of the systematic review of clinical decision rules and
serum biomarkers in the prediction of adverse outcomes from episodes of febrile
neutropenia. They were undertaken in 2008-2010, prior to the IPD analysis explored in the
later chapters, and updated during the collection phase of the IPD study; 2010-2012. The
updates were, in part, triggered by undertaking the role of Clinical Lead on the National
Institute of Health and Clinical Effectiveness commissioned guideline on the Prevention and
Management of Neutropenic Sepsis [128] and the international Guideline on the
Management of Paediatric Febrile Neutropenia [129].
Clinical decision rules
This section of the Chapter deals with rules based primarily upon clinical assessments at the
point of admission or recognition of an episode of FNP, and addresses how they have been
derived and validated in predicting risks of infectious complications.
Study inclusion and exclusion
Figure 10 and Figure 11 describe the flow of candidate and eligible articles though the
review process. In the initial review, 2057 articles were identified from electronic searches
undertaken in Febuary 2009 and 3 further articles were identified from examining the
bibliographies of systematic reviews and included studies. From this, 89 articles were
identified for detailed examination, of which 25 articles reporting on 24 studies were eligible
for inclusion in the review. The update of the review (searches undertaken in September
2011) added a further 9 articles reporting on 8 studies. A total of 10,431 patients were
included in these reviews.
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Potentially relevant articles identified
from databases
Excluded articles; n=1971
Not cancer = 109
Not FNP = 1027
Potentially relevant articles assessed
in detail: n = 86
Excluded articles; n=64
Not FNP = 2; Not children = 4;
Children not extractable = 13;
Not CDR = 24; No appropriate outcomes
= 2; Not testing discriminating ability of a
CDR = 4; Original article not available = 5
Data extraction undertaken
n = 25 articles; 24 studies
Quantitative data available
n = 21
Included in quantitative synthesis
n = 12
No quantitative data available;
=3
Identified
from
reference
lists: n = 3
Figure 10: Flow diagram of study selection process; original CDR review
Figure 11: Flow diagram of study
All studies included patients
23 years old. They included
and 1117 episodes of febril
for more detail.
election process; update CDR review
with a wide range of malignancies and patients
between 29 and 759 patients (median 132) wit
neutropenia per study (median 240), where sta
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from 1 month to
between 47
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Of the studies 29 deal with general infectious complications and ‘routine CDRs’ [5, 11-12, 22,
24-26, 69, 79, 130-148]and four address the specific issue of the detection of pneumonia
[149-152]. As described in the previous chapter, these studies address a distinct and
separate question than the use of a model of assessment of risk of complications of febrile
neutropenia. The review has been published [117] and its recommendation (to only
undertake chest radiography in the setting of signs or symptoms of lower respiratory tract
disease, or in patients with other comorbities which increase their risk of pneumonia) has
been incorporated into FNP guidelines [128-129]
Evaluation of Clinical decision rules
The 29 studies which examined general infectious complications included 15 which aimed to
derive a CDR [5, 11-12, 22, 24-26, 69, 79, 131-147]. Five studies did not describe a CDR [5,
69, 130, 142-143] as the data collected did not produce statistically significant predictors. A
total of 21 CDR were described. 6 studies sought primarily to validate a model’s
discriminatory ability [11-12, 22, 24, 130, 136], three also recalibrated a rule [12, 136, 144]
(see Table 3).
Four studies used a split sample to validate their rule [12, 26, 137, 141], and one study
provided data to test an alternative rule [69]. Six CDR have been subject to validation in
separate data sets from the derivation set [22, 134, 137, 141, 144, 153]. Bootstrap analysis
has been used in four cases [79, 140, 144, 147]. The remaining CDR were only explored in a
single dataset. Thirteen individual outcomes (Table 3) were predicted, these can be
summarised in five clusters: death, critical care requirement, serious medical complication,
significant bacterial infection, and bacteraemia.
Table 3: Clinical decision rules and outcomes under study
Citation Clinical prediction rule* Outcome #1 Outcome #2
Outcome
#3
Derivation Studies
Adcock 1999
High risk = hypotension/septic
shock, inflamed central line site,
recent high dose Ara-C
Gram positive bacteremia
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Alexander 2002
Low risk = Not
AML/Burkitts/Induction
ALL/Progressive-relapsed with
marrow involvement
(“Anticipated neutropenia
<7days”) and no significant
comorbidity (defined as
hypotension,
tachypnea/hypoxia <94%, new
CXR changes, altered mental
status, severe mucositis,
vomiting or abdominal pain,
focal infection, other clinical
reason for in-patient
treatment).
Bacteraemia
Serious
medical
complicatio
n
Death
Ammann, 2003
Final decision tree model: 4
covariates were used to classify
low risk; bone marrow
involvement, leukocyte count
>0.5 x 10
9
/L, with clinical signs
of a viral infection, and aged up
to 6 years at presentation. For
those with a leukocyte count
≤0.5 x 10
9
/L, they were further
classified according to CRP level
(≤ or >50mg/L).
Severe bacterial infection,
(death from bacterial
infection, a positive culture
of normally sterile body
fluids, radiologically proven
pneumonia, clinically
unequivocal diagnosis of a
bacterial infection, or
CRP>150 mg/L)
(model #2)
Low risk ≤3 factors. Risk factors
= bone marrow involvement,
absence of clinical signs of viral
infection, high serum CRP level,
low leukocyte count, presence
of a central venous catheter,
high haemoglobin level, and
Pre-B-cell leukaemia.
Severe bacterial infection
(death from bacterial
infection, a positive culture
of normally sterile body
fluids, radiologically proven
pneumonia, clinically
unequivocal diagnosis of a
bacterial infection, or
CRP>150 mg/L)
(model #3)
Low risk ≤4 factors. Risk factors
= bone marrow involvement,
absence of clinical signs of viral
infection, high serum CRP level,
low leukocyte count, presence
of a central venous catheter,
high haemoglobin level, and
Pre-B-cell leukaemia.
Severe bacterial infection
(death from bacterial
infection, a positive culture
of normally sterile body
fluids, radiologically proven
pneumonia, clinically
unequivocal diagnosis of a
bacterial infection, or
CRP>150 mg/L)
Ammann, 2004
(same
population as
Ammann 2003)
Low risk = all of: maximum temp
≤39.7C, no comorbidity
requiring hospitalisation,
leukocyte count >0.5 x 10
9
/L,
and in partial or complete
remission
Bacteraemia
Amman 2010
Applied after 24 hours: 4 points
for chemotherapy more
Significant adverse
outcome; Severe bacterial
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intensive than ALL
maintenance,5 points for
hemoglobin > 90 g/L, 3 points
each for white blood cell count
<0.3 x10
9
/L, platelet < 50 x10
9
/L,
any adverse event occurred in
preceding 24h. Scores ≤9 are
low risk.
infection, admission to
HDU/ICU for organ support,
severe sepsis or septic
shock, potentially life-
threatening event. death
Ageyman 2011
(Same
population as
Amman 2010)
Applied after 24 hours: shaking
chills ever observed,
haemoglobin > 90 g/L, platelet
< 50 x10
9
/L, any other need for
IP treatment. No risk factors =
low risk
Bacteraemia after 24h
Badiei 2011
Platelets <20 x10
9
/L,
temperature ≥39°C, ANC
<100/mm
3
, mucositis, abnormal
CXR on presentation. Risk of
infection greater with more risk
factors: no single threshold
applied
Life threatening infection
Delebarre 2010
[abstract only]
1 point for hematological
malignancy, chemotherapy at
high-risk of prolonged
neutropenia, 1 point for clinical
signs of local infection, fever
>39°C, white cell count
<500/mm
3
or monocytes
<100/mm
3
and procalcitonin
>0.3ng/ml. TWO points for
severe sepsis. High risk >1 point.
Severe infection
Hakim 2008
Score from cancer diagnosis:
AML = 20, ALL/lymphoma = 7,
Solids = 0 Clinical presentation
of serious unwell or toxic = 14,
fever at presentation: ≥39°C =
11, ANC <100/mm
3
= 10 points,
Total score <24 = low risk of
serious infection or sepsis
Serious infection or sepsis
(complications
rule)
Score from cancer diagnosis:
AML = 11, others = 0. Relapsed
disease = 11. Non-white patient
= 8, Clinical presentation of
serious unwell or toxic = 20.
Total score <20 = low risk of any
medical complication
Any medical complication
Hann 1997 No rule described.
Individual features = disease
type, IV line, shock, duration of
granulocytopenia and admission
Bacteraemia
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temperature.
Jones 1996
Low risk = ANC ≥200/mm
3
,
outpatient at onset, in remission
Bacteraemia
Clinical
infection
Klaassen, 2000
Low risk = AMC >100/mm
3
; Mid-
risk= AMC <100/mm
3
, and temp
≤39°C; High-risk =
AMC<100/mm
3
, but temp >39°C
Bacteraemia
Significant
bacterial
infection
(defined as
any blood or
urine
culture
positive for
bacteria,
interstitial
or lobar
consolidatio
n on CXR, or
unexpected
death from
infection
before ANC
recovery
(>0.5 x
10
9
/L))
(validation set) As original
Lucas, 1996
Low risk = no chills,
hypotension, or a requirement
for fluid resuscitation at
admission
Positive blood culture ICU
Septic
death
Mian 2010
[abstract only]
No clear rule – includes blood
culture and CRP results
Admission to critical care
Paganini 2007
Low risk <4. Mid-risk = 4. High
risk = >4. Advanced stage of
disease = 3 points, Comorbidity
= 2 points, Bacteraemia = 1
point
Death
(validation set)
Rackoff, 1996
Low risk = AMC >100/mm
3
; Mid-
risk= AMC <100/mm
3
, and temp
≤39°C; High-risk =
AMC<100/mm
3
, but temp >39°C
Bacteraemia
Clinical
reason for
admission
(validation set) Low risk = AMC >100/mm
3
.
Riikonen 1993 No rule described.
No variables emerged as
Bacteraemia
Suspected
sepsis/Fever
of Unknown
Focal
infection
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significant. Origin
Rojo, 2008 No rule described.
No variables emerged as
significant.
‘Unfavourable outcome’ -
Compound of:
haemodynamic instability,
new focus if bacterial
infection, 72h persistent
fever, unresponsive CRP, or
continuing +ve blood
cultures 72 hours after
treatment
Rondinelli, 2006
Low risk = 2.5 to 5 points:
Intermediate risk = 5.5 to 9
points: High risk = Greater than
9 points. 4.5 points for: clinical
site of infection; 2.5 points for:
no URTI; 2 points for: CVC; 1
point for: aged ≤5y, fever
>38.5°C, Hb ≤7g/dL
‘Serious infectious
complication’ – sepsis,
shock, +ve blood cultures,
infection-related death
Santolaya, 2001
Low risk = 0 factors or isolated
low plts or <7 days from
chemotherapy. High risk = >1
risk factor, or isolated high CRP,
hypotension or relapsed
leukaemia. Risk factors: CRP
≥90mg/L, hypotension, relapsed
leukaemia, plts ≤50 x10
9
/L,
chemotherapy within 7 days
Invasive bacterial infection
(positive blood culture – 2
for CoNS, positive bacterial
culture from usually sterile
site, or sepsis syndrome
and/or focal organ
involvement and
haemodynamic instability
and severe malaise)
Death
Tezcan 2006 No rule described.
Significant association between
hypotension, uncontrolled
cancer and mortality. Duration
of fever only independent risk
factor for microbiologically
documented infection.
Death
Clinically
suspected
infection
Microbiol
ogically
document
ed
infection
West, 2004
(internally
validated using
bootstrap)
Very high risk = temp >39.5°C
and CRT >3s; High risk = temp
>39.5°C or CRT >3s; Low risk =
neither
Requirement for critical
care within 24 hours of
presentation (fluid boluses
≥60ml/kg, inotropes or
ventilation)
Validation Studies
Amman 2010
Klassen, Amman 2003,
Santolaya, Alexander and
Rondellini rules
Bacteraemia
Serious
medical
complicatio
n
Invasive
bacterial
infection
Baorto, 2001 Low risk = AMC >100/mm
3
. Bacteraemia
ICU/Death
related to
bacteraemia
within 72
hours of
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admission
for FN
Recalibration Low risk = AMC >155/mm
3
.
Dommett, 2009
Low risk = Not
AML/Burkitts/Induction
ALL/Progressive-relapsed with
marrow involvement
(“Anticipated neutropenia
<7days”) and no significant
comorbidity (defined as
hypotension,
tachypnea/hypoxia <94%, new
CXR changes, altered mental
status, severe mucositis,
vomiting or abdominal pain,
focal infection, other clinical
reason for in-patient treatment)
and fever responding at 48h
Bacteraemia
Gala-Peralta,
2005
Low risk ≤2 of: <1yr, poor bone
marrow response (plt <75, ANC
<100/mm
3
.),uncontrolled solid
tumour or relapsed leukaemia,
chemotherapy <10d earlier,
rapid neutropenia, cardiac &
renal dysfunction
Positive blood culture
Macher, 2009
Klassen, Amman 2003,
Santolaya, and Rondellini rules
Bacteraemia
Serious
medical
complicatio
n
Invasive
bacterial
infection
Madsen, 2002
Low risk = AMC >100/mm
3
; Mid-
risk= AMC <100/mm
3
, and temp
≤39°C; High-risk =
AMC<100/mm
3
, but temp >39°C
Positive blood culture
Recalibration
Low risk = AMC >10/mm
3
; Mid-
risk= AMC <10/mm
3
, and temp
≤39.5°C; High-risk =
AMC<10/mm
3
, but temp
>39.5°C
Positive blood culture
Meidema, 2010 Amman 2010 (SPOG rule)
Serious medical
complication
Petrelli, 1991
Low Risk: patients with solid
tumors and lymphomas stage I-
II.High Risk: patients with
leukemias and lymphomas stage
III-IV
Positive blood culture
Santolaya, 2002
Low risk = 0 factors or isolated
low plts or <7 days from
Invasive bacterial infection
(positive blood culture – 2
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chemotherapy. High risk = >1
risk factor, or isolated high CRP,
hypotension or relapsed
leukaemia. Risk factors: CRP
≥90mg/L, hypotension, relapsed
leukaemia, plts ≤50x10
9
,
chemotherapy within 7 days
for CoNS, positive bacterial
culture from usually sterile
site, or sepsis syndrome
and/or focal organ
involvement and
haemodynamic instability
and severe malaise)
Tezcan, 2006
validation
Low risk = AMC >100/mm
3
Death
Clinically
suspected
infection
Microbiol
ogically
document
ed
infection
* unless stated, the rule dichotomises into low and high risk groups
ALL = acute lymphoblastic leukaemia. AML = acute myeloid leukaemia. AMC = absolute monocyte
count. CoNS = Coagulase-negative Staphylococcus CRP = C-reactive protein. CRT = capillary refill time.
CXR = chest X-ray. Hb = haemoglobin. Plt = platelets.
QUADAS criteria
There was variation in the quality and applicability of the studies with respect to population
under study (QUADAS questions “Was the spectrum of patients representative of the
patients who will receive the test in practice?” and “Were the same clinical data available
when test results were interpreted as would be available when the test is used in
practice?”). Thirteen definitions of febrile neutropenia were used, with twelve definitions of
fever and four of neutropenia. However, all definitions are clinically similar, with any
variation at the ‘lowest risk’ part of the spectrum of classification. In brief, most of the
studies allowed patients who presented with febrile neutropenia following standard
chemotherapy to be included. Some variations were found: eight studies excluded any
inpatients, and examined only new episodes in outpatients. Ten studies excluded patients
following stem cell transplants, and a further study stated no bone marrow transplant
patients were included. One study examined only ‘lower risk’ patients, to further
discriminate in this group [143]. The inclusion and exclusion criteria of the studies can be
seen in detailed form in
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Table 4: Participant characteristics by study, assessing applicability
Citation
Study
location
Study
years
Inclusion criteria Exclusion criteria
Total
number
of
patients
Total
number
of
episodes
Age of
patients
Adcock
1999
North
Carolina, USA
1995 -
1996
ANC <1000cells/
mm
3
, temperature
≥38°C, HIV-ve
33 88
Median 5y
(range 1y to
18y)
Alexander
2002
Boston, USA
1994 -
1995
ANC ≤500/ mm
3
,
temperature
>38.5°C.
Outpatient status.
Post stem cell
transplant
104 188
Mean 8.9y
(SD 5.7y)
Ammann
2004
Berne,
Switzerland
1993 -
2001
ANC ≤500cells/
mm
3
or
≤1000cells/ mm
3
and falling,
axilliary
temperature
≥38.5°C for ≥2h, or
once ≥39°C
Patients with FN
due to malignant
bone marrow
suppression, or
following
myeloablative
therapy.
132 364 Not reported
(Amman
2004,
subset
used)
As above As above
Patients with
established severe
bacterial infection.
111 285
Median 6.3y
(interquartile
range 3.2y to
12.1y)
Amman
2010
Multiple
Swiss and
German
centres
2004-
2007
ANC ≤500cells/
mm
3
, temperature
≥38.5°C for ≥2h
Post stem cell
transplant, aged
<1y or >18y
206 423
Median 6.9y
(interquartile
range 3.8y to
11.6y)
Agyman
2011
Same as
Amman 2010
Badiei
2011
Iran, Asia
2008-
2009
ANC <500cells/
mm
3
, oral
temperature
≥38.0°C ≥11h, or
once >38.5°C
Inpatients, post
stem cell
transplant, newly
diagnosed with
malignancy
68 120
Mean 6.5 in
“life-
threatening
infection”
group, 5.6y
in non~
group
Baorto
2001
St Louis,
Dallas &
Houston, USA
1990 -
1996
ANC <500cells/
mm
3
, temperature
≥38°C, 12m or
older
History of BMT 558 1171
Mean 8.0y
(range 1y to
23y)
Delebarre
2010
France,
Europe
2007-
2009
Unclear
Unclear; abstract
only
146 316
Mean 8y,
(range:0.5y –
17.5y)
Dommett
2009
South-East
England, UK
2004-
2005
ANC ≤1000cells/
mm
3
, temperature
≥38.0°C twice in
<12h, or once
None 368 762
Median age
5 years 7
months
(range 1
month to 17
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≥38.5°C
years 6
months).
Gala-
Peralta
2005
Barcelona,
Spain
2002
ANC ≤500/ mm
3
,
'fever'
(temperature not
defined)
30 62
Mean 8.7y
(range 1.2y
to 14.7y)
Hakim
2008
Boston, USA
2004-
2005
Outpatient, ANC
<500cells/ mm
3
,
oral temperature
≥38.0°C ≥11h, or
once >38.3°C
Inpatients, stem cell
transplant
recipients
332 332
Median 6y
(range 2.4
months –
21.6 years)
Hann 1997
Multiple
centres
across
Western
Europe
1986 -
1994
ANC ≤1000cells/
mm
3
, temperature
≥38.0°C twice in
<12h, or once
≥38.5°C, in an
EORTC trial
759 759 Median 8y
Jones 1996
North
Carolina, USA
1987 -
1993
ANC <500cells/
mm
3
, oral
temperature
≥38.0°C ≥12h, or
once >38.5°C
None reported, but
‘none of the
children were
undergoing BMT’
127 276
Mean 8y
(range 2m to
21y)
Klaassen
2000
Toronto,
Canada
1996 -
1998
ANC <500cells/
mm
3
or
≤1000cells/ mm
3
and falling.
Temperature
>38.0°C ≥2
occasions in ≥12h,
or once >38.5°C,
or localised
infection
New malignant
diagnosis; bone
marrow or stem-
cell transplantation
in preceding 6
months. Another
medical condition
that independently
required inpatient
observation.
Interstitial infiltrate
or lobar
consolidation on
chest x-ray
140 227
Median 6.8y
(range 6m to
17y:
derivation
set)
(validation
set)
Unclear Unclear 136
Median 7.6y
(range 1y to
18y:
validation
set)
Lucas 1996
New York,
USA
1990 -
1992
ANC <500cells/
mm
3
or
<1000cells/ mm
3
and falling,
temperature
≥38.0°C ≥2
occasions in ≥12h,
or once ≥38.5°C.
Outpatient status
Received blood
product
transfusions within
6 hours or cytosine
arabinoside within
2 days of
presentation
161 509
Mean 9.2y
(range 1y to
18y)
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Madsen
2002
Indianapolis,
USA
1997
New admissions
‘coded’ as 'fever of
unknown origin'
and ANC
<500cells/ mm
3
History of BMT.
AML. In-patient
status
76 157
Mean 8y
(range 2m to
18y)
Mian 2010
Arkansas,
USA
Unclear Unclear Unclear 29 51
Rrange:1y –
21y)
Paganini
2007
Multiple
centres
across
Argentina
(derived 1
institution,
validated in 7
further ones)
2000 -
2004
ANC <500cells/
mm
3
or
<1000cells/ mm
3
and falling,
temperature
>38.0°C ≥2
occasions in 24h,
or once >38.5°C
History of BMT 458 714
Mean 7y
(range 1m to
17.9y:
derivation
set)
(Paganini
2007
validation
set)
523 806 Mean 7.1y
(range 1m to
17.5y:
validation
set)
Petrelli
1991
Camargo,
Brazil
1988 -
1989
ANC ≤500cells/
mm
3
, temperature
≥37.5°C ≥3
occasions in ≥24h,
or once ≥38.0°C.
Outpatient status
Fever associated
with blood product
transfusions or
drugs
146 240 Mean 7.3y
Rackoff
1996
Indianapolis,
USA
1994 -
1995
ANC <500cells/
mm
3
, temperature
>38.0°C ≥3
occasions in ≥24h,
or once >38.5°C.
Outpatient status
72 115
Range 9m to
18y:
derivation
set
(validation
set)
1993 57
Validation
set not
reported
Riikonen
1993
Helsinki,
Finland
1989 -
1990
ANC <200cells/
mm
3
, temperature
>38.0°C ≥2
occasions in ≥4h,
or once >39.0°C
Antibiotics
(excluding Septrin)
in the preceding 3
weeks
46 91
Range 1y to
16y
Rojo 2008
Santiago,
Chile
2003 -
2006
Episode of febrile
neutropenia which
was ‘low risk’
according to the
PINDA criteria
33 47
Median 5.8y
(1.1y to
15.7y)
Rondinelli
2006
San Paulo,
Brazil
2000 -
2003
ANC <500cells/
mm
3
or
≤1000cells/ mm
3
and falling,
temperature
≥37.8°C ≥3
Second or
subsequent
episode. Episodes in
progressive disease
(<6m from between
completing therapy
283 283 Mean 5.2y
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occasions in ≥24h,
or once >38.0°C.
First episode per
patient (new or
relapsed disease)
and relapse).
History of BMT
Santolaya
2001
5 centres in
Santiago,
Chile
1996 -
1997
ANC ≤500cells/
mm
3
, axilliary
temperature
≥38.0°C ≥2
occasions 1h
apart, or once
≥38.5°C
Not reported 257 447
Mean 7y
(range 6m to
18y)
Santolaya
2002
6 centres in
Santiago,
Chile
1999 -
2000
ANC ≤500cells/
mm
3
, axilliary
temperature
≥38.0°C ≥2
occasions 1h
apart, or once
≥38.5°C
Not reported 170 263
Mean 7y
(range 7m to
17y)
Tezcan
2006
Antalya,
Turkey
1996 -
2004
ANC <500cells/
mm
3
or
<1000cells/ mm
3
and falling,
axilliary
temperature
≥38.0°C ≥2
occasions at 4h
intervals, or once
>38.3°C
Fever that occurred
following
transfusion of blood
and blood products
or administration of
G-CSF
240 621
Median 6y
(range 1m to
17y)
West 2004
California,
USA
1994 -
1998
ANC <500cells/
mm
3
or
<1000cells/ mm
3
and falling,
axilliary
temperature
≥38.0°C ≥3
occasions in 24h,
or once ≥38.5°C,
within 21d of
chemotherapy
Induction, relapse
and refractory
disease. Collapse
within 1h of
admission
143 303
Mean 7.6y
(SD 4.6y)
Age: y = years, m = months. ANC = absolute neutrophil count. HIV = human immunodeficiency virus.
BMT = bone marrow transplant.
Other QUADAS criteria
Biases due to threats to independent outcome assessment were present in some studies
(see Table 5). Note the three studies which used aspects of the outcome assessment in the
decision rule [19, 23, 132, 153]. In Alexander [23] the outcome of ‘significant medical
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complication’ included ‘hypotension and severe mucositis’, as did the rule describing high-
risk, making these features tautolgous and artificially inflating the sensitivity of the
‘predictive’ rule. Hypotension was found in 55% (5/9) patients and severe mucositis in 12%
(1/9) patients with a ‘significant medical complication’. In Ammann’s studies [19, 153], the
outcome of severe bacterial infections included episodes where CRP > 150 mg/dL without
other microbiological confirmation, and the rule included CRP ≤50 mg/dL. CRP > 150 mg/dL
was found in 50% (53/106) of episodes, but is unclear how many of these individuals had a
further reason to be classified as suffering ‘severe bacterial infection’. The study of
Delebarre [132] is only an abstract and the degree of incorporation bias cannot be
accurately assessed.
Table 5: Further informative QUADAS measures; CDR reveiw
Citation Study design Verification procedure biases Interpretation biases
Partial
verification
Differential
verification
Incorporation
bias
Review bias Review bias
Prospective or
retrospective?
Did the whole
sample or a
random
selection of
the sample,
receive
adequate
outcome
assessment?
Did patients
receive the
same
outcome
assessment
regardless of
the CDR
result?
Was the
outcome
assessment
independent of
the CDR?
Were the
CDR results
interpreted
without
knowledge
of the
results of
the
outcome
assessment?
Were the
outcome
assessment
results
interpreted
without
knowledge of
the results of
the CDR?
Adcock
1999
Retrospective Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes
Unclear –
not blinded
Unclear - not
stated
Alexander
2002
Retrospective Not stated Not stated
No – serious
medical
complication
included
hypotension &
mucositis (which
are part of the
CDR)
Yes Yes
Ammann,
2003 &
2004
Retrospective Yes
Yes, although
some tests
were
undertaken if
No – one
variable from
CDR was in
outcome
Unclear -
not blinded
Unclear - not
blinded
Page 62 of 410
clinically
indicated
assessment (C-
reactive protein
level, although
cutpoint
differed; 50mg/L
in CDR vs
150mg/L in
outcome
assessment).
Amman
2010 and
Agyman
2011
Prospective Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes Yes Yes
Badei
2011
Prospective Yes Yes Yes Yes Yes
Baorto,
2001
Retrospective Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes Yes
Unclear - not
blinded
Delebarre
2010
Prospective
No. Signs of
local infection
or severe
sepsis were in
rule &
outcome.
Unclear Yes
Unclear -
not stated
Unclear - not
stated
Dommett
2009
Prospective
No. Signs of
local infection
or severe
sepsis were in
rule &
outcome.
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes Yes
Unclear – not
blinded
Gala-
Peralta,
2005
Retrospective Yes Yes Yes
Unclear –
not blinded
Unclear - not
blinded
Hann
1997
Retrospective
(RCT trial
data)
Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes Yes
Unclear - not
blinded
Jones
1996
Prospective Yes
Yes, although
some tests
were
undertaken if
clinically
Yes Yes
Unclear - not
stated
Page 63 of 410
indicated
Klaassen,
2000
Prospective Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes Yes Yes - blinded
Lucas,
1996
Retrospective Yes Yes Yes Yes
Unclear - not
blinded
Madsen,
2002
Retrospective
electronic
record
Yes Yes Yes Yes
Unclear.
Review was
blinded, but
of unblinded
case notes
Macher
2011
Retrospective Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes
Unclear -
not stated
Unclear - not
stated
Mian
2010
Prospective Unclear Unclear Unclear
Unclear -
not stated
Unclear - not
stated
Paganini
2007
Prospective Yes Yes Yes Yes
No - but
mortality
Petrelli,
1991
Prospective Unclear Yes Yes Yes No
Rackoff,
1996
Prospective
(Derive) and
Retrospective
(Validate)
Yes Yes Yes
Yes (Derive)
and
Unclear –
not blinded
(Validate)
Unclear - not
blinded
Riikonen
1993
Prospective Yes Yes Yes Yes No
Rojo,
2008
Retrospective Yes Yes Yes
Unclear -
not blinded
Unclear - not
blinded
Rondinelli,
2006
Retrospective Unclear Yes Yes Yes Yes
Santolaya,
2001
Prospective Yes
Yes, although
some tests
were
undertaken if
clinically
indicated
Yes Yes Yes - blinded
Santolaya,
Prospective Yes
Yes, although
some tests
Yes Yes Yes - blinded
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2002
were
undertaken if
clinically
indicated
Tezcan
2006
Retrospective Yes Yes Yes Yes
Unclear - not
stated
West,
2004
Retrospective Yes Yes Yes
Unclear -
not blinded
Unclear - not
blinded
Quality of CDR derivation
The 22 reports of attempts to derive a CDR varied in population, outcomes chosen and the
number of those outcomes as discussed above. They also varied in the variables assessed,
model-building technique, the way that missing data were reported and handled, the way
that multiple-episode data were used and in the use and categorisation of continuous and
categorical variables. All of these features may have influenced the CDRs produced and
provide some explanation of the differences between them.
The number of events per variable considered is generally important in producing replicable
studies. Most studies building a CDR used a large number of variables (median 16, range 2 to
39) and had a small number of events (median 41, range 4 to 179) with 76% (16/21) studies
having less than ten events per variable under consideration. No study had more than 14
events per variable (see Appendix 6).
The technique used to build the model also varied. Almost all were built using multivariable
regression (see Appendix 7 for details). Five models from four publications used alternative
approaches. Two models did not use multivariable analysis [23, 133], two used CART
(classification and regression tree) techniques [131]. One model [79] was offered alongside a
logistic regression, and came to different conclusions from the same dataset. No model
building study clearly assessed if relationships between the outcome and the explanatory
variables could hold non-linear functional forms, and with the exception of one study [144,
147], nor did they clearly examine co-linearity (the issue of multiple variables being highly
correlated as described in chapter 3).
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Continuous variables, such as age, blood pressure and absolute monocyte count, were used
in the model derivation by seven studies as continuous data and they went on separately to
create categories (three by recursive partitioning [141, 144, 147], two by ROC analysis[139,
146],and unstated in the remaining two which were reported as abstracts only [132, 145]).
Five studies used some variables in continuous form and making others ordinal [5, 69, 137,
140, 142] In these studies, four did not state clearly how the cutpoints had been
determined, one stated ‘clinical judgment’ was used [5]. A further eight used only
categorised variables. Only one of these described clearly a literature-based choice of
cutpoints [26]. Of the derivation studies, three did not use purely categorical variables [137,
141-142], 15 did not clearly state the reasons for defining their cutpoints, 3 used ‘clinical
judgement’ [5, 26, 146] and one study stated they had used ‘trend to significance’ from
bivariable analysis [133] (see Appendix 7).
Multiple episodes in individual patients were treated primarily as if they came from
unconnected individuals in twelve studies (see Appendix 7). A further three studies
performed a secondary analysis which looked at only the ‘first included case’ and found ‘no
significant differences’ [79, 139, 153]. The first case approach is not necessarily the patient’s
first-ever presentation with a febrile neutropenic episode, but is the first recorded during
the study in question. Other approaches to address the issue of multiple episodes included
the use of only first episode data (four studies) [5, 134, 138, 146] and extended modelling
techniques that try to account for the clustering; a generalised estimating equation (four
studies) [25, 141, 144, 147] or generalised linear mixed models (two studies) [26, 140].
The issue of missing data was described in only eight of the derivation studies [26, 79, 134,
141, 144, 146-147, 153], six of them used a form of complete case analysis (after exclusion
of potential variables where <90% of cases had collected the information in two linked
studies) and two linked studies used imputation [144, 147]. No study details an assessment
of the type of missingness of the data, although seven of the eight who commented on
missing data analysis also described the extent of the problem. The remaining studies
neither clearly defined the quantity of missing data nor how it was addressed (details in
Appendix 7).
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Clinical Decision Rule performance
The CDRs designed to predict general infectious complications have diverse test
performance. This heterogeneity has largely been explored using a narrative structure, as
pooling across all the studies was not possible due to the varied rules, outcomes and
populations studied. Initial hypotheses to explain the differences included: the design of the
study (derivative better than validating), the population (both geographical, where
developing-world studies would be different than developed-world, and case-mix, where
less success was predicted from populations where higher-risk cases had been systematically
removed), the complexity of the rule (more complex rules would be better) and outcomes
chosen (the rules differing between outcomes, without a clear a priori hypothesis of which
outcomes may be easier to detect). These were examined by analysis of the tabulated CDR
performance data (Appendix 8) and graphically with plots of sensitivity and specificity
(Figure 12, Figure 13, Figure 14, Figure 15, Figure 16)
Examining potential reasons for the differences found that the derivation studies as
expected, had better accuracy than validation studies. For example, for the outcome
“serious/invasive infection” the median LR- = 0.06 (range 0 to 0.33) in derivation studies
compared with median LR- = 0.35 (range 0.11 to 2.28) for validation studies. This was less
marked but similar for “bacteraemia”, the median LR- = 0.21 (range 0 to 0.72) in derivation
studies compared with median LR- = 0.33 (range 0 to 0.74). The results of a pooled analysis
of the ‘Rackoff’ and ‘Alexander’ rules (see later for details) supported this previously noted
overestimation of the rule performance. The choice of outcome also appears to alter the
rule performance, but the different number of studies and the heterogeneity of rules and
populations make this difficult to examine clearly.
Those CDRs developed in a population where the highest risk patients were excluded (e.g.
bone marrow transplant recipients) did not seem to be particularly better or worse than the
rules developed without these exclusions. The few rules derived in South America appeared
to be from higher quality studies [22] but not significantly different in terms of performance
in their original setting than other rules, but did not show geographical transportability (see
Figure 14 and Figure 16, explored below). The issue of geographical and temporal replication
has been infrequently examined in these studies.
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Examination of the detailed content of all the proposed rules shows they address four major
domains (Appendix 9. Individual factors used in clinical prediction rules). The first can be
considered stable patient-related factors, including age and the underlying disease. The
second group reflects treatment; the presence of a central venous catheter and the type of
or duration since last chemotherapy. The third group reflects episode specific clinical
features, such as maximum temperature, the patient’s blood pressure or clinical features of
infection. The final group contains episode specific laboratory test values. These are various
markers of bone marrow function where, excepting [24], each rule uses a single item which
reflects one of the three major cellular components: haemoglobin, platelets, total white cells
or subset of neutrophils or monocytes, and serum inflammatory markers (C-reactive
protein). The results of the detailed systematic review of the predictive value of such serum
inflammatory markers follows in the later part of this chapter.
The complexity of the rule e.g the Rackoff rule of AMC > 100 cells/mm
3
compared with the
five items of the PINDA rule does not seem to have importantly improved their predictive
value, though this is difficult to judge effectively as the rules have not been subject to the
most extensive validation to enable such comparisons to be undertaken.
When addressing the nature of individual factors found to be significantly associated with
adverse outcomes there are many similarities (Appendix 10, tables a-c, subdivided by
outcome class). In predicting bacteramia, the disease state (induction/remission or bone
marrow involvement) appears important. Age does not appear a strong linear predictive
factor. The presence of a central line and use of higher-intensity chemotherapies may be.
Episode related factors of importance include outpatient status, other co-morbidities, the
presence of respiratory distress (including proven pneumonia), hypotension or shock,
mucositis and maximum temperature. A clinical site of infection is probably not a predictive
factor. Blood tests with importance include platelet and absolute monocyte count, and
potentially higher levels of haemoglobin; neutrophil count appears unimportant.
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To predict significant infection (rather than bacteramia alone), various other factors are
added. The age of the patient achieves a significant linear prediction ability and a clinical site
of infection is important. Outpatient status has not been assessed in this setting, so
comment is not possible. Low haemoglobin is also associated with adverse outcomes in
some studies [137], and the opposite in others, and once again neutrophil counts are not
important.
The few studies that address ICU and death find that the age and disease state remain
important, as do clinical assessments of circulatory and respiratory compromise. Higher
temperatures remain highly predictive, and neutrophil counts appear unrelated to these
outcomes, where monocyte and platelet counts retain some value.
Quantitative meta-analysis
The results of combining studies which used identical clinical decision rules was undertaken
in three cases in the original review and supplemented with a further four in the update
review. The three-level Rackoff rule [141] to examine bacteraemia (a total of 7 data sets:
[12, 26, 69, 136, 141] was not updated, nor was Paganini’s rule to predict mortality [137]
(with one derivation and one validation set). There was sufficient data to update a meta-
analysis of the Santolaya (PINDA) rule for serious infectious complications [139] and
additional data to undertake a meta-analysis of the validity of the Alexander, Amman 2004,
SPOG and Klaassen rules.
The results of the Rackoff rule combined analysis show a moderate ability to discriminate
between three groups of individuals at low, moderate and high risk of bacteraemia.
Exclusion of an outlier ([69]; see Figure 2) led to a more Normal distribution of the posterior
probability plots, in keeping with it being qualitatively different than the other studies. A
further sensitivity analysis excluding the initial rule derivation study demonstrated reduced
discriminatory ability (see Table 6.)
The most accurate estimate of predictive accuracy is likely to come from the analysis of 5
data sets (excluding the derivation and outlier); LR [low] = 0.26 (95% CrI 0.08 to 0.72) , LR
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[medium] = 0.72 (95% CrI 0.14 to 2.15), LR [high] = 3.11 (95% CrI 1.25 to 8.01). (See Figure
3.)
Table 6: Combined analysis of Rackoff rule data with alternative exclusions
LR[High] LR[Middle] LR[Low]
All Included
3.03
(95% CrI 1.28 to 6.5)
0.81
(95% CrI 0.14 to 2.15)
0.27
(95% CrI 0.06 to 0.79)
Excluding Tezcan
3.2
(95% CrI 1.49 to 6.88)
0.76
(95% CrI 0.3 to 1.73)
0.22
(95% CrI 0.06 to 0.6)
Excluding Derivation
2.9
(95% CrI 1 to 7.2)
0.77
(95% CrI -0.08 to 2.82)
0.32
(95% CrI 0.08 to 0.93)
Excluding Derivation
and Tezcan
3.11
(95% CrI 1.25 to 8.01)
0.72
(95% CrI 0.14 to 2.15)
0.26
(95% CrI 0.08 to 0.72)
Figure 12: Pooled and individual results of the ‘Rackoff’ model studies
Key for Figure 12
O & blue = low vs. medium-high studies
X & grey = low/medium vs. high studies
Dark blue = MCMC summary estimates
LR [low] = 0.20 (95% CrI 0.052 to 1.54)
LR [medium] = 0.83 (95% CrI 0.31 to 1.29)
LR [high] = 3.28 (95% CrI 0.40 to 7.32)
Grey dotted = Bivariate summary estimates
LR [low] = 0.30 (95% CI 0.14 to 0.63)
LR [medium] = not estimable
LR [high] = 3.01 (95% CI 2.26 to 4.00)
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If the meta-analysis is restricted to studies in Chile (as with the original review), the PINDA
group (Santolaya) model shows a similar ability to differentiate between low- and high- risks
groups when considering a wider definition of ‘serious infection’, (LR [low] = 0.17 (95% CI
0.12 to 0.23) LR [high] = 2.87 (95% CI 2.43 to 3.38) ). The Paganini model demonstrates an
ability to quite accurately predict mortality LR [low] = 0.11 (95% CI 0.04 to 0.30), LR
[medium] = not estimable, LR [high] = 11.0 (95% CI 8.08 to 15.0). However, in undertaking
this geographically restricted analysis, the results may be falsely reassuring.
Figure 13: Pooled and individual results of the ‘Rackoff’ model studies
excluding derivation and Tezcan
Figure 14: Pooled and individual results of the ‘PINDA' model
studies from South America
Key for Figure 13
Dark blue = MCMC summary estimates
LR [low] = 0.26 (95% CrI 0.08 to 0.72)
LR [medium] = 0.72 (95% CrI 0.14 to 2.15),
LR [high] = 3.11 (95% CrI 1.25 to 8.01)
Key for Figure 14
Random effects model summary estimates
LR [low] = 0.17 (95% CI 0.12 to 0.23)
LR [high] = 2.87 (95% CI 2.43 to 3.38)
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When the PINDA rule is used in datasets from Europe, there is a marked inconsistency and
lack of repeatability in the results (see Figure 16) . This apparent lack of geographical
transportability is highly important when deciding to practically use a decision rule.
Figure 16: Pooled and individual results of the ‘PINDA' model studies from Europe and South America
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for PINDA rule
Figure 15: Pooled and individual results of the ‘Paganini’ model
studies
Amman
2010
Macher
2010
Key for Figure 15
O & blue = low vs. medium-high studies:
X & grey = low/medium vs high studies
Grey = Random effects model summary estimates
LR [low] = 0.11 (95% CI 0.04 to 0.30)
LR [medium] = not estimable
LR [high] = 11.0 (95% CI 8.08 to 15.0)
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As no further studies allow evaluation of the Paganini rule, no further comment can be
made.
The update review allowed for the analysis of five further rules: Klaassen, Amman 2003 (in
which meta-analysis was undertaken), and the Rondellini, SPOG and Alexander rules (where
data were not suitable for meta-analysis).
The “Klaassen” rule is based on a single feature: an absolute monocyte count of greater than
100/mm
3
to predict patients less likely to have significant infection. Data were pooled from
four studies from the original review [12, 26, 136, 141] and two new sources [130, 144]. The
results of this analysis give a pooled average sensitivity of 88% (95% CI 84 to 91%) and
specificity of 36% (95% CI 27 to 45%), see Figure 17.
Figure 17: Pooled and individual results
of the ‘Klaassen’ model studies
The “Ammann” rule was assessed in the three studies providing data to test this rule to
detect serious consequences of FNP [79, 130, 144]. The combined average sensitivity was
98% (95%CI 91 to 99%) but pooled average specificity only 13% (95% CI 8% to 21%), see
Figure 18.
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The “Alexander” rule again examined adverse clinical consequences. This rule was assessed
by three studies [134, 144, 154]. There was marked heterogeneity in the results of these
three studies (see Figure 19). When used at reassessment after 48hrs of hospitalisation,
there was marked improvement in the discriminatory ability of the rule [154] (sensitivity =
100%, specificity = 39%). The derivation was undertaken in North America, the evaluations in
Europe.
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Figure 18: Pooled and individual results of the 'Amman' model studies
Figure 19: Individual results of the 'Alexander' model studies
Key for Figure 18
Random effects model summary estimates
LR [low] = 0.15 (95% CI 0.04 to 1.12)
LR [high] = 1.12 (95% CI 0.98 to 1.25)
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The rule of Rondellini [138] describes a low-risk group for adverse clinical consequences, and
was assessed in two validation datasets. These demonstrated a sensitivity of 84%[144] and
62%[130] and both estimated specificity at 43%.
The SPOG2003 was only evaluated in one study and varies from the other systems in that it
is applied after 8-24 hours of hospitalisation. This model was shown to have a sensitivity 92%
and specificity of 45%[144]. A validation of this model demonstrated poorer sensitivity (82%)
and slightly better specificity (57%) [155], using data from a similar region (both European)
but in countries using slightly different primary treatment regimes.
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Biomarkers studies
This section of the Chapter addresses studies which have examined the role of serum
biomarkers in the prediction of infectious complications. The assessment of such biomarkers
would be ideally undertaken as additional to previously gathered clinical data, but the
studies undertaken did not commonly appear to have this design. Accordingly, a decision
was made to review them separately, and update that review independently.
Study inclusion and exclusion
Figure 20 describes the flow of candidate and eligible articles though the original review
process. 368 articles were identified from electronic searches, of which 72 articles were
identified for detailed examination. Seven further articles were identified from examining
systematic reviews and the bibliographies of included studies. From this, 27 articles
reporting on 25 studies were eligible for inclusion in the review, with 26 articles providing
outcome data. Of these, 13 could be included in the quantitative synthesis.
The update review found 13 further studies, of which quantitative data were included from
12 studies (Figure 21).
In total 38 studies were included in the review, of which 37 provided quantitative data and
22 studies were included in the meta-analyses.
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Potentially relevant articles identified from
databases; n = 368
Excluded articles; n = 296
 Not cancer = 20
 Not FNP = 105
 Not children = 19
 Not marker = 117
 No appropriate outcomes = 2
 Not testing marker = 31
 Two gate design = 2
Potentially relevant articles assessed in
detail; n = 72
Excluded articles; n = 52
 Not FNP = 9
 Not children = 7
 Children not extractable = 18
 Not marker = 2
 No appropriate outcomes = 3
 Data not extractable = 1
 Not testing marker = 10
 Duplicate publication = 1
 Original article not available = 1
Data extraction undertaken
n = 27
Studies with quantitative data available
n = 25
Included in quantitative synthesis
n = 13
‘Duplicate’ publication, n= 2
(One erratum for previous article & one
study published over 2 articles)
Identified from
reference lists;
n = 7
Figure 20: Flow diagram of study selection process; original biomarkers review
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Potentially relevant update articles
identified from databases
n = 74
Excluded articles; n = 42
Potentially relevant articles assessed in
detail
n = 32
Excluded articles; n = 19
Not FN / not extractable FN, n = 1
Not children, n = 4
Children not extractable, n = 1
Not marker, n = 0
No appropriate outcomes, n = 1
Data not extractable, n = 3
Not testing marker, n = 0
Duplicate publication, n = 5
Original article not available, n = 0
Non-English, n = 3
Included in previous review, n = 1
Data extraction undertaken
n = 13
Studies with quantitative data available
n = 12
Data not extractable, n = 1
Identified from
reference lists
n = 0
Figure 21: Flow diagram of study selection process; update biomarkers review
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Evaluation of Biomarkers studies
The studies included a total of 3071 patients (each included between 19 and 278 individuals,
median 56) and over 5169 episodes (between26 and 566, median 94, where stated). Twenty
four different markers of inflammation or infection were assessed (see Table 7). The mean
age of children ranged from 5.7 to 10 years (where age stated). The studies were undertaken
between 1989 and 2009 (where stated) in Europe, North America, South America, North
Africa and Asia and Australasia.
Table 7: Summary of biomarkers studied.
Marker Total studies
CRP 29
IL6 16
IL8 15
PCT 14
IL10 2
TNF-alpha 2
IL1 2
IL5 2
IL2-R 2
IL12 1
IL10 1
MCP 1
ESR 1
tADA 1
SAA 1
IFN-gamma 1
T-reg 1
sTNFRII 1
sTREM 1
Derivative of rO2 metabolites 1
Biological antioxidant potential 1
LDH 1
Glucose 1
Blood urea nitrogen 1
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Outcomes examined
The studies reported diverse outcomes including bacteraemia, fungal infection, gram
negative and gram positive bacteraemia, significant/documented bacterial infection,
systemic inflammatory response syndrome (SIRS), sepsis, intensive care unit (ICU) admission,
death, and prolonged (>5days) hospital stay ( Table 8 ).
Table 8: Markers and endpoints in each included biomarkers study.
Citation
Markers
assessed
Endpoint #1 Endpoint #2 Endpoint #3 Comments on endpoints
Asturias
2010
CRP Fever Bacteraemia
Ammann
2003
CRP
Significant
bacterial
infection
Defined as death from bacterial
infection, a positive culture of
normally sterile body fluids,
radiologically proven pneumonia,
clinically unequivocal diagnosis of a
bacterial infection, or a serum C-
reactive protein level (CRP) above 150
mg/L as an indirect sign suggesting
severe bacterial infection
Avbratha
2009
CRP
Bacteraemia
or clinically
documented
infection
Barnes 2002 PCT Length of stay Stay of <5d or ≥5d
de Bont 1999
CRP, IL6,
IL8
Bacteraemia
Cost 2011 IL8, IL5
Bacteremia &
clinical sepsis
Delebarre
2011
PCT
Severe
infection
Defined by bacteraemia, severe
bacterial infection, invasive fungal
infection or probable infection
Diepold 2008
IL6, IL8,
CRP
Bacteraemia
Fever lasting
≥5d but
culture -ve
Dylewska
2005 a & b
PCT, CRP Bacteraemia
Clinically
defined
infections
(UTI,
neurological,
GI or
respiratory)
Microbiologic
ally defined
other
infection
FUO was the default category
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El-Maghraby
2007
CRP, IL8,
MCP
Bacteraemia
or clinically
documented
infection
Hatzistiliano
u 2007
PCT, CRP
Microbiologic
al or clinically
documented
infection
(excludes
viral)
Hatzistiliano
u 2010
PCT,
CRP,
TNF-
alpha,
IL8, IL1b,
sTNFRII
Bacterial
infection
Viral infection
or PUO
Heney 1992 CRP, IL6 Bacteraemia
Hitoglou-
Hatzi 2005
CRP,
PCT,
tADA
Significant
bacterial
infection
Hodge 2006
IL5, IL8,
IL12,
CRP
Positive blood
culture
Hodge 2011
IL2, TNF-
alpha,
TNF-
gamma,
T-reg
cells
Positive blood
culture
Katz 1992 CRP
Clinically or
bacteriologica
lly
documented
infection
Septicemia
(+ve blood
cultures &
unwell clinical
appearance)
Kharaya
2010
IL6, PCT Bacteraemia
Kitanovski
2006
CRP,
PCT, IL6
Bacteremia &
clinical sepsis
Clinically or
microbiologica
lly
documented
local infection
Lehrnbecher
1999
CRP, IL8,
IL6
Clinically
documented
infection
Fungal
infection
Bacteraemia
(gram-type)
FUO was the default category
Lehrnbecher
2004
IL6, IL8
Significant
bacterial
infection
Defined as bacteraemia, localised
infection or pneumonia
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Lodhal 2011 PCT, CRP Bacteraemia
Split into gram-positive and gram-
negative infections
Mian 2009
CRP, IL6,
IL2, IL10,
IL8, TNF-
alpha
Intensive care
admission
Miedema
2011
CRP, IL8,
PCT,
sTREM
Proven or
suspected
bacterial
infection
Defined as documented bacteria from
sterile site or clinically documented
infection or clinical sepsis
Nishikwa
2010
dROM,
Biologica
l
antioxid
ant
potentia
l, CRP
Systemic
inflammatory
response
syndrome
Reitman
2010
PCT Bacteraemia
Richardson
2009
CRP Bacteraemia
Riikonen
1992
IL1, IL6,
TNF-
alpha,
SAA
Bacteraemia
suspected
sepsis
Focal
infection
"No infection" was the default
category
Riikonen
1993
CRP Bacteraemia
suspected
sepsis
Focal
infection
"No infection" was the default
category
CRP
Documented
bacterial
infection
Probable
bacterial
infection
Viral infection
Documented bacterial infection
defined as bacteraemia (two sets
positive for commensals) or sterile
site infection; Probable bacterial
infection defined as cultures negative
but severe medical course e.g.
purulent gingivostomatitis, CXR+; FUO
was the default category
Santolaya
2001
CRP
Invasive
bacterial
infection
Defined as positive blood cultures – 2
for CoNS, positive bacterial culture
from usually sterile site, or sepsis
syndrome and/or focal organ
involvement and haemodynamic
instability and severe malaise
Santolaya
2002
CRP
Invasive
bacterial
infection
Defined as positive blood cultures – 2
for CoNS, positive bacterial culture
from usually sterile site, or sepsis
syndrome and/or focal organ
involvement and haemodynamic
instability and severe malaise
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Santolaya
2007
CRP Death
Santolaya
2008
CRP, IL8,
PCT,
Glucose,
Blood
Urea
Nitrogen
Severe sepsis
Defined as sepsis + respiratory or
cardiac compromise, or + 2 other-
organ compromise) not apparent
during the first 24h of admission
Secmeer
2007
CRP,
PCT, ESR
Bacteraemia
Documented
bacterial
infection
(microbiologic
ally or
clinically)
Duration of
fever
Soker 2001
IL2-R,
IL6, IL8,
TNF-
alpha,
IL1
Bacteraemia
Spasova
2005
CRP, IL6,
IL8, IL10
Bacteraemia
Microbiologica
lly or clinically
proven local
infections
without
bacteraemia
Stryjewski
2005
PCT, IL6,
IL8
Sepsis Septic shock
Sepsis (positive culture - two
consecutive +ve if CoNS, fever,
tachycardia, or tachypnoea); septic
shock defined as sepsis plus need for
inotropes/vasopressors
QUADAS criteria
Analysis of the study quality according to modified QUADAS criteria revealed few
informative items. The quality was on the whole good (Appendix 11). The worst identified
flaw was in Amman study where there was potential contamination of the reference
standard with the diagnostic test (the outcome included CRP >150 mg/dl while the
predictive test included CRP). One short report did not detail the exact outcome used [156].
The major deficiencies in most studies were failure to report whether the marker test and
outcomes were interpreted blind to each other; only three of the studies by Santolaya
clearly documented that this was the case. Detailed analysis of the criteria presented in the
published abstracts from conferences in which results were reported was very difficult.
Applicability to a general clinical population was fair for those studies that presented
information about the included population (Table 9,) although most studies failed to clearly
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describe their selection criteria. The Santolaya 2008 [157] study was specifically designed to
examine only the high-risk (by CDR) group, and their data may be considered as belonging to
an importantly clinically distinct population.
Table 9: Participant characteristics by biomarkers study
Citation
Study
location
Study years Inclusion criteria
Exclusion
criteria
Number
of
patients
Number
of
episode
s
Average age
of patients
Ammann
2003
Bern,
Switzerlan
d
1993 to
2001
ANC ≤500cells/
mm
3
or
≤1000cells/ mm
3
and falling,
axillary
temperature
≥38.5°C for ≥2h,
or once ≥39°C
Established
severe
bacterial
infection at
presentation,
or episodes of
FN due to
bone marrow
involvement
by the disease
itself, i.e. at
the time of
diagnosis or
following a
myeloablative
therapy.
111 285
Median age
at first
episode =
6.3y
(interquartile
range 3.2y to
12.1y)
Asturias
2010
Guatemal
City,
Guatemal
a
April 8 to
October 15
2008
Children with
cancer, age
<18ys and
hospitalised with
fever and
neutropenia
Hospitalisation
<48hrs,
antibiotic
therapy 7 days
before
admission,
prior bone
marrow
transplant
88 102
Mean age:
6.5 yrs; SD:
+/- 4.4 yrs;
range: 8
months to 18
yrs
Avabratha
2009
Mangalor
e, India
Not stated
Children aged 1-
15yrs with
malignancy and
febrile
neutropenia
Liver disease 33 50
Mean age 6.9
y
Barnes
2002
Melbourn
e,
Australia
Not stated
"Febrile
neutropenia"
not further
specified
Not stated 37 39 Not stated
Cost 2011
Dallas,
Texas,
United
States
March 2010
to Dec 2010
Paediatric
oncology
patients
hospitalised with
Not stated 120 120 Not stated
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febrile
neutropenia
de Bont
1999
Groningen
, The
Netherlan
ds
1998
Chemotherapy
related
neutropenia
(granulocytes
<500cells/ mm
3
or leucocytes
<1000cells/
mm
3
) and
≥38.0°C for 6h,
or once ≥38.5°C
On antibiotics
or post
BMT/stem cell
transplant
19 72
Not stated ,
all <16y
Diepold
2008
Freiburg,
Germany
Not stated
ANC ≤500cells/
mm
3
,
temperature
≥38.0°C for >1h,
or once >38.5°C
Not stated 69 123
Median 7y
8m (range
1m to 20y)
Dylewska
2005 a & b
Bydgoszcz
, Poland
Not stated
ANC ≤1000cells/
mm
3
,
temperature
≥38.0°C (once,
axilliary)
Not stated 66 108
Mean 9.6y
(Range 2y to
20y)
El-
Maghraby
2007
Cairo,
Egypt
2004-2005
ANC ≤500cells/
mm
3
,
temperature
≥38.0°C twice in
<6h, or once
≥38.5°C
Systemic
antibiotics
(except
Septrin) wihin
previous week
76 85
Mean 7.1y
(range 1.5y
to 18y)
Hatzistilian
ou 2007
Not stated Not stated
ALL patients
only. ANC
≤500cells/ mm
3
or leukocytes
≤1000cells/
mm
3
,
temperature
≥38.0°C for 6h,
or once ≥38.5°C
Not stated 29 94
Mean 5.8y
(SD 2.9y)
range 1y to
14y
Hatzistilian
ou 2010
Greece/Eu
rope
Not stated
Children with
acute leukemia
and febrile
neutropenia
Study also
looked at febrile
non-neutropenic
and afebrile non-
neutropenic
children
Not stated 0 0
Group A -
mean 5.8;
range 1-14y;
Group B - not
stated
Heney
1992
Leeds, UK Not stated
Temperature
≥38.0°C twice in
<24h, or once
Not stated 33 47
Mean 7y
(range 7m to
15y)
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≥38.5°C
Hitoglou-
Hatzi 2005
Thessaloni
ki, Greece
Not stated
ANC ≤500cells/
mm
3
or
leukocytes
≤1000cells/
mm
3
,
temperature
≥38.0°C for 6h,
or once ≥38.5°C
Not stated 67
Not
stated
Mean 6.4y
(range 1y to
14y)
Hodge
2006
North
Adelaide,
Australia
Unclear
ANC ≤1000cells/
mm
3
,
temperature
≥38.0°C
(sustained) or
once ≥38.5°C
Not stated 31 31 Not stated
Hodge
2011
Australia Not stated
Paediatric
oncology
patients with
febrile
neutropenia
Not stated 27 26 Not stated
Kharya
2010
Dehli/Indi
a
Not stated
Children with
febrile
neutropenia
Not stated * 129 Not stated
Katz 1992
Dallas,
USA
November
1989 to
June 1990
Outpatients
only. ANC
≤500cells/ mm
3
,
temperature
≥38.0°C for 6h,
or once ≥38.5°C
Already on
antibiotics
(except
Septrin)
74 122
Mean 6.3y
(range 2m to
17y)
Kitanovski
2006
Ljubljana,
Slovenia
Not stated
ANC
≤500cells/mm3
or
≤1000cells/mm3
and
falling,tympanic
temperature
≥38.0°C for 6h,
or once ≥38.5°C
Not stated 32 68
Median 7.6y
(range 1y to
18y)
Lehrnbech
er 1999
Wurzberg,
Germany
Unclear
ANC ≤500cells/
mm
3
or within
72hrs of
chemotherapy
and falling,
temperature
≥38.0°C twice in
<4h, or once
≥38.5°C
Febrile >24h
before
admission and
antibiotics
(except
Septrin) within
previous 72h
56 121
mean 8y
(range 3m to
20y)
Lehrnbech
er 2004
Bonn,
Frankfurt
&
Not stated
ANC ≤500cells/
mm
3
,
temperature
Fever >24h
before
146 311
Mean 9y
(range 0.5y
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Wurzburg,
Germany
≥38.5°C presentation to 28y)
Lodahl
2011
Denmark/
Europe
25
September
2000 to 28
June 2001
Children (<16 y)
admitted to
hospital with
febrile
neutropenia
Not stated 85 230
Median 5.7 y;
rang 4 month
to 15 years
Mian 2009
USA/Nort
h America
Not stated
Febrile
neutropenia
Not stated 29 51 Range 1-29
Miedema
2011
The
Netherlan
ds
April 1999
to August
2002
Children with
malignancy and
febrile
neutropenia
None 29 43
Median age
8y in both
groups and
range 6-13y
(bacterial
infection)
and 6-12y (no
bacterial
infection)
Nishikawa
2010
Japan
Feb 2008 to
June 2009
Patients with
lymphoma or
leukaemia in
remission
Not stated 27 36
Mean 10y
(range 1-19)
Reitman
2010
United
States of
America
11 month
period (year
not stated)
Fever (>38
degrees celcius)
and severe
neutropenia (not
defined)
Not stated 89 89 Not stated
Richardson
2009
United
States of
America
Jan 2006 to
April 2008
Children with
cancer or
aplastic
anaemia, fever
and neutropenia
Not stated 48 142
Mean ages in
2 groups
were 8.4y (SD
5.6) and 8.5y
(SD 5.1)
Riikonen
1992
Helsinki,
Finland
Not stated
ANC ≤1000cells/
mm
3
,
temperature
≥38.0°C twice in
4h, or once
≥39°C, or
clinically 'poor
condition'
Antibiotics in
previous 3
weeks (except
Septrin)
46 105 Not stated
Riikonen
1993
Helsinki,
Finland
1989-1990
ANC ≤200cells/
mm
3
,
temperature
≥38.0°C twice in
4h, or once
≥39°C
Antibiotics in
previous 3
weeks (except
Septrin)
46 91 Not stated
Santolaya
1994
Santiago,
Chile
1991-1992
ANC ≤500cells/
mm
3
,
temperature
Antibiotics in
previous 72h
or surgery
75 85 Not stated
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≥38.0°C twice in
<24h
within 5d
Santolaya
2007
6
hospitals
in
Santiago,
Chile
2004 to
2005
PINDA 'High Risk'
only. ANC
≤500cells/ mm
3
,
temperature
≥38.0°C ≥2
occasions ≥1h
apart, or once
>38.5°C
Low risk
episodes and
BMT patients
219 373 Not stated
Santolaya
2008
6 centres
in
Santiago,
Chile
2004-2006
ANC ≤500cells/
mm
3
and 'fever'
Low risk
episodes. Early
onset (<24h)
severe sepsis
278 566 Mean 7.75y
Secmeer
2007
Ankara,
Turkey
January
2004 to
January
2005
‘Neutropenia'
with
temperature
≥38.0°C for ≥1h,
or once ≥38.3°C
Not stated 49 60
Median age
7.7y (range
2y to 16y) in
patients
without
documented
infection and
7.2y (range
2.5y-18y) in
patients with
documented
infection.
Soker 2001
Diyarbakir
, Turkey
Not stated
ANC ≤500cells/
mm
3
,
temperature
≥38.0°C twice in
<4h, or once
≥38.5°C
Antibiotics
within 72h
(except
Septrin)
23 48
Mean 7y
(range 2y to
14y)
Spasova
2005
Plovdiv,
Bulgaria
January
2003 to
June 2004
ANC ≤500cells/
mm
3
, axilliary
temperature
≥38.0°C ≥2
occasions ≥1h
apart, or once
>38.3°C
Not stated 24 41
Average not
stated.
Range 2m to
19y
Stryjewski
2005
Washingt
on, DC,
USA
Not stated
ANC ≤500cells/
mm
3
, axilliary
temperature
≥37.5°C or
oral/rectal
temperature
≥38.0°C
Fever >24h
before
admission or
antibiotics
(except
Septrin) within
previous 72h
56
Not
stated
Mean 6.7y
(range 5m to
17y)
Santolaya
2001
5 centres
in
Santiago,
Chile
1996-1997
ANC ≤500cells/
mm
3
,
temperature
≥38.0°C ≥2
occasions ≥1h
apart, or once
None stated,
but no BMT
patients
257 447
Mean 7y
(range 6m to
18y)
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>38.5°C
Santolaya
2002
6 centres
in
Santiago,
Chile
1999-2000
ANC ≤500cells/
mm
3
,
temperature
≥38.0°C ≥2
occasions ≥1h
apart, or once
>38.5°C
None stated,
but no BMT
patients
170 263
Mean 7y
(range 7m to
17y)
Data handling
Nine studies used a statistical technique to investigate if the predictive value of the serum
marker was affected by other measured factors [30, 79, 139, 145, 158-162]. In five of these
[79, 139, 145, 158, 161] an adjusted estimate was produced, using linear multivariable
approaches. In these studies, the number of primary adverse events per predictive variable
assessed ranged from 2.4 [79], to 11.6 [161] with one study having too little information to
be able to assess this [145]. The other four studies [30, 159-160, 162] concluded the other
measured variables did not affect the marker’s diagnostic value. There was a lack of clarity in
reporting the statistical approaches they used.
Assessment of the effect of multiple episodes per patient was undertaken in four studies; de
Bont [158] used patients as a random-effect in their regression analysis, the other three
studies [79, 160-161] undertook ‘first-vs. last’ episode comparison and found ‘no significant
difference’. Three papers describe no adjustment [139, 163-164], and the other studies
make no mention of adjustments for clustered episodes. In three papers, only one episode
per patient is used [165-167]
Thirty three of the 38 studies did not comment upon missing data. The five studies that did
consider this issue used a complete-case analysis (with one study excluding potential
variables with >10% missing values [79]). No studies clearly examined the nature of the
missing data [79, 168-169].
Twenty five of the 38 included studies used a cut-point for marker test results, in 12 of the
studies this was determined by the dataset being examined (eg by ‘ROC analysis’ or by
maximising the sensitivity of the test)[30, 139, 158, 161, 163, 168, 170-175]. In six studies
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the cut-point chosen was based on previous literature or alternative datasets [27, 156, 176-
178], and in eight studies the choice was not explained[79, 142, 159-160, 169, 179-180].
Four studies did not go on to undertake an analysis with a dichotomised result [164, 166-
167, 174, 181-187].
Six studies examined categorical variables as potential modifiers of the predictive ability of
serum markers. Five of these used a grouping schema which was not explicitly justified [79,
139, 159, 172, 179] and one study [158] appeared to use ungrouped categorical data
(malignancy). (See Appendix 12 for more detail.) As no study concluded these had any
effect, no positive bias can have been introduced. However, given the lack of justification of
the groupings, important interactions may have been missed.
Predictive performance of biomarkers
For the original review, quantitative data were pooled by three meta-analysis techniques, to
explore the strengths and weaknesses of a variety of approaches. The review publication
focussed on exploring both the methodological and clinical findings from the review [114].
The studies used in this were eleven studies providing data on CRP [27, 79, 159-160, 169,
172-173, 176, 179, 184], four studies also provided data on PCT [163, 173, 179, 184] and
four provided data on the use of IL6 [163, 168-169, 171].
Analyses were originally possible for CRP (microbiologically or clinically documented
infection), PCT (microbiologically or clinically documented infection) and IL6
(microbiologically or clinically documented infection, and gram –ve bacteraemia). Individual
results for the four most frequently reported markers (CRP, PCT, IL6 and IL8) and outcomes
are given in Table 10. These data have been used below to illustrate the advantages and
challenges of conventional approaches to meta-analysis of diagnostic test data.
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Table 10: Individual biomarkers study results used in pooled analyses presented by marker, outcome and
cutoff.
Citation Cutpoint Sensitivity (95% CI) Specificity (95% CI) Method of derivation
CRP: Bacteraemia
Spasova 2005 20 1 (95% CI 0.78 to 1)
0.04 (95% CI 0.01 to
0.18) mean/sd
Spasova 2005 50
0.21 (95% CI 0.08 to
0.48) 1 (95% CI 0.88 to 1) mean/sd
Spasova 2005 90 0 (95% CI 0 to 0.22) 1 (95% CI 0.88 to 1) mean/sd
Riikonen 1993 20
0.65 (95% CI 0.41 to
0.83)
0.3 (95% CI 0.21 to
0.41)
2*2 extracted from
text/graph
Riikonen 1993 50
0.18 (95% CI 0.06 to
0.41)
0.73 (95% CI 0.62 to
0.82)
2*2 extracted from
text/graph
CRP: Documented & Clinical Infection
Spasova 2005 20 1 (95% CI 0.87 to 1)
0.06 (95% CI 0.01 to
0.28) mean/sd
Spasova 2005 50
0.92 (95% CI 0.75 to
0.98) 1 (95% CI 0.81 to 1) mean/sd
Spasova 2005 90
0.44 (95% CI 0.27 to
0.63) 1 (95% CI 0.81 to 1) mean/sd
Secmeer 2007 50
0.68 (95% CI 0.48 to
0.83)
0.46 (95% CI 0.3 to
0.62)
sensitivity/specificity
reported
Katz 1992 20
0.71 (95% CI 0.59 to
0.81)
0.32 (95% CI 0.22 to
0.44)
sensitivity/specificity
reported
Katz 1992 50
0.46 (95% CI 0.34 to
0.58)
0.75 (95% CI 0.63 to
0.84)
sensitivity/specificity
reported
Katz 1992 100
0.22 (95% CI 0.13 to
0.34)
0.94 (95% CI 0.85 to
0.98)
sensitivity/specificity
reported
Riikonen 1993 20
0.62 (95% CI 0.43 to
0.78)
0.28 (95% CI 0.18 to
0.4)
2*2 extracted from
text/graph
Riikonen 1993 50
0.15 (95% CI 0.06 to
0.34)
0.71 (95% CI 0.59 to
0.8)
2*2 extracted from
text/graph
El-Maghraby
2007 90
0.69 (95% CI 0.57 to
0.8)
0.73 (95% CI 0.54 to
0.86)
2*2 extracted from
text/graph
Ammann 2003 5
0.97 (95% CI 0.91 to
0.99)
0.12 (95% CI 0.08 to
0.18)
sensitivity/specificity
reported
Ammann 2003 50
0.48 (95% CI 0.38 to
0.58)
0.7 (95% CI 0.62 to
0.77)
sensitivity/specificity
reported
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Santolaya 1994 40
0.95 (95% CI 0.85 to
0.98)
0.77 (95% CI 0.59 to
0.88)
2*2 extracted from
text/graph
Kitanovski 2006 60
0.63 (95% CI 0.39 to
0.82)
0.69 (95% CI 0.56 to
0.8)
sensitivity/specificity
reported
Hitoglou-Hatzi
2005 20
0.9 (95% CI 0.74 to
0.96)
0.21 (95% CI 0.11 to
0.36) mean/sd
Hitoglou-Hatzi
2005 50
0.76 (95% CI 0.58 to
0.88)
0.74 (95% CI 0.58 to
0.85)
2*2 extracted from
text/graph
Hitoglou-Hatzi
2005 90
0.66 (95% CI 0.47 to
0.8)
0.87 (95% CI 0.73 to
0.94) mean/sd
Santolaya 2001 90
0.75 (95% CI 0.69 to
0.81)
0.8 (95% CI 0.75 to
0.84)
sensitivity/specificity
reported
Hatzistilianou
2007 50
0.9 (95% CI 0.8 to
0.95)
0.79 (95% CI 0.63 to
0.9)
sensitivity/specificity
reported
CRP: Gram-ve Bacteramia
Lehrnbecher
1999 20
0.88 (95% CI 0.53 to
0.98)
0.34 (95% CI 0.26 to
0.43)
sensitivity/specificity
reported
Lehrnbecher
1999 50
0.88 (95% CI 0.53 to
0.98)
0.5 (95% CI 0.41 to
0.59)
sensitivity/specificity
reported
Lehrnbecher
1999 100
0.88 (95% CI 0.53 to
0.98)
0.78 (95% CI 0.69 to
0.85)
sensitivity/specificity
reported
CRP: Death
Santolaya 2007 90
0.79 (95% CI 0.52 to
0.92)
0.61 (95% CI 0.56 to
0.66)
2*2 extracted from
text/graph
CRP: Sepsis
Katz 1992 20 1 (95% CI 0.65 to 1)
0.32 (95% CI 0.24 to
0.41)
sensitivity/specificity
reported
Katz 1992 50
0.71 (95% CI 0.36 to
0.92)
0.67 (95% CI 0.58 to
0.75)
sensitivity/specificity
reported
Katz 1992 100
0.71 (95% CI 0.36 to
0.92)
0.71 (95% CI 0.62 to
0.79)
sensitivity/specificity
reported
Santolaya 2008 90
0.54 (95% CI 0.45 to
0.63)
0.63 (95% CI 0.59 to
0.67)
2*2 extracted from
text/graph
PCT: Documented & Clinical Infection
Secmeer 2007 0.1
0.2 (95% CI 0.09 to
0.39)
0.74 (95% CI 0.58 to
0.86)
sensitivity/specificity
reported
Secmeer 2007 0.2
0.12 (95% CI 0.04 to
0.29)
0.89 (95% CI 0.74 to
0.95)
sensitivity/specificity
reported
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Secmeer 2007 0.3
0.11 (95% CI 0.04 to
0.28)
0.94 (95% CI 0.81 to
0.98)
sensitivity/specificity
reported
Secmeer 2007 0.4
0.07 (95% CI 0.02 to
0.23)
0.94 (95% CI 0.81 to
0.98)
sensitivity/specificity
reported
Hitoglou-Hatzi
2005 0.55
0.97 (95% CI 0.83 to
0.99)
0.58 (95% CI 0.42 to
0.72) mean/sd
Hitoglou-Hatzi
2005 0.1
0.97 (95% CI 0.83 to
0.99)
0.47 (95% CI 0.32 to
0.63) mean/sd
Hitoglou-Hatzi
2005 0.2
0.97 (95% CI 0.83 to
0.99)
0.5 (95% CI 0.35 to
0.65) mean/sd
Hitoglou-Hatzi
2005 0.3
0.97 (95% CI 0.83 to
0.99)
0.5 (95% CI 0.35 to
0.65) mean/sd
Hitoglou-Hatzi
2005 0.4
0.97 (95% CI 0.83 to
0.99)
0.53 (95% CI 0.37 to
0.68) mean/sd
Hatzistilianou
2007 0.2
0.97 (95% CI 0.89 to
0.99)
0.97 (95% CI 0.85 to
0.99)
sensitivity/specificity
reported
Kitanovski 2006 0.55
0.94 (95% CI 0.72 to
0.99)
0.71 (95% CI 0.58 to
0.82)
sensitivity/specificity
reported
PCT: Sepsis
Santolaya 2008 2
0.57 (95% CI 0.48 to
0.66)
0.46 (95% CI 0.41 to
0.5) mean/sd
PCT: Bacteraemia
Kitanovski 2006 0.1
0.33 (95% CI 0.1 to
0.7)
0.78 (95% CI 0.65 to
0.87)
sensitivity/specificity
reported
Kitanovski 2006 0.2
0.33 (95% CI 0.1 to
0.7)
0.89 (95% CI 0.79 to
0.95)
sensitivity/specificity
reported
Kitanovski 2006 0.3
0.33 (95% CI 0.1 to
0.7)
0.93 (95% CI 0.83 to
0.97)
sensitivity/specificity
reported
Kitanovski 2006 0.4
0.33 (95% CI 0.1 to
0.7)
0.95 (95% CI 0.86 to
0.98)
sensitivity/specificity
reported
IL6: Gram-ve bacteraemia
Lehrnbecher
1999 235 1 (95% CI 0.82 to 1)
0.63 (95% CI 0.53 to
0.72)
sensitivity/specificity
reported
Lehrnbecher
2000 1000
0.74 (95% CI 0.51 to
0.88)
0.96 (95% CI 0.9 to
0.98)
sensitivity/specificity
reported
IL6: Documented & Clinical Infection
Kitanovski 2006 235
0.88 (95% CI 0.64 to
0.97)
0.87 (95% CI 0.75 to
0.93)
sensitivity/specificity
reported
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Riikonen 1992 235
0.1 (95% CI 0.03 to
0.3)
0.98 (95% CI 0.91 to
1)
2*2 extracted from
text/graph
Riikonen 1992 1000 0 (95% CI 0 to 0.16) 1 (95% CI 0.94 to 1)
2*2 extracted from
text/graph
Lehrnbecher
2004 235
0.89 (95% CI 0.82 to
0.94)
0.91 (95% CI 0.86 to
0.94)
sensitivity/specificity
reported
Lehrnbecher
2004 1000
0.11 (95% CI 0.06 to
0.18)
0.99 (95% CI 0.97 to
1)
sensitivity/specificity
reported
Diepold 2008 42
0.9 (95% CI 0.81 to
0.94)
0.86 (95% CI 0.69 to
0.94)
sensitivity/specificity
reported
IL6: Bacteraemia
Diepold 2008 240
0.64 (95% CI 0.39 to
0.84)
0.75 (95% CI 0.65 to
0.82)
sensitivity/specificity
reported
IL8: Sepsis / Prolonged illness
Santolaya 2008 200
0.49 (95% CI 0.4 to
0.58)
0.71 (95% CI 0.67 to
0.75)
2*2 extracted from
text/graph
Diepold 2008 30
0.87 (95% CI 0.78 to
0.93)
0.61 (95% CI 0.42 to
0.76)
sensitivity/specificity
reported
IL8: Bacterial infection
Diepold 2008 90
0.64 (95% CI 0.39 to
0.84)
0.62 (95% CI 0.52 to
0.71)
sensitivity/specificity
reported
IL8: Documented & Clinical Infection
El-Maghraby
2007 62
0.71 (95% CI 0.59 to
0.81)
0.77 (95% CI 0.58 to
0.89)
2*2 extracted from
text/graph
Lehrnbecher
2004 320
0.56 (95% CI 0.46 to
0.65)
0.79 (95% CI 0.73 to
0.84)
sensitivity/specificity
reported
Lehrnbecher
2004 500
0.44 (95% CI 0.35 to
0.54)
0.89 (95% CI 0.84 to
0.93)
sensitivity/specificity
reported
To illustrate the methods and associated challenges, syntheses were undertaken using both
classical and Bayesian approaches.
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Method 1 Classical statistical analyses
Data were combined using a single cut-off from each study using the STATA routines
metandi and midas for analyses of 3 studies and over. For analyses of four or more
studies, a random effects linear regression using xmelogit was fitted for bivariate
estimates.
The HSROC curve (Figure 22a) derived from 11 studies [27, 79, 139, 159-160, 163, 169, 173,
176, 179, 184] demonstrates moderate diagnostic ability for CRP to detect ‘documented
infection’ (Area under the ROC curve 0.78 (95% CI 0.74 to 0.81)). This assumes that a higher
cut-off produces a lower sensitivity and higher specificity. However, the plot demonstrating
each study’s cut-off (in mg/dl) shows that the assumption of threshold variation is not
adhered to (Figure 22b): rather than the threshold value steadily falling from high cutoff
values in the bottom left through middle values in the mid-point of the curve, to low values
in the upper right, we see values of 50 and 60 preceding 90. This should raise doubts about
the validity of the summary ROC curve produced. As demonstrably different thresholds are
used in creating this pooled analysis, the production of a single bivariate estimate of the
‘test effect’ is clearly meaningless.
a) Circles weighted according to study precision b) Marker points showing threshold (mg/dl)
Figure 22:HSROC curve plots of CRP for the diagnosis of ‘documented infection’
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Analysis of PCT[163, 173, 179, 184] suggest a better discriminatory ability (Area under the
ROC curve 0.93 (95% CI 0.90 to 0.95)). Though based on only two different cut-offs, the
threshold findings are replicated in the PCT data (Figure 23).
While this finding represents only a pair of markers across one outcome, this should raise
doubts about the validity of the technique of HSROC determination, which assumes
threshold values will follow an expected path, when data about the actual threshold are
available and could be used more effectively by an alternative meta-analysis technique.
a) Circles weighted according to study precision b) Marker points showing threshold (mg/ml)
Figure 23: HSROC curve plots of PCT for the diagnosis of ‘documented infection’
For studies with similar outcomes and cut-off values, meta-analysis was undertaken using a
random effects bivariate approach. Data were sufficient to undertake this in two outcome
groups over three markers (see Table 11: Bivariate estimates of diagnostic precision of
various markers and outcomes and Figure 24).
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Table 11: Bivariate estimates of diagnostic precision of various markers and outcomes
Marker Outcome Cut-off
Sensitivity
(95% CI)
Specificity
(95% CI)
CRP
(7 studies)
Documented
infection
>50 mg/dl
0.65 (0.41 to
0.84)
0.73 (0.63 to
0.82)
PCT
(3 studies)
Documented
infection
>0.2 mg/ml
0.96 (0.05 to
0.99)
0.85 (0.53 to
0.97)
IL6
(3 studies)
Documented
infection
>235 pg/ml
0.68 (0.15 to
0.96)
0.94 (0.84 to
0.98)
IL6
(2 studies)
Gram –ve
bacteraemia
>1000 pg/ml
0.78 (0.57 to
0.91)
0.96 (0.92 to
0.99)
Figure 24: Bivariate pooled estimates of sensitivity and specificity for CRP, PCT & IL6
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There is considerable heterogeneity in these results; sensitivity being the most
heterogeneous in all markers, and specificity being most heterogeneous in PCT and CRP.
Method 2. Prediction within a Bayesian framework
Meta-analysis of data for IL6, PCT and CRP was attempted for documented infections using a
similar approach to that used in the clinical decision rules review.
The analysis of data from the IL6 studies to predict documented infection demonstrated a
very wide range of average estimates of diagnostic accuracy. In particular, the uncertainty
around the proportion of individuals with disease/non-disease in the groups 235-1000pg/ml
and >1000pg/ml led to the median estimates reversing the ‘sensible’ order of results,
implying that higher levels of IL6 were less likely to be associated with disease. (LR
<235pg/ml 0.35 (95% CrI 0.02 to 0.96), LR 235-1000pg/ml 9.54 (95% CrI 0.02 to infinite) and
LR >1000pg/ml 8.0 (95% CrI 0.05 to 9.8). The heterogeneity between individual study
estimates is extreme, particularly for sensitivity, where one of the three available data
points for 235pg/ml overlies the cut-offs at 1000pg/ml. Meta-analysis is therefore
inappropriate (see Figure 25).
Figure 25: IL6 for documented infection
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Analysis of the four PCT studies and eleven CRP studies proved impossible using this
analytical technique.
The data from the four PCT studies show extreme heterogeneity in sensitivity and specificity
(see Figure 26). In order to reduce the variables under consideration, the cut-offs analysed
were limited to 0.2pg/ml and 0.55pg/ml, but this still require six data points (vs. seven in the
IL6 example) to provide information on seven independent variables (a total of three
proportions in diseased and undiseased populations, and four variance-covariance
estimates). Assessments based on such limited data tend to be very unstable.
Figure 26: PCT for documented infection
Attempts to reduce the variables to be fitted further, by simplification to an assumption of a
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effects model did not succeed, probably as some simulation instances require the
(nonsensical) reversal of the arrangement of proportions of individuals in the ordered
categories and occasionally ‘negative’ proportions.
Similar problems were encountered when attempting to fit the model to the eleven studies
with CRP values for documented infection (see Figure 27). Here reduction to three cut-offs
was undertaken (20, 40-60, 90-100) along with univariate and fixed effects approaches. The
model produced extremely uncertain results, particularly estimating the proportion of
individuals with disease/nondisease whose CRP ranged from 40 – 100 (between cutoff 2 and
3) where the 95% “credible” interval ranged from -3% to +39%.
Figure 27: CRP for documented infection
Performance
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156, 163, 169, 174]) and additionally five interleukin-8 (IL-8) studies [156, 166, 168, 176,
185] in their ability to detect significant infection.
The pooled estimates remain clinically and statistically heterogenous, with the most
appropriate and advanced synthesis technique (multiple threshold approaches using a
Bayesian multinomial framework) producing clinically uninterpretable results (see Table 12
and Figure 28).
Table 12: Multivariate meta-analysis of biomarkers to detect significant infection (clinically or microbiologically
documented infection)
Threshold Likelihood ratio 95% credible interval*
CRP
CRP <20 mg/dL 0.25 0.07 to 1.14
CRP 20-50 mg/dL -0.44 -8.81 to 8.27
CRP 50-90 mg/dL 0.39 -1.04 to 2.77
CRP >90 mg/dL 2.41 0.87 to 16.74
PCT
PCT <0.2 ng/mL 0.42 0.009 to 2.1
PCT 0.2-0.5 ng/mL -0.11 -22 to 23
PCT >0.5 ng/mL 3.1 0.9 to 8.8
IL-6
IL-6 <235 pg/ml 0.353 0.005 to 1.052
IL-6 235-1000 pg/ml 7.981 -1.669 to 65.45
IL-6 >1000 pg/ml 7.05 0 to 1699
IL-8
IL-8 <60 pg/ml 0.3 0.12 to 0.59
IL-8 60-320 pg/ml -0.95 -14.55 to 7.34
IL-8 320-500 pg/ml 0.31 0.06 to 3.89
IL-8 >500 pg/ml 9423 0.02 to 1.19E+10
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Figure 28: ROC plots of biomarkers detection of infection
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Additional studies provided information that could not be incorporated into the meta-
analysis, the details of which are given in Appendix 13. PCT was further examined and shown
to have moderate sensitivity (66%) and specificity (85%) with a very high study-defined cut-
off of 3.3 ng/ml in patients with bacteraemia [174], had different median values between
septic and non-septic patients (0.5 vs 0.24 ng/ml)[30], or baldly stated to be associated with
significant infectious complications in a multivariate analysis [190] (but all had insufficient
data to produce variance estimates). An early study examined the values of PCT levels in
patients with short (<5 day) and prolonged admissions and demonstrated a difference in
means[170]. The other study to report PCT values [161] did so in only the high-risk group of
patients, and failed to find a difference in mean values at admission or 24 hours.
CRP was also reported in studies that could not be added to the meta-analysis because of
they provided insufficient data to calculate variances [22, 158, 172, 177, 183, 186-187, 191].
These studies also produced a range of point estimates, generally indicating a small increase
in average values in those patients with adverse infectious outcomes, compared to those
without. Where entered into multivariable models [22] CRP did not have any independent
predictive value.
IL6 and IL8 were examined in a small number of additional studies. An analysis of all-age
patients demonstrated an independent predictive value for IL8 and IL6 [158] against a
limited range of clinical variables, and both were shown to be significantly higher in patients
requiring ICU admission [145]. A study examining multiple cytokines found a higher median
IL8 value in bacteraemic patients (0.3 vs 0.02 ng/ml) and showed this varied by the type of
organism isolated (gram negative bacteria
0.91 vs gram positive 0.13 ng/ml) [164]. A similar finding was reported by Strewjeski [30]
showing 0.45 ng/ml vs. 0.15 ng/ml IL8 median values when using a broader definition of
bacteraemia and culture negative sepsis. Santolaya’s group also examined IL8 values [161] in
the high-risk group of patients, and failed to find a difference in mean values at admission or
24 hours. IL6 was examined in distinguishing bacteraemia and was reported as showing
around 65% sensitivity and 70% specificity with a data derived cut-off of 137 pg/ml. [174]
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One study (reported as an abstract) showed a combined result for IL5 and IL8 of “sensitivity
0.88, specificity 0.48” but no cut-offs were given [165], and when compared with an earlier
report of 100% sensitivity and 88% specificity [177], this in keeping with the general trend of
decreasing accuracy with repeat assessments of tests.
There are a range of other novel biomarkers under limited investigation that have been
revealed by these reviews. These data are reported in detail in Appendix 13. These are very
sparse, based on one or two studies, and clinical conclusions cannot be reasonably drawn
from them.
Trajectory of biomarkers
Six studies explored the role of serial biomarkers to detect documented infection or
sepsis.[173, 180] [157, 189, 192-194] There were insufficient data available for meta-
analysis. In one study, the difference between mean CPR, PCT and IL-8 at 24 hours in
children with and without sepsis was more pronounced than at presentation.[157] Similarly,
the sensitivity of PCT in predicting bacterial infection was higher at 24 to 48 hours compared
with presentation in another study.[194] These finding are in keeping with the results of the
clinical decision rules where a 24h+ assessment has been performed.[144, 154] In the study
by Hatzistilianou et al the seven-day trend of PCT and CRP was depicted graphically and PCT
showed a more rapid decline in patients treated for bacterial infection as compared to
CRP.[192]
Four studies provided direct comparisons of the discriminatory power of admission values of
PCT and CRP.[157, 192-193, 195] Three of these studies reported area under the receiver
operator curve (ROC) estimations.[192-193, 195] In these three, the data showed PCT
consistently had a better discriminatory estimate than CRP with AUC range of 0.66 to 0.869
compared with 0.43 to 0.728. The fourth study reported no significant benefit of PCT over
CRP.[157] Procalcitonin also had higher discriminatory power than IL-6 in one study[195] and
Il-8 in another,[192] which was not confirmed in a further study.[157] Meta-analysis of these
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direct comparisons of diagnostic accuracy assessments was not possible from the data
available.
Conclusions
This series of systematic reviews of clinical decision rules studied patients with a wide range
of malignancies and including between 29 and 759 patients (median 132) per study and with
between 47 and 1117 episodes of febrile neutropenia per study (median 240). The
biomarkers reviews included 4689 episodes of FN, investigating 24 different makers of
inflammation or infection (14 biomarkers from original review; additional 10 updated
review). The following Chapter explores the implications of these data and identifies where
they point to the development of an IPD meta-analysis.
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Chapter 5: Discussion of the results of systematic reviews of Clinical
Decision Rules and Serum Biomarkers
A robust risk stratification model that reliably predicts which children are at very low or very high
risk of having a significant infection could have important implications for clinical care. Those at very
low risk could be treated with reduced intensity antibiotic therapy and spend a shorter period in
hospital. Those at high risk of complications could be targeted for more aggressive management.
While the systematic reviews were being conducted for this thesis, there was clear evidence of many
differing policies for the management of FNP in practice [51, 53] with lack of agreement about how
risk stratification, if any, was used.
The previous chapters presented the methods and results of a series of systematic reviews with
updates assessing and summarising existing research evidence. These studied clinical examination to
identify infectious complications; and the value and added value of specific serum biomarkers in this
regard.
Studies were reviewed for their ability, as diagnostic tests, to accurately differentiate groups of
patients who did and did not have the condition of interest. Appraisal was undertaken using the
QUADAS criteria for quality. Synthesis of these data were undertaken, where possible, to provide the
most accurate estimates of predictive accuracy available. Poor quality of execution and design of
studies may produce problems which introduce bias (systematic difference) or significant variation
that limits the generalisability of a study’s findings. In studies of a diagnostic test, these may be
categorised as: those which arise from the population studied; the technology used in undertaking
the testing; the outcome assessments made; and the nature of the test interpretation [74]. Although
clinical examination in the rules described here did not raise issues around the technologies used, it
does raise a potential issue with studies of multiple individual investigators undertaking a ‘physical
skill’. Some physicians are likely to have better auditory or tactile discrimination, and there will be
differences between them in the accuracy of their measurements (for example, the reproducibility
of precise auditory findings in chest examination is poor [196]). Technical issues about the
reproducibility of measurements of biomarkers were raised in the third group of reviews, though the
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use of similar quality-assured techniques for the common and commercially available tests
constrains these problems.
Studies using clinical features to predict infectious complications
The development and verification of clinical decision rules to predict significant infectious
complications were studied in a systematic review that was updated during the development of
national[128] and international guidelines [129]. The review was updated specifically in response to
the international guideline, as part of my role as Chair of the risk stratification section of the
guideline.
The studies examining clinical decision rules to predict infectious complications produced 21 models,
and contained eleven datasets used to validate previously derived models. They studied a variety of
outcomes, with individual differences in definitions, but covered five main categories: death, critical
care requirement, serious medical complication, significant bacterial infection, and bacteraemia.
The validity assessment undertaken suggests that the biases in study design were relatively minor.
The most common was a potential for clinical review bias, where clinical information may lead to
one final outcome being favoured unfairly over another, which occurred in 19 of the 26 studies.
However, the potential effect of this is mitigated by the largely objective nature of the outcomes, for
example: microbiologically positive blood culture results, severe sepsis and death. Evidence for the
theoretical reduced influence of study design on objective outcomes is present for therapeutic
studies [75], but not for those of diagnostic accuracy [74]. Partial verification bias may technically be
a threat to studies in which certain ‘outcome assessment tests’, for example swabs of lesions were
undertaken only when clinically indicated, but these are clinically reasonable variations and unlikely
to lead to a strong bias. If a lesion is not present to be swabbed, it cannot be the unidentified source
of an infection.
Two potential problems are in the use of aspects of the outcome assessment in the decision rule [19,
23, 153]. This was most marked in the Alexander study [23] where the outcome of ‘significant
medical complication’ included ‘hypotension and severe mucositis’, as did the rule describing high-
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risk. This incorporation bias leads to diagnostic tautology, theoretically improving the accuracy of a
‘test’ [74]. The results from this study are likely to be overly optimistic.
The studies which set out to derive a CDR varied in their populations, the number and type of
outcomes studied, variables assessed, model-building technique, reporting and handling of missing
and multiple-episode data and in the use and categorisation of continuous and categorical variables.
All of these features may have influenced the CDRs produced and provide some explanation of the
differences between them.
Building stable predictive models requires between 10 – 20 events per variable considered [84] and
while some argument has been made to relax this value [197] these simulation studies have only
examined single predictors rather than the multiple predictors used here. We found that 76% of the
CDR derivation studies had less than ten events per variable under consideration, and no study had
more than 14 events per variable. The small sample size makes models more likely to be overfitted
to their original dataset and disappointing in clinical practice [83]. Only one study [140] modified
model parameters to account for the small sample size and low number of events per variable.
The technique used to build the model is also extremely important. There are a number of families
of techniques, including multivariable regression, neural networks and classification and regression
trees (CART models). No clear superiority for one technique has been demonstrated [78]. Of the
studies that derived CDRs in this review, almost all were built using multivariable regression. One
model used CART techniques [79] alongside a logistic regression and came to different conclusions
from the same dataset. This highlights an acknowledged difficulty with model building (that differing
techniques may reach different conclusions from the same information without it being clear which
is the ‘most correct’.
The models all assumed linear relationships between the outcome and the explanatory variables,
but for some variables relationships have different forms. A classic example of a non-linear
relationship is the S-shaped curve of oxygen dissociation from haemoglobin, or the J-shaped
associations of body-mass index and mortality. It is not clear in these studies if this assumption of
linearity of the variables was assessed, but failing to do so may misjudge a predictor as unimportant
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[198]. There are plausible reasons to assume that patient age may have a non-linear ‘U’-shaped
relationship with infection and outcome [199], as should time-from-chemotherapy. Bone marrow
suppression may have a more complex influence upon likelihood of infection than a simple linear
relationship (for example of non-linear relationships, see Figure 29a & b).
Figure 29: Examples of non-linear relationships
a) y = 1-x
2
b) y = –ln(x)
The relationships shown in Figure 29 are inventions, and extreme, in that they proposes that the risk
of infection (y axis) is always present with ‘zero’ neutrophils (x axis). Figure 29a supposes that the
risk is at a very high level, a near plateau, when the count is below around 0.175. This could be
justified by a hypothesis which requires a certain number of circulating cells to be present for
adequate infection surveillance. Figure 29b supposes that there is a log-linear inverse relationship,
with the risk relating not to a straight line of the neutrophil count but to the natural log of the count.
This could well be possible if the neutrophil count was log-normally distributed.
The selection of variables for the final model is crucial. Selections can be performed by taking all
possible explanatory variables, and excluding those which are not statistically significant (backwards
elimination), or by adding, one-by-one, the most statistically significant individual factors (forwards
selection), or a combination of the two, adding and removing variables to build the statistically best
fitting model (stepwise). These techniques, when selection is driven by a ‘p-value’ are seriously at
risk of choosing variables with chance relationships and resulting in unstable models [81]. These
techniques will also exclude variables that confound each other from entering a multivariable
analysis [82]. This happens if two variables which measure very highly related parameters (for
example, the concentration of haemoglobin in the blood – which is carried within red blood cells,
y
x
x
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and the red cell count) are both related to the risk of infection, any model which uses one of these
will show the variable to be significant and important. If the model uses both, the ‘strength’ of each
will be mopped up as the model attempts to account for the other variable, making both appear
‘insignificant’. In essence, although selecting variables only by looking at how significantly they are
associated with outcomes in the dataset being examined produces highly effective descriptions of
that data, it doesn’t improve the ability of the model to describe the real population from which
those data were drawn [83]. Only one of the models clearly examined co-linearity; the issue of
multiple variables being highly correlated which may account for the differing ‘marrow suppression’
markers being used in different CDRs.
When moving beyond the very first stages of exploration in a new area, variables should be selected
on the basis of clinical evidence or physiological reasoning [85]. In these studies, this was stated to
be the case in seven of the studies, and although unstated in the others, the selection of similar
variables implies congruent thinking. This could ameliorate the potential inflation of results.
Continuous variables, such as age, blood pressure and absolute monocyte count, will have their
most accurate predictive value in a model if used as their actual value. Clinicians seem to find the
use of continuous variables in this setting uncomfortable, and prefer to use categorised values.
Repeated studies examining prognostic model building have shown that the collapsing of continuous
variables into ordinal categories or dichotomies is often undertaken using methods which are highly
likely to give spurious results. [78, 80] The problem comes from analyses where a particular set of
data is examined, by looking at the ROC curve or recursive partitioning analysis, to find the cut-point
that achieves greatest differentiation between the diagnostic or prognostic categories. In doing this,
effectively multiple tests are being undertaken and the reported p-value associated with the final
choice is likely to be a gross exaggeration of the true ‘significance’ of the value. Approaches using
clinically or pathophysiologically meaningful values, or ones previously described, avoid these
problems. The choice of how to group categorical variables may give rise to similar problems. In the
studies where an explanation is given are evaluated, the decisions seem to have been made with a
combination of data-driven ‘optimal’ cut-points then modulated to give clinically sensible numbers
(e.g. Rackoff [141] and the use of 100 cells/mm
3
as a cut-off for absolute monocyte count).
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A further issue is the assumption of independence that underlies most of the techniques used. In 12
studies, multiple episodes in individual patients are treated as if they come from unconnected
individuals. Underlying this needs to be the chance of the first, second, third etc. episodes having the
same outcome: this clearly cannot be the case if one of the outcomes under consideration is death.
In studies that undertook a further analysis which looked at only the ‘first case’ and found ‘no
significant differences’ between the approaches, they used this as justification for assuming
independence, but this is likely to be underpowered for the rarer outcomes of death and severe
infectious complications. Other approaches to address this problem include the use of only first
episode data. This has the disadvantage of decreased numbers of episodes analysed and consequent
decreased power and efficiency. Four studies reported the use of extended modelling techniques
that assessed and accounted for clustering to try to avoid such problems. No study reported the
degree of interpersonal and intrapersonal variability to quantitatively estimate the degree of bias
introduced by undertaking the simplistic approaches, and so it becomes difficult to assess the
potential error introduced.
The way that missing data are handled can also introduce bias and reduce efficacy. Data can be lost
or go missing in ways that introduce bias, or in ways that do not introduce bias but reduce the
efficacy of the study. Non-biased data loss, for example by the bad luck of a power failure in the lab
meaning a blood test can’t be analysed, is described as “missing completely at random” (MCAR). The
data are missing for no reason but random chance. Potentially biased missing data comes in two
sub-categories: the first is where the missing element is intimately linked to something known and
recorded, for example the patient’s condition meaning arterial blood gas measurements are
available on only the sickest children in a cohort. These missing values, which are related to other
known and measured factors, are confusingly called “missing at random” (MAR). These missing data
are potentially imputable from the data that exists. The second sub-category of bias-inducing data
loss is where there is no possibility of linking the missing data to known items. For example, it may
be that patients presenting during the first few weeks of a new physician joining a hospital team are
less likely to have all the correct blood tests done as the admitting doctor is not familiar with the
study protocol. There will be a systematic difference between those with missing data and those
without (new doctor versus experienced doctor) but the reason why the data were missing is not
linked to anything the researchers can know (assuming no-one tells them the doctors changed jobs).
This type of bias-inducing missingness is called “missing not at random” (MNAR).
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The CDR derivation studies described how missing data were handled in only eight of the 21 studies.
In six of these a form of complete case analysis was used. No study details an assessment of the type
of missingness of the data. While MCAR cases can be ignored, using a ‘complete case’ or ‘available
case’ analysis, it reduces the number of episodes, but doesn’t introduce bias. However, undertaking
this type of ‘available case’ analysis when there is a MNAR or MAR problem introduces a form of
selection bias. The development of imputation techniques, where the missing elements are
replaced by one of a number of reasoned methods, provides a way of increasing the efficiency of a
study without introducing bias when data are MAR.[200] No study used such techniques, though it
should be acknowledged that these approaches are not without problems. [201]
The CDR to predict infectious complications had diverse test performance across diverse outcomes.
Initial hypotheses to explain the differences included: the design of the study, the population (both
geographical and case-mix), the complexity of the rule and outcomes chosen. Tabular and graphical
analysis, supplemented by minimal quantitative data, supported the following assertions: validation
studies produced estimates of lower test accuracy and rule complexity, case-mix did not clearly
explain differences between test performance, and geography appears very important. Differences
related to the outcome of interest may be present, with rules to predict infectious complications
being more sensitive and less specific, rules to predict death/ICU admission being more specific but
less sensitive, and rules predicting bacteraemia spanning a range of results, although this was
difficult to separate from the other proposed factors.
Where the aim was to define a group of patients who would not develop adverse outcomes from
their episode, high sensitivity (capturing all the diseased individuals within the high-risk category)
was of primary importance. This would enable those in the low-risk group to be treated with
reduced intensity, without concern of ‘missing’ patients who would develop problems. There
remains a need to trade off sensitivity against specificity (as discussed earlier): the most sensitive
rule would be to call all patients ‘high risk’. This would result in no missed adverse outcomes, but
would over-treat a large proportion of patients.
The performance of the AMC/Temperature criteria proposed by Rackoff [141] to exclude
bacteraemia was assessed across multiple datasets. This model, being tested by different groups
across time and in different centres, has the greatest strength of evidence. The most appropriate
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pooled estimate of the rule’s effectiveness comes from a random effects model assuming no
threshold variability, and excluding both the derivation sample and an outlying study using a
different outcome definition. This led to estimates of moderate discriminatory ability LR [low] = 0.26
(95% CrI 0.08 to 0.72) , LR [medium] =0.72 (95% CrI 0.14 to 2.15), and LR [high] = 3.11 (95% CrI 1.25
to 8.01); a low-risk result led to the odds of infection being roughly one quarter of the overall
prevalence, a medium risk result was associated with a marginally reduced chance, and a high-risk
result approximately three times the odds of an infection being diagnosed.
The exclusion of the derivation sample is justified as this data produced the rule, and would always
improve accuracy (this was also demonstrated in reviewing the test performance of individual
studies). The single non-US study excluded showed a strikingly lower utility for the rule; this differs in
geographical area and reports the wider outcome of ‘documented microbiological infection’ rather
than a narrow bacteraemia diagnosis. As explored above, resolving the reasons for this
heterogeneity is very difficult within this group of studies.
The technique used to summarise the data from the data sets used a Markov-chain Monte Carlo
approach to estimate the proportions of bacteraemic and non-bacteraemic patients in each risk
group. Data from studies which used a similar rule but provided only low versus medium/high risk
categories [12, 69] were also included in this analysis. These proportions were used to calculate
likelihood ratios for each risk category and corresponding 95% credible intervals were derived from
the posterior probability distributions. This analysis technique accounts for heterogeneity due to the
sampling variation within populations, and variation of sampling from different populations.
Multivariate models were investigated to assess how well they ‘fit’ the data under investigation.
Compared to the simple assumption of a random effect variation between studies independently in
affected (outcome positive) and non-affected individuals, two layers of multivariate model were
tested. The first proposes a bivariate relationship between the cut-offs within each study: that is,
that the population of ‘low’, ‘middle’ and ‘high’ risk individuals may vary differently in each study
and is best estimated by two random-effect variables. The second attempts to model a further layer
of heterogeneity: connections between the differences in the affected and unaffected populations
across the studies. This is usually explained as different cut-off thresholds for the tests actually
applied in different studies. In the analysis undertaken here, the test cut-offs are explicit and
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objective (AMC >100, or AMC <100 with maximum temperature measured as either under or over
39°C), with minimal room for intra-study variability in how the rule is applied, and so there is
minimal or no threshold variation. The data produced by these three models showed that there was
a benefit from multivariate modelling within the affected/unaffected populations, as measured by
the Deviance Information Criterion (DIC). The DIC is a value representing how poorly the data fit the
statistical model, with lower numbers indicating a better fit. It has no direct, absolute,
interpretation; rather should be interpreted to inform the choice of models that produce the lowest
DIC. In this case, the multivariate modelling technique reduced the DIC from 180 to 105. Adding
further complexity to the procedure did not reduce the DIC any further, and a combination of the
statistical and theoretical advantages of the second technique led to this being the favoured
approach.
The study of one other model is worth noting particularly. The Santolaya model showed a good
ability to differentiate between low- and high- risk groups when considering a wider definition of
‘serious infection’ where it was developed and tested in Chile; LR [low] = 0.17 (95% CI 0.12 to 0.23),
LR [high] =2.87 (95% CI 2.43 to 3.38). However, when the rule was applied to data collected in
Europe it showed very poor discriminatory ability, well outside of that expected by chance variation.
This highlights the need for models to be evaluated within different geographical settings, as
undetermined factors may vary the diagnostic utility.
Unlike the first review, which focussed fully upon CDR at the point of presentation with FN, the
update review also examined CDR with applied criteria to information applied beyond this. These
showed that re-evaluation at eight to 16 hours [144] or 48 hours [154] was more efficient that initial
examination, probably explained by the declaration of initially occult infections within the first few
hours of admission.
Studies using biomarkers to predict general infectious complications
The predictive value of serum markers of inflammation and infection in children presenting with
febrile neutropenia was studied in an updated systematic review that included a total of 38 studies,
examining 24 biomarkers. Of these, 37 provided quantitative data and 22 studies could be included
in the meta-analyses.
Page 114 of 410
Figure 30: ‘Inch -deep, mile-wide' approach to biomarker investigation
The studies presented similar methodological challenges to the decision rules review and had
problems of reporting and analysis.
It was seldom reported if the test was interpreted ‘blind’ to the results of the outcome analysis, and
vice-versa. Most studies failed to assess if the marker had any supplementary value over and above
the simple admission data or clinical decision rules. In itself this does not undermine the
interpretation of the predictive value of the marker; it merely reduces the ability of the healthcare
practitioner to understand how to value this information when combined with the clinical
knowledge they already possess.
As with the clinical decision rules, analysis of the data was frequently undertaken at the level of
independent episodes, taking no account of the potential of multiple admissions for the same
patient being present. When undertaken, the comparisons used appeared underpowered to detect
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small but meaningful differences. Missing data were not examined for the nature of their absence,
and no attempt at imputation was reported.
The studies frequently used different test cut-off values to report their findings, and these were
largely driven by the dataset from which they were then applied. In these cases, the estimates
produced are likely to be significant overestimations of accuracy, as data driven choices best
describe the dataset they are derived from rather than estimate the data structure of the wider
population. The use of previously defined cut-off values (in six studies) probably provides more
trustworthy estimates. Unlike the CDR reviews, there were moderate event-per-variable ratios and
few assessments of multiple outcomes within these studies as generally a limited number of
potential predictors were under investigation.
Quantitative pooling of the results of the studies presented challenges of sparse data in specific and
different subgroups, producing great uncertainty in pooled estimates.
In the included studies, a series of cut-off levels are reported to predict selected outcomes with the
marker in question. Pooling these different levels into a single estimate of ‘test effect’ is
meaningless: the estimated sensitivity and specificity do not have a clear relationship to a
measurable cut-off value. One approach would be to only use a single cut-off value, but with so few
data points this ‘wasteful’ approach is extremely unhelpful. A more useful approach is to create a
hierarchical summary receiver operator curve (HSROC) which describes the average ROC curve
derived from the individual curves produced from each study. In this way, it describes the ‘average’
relationship between a continuous cut-off value and discriminatory ability in the ‘average’
population. This is unlike the setting of artificial scores generated in a clinical decision rule, where
the ordinal cut-offs do not reflect a continuous variable. A reasonable alternative to the HSROC
approach would be to undertake a series of summaries at the variously reported cut-offs, making
sure the data are only used once for each study by creating a series of 2*k tables, where (k-1) is the
number of cut-offs.
The functions used to create the HSROC take the data points from different studies as reflecting a
series of individual ROC curves that vary between studies because of sampling, population and
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threshold variation: the key elements of multivariate meta-analysis. The summary drawn from this
maximises the fit of a curve combining the individual curves: a ‘hierarchical’ summary ROC. The
function does not take into account the actual value of the thresholds. This is frequently reasonable,
as it is impossible to quantify the thresholds used by different operators to call an X-ray ‘positive’ for
pneumonia or a vessel ‘compressible’ on ultrasound examination and so demonstrating blood flow
and ruling out thrombosis. In cases where the values are known though, an ordered relationship
should be possible to determine.
A technique to undertake this ordered pooling was undertaken with the same meta-analysis
technique developed on the systematic review of clinical decision rules for risk prediction in febrile
neutropenia. It estimated the true proportion of diseased or non-diseased individuals in each
category, constraining each cut-off to be generated from data specific to the reported value of the
serum marker, and linking each cut-off with a multivariate normal distribution to reflect different
population samples.
This approach failed to produce meaningful results for the ability of IL6, IL8, PCT or CRP to
distinguish patients who developed a documented infection from those who did not. This is likely to
be due to the massive heterogeneity of the data and the small number of data points available to
estimate a large number of model parameters.
In two studies [79, 139] where adjustments were undertaken for other elements of clinical
information, CRP added to the predictive ability of simple decision rules. Given this, and the
unconfirmed impression of better predictive ability of the other serum markers, it is reasonable to
hypothesise that these will add even greater benefit to clinical decision rules.
Direct comparisons of the different biomarkers were very limited, and unsuitable for meta-analytic
pooling. They suggested that PCT or IL8 may be better than CRP, and that CRP may have a small
additional value above clinical examination. Data for the other markers were too sparse to
reasonably interpret. These conclusions should be read with the understanding that these are
uncertain and unstable, and only small amounts of new data may substantially alter the findings.
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Studies to detect radiographic pneumonia
As a by-product of the initial systematic review of clinical decision rules [113], four studies [149-152]
were identified that examined the role of clinical examination in excluding pneumonia. They were
undertaken in similar clinical populations which allowed meta-analysis of results and pooling of the
higher quality studies using a classical binomial random effects model produced imprecise estimates
of sensitivity 75% (95% CI 56.4% to 93.6%) and specificity 67.9% (95% CI 55.9% to 79.9%).
The implications of these results are that for populations with a similar prevalence of pneumonia
(~5%), the absence of signs or symptoms of infection on clinical examination produces a post-test
probability of pneumonia of about 1.5%. Given low level of risk, this can justify the routine
withholding of chest radiographs to children who do not have signs or symptoms of lower
respiratory tract infection. This will reduce the cost, resource demand and exposure of the child to
radiation. However, the clinician must remember that a number of children will have an occult
pneumonia and chest X-rays undertaken in a patient with an unresolving fever may be fruitful
despite an absence of signs.
The conclusions we reached in a published review [117] were incorporated into national [202] and
international [129] guidelines for the management of FN, which recommend only undertaking chest
radiography in the setting of specific clinical indications.
Conclusions
The reviews undertaken and updated for this project demonstrated that a wide range of CDR for the
prediction of poor outcomes during episodes of febrile neutropenia in children had been derived,
and that there was potential for additional value to be gained from the incorporation of serum
biomarkers. None of the rules identified had been subject to the extensive geographical and
temporal discriminatory validity assessments that mark the highest quality CDR, and many potential
difficulties with different outcomes, variable selection and model building were identified. Many of
these issues arose from the challenges of combining the aggregate information presented in printed
reports of the studies undertaken.
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To maximise the value of the information already collected by these and other cohorts of children
with FN, an individual-patient-data (IPD) meta-analysis was justified. This was required to develop
and test new and existing prediction models; enable the construction of ‘true’ ROC curves based on
the original data; allow comparison and alignment of different clinical outcomes; and accurately
assess the effect of within-patient clustering of episodes. The effective added-value of markers to
clinical rules could also be measured more comprehensively. The next sections of this thesis explore
in detail the theoretical and practical methods used in forming the collaborative and undertaking the
IPD analysis, and report the results of the main analyses in detail.
This intention of this endeavour is to provide a firmer basis for stratified treatment, either in the
context of randomised trials of reducing intensity and duration of therapy for those at low risk of
severe infectious complications, or of novel methods of early support for those at highest risk. Only
in the collation of large quantities of data can we seek to address such questions in this common and
occasionally fatal complication of therapy.
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Chapter 6: Methods for the Individual Participant Data meta-analysis
Previous chapters identified a wide range of rules that have that been developed to predict poor
outcomes during episodes of febrile neutropenia in children who have been treated for cancer.
None of these has been subject to the extensive geographical and temporal discriminatory validity
assessments that mark the highest quality CDR. The systematic review of these existing CDRs
identified many potential difficulties with different outcomes, variable selection and model building
and consequently was unable to reach any firm conclusions. A complementary systematic review of
studies of serum markers used similarly to predict outcome found similar problems of extremely
heterogeneous data and only tentative conclusions could be drawn.
The problems identified are inherent to meta-analysis of aggregate data. Limitations of reporting in
published studies mean that we do not have access to the exact distributions of data, or the full
range of univariable estimates of predictive power. These issues could have been partially addressed
by collecting more detailed summary data from the authors of the original studies. However, this
would not allow cross-study validation of different rules or alternative rule building. To meet these
challenges, and to maximise the value of the information already collected by these groups and in
other cohorts of children with febrile neutropenia, we initiated an international collaborative
systematic review and individual participant data meta-analysis. This was intended to enable us to
develop and test new prediction models in order to provide a firmer basis for risk stratification,
including deriving a simple clinical decision rule, and to test existing rules. Subsequent to this
formulation, treatment trials in this common and occasionally fatal complication of therapy could be
undertaken.
Rationale for individual patient data meta-analysis in risk stratification in
febrile neutropenia
Individual patient data meta-analysis in therapeutic studies has been developed over two decades to
improve the precision and reliability of answers to questions of treatment.[203-204] More recently,
the approach has been promoted for the synthesis of diagnostic[205] and prognostic[206] studies to
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improve the quality of answers to important prognostic questions [111] and matters of diagnostic
accuracy.[207] These techniques have been applied to real world clinical datasets [208-209] where
they have clarified existing understanding of particular prognostic variables and enhanced an
understanding of how different diagnostic tests can be used.[210]
Failure to approach meta-analysis and prediction model building in a coherent and technically sound
way does not just lead to mathematical or statistical problems. Failure to address the problems of
statistical interpretation has clear and real clinical implications.[211] Systematic review and use of
summary prognostic data may be unreliable as the published data may be incomplete (missing vital
information for meaningful meta-analysis)[78], and appear very susceptible to significant publication
bias (with prognostic markers showing ‘highly significant’ responses being more likely to be
published).[212] It has been suggested that the use of IPD in predictive settings may be even more
valuable than in therapeutic reviews.[78]
It has been shown that smaller published studies are much more likely to demonstrate powerful
relationships [71, 109] and nearly all studies of prognostic markers in cancer are ‘positive’.[76] These
problems are compounded by widespread over-citing of articles with high and unrepresentative
predictive values[213] and the selective reporting of specific outcomes with ‘significant’
associations[76].
These problems suggest that the classical systematic review approach will have the potential to
introduce greater problems that it solves, and any approach to such analysis should clearly account
for these potential difficulties. One method is to use a clearly defined and ‘complete’ population of
studies (e.g. the EORTC breast cancer marker studies[214]) another is the use of only large published
studies (e.g. the Fibrinogen Studies Collaboration[215]), both aiming to avoid publication/selective
reporting biases.
In the realm of therapeutic assessments, there is clear empirical research demonstrating that study
design affects outcome.[216] The issues of study design and the introduction of bias have also been
assessed by empirical research in predictive studies, but with less conclusive results. Kyzas has
examined a series of 20 meta-analyses and evaluated how they assessed potential sources of bias,
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and the effect they had on the overall conclusion.[76] This failed to show a significant effect of any
of the study design measures they examined (blinding, prospective/retrospective, outcomes, time
period, assay description or reference). This finding leads to the conclusion that there is no clear
reason to exclude studies purely on the basis of their study design.
Equally important are the harmonisation of study data sets. This will allow the standardisation of
endpoints, where the reports in papers show inconsistent reporting of ostensibly similar outcomes,
or differing assay methods for proposed markers.[78] In a similar way, these benefits apply to issues
of diagnostic accuracy.[210]
A further challenge avoided in the use of IPD is the un-categorisation of continuous outcome
variables, the categorisations of which themselves may have be biased[80], driven by ‘significance’
based testing.
This is allied to the frequent use in primary studies of multiple data-driven analyses. The method
used in the IPD analysis is based on firmly pre-specified potential predictor variables, built upon the
clinical experience of the collaborative group and the systematic reviews explored in the preceding
chapters. This guards against purely data-driven analyses which have a tendency to over-estimate
any predictive value.[111]
In the reviews, we found the studies building a CDR used a large number of variables (median 13,
range 2 to 39) and had a small number of events (median 36, range 4 to 178) with 76% studies
having fewer than ten events per variable under consideration, and no study having more than 14
events per variable. These low event-per-variable ratios make predictive conclusions drawn from
them to be unstable, and estimates of predictive power to be over-optimistic.[83] A collaborative
IPD approach allowed us to consolidate the information and greatly increase the number of events
studied from the same number of predictive variables.
The raw data also allowed a detailed analysis of the clustering of events (multiple episodes per
patient) and variation at the level of the individual patient. This issue is significant when assessing
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the problems identified in the aggregate data reviews. Multiple episodes in individual patients were
treated primarily as if they came from unconnected individuals in most of the CDR and serum
marker studies, which may have been inappropriate.
The functional form of the data, examining a priori non-linear/fractional polynomial relationships,
can be assessed in detail in a large IPD analysis. No study assessed in the systematic reviews
attempted to fit non-linear forms to the data. This was unsurprising, as the development of practical
techniques to undertake this was very recent.[198]
Finally, IPD allowed us to not only test existing rules and combine data which have attempted to
examine the rules, but potentially develop a more robust rule for future use worldwide.
In summary, the key benefits of prognostic IPD analysis generally are that:
 Analyses are not restricted to those of the published results or subgroups
 Analysis techniques, inclusion criteria and outcomes definitions can be standardised across
studies
 Larger numbers of data points allow more powerful statistical conclusions to be drawn,
including checking modelling assumptions
 The detailed data allows assessments to be made to account for missing data at the
individual-level
 IPD can model data more appropriately, for example analysing continuous variables on their
continuous scale (unlike in many prognostic studies, where such variables are reported
categorised)
 Analysis can account for clustering (e.g. of patients within studies) and correlated
information (e.g. multiple events per individual)
 Multivariate models can be created across differing health care settings
 Individual data sets can be reviewed for completeness and accuracy
 The analysis can provide extensive internal cross-validation to guard against data-driven
exaggerations of predictive power
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Forming the Collaborative Group
The “Predicting Infectious ComplicatioNs In Children with Cancer” (PICNICC) collaboration was
formed around a nucleus of an international group of clinical experts who I had met and discussed
potential collaboration as part of the development of the MRC fellowship proposal with. The
systematic reviews described in the preceding chapters identified further key studies and
researchers who were then invited to join the collaborative group.
Oral presentations on the problem of risk stratification in febrile neutropenia at separate
conferences for the Royal College of Paediatrics and Child Health (2009) and the International
Society of Paediatric Oncology (SIOP, 2008) also identified further studies and partners. Parallel to
these approaches to clinicians and researchers, there was an integrated move to include
parents/carers in the Collaboration (see next section). These presentations led to further interested
groups contacting the Secretariat.
Following the SIOP presentation, the slides were placed on the international, though developing-
world focussed, paediatric oncology website "Oncopedia". From this, I was approached by three
more groups and located another group working on FNP stratification and through a mutual
colleague, approached the main author, who also agreed to join the collaborative. The Centre for
Reviews and Dissemination (CRD) website hosted the project page, which drew in one further group.
Ethical approval was obtained from University of York Health Services Research Ethics and Research
Governance Committee, and from York NHS Research Ethics Committee after considerable input
into assessing the ethical implications of IPD projects like PICNICC (see subsequent section for
detail).
A full draft protocol was presented at SIOP in 2010. Following the presentation and distribution of
copies of the IPD protocol, letters of invitation were sent by email and paper to principle authors (of
the studies identified in the systematic reviews) and those not already engaged. This generated
further contacts from follow-up emails to this group and their contacts and then included. A complex
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series of approaches and telephone conferences also led to the inclusion of data from 4 EORTC trials.
The flowchart of how study groups were contacted and their involvement requested is detailed in
Appendix 14, and examples of the nature of the documentation in Appendix 15.
An important element in confirming the nature of the relationships between the data and the
collaborative group was to set a clear publication policy. It was agreed that the main results of the
meta-analysis would be published and presented in the PICNICC name, comprising groups supplying
data for analysis and the Advisory group. Any subsequent technical papers which describe
innovations in the methodologies used in the meta-analysis would acknowledge the Collaborative as
the source of the data.
Rationale for parent/carer involvement
The development of shared research initiatives between patient/clinician/researchers has been a
notable change in the practice of clinical research over the last decade.[217] It remains shocking to
many researchers, clinicians and patients to learn that their views are often strikingly different than
each other.[218] A systematic review of studies which describe the process of research planning and
priority setting undertaken by the James Lind Alliance [219] demonstrated that the involvement of
patients and parent/carers was extremely infrequent.
The PICNICC group has sought to involve parent representation from early in the process.
Experiences of other researchers who had engaged patients in IPD collaborative were sought. Clare
Vale, MRC Trials Unit, had worked with women in a cervical cancer IPD collaboration [220] and
found the patient experiences redirected the focus of the IPD group onto many patient important
elements. The benefit of lay involvement in improving the clarity of presentation of information and
structure of investigation has also been suggested.[221]
Initial approaches were made to the Chair of the Patient Advocacy Committee (PAC) at the
Children’s Cancer and Leukaemia Group (CCLG: a charity networking parents, clinicians and allied
health professionals in the UK and Ireland who treat childhood cancer) and to the Manager of
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Candlelighters (the Yorkshire Children’s Cancer charity) to seek their advice and suggestions for
volunteers. From these meetings, a lay summary of the project evolved, written in a ‘journalistic’
style and commented upon by the CCLG PAC and Play Leaders at the Leeds children’s cancer unit
(see Appendix 16).
The project request for volunteers was highlighted by the CCLG PAC team and a short article printed
in the Candlelighters monthly magazine, and a web page made available from the CRD site
(http://www.york.ac.uk/inst/crd/projects/risk_stratification_febrile_neutropenia.htm). This led to
the involvement of two parents, one of whom had experienced the death of her child, one whose
child had been free from disease for over four years.
The involvement of these individuals led to a discussion about the nature and parent/family view on
the understanding of risk in the setting of febrile neutropenia. After involvement in the initial
refinement of the protocol, one volunteer withdrew, but the second continued and inputted
through the process including attending and taking part in the Collaborators meeting. It was clear
that the representatives involved had not wished to be actively involved in the process of systematic
reviewing, data extraction or analysis, but added opinions to discussions about the nature of the
adverse effects of FNP and provided their own professional (non-medical) expertise in advancing the
project, particularly in respect of ethical issues and dissemination of data.
Ethical and regulatory considerations
It has been suggested that the re-use of individual participant data from randomised trials within
meta-analyses that address the same clinical questions should be exempt from further ethical
review requirements. This is because the data are from studies which have already obtained
individual consent and ethical approval.[215, 222] The use of data that had been obtained outside
specific research studies, or where the meta-analysis has different aims, remains unclear. A
consultation exercise undertaken in 2008 by the National Cancer Research Institute (NCRI) found
that the belief of most respondents was that material and data collected from cancer patients
should be used, without identifiable information, as broadly as possible and that retrospectively
seeking consent was inappropriate.[223] The European Treaty on Biomedical Ethics permits the use
of data without specific consent [224] (15.2.i/ii) where there is minimal risk and potential benefit to
similar persons
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Within the UK, legislation controls the use of patient data for the purposes of research, most
recently the National Health Service (NHS) Act 2006. This has been interpreted by the UK Medical
Research Council (MRC) and summarised in a guidance document. These guidelines state that where
possible, data should be released under specific consent. Where this is impractical, anonymised data
should be used, and if this is impossible then an application to the Ethics and Confidentiality
Committee of the National Information Governance Board for Health and Social Care is required to
obtain access.[225] Wherever data is used that has not had specific consent, consent should be
sought from an appropriate Research Ethics Committee (REC).[226]
The data sought for the “Predicting Infectious ComplicatioNs In Children with Cancer” (PICNICC)
Collaborative IPD review was anonymous (i.e. the Collaboration could not identify the patient from
their data) and unlinked (i.e. their data could not be mapped onto a subsequent dataset, with the
potential for breaking anonymity). The project Advisory group could not conceive of any harm that
may have been occasioned by the use of such anonymous, unlinked data, and that there was a
considerable benefit of an improved risk stratification system for episodes of febrile neutropenia for
children and young people with cancer. This view was also supported by the parent representatives
in the collaboration. Data were sought from formal randomised controlled trials and prospective
observational studies, and also informal studies of data routinely collected in clinical practice or as
part of quality improvement projects. The transfer of the information from the original researchers
to the Collaborative was requested by secure, encrypted electronic methods.
Within the UK, it was considered the project would require NHS REC approval for the use of patient
data that had been recorded without specific research consent. Similar processes were discovered to
apply in Australia [227], New Zealand[228], and Canada.[229] In other locations (such as Germany or
the United States of America [230]) such data are exempt from the need for formal REC approval,
but researchers are advised to have such protocols reviews by ethics boards to assure quality and
ease publication.[224] In respect of this, we applied for and received approval for the PICNICC IPD
protocol from the University of York Health Services Research Ethics and Research Governance
Committee, and from the York NHS REC, both of whom determined that a full application was not
required and gave consent from the Chair.
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Methods
The full protocol of the PICNICC IPD analysis is provided in Appendix 17. It was developed,
registered and published prior to commencement of the analysis.[231] The remainder of this
chapter outlines the key methods and most important aspects of approach and analyses, paying
particular relevance to the part of the PICNICC project undertaken for this PhD submission.
Aims
The primary clinical aim of this IPD analysis was to quantify the risk of adverse clinical outcomes
according to clinical variables in children and young people undergoing treatment for malignant
disease who present with an episode of febrile neutropenia; i.e. to identify which variables are
prognostic, and which have the most independent prognostic importance. This was planned to lead
to the development of a new risk prediction model containing multiple prognostic factors in
combination, and permit this to be validated.
A further aim was to develop and explore practical and methodological issues around the use of
pooled IPD analysis in the development of prediction models, and in the graphical display and
communication of such information.
Inclusion and Exclusion Criteria
Studies were considered for inclusion in the IPD meta-analysis if they were:
 cohort studies of children and young people
 presenting with febrile neutropenia
 with either prospective or retrospective data collection, including randomised trial data
 provided data for all essential predictive variables in >50% of included episodes
 provided two or more study-defined-outcomes in >90% of each individual episodes of FNP
These criteria were selected to efficiently gather information which would inform the better
understanding of the predictive ability of a range of pre-specified factors, chosen from the
systematic reviews conducted to underpin this investigation.
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Studies were excluded if they:
 Were case-series (for example, of only ‘gram negative bacteraemia’)
 Did not record data on all ‘essential’ predictive variables or could not provide sufficient
outcome data
These exclusions were intentionally minimal, and produced to remove datasets which could not be
informative about the outcomes of their patients or contained so few of the predictive variables that
they would not be able to be used in developing a prediction model.
Studies were included which focus on collection of data from children and young people (between 0
and 24 years old). The inclusion of young people up to the age of 24 years is to address a paucity of
research on individuals in the ‘young adult’ age range.[232] Data from individual patients aged 25
years and older were excluded from this analysis. The median age of inclusion in the children’s
cohorts examined in the systematic reviews reported in the previous chapters was around seven
years old (ranging from one month to 23 years), and the adult study from the MASCC group [13] has
a median age of 52 years (ranging from 16 to 91 years old).
Mapping Procedures
In order to harmonise outcomes and maximise the usefulness of the data to be collected, a series of
a priori mapping procedures were planned, in consultation between two clinical experts (RSP and
Julia Chisholm). These procedures were verified by the collaborators' meeting.
The procedures undertaken included microbial infection types/sources and classification in to
severe/non-severe, summarising the “intensity of chemotherapy”, addressing issues with different
approaches to reporting “vital signs” and clarifying the value of continuous variables when they fall
below the limits of assay detection.
Mapping of microbial sources to outcomes
The principle of this process was to create an a priori list of microbiological infections/sources which
can be used to classify infections as ‘severe’ or ‘non-severe’, as detailed in Appendix 18. While this
will never be a perfect system – for example some patients with Pseudomonas pneumonia may not
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be significantly unwell, where some children with rhinovirus infection may be severely unwell –
examples which cross these boundaries will be rare. In some cases the information on the
microbiological outcome was supplemented by clinical site information in the dataset, in others it
was not.
The rationale for this mapping was to create a homogenous and unconfounded outcome; one
unaffected by any therapeutic manoeuvre, for use in model building and verification.
Mapping of chemotherapy Intensity
A range of treatment intensity approaches have been previously described, including variations of
the “intensity of treatment rating scale”.[233] The data delivered to the PICNICC collaboration
contained a range of information, from the highly specific sub-elements of treatment courses (e.g.
BFM acute lymphoblastic leukaemia (ALL) Induction Phase Ib) to the general (e.g. “More intense
than ALL maintenance treatment”).
In view of this, a three-intensity plan was undertaken to homogenise the information and maximise
the quality which was included:
 Equal to or less intensive than ALL maintenance
 Standard chemotherapy more intensive than ALL maintenance
 Stem cell transplant procedures
Mapping of Respiratory & Circulatory results
A number of studies provided continuous variables (heart rate, respiratory rate, blood pressure)
where a number of other data sets provided statements of respiratory or circulatory compromise.
Where a description of respiratory or circulatory compromise has been given – for example, by
explicit statement of use of supplemental oxygen – this has been used. For those where continuous
variables alone were given, a mapping exercise was undertaken.
Normal children have been extensively studied for the variation and distribution of respiratory and
circulatory parameters, with the development of centile charts for such variables. In view of the
extreme nature of compromise in respiratory rate (where tachypnoea alone is not always associated
with a failure of gas exchange or the need for other support) those greater than the 99
th
percentile
[234] have been mapped to “compromised”. For blood pressure, the lower 5
th
percentile has been
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used (in keeping with the definition of systemic inflammatory response syndrome[235]), calculated
as age(yrs)*2 + 65 mmHg.[236] The latter approach assumes a 50
th
percentile height of patient.
Mapping of biomarkers and age
A number of studies provided age as months; other studies provided the information in days. To
convert to a common metric, the months data was multiplied by (m/12 * 365.25). Rounding is
assumed to have happened both up and down, so that a 10.6m old would have been recorded as
11m, as would a 11.4m old, making the ‘round’ month the mid-point.
Inflammatory marker continuous variables (e.g. CRP, interleukins, PCT) have a log-normal
distribution.[156, 237] For values below assay detection limits, the mean of the log-normal of the
distribution of the ‘counted’ values was taken as the true mean, and the proportion of patients
below the limit of detection calculated, with the median ‘unmeasured’ value imputed for all those
below the cutoff.
Core dataset and variables
The predictor variables and adverse outcomes sought from studies were based on our systematic
reviews of aggregate data and clinical experience.
Predictor variables requested were divided into ‘essential’ and ‘desirable’ items and categorised as
patient-related, episode-related-clinical and episode-related-laboratory variables.
Patient-related variables
 Age
 Underlying tumour type
 Marrow involvement/remission status
 Chemotherapy type and time elapsed since last cycle
 Presence of central venous line
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Episode-related clinical variables
 In-patient or out-patient at onset of episode
 Maximum temperature
 Antibiotic therapy used
 Respiratory rate (or compromise)
 Circulatory (or compromise)
 Severe mucositis
 Global assessment of illness severity
Episode-related-laboratory variables
 Haemoglobin
 Platelet count
 White cell count
 Neutrophil count
 Monocyte count
 C-reactive protein
 Procalcitonin
 Interleukin-6
 Interleukin-8
The outcomes of primary interest from each episode were:
 Death
 Intensive care admission
 Need for moderate organ support (fluid bolus, oxygen)
 Clinically documented infections
 Microbiologically documented infections
To be eligible for inclusion, studies had to be able to provide two or more of these outcome
measures for at least 90% of episodes.
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If available, data were also requested on:
 Duration of fever
 Duration of admission
The adequacy of data sources was assessed with an initial survey of data available from
collaborators is provided in Appendix 19.
Providing Data
Anonymised de-identified data
Datasets were requested in anonymised format with all directly identifiable material such as name,
address, postcode, medical number removed. A patient identification number was requested to
facilitate communication and data queries. For the purposes of the analyses planned, the age of the
patient (an indirect identifier) was considered essential, and requested to be provided [238] despite
some concerns that in small population this could provide a potential patient-level identifier.
Data format
The data were accepted in any electronic formats, but the ideal was a ‘flat’ spreadsheet format (such
as Excel), with one episode per row and variables in columns. To make the cleaning and checking of
the data as straightforward as possible guidance on data provision was provided, such as “Each
patient should have an in-cohort unique identifier (such as a simple number 1,2...n) to highlight
repeated episodes in the same patient”. Suggested coding was also provided (Appendix 20) along
with an example flat file. Data were re-coded on receipt to ensure consistency.
Transfer of data
Data were transferred using a secure password-protected web server (Dropbox.com) or via PGP-
encrypted email. This permitted a secure and identifiable connection to the University of York
servers and minimised the possibility of data loss.
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The raw files were named according to a specified convention and archived as an unmodified record
of the original provided data. Copies of the received files were made and used in the subsequent
cleaning and analysis work (see Appendix 21; Data manipulation SOPs).
Data checking
Simple checks of data integrity were undertaken prior to analysis:
The first review was to confirm that the supplied coding sheet and data file corresponded, and to log
any initial uncertainties. Data columns were reordered in line with the PICNICC master data file
structure, and the presence of the essential variables and outcomes verified at the ‘column’ level.
This was followed by recoding and examination for missing data.
Further data checks were undertaken in Excel:
 age checking (not negative or zero and not older than 9,125 days (25 years); consistency of
patient DOBs, and sensible diagnosis & age relationships)
 episodic checking ordering by age and DOB and then by admission date and looking for
odd/inconsistent elements (>6m in between FNP episodes)
 time-since-chemotherapy (not negative or >42 days), and looking for consistency with other
episodes
 white cell indices (not ‘zero’, and components e.g. ANC and AMC are not greater than the
total WCC)
Subsequent queries and their resolutions were recorded, and when finalised, the data source was
locked. Any problems or inconsistencies flagged during these procedures were discussed with the
individual responsible for each study and amended as appropriate by consensus.
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Plan of investigation
Method of analysis
The key elements in the development of a good clinical decision rule are: high quality rule-building
with unbiased data, sensible validation and assessment of generalisability, and finally
implementation in a real-world clinical setting. The building of a rule requires the data to be
collected without systematic errors, subsequent construction of an accurate prediction model, and
the development, using clinical criteria, of an appropriately usable decision rule.
The construction of a prediction model could be accomplished using one of a series of different
models. These different analysis techniques include: multivariable regression analysis, classification
and regression tree (CART) models, and neural nets. There is no clear evidence that one method is
superior to any other.[109] The chosen primary method of analysis for the PICNICC study was logistic
regression as this has the widest clinical understanding and applicability.
Logistic regressionmodelling
This technique seeks to quantify the relationships between predictor variables and the chance of a
specified outcome by estimating the relative likelihood of the outcome occurring with increasing
values of the predictor.
The equation produced at the simplest level takes the form:
[1] Logit(p
ik
) = β
0
Logit(p
ik
) is the log-odds (natural logarithm of p
ik
/ (1- p
ik
)) of an outcome, for example, bacteraemia
in the k'th patient of the i'th study.
β
0
is the intercept of the slope described by the equation – the expected log-odds of bacteraemia.
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This equation is clinically meaningful only if each patient in each study has the same risk of
bacteraemia, which cannot be predicted by any other factor. This is obviously not the case.
Adding another level of complexity is to try to explain some of the variation:
[2] Logit(p
ik
) = β
0
+ β
1
t
ik
t
ik
is the value of a covariate, a candidate of a predictor variable (potential prognostic factor, for
example maximum temperature) in the k'th patient of the i'th study.
β
1
is the co-efficient, alternatively understood as the ‘weight’, ‘slope’ or ‘multiplication factor’ for
that explanatory variable. The value exp(β
1
) gives the odds ratio of the candidate predictor; it
compares the odds of the outcome for two episodes that vary by one unit of t
ik
. This value, along
with a 95% confidence interval, can be used to summarise the predictive effect of t
ik
.
Categorical variables can also be used in these equations by the use of ‘dummy’ or coding variables.
This formula assumes that the risk of bacteraemia can, to some extent, be predicted from the
maximum temperature prior to admission. The equation also presumes that the risk is the same in
each study, and that the change in risk (per degree of temperature) is also the same – essentially
treating the whole dataset as if it were one large study. This may well be untrue, with altering rates
of bacteraemia across studies. To incorporate this, we need to add:
[3] Logit(p
ik
) = β
0i
+ β
1
t
ik
β
0i
is a parameter for each study, which can be thought of as allowing different intercepts , which are
the baseline risks of bacteraemia, to account for differences in populations. This keeps the same
slope of the temperature-bacteraemia line (‘fixed effect’ covariate).
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If we suggest that there may be a real difference in the relationship between temperature and
bacteraemia in different studies which is beyond that expect by chance sampling, then we must also
allow the β
1
to vary in from study to study (‘random effect’ covariate):
[4] Logit(p
ik
) = β
0i
+ β
1i
t
k

1i
~ N(β
1
, τ
2
β1
)
This introduces a second assessment of between-study variability related this time to the
temperature covariate. τ is the between-study standard deviation in the 
1
values. If τ is zero, then 
1
is the same (fixed) in each study, and this equation becomes the same as [3]. In either case, 
1
is the
effect of a degree-change in temperature on the risk of bacteramia, on average, across all the
various studies.
In straightforward terms, estimating a fixed effect covariate assumes the same effect is present
across each study, and any differences are due to chance sampling. A random effect covariate
assumes that the estimates are drawn themselves from a normal distribution of true effects; that
the estimates are both different by sampling, and that real differences may also be present between
studies. The clinical interpretation of this can be difficult, if the heterogeneity in this estimate is
large, as it means it becomes difficult to predict what the value of a one-degree temperature change
is in any given setting. An exception to this is in settings where a study has contributed to the
analysis; in these areas a reasonable estimate of the specific value of the covariate can be made
more accurately using ‘shrunken’ estimates.
When multiple predictors are considered the equation stays very much the same, but adds in further
covariates. In adding further covariates we move from assessing univariate models to multivariable
ones:
[5] Logit(p
ik
) = β
0i
+ β
1
t
ik
+ β
2
m
ik
+ β
3
y
k
Page 137 of 410
Each further covariate (e.g. m = monocyte count) has a different corresponding co-efficient. Again,
these may be fixed effects (as above) or allowed to have a random-effects estimate. It also allows
some covariates to be entered at study-level only, for example the study ‘year’ may be entered as a
potential explanation: β
3
y
i
(note the lack of ‘k’ in the subscript).
Combining these approaches allows random effects for some aspects of the model, for example,
differences in the intercept and some covariates, and for other covariates assume the same slope
across studies (fixed effects).
In clinical terms the multi-level model can describe how baselines rates of an outcome (e.g.
proportion of bacteraemia) vary between studies – this is the intercept component. It can also
explore which predictive factors have different strengths of influence in different studies – the
‘slope’ or coefficient. If a predictive factor is found to have strikingly different (heterogeneous)
coefficients across different studies the potential explanation for this needs to be explored. If no
consistent pattern emerges then the practical implication is that it is impossible to use this in a
model which will be generalisable in future as the power of the predictor will be impossible to judge.
The alternative situation, where slopes are similar between studies, strengthens the confidence in it
being predictive in future practice.
Advanced issues [optional]
Further layers of clinically reasonable complexity can be added to this situation. The first is that
there may be situations where the explanatory factor has qualitatively different effects in different
settings. For example, it may be that platelet counts have little predictive value in areas of the world
where transfusions are simple, cheap and safe, and have strong predictive value in areas where
platelet transfusions are difficult to give. In this setting, the basic equation is similar, but the values
of β
1
vary between studies where transfusions are common (
c
) and uncommon (
u
):
[6] Logit(p
ik
) = β
0i
+ β
1Ci
p
k
+ β
1Ui
p
k

1Ci
~ N(B
1C
, τ
2
B1
)

1Ui
~ N(B
1U
, τ
2
B1
)
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The logical extension to this variant is that τ
2
1
may also differ between groups, allowing more or less
variability in the platelet-bacteraemia relationship in high versus low transfusions settings. These are
‘group random effect’ models.
A further factor which may need consideration is the how predictions may differ between studies
because of unidentified biases. For example, temperature may seem valuable, yet this is only a
reflection of different studies having different mean values of maximum temperature (ecological
bias).[239]
This can be assessed by looking at how the covariates of the ‘study mean’ temperature (β
1A
for
‘across study’ and ‘ť for mean-temperature) differ from those of the individual patient temperature
(β
1W
for within-study). Technically, the individual element component is ‘centred’ to make it more
comparable by subtracting it from the mean study temperature. The equation becomes:
[7] Logit(p
ik
) = β
0i
+ β
1A
ť
i
+ β
1W
t
ik
-ť
i
This then allows a statistical test of the difference in β
1A
andβ
1W
to be undertaken, with the null
hypothesis that there will be no difference (i.e. there is no ‘ecological bias’).
There may also be situation where a candidate predictor variable (e.g study year ‘y’) may not by
itself have any predictive value, but it alters how effectively monocyte count ‘m’ predicts
bacteraemia. This can be estimated by looking at the ‘interaction’ term of y
k
* m
ik
[8] Logit(y
k
) = β
0i
+ β
1
t
ik
+ β
2
m
ik
+ β
3
y
k +
β
4
y
k
* m
ik
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Assessment of study and data quality
At the time the PICNICC protocol was produced there was very little advice in the literature for
assessing the quality of prognostic studies. Altman and Lyman have presented suitable criteria that
those initiating a primary prognostic study should consider [240], and they suggest that every effort
should be made to limit potential biases and to emulate the design standards of a clinical trial.
Ideally the data should be collected prospectively, with little missing data for predictors or
outcomes, and with pre-defined hypothesizes. We chose to use the format of QUADAS, as used in
the systematic review, to help inform the assessment of the quality of the IPD obtained. The
influence of any studies considered problematic (e.g. those with large missing data, or lots of
incomplete follow-up) in the prediction model was also considered in the later analyses. Since the
protocol was developed, there have been further publications exploring the assessment of bias in
prognostic studies [241-242], and these issues have also been considered.
Model development
The protocol [231] for model development set out that after data checking for consistency, model
building would initially incorporate the simplest predictor variables (malignant diagnosis, age, time
since chemotherapy, and maximum recorded temperature) before standard additional variables
(such as clinical assessments of compromise, in/out-patient status, white cell counts or other
haematological parameters) were added. Further specialist tests (e.g. CRP and IL6 levels) were finally
to be added. The type of antibiotic therapy used was always incorporated into model as a categorical
variable in a sensitivity analysis.
Potential sources of heterogeneity (e.g. in effects of particular variables across studies, or by
individual-level variation) were incorporated as random-effects when appropriate and the effect
assessed. The models were assessed for improvement in fit using an Akaike’s Information Criterion,
with a p-value of < 0.15 used for inclusion; we use a 15% level rather than a 5% as we felt this was
more conservative and would avoid missing important covariates. However, at the stage of
determining our final model, we checked that the model’s predictive accuracy (discriminatory
ability) would be improved by the inclusion of variables whose significance was between 5% and
15%. If predictive accuracy was not improved then these variables would be removed.
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This approach (of adding specialist tests only after considering the simpler tests) maximizes the
utility of a model by ensuring that if extra tests with additional costs are required, they are shown to
add considerable predictive power to existing simpler variables.[80] We used bootstrapping and
shrinkage to adjust for potential over-optimism (bias) in parameter estimates.
The bootstrap procedure creates a series of ‘new’ datasets which are compiled from rows re-
sampled from the original dataset at random, with replacement, i.e. allowing any individual patient-
episode to enter the new bootstrapped dataset multiple times.[85] This is based on the principle of
random sampling reflecting the true value of a studied item within a population, and simulates the
expected random variations that will appear in when a prediction model would be used in clinical
practice. These new datasets are then subject to the analyses which are under consideration. The
results of these bootstrap analyses are examined and an average value, along with observed or
calculated confidence intervals for each of the chosen parameters, can be drawn. For the analyses in
this thesis, the bootstrap procedures were undertaken using R.
Shrinkage [243] is process of producing a reduction in the predictive estimates of a regression
equation because there is an empirically proven expectation that prediction models generally
perform less well in validation datasets than derivation ones. By applying a ‘calculated pessimism’ to
the estimates this may be avoided. The approach used here follows the shrinkage after estimation
approach using a heuristic uniform shrinkage factor s, calculated as
[1] s = (model 
2
– p) / model 
2
model 
2
= likelihood ratio of the fitted model
AIC = model 
2
– 2p
where p = number of fitted predictors in the final model, taken from the formulae of [243] Chapter
13 (p233 and p235).
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Continuous candidate variables were assessed using the best fitting functional form considering
appropriate transformations or fractional polynomials (also assessed using an Information Criterion)
as suggested by previous evidence.
An analysis comparing the new model that we develop with other validated models, for example
that of Santolaya [22] was also planned a priori to exclude data sets used to derive any of the
models. This provided an opportunity to test these rules against data from other geographies and
eras, particularly in light of the demonstration of lack of geographical transportability.[115]
The protocol acknowledged there would be unforeseen challenges caused by the variations in the
data formats and completeness of studies, and acknowledged establishing the definitive analysis
plan will be an iterative process and could even require novel methodological developments.
Assessing model performance
An important use of a prediction model is to classify patients into risk groups. The developed model
will produce a risk score for each individual, based on their own predictor values. The calibration of
the prediction model was assessed by placing children into deciles ordered by predicted risk and
considering the agreement between the mean predicted risk and the observed events in each decile;
the slope of this line should be one if the model and reality agree.
To produce a clinical decision rule (CDR) a cut-off value was required. In order to do this, the
collaborators, including patient representation, discussed the value below which it would be
considered acceptable to be termed “low risk” of bacteraemia at the congress. Through expert
opinion, and in keeping with the previous publications of the SPOG group, a “5% risk of
bacteraemia” was agreed. Further issues with this decision and approach are explored in Chapter 10.
The decision rule derived from this was simply to classify the output of the prediction model as being
“low risk” if it was less than 5%, and “high risk” if 5% or higher. This was cross-validated by
comparing the classification of each patient with their actual outcome, allowing an estimate of the
sensitivity and specificity of the prediction model. Then, by varying the chosen cut-off level, a
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receiver operating characteristic (ROC) curve summarising the sensitivity and specificity of the
prediction rule across the range of cut-offs was produced by the R package pROC, along with an
evaluation of the overall discriminatory ability summarised as the Area Under Receiver Operating
Characteristic curve (AUC ROC) with 95% confidence interval.
The prediction model was tested by checking performance against the data from all, bar one, of the
studies in turn (cross validation of intrinsic prognostic performance)[209] and using the bootstrap
procedure.[81] This approach is intended to adjust for over-optimism in the estimation of model
performance due to validation in the same dataset that was used to develop the model itself. The
cross-validation approach (leave one study out at a time) has been referred to as internal-external
validation, and is a way of maximising the data toward the prediction model development whilst also
externally examining model performance. It tests the systematic biasing of the data in order to
assess robustness to variations in study-level variation, for example population, geography and era.
Both methods are limited in the reliance in re-using the dataset which derived the rule, but are as
robust a method as possible in internally testing the rule.
The improvement in model performance by adding prognostic factors when deciding between more
complex model sets was assessed by net reclassification improvement (NRI) [244]. This is a measure
of the overall ‘benefit’ of a new classification model. It is calculated by taking patients with, and
without, the outcome separately. Patients who are correctly classified with the new score, but were
incorrect in the old one, are given a score of +1, and those who are reclassified incorrectly are scored
-1. The unchanged are scored zero. The totals are summed, and divided by the number of patients in
that outcome group. For patients with the outcome, this value is the improvement in sensitivity, for
those without it is the improvement in specificity. These two values are then added together to give
the net reclassification improvement. A larger value indicates a greater improvement.
Validation and future implications
A comparison of the predicted and observed event rates to assess calibration (as described above)
and the area under the ROC curve to assess discriminatory ability in new data was proposed as a test
bed for the newly generated model. However, such an analysis was outside the initial scope of this
project.
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These steps should produce the most precise and accurate prediction model that can be created
from the IPD data set. The next step is to take these estimates to derive a clinical prediction rule
from which management decisions may be made. This requires clinically informed decisions to be
about where alternative strategies should be undertaken. For example, what risk of an emerging
clinically documented infection would be acceptable before patients could be considered suitable
for out-patient therapy? The setting of these thresholds can inform the rational derivation of a rule,
along the lines suggested by Vickers.[245] Such decision will require more involved engagement
from a wider panel of parents and young people, and should be subject to further detailed study.
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Chapter 7: Description of the Individual Participant Data
Introduction
Preceding chapters have described the issues in managing febrile neutropenia, focussing on the
possibility a risk stratified approach to initial management, to improve quality of life and not
increase any infectious complications of anti-cancer treatment. An extensive analysis of the existing
research evidence has been undertaken, including systematic reviews undertaken in 2008/9 and
updates done in 2011/12. These led to the clear decision to progress to an IPD analysis to develop
these ideas further and attempt to make best use and maximise the utility of the existing data sets.
This thesis reports the primary results of the IPD analysis, describing the development of the
collaborative group, a description of the datasets demographics, and the results of analyses for the
main outcome of “microbiologically documented infection”.
The Collaboration
For this project we established the Predicting Infectious ComplicatioNs In Children and young people
with Cancer” (PICNICC) Collaborative, the formation of which is described in Chapter 6. This consists
of 22 different study groups from fifteen countries.
Figure 31: Map of the World indicating the location of Collaborators.
The PICNICC collaboration comprises those who have contributed data and/or for significantly
developed the project. It includes paediatric oncologists & haematologists, infectious disease
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specialists, statisticians and methodologists and parent/carer representatives. Each brings a different
and important element to the discussions and direction of the Collaboration.
Current members are: Roland A Ammann, Thomas Kuehne , Felix Niggli, David Nadal (Switzerland),
Ian Hann (Ireland), Lillian Sung, Robert Klaassen, Sarah Alexander (Canada), Thomas Lehrnbecher,
Arne Simon (Germany), Karin Meidema,Wim JE Tissing (Netherlands), Neil Ranasinghe, Sally Amos,
Susan Hay, Lesley Stewart, Bob Phillips, Daniel Yeomanson, Alex J Sutton, Richard Riley, Julia
Chisholm, Rachel Dommett (GB), Elio Castagnola (Italy), Pamela Silva, Juan Tordecilla (Chile), Maria
Spassova (Bulgaria), Hana Hakim, Glen Stryjewski (USA), Gulsun Tezcan (Turkey), Lidija Kitanovski
(Slovenia), Ajay Gupta (India), Gabrielle Haeusler (Australia), Tiene Bauters, Geneviève Laureys
(Belgium), Marianne Paesmann, Peter Donnelly (EORTC).
Ethical and Regulatory Barriers
We undertook an auxiliary investigation into the ethical and regulatory considerations involved in
sharing IPD for risk stratification work, based on the ethical and regulatory principles and
information collected and presented in Chapter 6. All 36 groups that were initially approached
(including collaborators and those who expressed an interest but did not provide data) were
surveyed about their experiences of the process. These results are summarised in the Table 13 and
have been published elsewhere [246]. In some European countries and USA, specific applications
were made and consent obtained to share the information. Other groups were able to share their
data from previous investigations without further formal approval. To our knowledge, no potential
collaborative group had their request to share such data declined.
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Table 13: Consent sought to collaborate in an IPD analysis of predictive features
Country Study type(s)
Ethics review board
approached/answer
Belgium Prospective study
Yes, from both University Hospital
review board, agreed
Bulgaria Prospective study No, prior consent to primary study
Canada Prospective study
No, prior consent to primary
studies
Canada Prospective study
Yes, from Institutional Review
Board, agreed
Chile Prospective study
No, prior consent to primary
studies
Germany Prospective study
No, prior consent to primary
studies
Italy Prospective study
No, prior consent to primary
studies
Netherlands Prospective study
No, prior consent to primary
studies
Slovenia Prospective study
Yes, from National Medical Ethics
Committee, agreed
Switzerland
Prospective and retrospective
studies
Yes, from University Hospital
review board, agreed
Turkey Audit No, not required
UK Audit
Yes, from NHS Research Ethics
Committee, agreed
USA Retrospective notes review
Yes, from Institutional Review
Board, agreed
USA Prospective studies
No, prior consent to primary
studies
Unobtained data
We were unable to obtain data from 30 studies identified in our systematic reviews (see Table 14 for
details; this is 58% of all identified studies and 51% of all identified episodes). Explanations were
provided by the authors of three studies. In two cases (Riikonen, Heney), data were from studies
conducted over 20 years ago and were no longer retrievable. In another case (Hodge), data were not
provided by the group despite follow-up emails and a confirmation of interest in the project. The
authors of the other 28 studies did not respond to our invitations.
Page 147 of 410
Table 14: Studies where IPD was sought but not obtained
Study Number
of
episodes
Adcock 1999 33
Baorto 2001 558
Barnes 2002 39
Diepold 2008 123
Dylewska 2005 a & b 108
El-Maghraby 2007 85
Gala-Peralta 2005 30
Hatzistilianou 2007 94
Heney 1992 47
Hitoglou-Hatzi 2005 67
Hodge 2006 31
Jones 1996 127
Katz 1992 122
Lucas 1996 161
Madsen 2002 76
Paganini 2007 981
Petrelli 1991 146
Rackoff 1996 72
Riikonen 1992 105
Riikonen 1993 91
Rojo 2008 33
Rondinelli 2006 283
Santolaya 1994 85
Santolaya 2001 447
Santolaya 2002 263
Santolaya 2007 373
Santolaya 2008 566
Secmeer 2007 60
Soker 2001 48
West 2004 143
Page 148 of 410
The PICNCC project was focused primarily on the development and evaluation of a new CDR, and the
aggregate data from these studies was not sufficient to be included in the analysis, for example, by
utilising a two-stage approach to meta-analysis of parameter estimates. Apart from date of
publication, where older studies were less likely to be included, there was no clear evidence of
systematic variation between the studies included in PICNICC and studies from which data could not
be obtained in terms of number of participants (p=0.66), number of episodes (p=0.93), number of
events (p=0.67), direction of data collection (p=0.13) or geographical region (p=0.25). An IPD analysis
of predictive factors differs importantly from a systematic review of treatments because the issues
of within-study bias and publication bias appear much more troublesome in prognostics than in
therapeutic trials. Also, it is less clear that all available evidence is required to be collected to
produce the most accurate estimate of the chosen effect; rather a comprehensive and unbiased
collection of information is preferred so that the IPD studies are a representative sample of the
populations to which the CDR is to be applicable.
Quality assessment of the included studies
Quality assessment in prognostic/predictive studies is an area of ongoing methodological
refinement. At the time that this protocol was devised there was no published guideline , although
Hayden [242] has recently suggested a framework for such assessments. In keeping with the
systematic reviews undertaken, the assessment of quality followed the QUADAS approach (see
Appendix 22, Table 43). These are very similar to the assessments undertaken for the studies
included in the published systematic review, as few extra studies were included (notably the EORTC
trials).
There appear to be very few differences between the included datasets in the design features
proposed to place studies at increased risk of bias (adequate population sampling, adequate
reference standards and unbiased collection of prognostic information; see approach (Appendix 22,
Table 43,
Table 5: Further informative QUADAS measures and Appendix 11. Full list of QUADAS criteria for
included biomarkers studies). This is reassuring and to be expected in the clear and simple study
structure of the collection of a cohort of patients presenting to hospital with a well-recognised
cluster of symptoms such as FNP.
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Overview of the data collected
Data collected prior to the cut-off in November 2011 for analysis in this thesis (the derivation
dataset) included 22 datasets from 16 collaborative groups. These contained information from 5,127
episodes of FNP in 3,504 patients (see Table 15). The PICNICC collaboration aims to collect further
datasets to undertake independent analyses of the CDR produced.
Table 15: Location and patient numbers per dataset
Study Group Origin Patients Episodes
Alexander Boston, USA 103 187
BaselSPOG Basel, Switzerland 6 9
BernSPOG Bern, Switzerland 69 171
BonnSPOG Bonn, Germany 35 44
EORTC-XIV Pan-European 149 149
EORTC-IX Pan-European 315 315
EORTC-XI Pan-European 301 301
EORTC-XII Pan-European 21 21
Genoa Genoa, Italy 259 703
Hakim Memphis, USA 332 332
Kitanovski Ljubljana, Slovenia 32 68
Klaassen Ottowa, Canada 226 431
Lehrnbecher Frankfurt, Germany 146 311
PINE South-East England, UK 762 812
RetroBern Bern, Switzerland 132 364
Silva Santiago, Chile 30 52
Spassova Plovdiv, Bulgaria 80 199
Styjewski Washington, USA 56 56
Sung Toronto, Canada 75 75
Tezcan Antalya, Turkey 57 145
Tissing Groningen , The Netherlands 114 258
ZurichSPOG Zurich, Switzerland 72 154
TOTAL 3504 5127
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Missing data
The issue of missing data was more significant than originally envisaged. This is almost entirely at the
level of study whereby predictor or outcome variables were not recorded by the studies (see Figure
32). The proportion of partially present, partially missing, data was small.
Figure 32: Per study proportion of missing predictors
The graphical representation of multi-dimensional information is a challenge. During this thesis, a
variety of approaches have been used, and the most successful seems to be a variant of the
“heatmap” approach (see Figure 32 and Figure 33) which have not been used widely in health care
research outside of molecular biology, but do have a long tradition in social sciences [247]. This
allows the pattern of response in the same variable to be assessed, or the pattern of information
delivery by the same study. A colour-coded key displays the information semi-quantitatively, in this
case the proportion of missing data, where the ‘cool’ paler yellows indicate very small quantities of
missing data, the orange regions are approximately 50% missing, and the reds indicate high degrees
of missingness.
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A similar pattern of data absence and missingness is found in the outcome variables (see Figure 33).
Figure 33: Per study proportion of missing outcomes (heatmap)
The visual impression of the data can be altered by changing the colour gradient, in this case (Figure
34) using a traffic light approach making all combinations of study/variable with more than 50%
missing information red and those with less than 10% missing a shade of green.
Figure 34: Per study proportion of missing outcomes (‘traffic light’ colour scheme)
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The issue of missingness can also be considered per-episode-per-variable, ignoring the study-level
element (Table 16). The missing data ranged from 4 out of 5,127 individual features (tumour type
not recorded) to 5,034 out of 5,127 episodes (procalcitonin not reported), that is data being largely
absent.
Table 16: Missing data (episodes in whole dataset)
Item N
missing
Proportion
missing
Item N
missing
Proportion
missing
sex 516 0.1 mucositis 3084 0.6
age in days 5 0.00097 severe mucositis 2228 0.43
date 1772 0.34 haemoglobin 2499 0.48
tumour 4 0.00078 platelets 2411 0.47
marrow
involvement
4097 0.79 white cell count 2020 0.39
remission 3225 0.63 absolute
neutrophil count
650 0.13
relapse disease 2750 0.53 absolute
monocyte count
3468 0.67
chemotherapy
intensity
2302 0.45 C-reactive protein 3551 0.69
time since
chemotherapy
3111 0.6 procalcitonin 5034 0.98
central venous line
(CVL)
2007 0.39 interleukin 6 4701 0.91
CVL type 3711 0.72 interleukin 8 4672 0.91
out-patient at
onset
1971 0.38 death 317 0.061
temperature 2336 0.45 ICU duration 2484 0.48
respiratory rate 4933 0.96 need for organ
support
4302 0.83
respiratory
compromise
3093 0.6 severe infection 685 0.13
pulse rate 4787 0.93 clinically
documented
infection
955 0.19
shock 2508 0.49 microbiologically
documented
infection
375 0.073
systolic blood
pressure
4555 0.88 bloodstream
infection
23 0.0045
diastolic blood
pressure
4557 0.88 duration of fever 3748 0.73
severe unwell 1940 0.38 duration of
admission
2206 0.43
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The patterns of missing data have importantly affected the analyses conducted, as will be explored
in detail in subsequent chapters.
Demographics
Age
The overall distribution of ages in the PICNICC dataset is shown in Figure 35;
Figure 35: Age distribution of PICNICC dataset
The median age at first episode recorded was 6.5y (mean 8.4y, range 50 days to 25 years, IQR 3.4y to
12.8y). This wide age variation is to be expected from groups undertaking the care of children with
cancer, some of whom are born with malignant disease or develop it soon after birth. Twenty-four
children aged six months old or younger presented with FN in this dataset; most patients had acute
leukaemia; either infant ALL (4) or AML (8).
The age distributions varied in the different datasets (see Figure 36 and more detail in
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Appendix 22. Further detailed information on the IPD data, Table 44).
Figure 36: Age distributions of patients per study
The figure demonstrates that the EORTC studies (XIV, XI and XII) have an older population than the
other, predominantly paediatric, datasets. This reflects the organisation of health care and the
centre-based approach to most of these studies. In most locations (with the exception of the
multicentre, all-age EORTC studies), care is delivered to patients who are classified as children (with
an upper age limit varying between units; some definitions include <16 years, others <18 years,
others <19 years and in full-time education) and these studies were undertaken in paediatric units,
rather than across cancer services generally.
Tumour types
A wide variety of malignancies were represented in the included studies, in keeping with the
disparate nature of rare and very rare diagnoses treated in paediatric oncology/haematology units
(see Figure 37, and per-study data in Figure 57).
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The data include for two non-cancer groups (the “non-malignant” category and LCH: Langerhans Cell
Histiocytosis). In both these categories, the underlying disease types had been treated with
chemotherapy; primarily for stem cell transplantation of haemoglobinopathies or
immunodeficiencies in the non-malignant group, and relatively low-dose cytotoxic treatments for
multi-system or organ-at-risk LCH. The inclusion of this group of non-cancer patients (36 episodes in
19 patients) can be justified on the grounds that they are treated, for all practical purposes, the
same way as the patients with malignant disease; the chemotherapy they are exposed to brings
similar risks of immunosupression and life threatening infection. Furthermore, the inclusion of such
a small number, even if they were to have different predictors of outcome, would be very unlikely to
alter any conclusions drawn from the excess of 5,000 episodes in the IPD analysis.
Tumour types
Counts
ALL
AML
Brain
Carcinoma
Ewings
GCT
Hepato
HGBrain
Hodgkins
HR-NBL
LCH
LGBrain
LR-NBL
Lymphoma
NBL
NHL
Nonmalignant
Osteo
Other
Retino
RMS
Sarcoma
Solid
Wilms
0 500 1000 1500
Figure 37: Counts of episodes of FN by tumour type
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The distribution of age and disease type generally follows the expected pattern of incidence (see
Appendix 22, Figure 58). Some examples include how ALL is a disease of younger children (with a
further peak in the mid-50s, which is beyond the range of this study), along with retinoblastoma,
neuroblastoma (NBL) and Wilm’s tumour. This is unlike AML which has a relatively consistent
incidence across ages, and osteosarcoma or Ewing’s sarcoma which peak in the teenage years.
Gender distribution
There were slightly more males in most of the studies, with 56% male patient-episodes (see
Appendix 22, Table 45). Two data sets (EORTC-XIV and Hakim) did not provide gender data on their
patients.
This slight male preponderance is in keeping with the male preponderance of cancer in children as
recorded by population registries (54.1%) [248]. There is no suggestion in any of the dataset that
patient gender prevented access to healthcare.
Multiple episodes
The study designs led to notable differences in the distribution of numbers of episodes of FNP per
patient, as illustrated in Figure 38. The design of the EORTC studies, the Hakim and Styjewski and the
Sung trial allowed each patient to be included only once.
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Figure 38: Number of episodes per patient per study
For studies with multiple episodes, there were a median of two (mean 2.4, range 2-14, IQR 1-3)
episodes reported per patient (Appendix 22, Table 46). In most of these studies, the counts followed
a Poisson distribution, but the Genoa and PINE datasets in particular have an excess of one-episode
patients. This may be due to the high number of HSCT patients in the Genoa dataset (who may have
a single, prolonged episode but are treated once, usually at the culmination of their therapy). The
PINE dataset was gathered across 47 sites over a 12 month period, and there may have been a
greater chance of failure to accurately capture linked episodes in this more dispersed study.
A small number of patients (58) had six or more episodes of FN. These did not differ from the less-
frequently included patients in gender, date of episode, age, or tumour type (p=1 by 
2
or Wilcoxon
rank-sum tests as appropriate).
Outcomes reported
For each of the IPD studies individual outcome data were requested per episode for: death,
intensive care admission (ICU: occurrence or duration), need for moderate organ support (e.g. fluid
bolus, oxygen supplementation), any clinically documented infections (CDI) and any
microbiologically documented infections (MDI). Where possible, MDI were defined as bloodstream
or “other site”. Data were requested on the durations of fever and admission.
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Each dataset reported on quite different sets of outcomes. The outcomes most frequently reported
by the studies were microbiologically documented infection (MDI), death, bloodstream infection and
the a priori composite measure “severe infection”. The proportion of episodes where data was
available for the outcomes is shown in Table 17. The variation is almost entirely at the level of the
study, with near-complete outcome assessment for individual elements within the study.
Table 17: Percentage of episodes with known outcomes
Death ICU Organ
support
Severe
infection
CDI MDI Bloodstream
infection
Duration
of fever
Duration
admission
Alexander 100 0 100 100 0 100 99.5 100 100
BaselSPOG 100 100 0 100 0 100 100 100 100
BernSPOG 100 100 0 0 0 100 100 0 100
BonnSPOG 100 100 0 0 0 100 100 100 100
EORCT-XIV 100 0 0 100 100 100 100 96 0
EORTC-IX 100 0 0 100 100 100 100 0 0
EORTC-XI 100 0 0 100 100 100 100 0 0
EORTC-XII 100 0 0 100 100 100 100 100 0
Genoa 99.6 0 0 100 100 100 100 0 0
Hakim 100 100 100 100 100 100 100 93.7 100
Kitanovski 100 100 100 100 100 100 95.6 97.1 85.3
Klaassen 100 100 0 100 100 100 100 0 72.6
Lehrnbecher 0 0 0 100 100 100 100 0 0
PINE 99.9 100 0 83.1 99.9 100 99.3 0 99.9
RetroBern 100 0 0 100 100 0 100 0 100
Silva 100 100 100 100 100 100 100 100 100
Spassova 100 100 0 100 100 100 100 0 100
Styjewski 100 0 0 100 0 100 100 0 0
Sung 100 0 0 0 0 100 100 100 98.7
Tezcan 98.6 98.6 0 100 100 100 100 90.3 0
Tissing 100 100 83.7 0 0 95.7 95 84.1 70.9
ZurichSPOG 100 100 0 100 0 100 100 99.4 100
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The proportions of microbiologically documented infection (MDI), death, blood stream infection and
calculated “severe infection” differ markedly between studies (see detail in Appendix 22, Table 47).
Figure 39: Proportion MDI (per study)
The range of proportions of MDI varied from 12% of episodes in the Sung dataset to 53% in the
Tezcan dataset (see Figure 39). The potential reasons for this variation according to the individual’s
presenting features are explored in the later part of this chapter (where univariate predictors are
examined) and in the next chapter. Study-level differences are difficult to ascertain from study level
features: the fever definitions and trial date are not explanatory, nor is retrospective/prospective
data collection. Geography, regionalised as Western Europe, Central Europe, North America and
South America has some explanatory power; with Central European studies (Kitanovski, Tezcan and
Spassova) being significantly associated with greater rates of occurrence of MDI, bloodstream
infection and severe infections.
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The outcomes of severe infection and bloodstream infection are highly correlated with MDI
(Pearson’s =0.89 and =0.82 respectively, p<0.001) and show, similar patterns of variability.
Mortality rates in the PICNICC dataset are very small, around 1% in most series. This is compatible
with recent experience and reports given the aggressive nature of the antibiotic and resuscitation
regimes in use. The datasets with larger point estimates of mortality rates (still 5% or smaller) have
confidence intervals in keeping with the overall pattern.
Table 18: Summary statistics for continuous outcomes
Admission duration (days) Fever duration (days)
Mean Median Min Max Mean Median Min Max
Alexander 6.8 5.0 1.0 37.0 2.3 2.0 1.0 10.0
BaselSPOG 7.9 7.0 3.0 14.0 2.8 0.0 0.0 6.0
BernSPOG 7.9 5.0 1.0 60.0 NA NA NA NA
BonnSPOG 5.6 5.0 1.0 19.0 2.0 1.0 0.0 10.0
EORCT-XIV NA NA NA NA 5.1 3.0 0.0 31.0
EORTC-IX NA NA NA NA NA NA NA NA
EORTC-XI NA NA NA NA NA NA NA NA
EORTC-XII NA NA NA NA 2.8 2.0 1.0 10.0
Genoa NA NA NA NA NA NA NA NA
Hakim 6.2 4.0 0.0 146.0 2.9 1.1 0.0 73.4
Kitanovski 10.0 8.0 4.0 40.0 4.6 4.0 1.0 21.0
Klaassen 5.1 3.0 0.0 93.0 NA NA NA NA
Lehrnbecher NA NA NA NA NA NA NA NA
PINE 7.4 5.0 0.0 105.0 NA NA NA NA
RetroBern 6.1 5.0 0.0 58.0 NA NA NA NA
Silva 6.0 4.0 1.0 26.0 12.2 2.0 0.0 24.0
Spassova 4.5 3.0 0.0 23.0 NA NA NA NA
Styjewski NA NA NA NA NA NA NA NA
Sung 6.4 4.0 2.0 49.0 1.7 1.0 0.0 14.0
Tezcan NA NA NA NA 5.3 3.0 1.0 28.0
Tissing 3.1 2.0 1.0 13.0 10.7 8.0 2.0 37.0
ZurichSPOG 7.7 7.0 1.0 28.0 3.4 2.0 0.0 23.0
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Data for duration of admission and duration of fever are reported less often, only 12 datasets
provided information on duration of fever, and 14 on duration of admission (see Table 18, and
Appendix 22, Figure 59 & Figure 60). The duration of admission seems to relate mainly to the policy
of patient discharge in each unit, with median durations of 5 days (a “traditional” approach). The
duration of fever is more consistent across studies, with a median of around two days. No study
level characteristics were found to influence these durations.
Description of the predictors
Predictor variables for microbiologically documented infection have been split into patient-specific
background features, the demographics of the patients, as noted in the preceding section; episode-
specific background factors, such as the intensity of preceding chemotherapy, and the presence of a
central venous line; episode-specific clinical features such as maximum temperature and heart rate;
and episode-specific laboratory features including biomarkers of inflammation and elements of the
full blood count.
The data are addressed in each section below.
Episode-specific background factors
These features are elements of the treatment that the patient is undergoing at the time of the
episode of FN. These are not fixed (like age, and malignant diagnosis), but neither are they clinical
impressions of the child or young person’s physiological response to FN. They include the intensity of
chemotherapy, the time since chemotherapy was delivered, the status of the cancer (in remission,
relapsed or not), and the presence of a central venous line.
Remission
The meaning of remission is sometimes interpreted differently in different malignant diseases, and
even between different groups examining the same disease. For example, in leukaemia there is a
clear and consistent definition of remission (fewer than 5% of the marrow involved by leukaemic
cells), but there is a range of alternative interpretations of how a solid malignancy is described as
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being in remission. Some definitions may be based on an on-treatment scan showing a good
response (defined as >33% reduction in primary tumour volume, or >50% by some groups) or clear
scans showing no evidence of disease by physical or metabolic criteria. The definitions used in each
dataset were not able to be provided.
Time-since-chemotherapy
Time-since-chemotherapy is also confusing, as the treatment of many malignancies varies, and so
the effect of this variable upon immunosuppression may differ between different tumour types, and
between the same malignancy at different stages of therapy. The classic approach to treating solid
malignancies is to give cycles of chemotherapy, waiting for clinical and bone marrow recovery before
commencing a further cycle. The expected nadir in marrow function is between day 10 and 14 of
commencing chemotherapy. In contrast, in some protocols for acute leukaemia there is a
maintenance phase of treatment where chemotherapy is given as an oral medication on a daily basis
with dose titrated against toxicity. In other parts of acute leukaemia treatment, chemotherapy is
given intermittently over 10-21 days. Details of which phase of therapy was undertaken prior to each
episode were not requested, so the uncertainty of interpreting this variable has meant that the IPD
analysis has not used this information.
Central venous lines
Central venous lines (CVL) are used to deliver chemotherapy directly into major veins (usually the
superior vena cava in the upper part of the chest) and allow blood to be taken for regular tests while
minimising trauma to the child. They vary by number of lumens (separate tubes within the line),
usually having between one and three. They also differ in that they may be tunnelled (with the tube
exiting the major vein and passing under the skin for a distance before the access point) or
untunnelled. There are two major types of tunnelled lines which have different types of access for
administration of products or taking of blood tests. If the end of the line emerges out of the skin
they are known as Hickman-style lines, and if it ends beneath the skin with a palpable metal/plastic
port which can be easily accessed with a short needle, known as a Port-a-cath. The different types of
lines are used in different ages of patients and sometimes for different types of chemotherapy.
Page 163 of 410
Table 19: Presence of CVL (per study)
Percentage
with CVL
Number
of
episodes
with CVL
Number of
episodes
without
CVL
Line type if given NA
Port Hickman Untunnelled
BaselSPOG 100% 9 0 0
BernSPOG 76% 130 41 0
BonnSPOG 93% 41 3 0
Genoa 94% 664 39 0
Hakim 95% 317 15 27% 69% 4% 0
Kitanovski 63% 43 25 13% 0% 0% 0
Klaassen 84% 364 67 81% 33% 0% 0
Lehrnbecher 97% 301 8 2
RetroBern 50% 183 181 51% 6% 0% 0
Silva 98% 51 1 9% 6% 1% 0
Spassova 100% 199 0 0% 4% 0% 0
Styjewski 100% 56 0 0
Tissing 100% 258 0 0
ZurichSPOG 83% 128 26 0
Table 19 shows the proportion of patients with a central line, and the type of line in use. For most
studies, each patient has a CVL of some type, but with marked variation in the type of line used.
Chemotherapy intensity
Chemotherapy intensity was collapsed into one of three categories for the IPD analysis (as described
in detail in Chapter 6) consisting of: low intensity (at or less than the ongoing maintenance
treatment used for acute leukaemia); HSCT, haemopoietic stem cell transplantation, very intensive
chemotherapy which requires rescue with haemopoietic stem cells, commonly known as a ‘bone
marrow transplant’; and standard intensity, which covers all of the middle ground between these
extremes.
Eleven datasets gave information directly, or indirectly, on the chemotherapy used per patient and
so could define the level of intensity (see Table 20). In one very small dataset, only standard-
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intensity chemotherapy had been used (BaselSPOG) and only two datasets (PINE and Genoa)
included patients that had undergone HSCT. In all other studies, patients who had received HSCT
were excluded from the data collection.
Table 20: Number of patients receiving each level of chemotherapy intensity (by study)
Low Standard HSCT NA
BaselSPOG 0 9 0 0
BernSPOG 26 145 0 0
BonnSPOG 4 40 0 0
Genoa 23 504 176 0
Kitanovski 1 65 0 2
PINE 218 577 17 0
RetroBern 32 332 0 0
Silva 1 51 0 0
Spassova 4 194 0 1
Sung 1 74 0 0
Tissing 14 193 0 51
ZurichSPOG 17 137 0 0
Episode-specific clinical features
Features in this grouping relate to the individual as they present with each episode, and are may be
more varied between individuals and between different episodes for the same individual than those
classified as “background” features. They tend to be assessed by simple clinical examination on
presentation by the first-contact healthcare providers.
Maximum temperature
There were generally similar maximum temperatures in the study groups represented; some
differences in inclusion were introduced by either strict adherence to a minimum fever, or including
patients who were being treated for suspected infection, regardless of temperature or neutrophil
count (see Figure 40, giving a box and whisker plot of the distribution per study, and
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Appendix 22. Further detailed information on the IPD data, Table 22). For information, a
normal body temperature is considered to be between 36.5
º
C and 37.2
º
C, depending upon
method of measurement.
Figure 40: Box-and-whisker plot of distribution of temperature (by study)
Mucositis
Mucositis is the inflammation and ulceration of the gastrointestinal mucosa associated with
many chemotherapy treatments and radiotherapy. It can affect all parts of the
gastrointestinal tract, from mouth through oesophagus, stomach, small and large bowel to
sigmoid colon. Estimates of mucositis in the datasets were provided as measures of severity,
or by a dichotomised approach describing the presence/absence of severe mucositis.
Sometimes extensive free text comments on the state of patient at admission were present
allowing recoding of mucositis into the commonly used 0-IV grading of the CTC (Common
Toxicity Criteria) grading structure, or the information was provided as a three-level
assessment (where none, mild and severe were coded as zero, I and III respectively). This
approach led to a bimodal pattern in some study groups (as shown in Table 21) but the
information was generally consistent.
Temperature (C)
36 38 40 42
BaselSPOG BernSPOG
36 38 40 42
BonnSPOG EORCT-XIV
36 38 40 42
EORTC-IX EORTC-XI
EORTC-XII Hakim Kitanovski Klaassen RetroBern Silva
S assova
36 38 40 42
St ewski Tissin
36 38 40 42
ZurichSPOG
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Table 21: Mucositis (graded)
Grade 0 Grade I Grade II Grade III Grade IV Severe Non-
severe
NA
Alexander 0 0 0 0 0 0 0 187
BaselSPOG 7 1 1 0 0 1 8 0
BernSPOG 113 22 12 18 6 24 147 0
BonnSPOG 29 7 7 1 0 1 43 0
EORCT-XIV 0 0 0 0 0 0 0 149
EORTC-IX 0 0 0 0 0 0 0 315
EORTC-XI 0 0 0 0 0 0 0 301
EORTC-XII 0 0 0 0 0 0 0 21
Genoa 0 0 0 0 0 0 0 703
Hakim 288 26 0 18 0 18 314 0
Kitanovski 41 13 0 10 0 14 54 4
Klaassen 395 10 5 16 4 21 410 1
Lehrnbecher 229 10 36 23 12 35 275 1
PINE 0 0 0 0 0 53 759 812
RetroBern 278 0 0 26 0 78 246 60
Silva 0 0 0 0 0 0 0 52
Spassova 132 18 0 49 0 49 150 0
Styjewski 0 0 0 0 0 0 0 56
Sung 40 6 5 3 2 19 56 19
Tezcan 0 0 0 0 0 0 0 145
Tissing 0 0 0 0 0 0 0 258
ZurichSPOG 79 20 32 12 11 23 131 0
Out-patient status
The proportion of out-patient episodes varied according to study design, with some studies
only examining patients presenting from outside hospital. Other studies did not provide data
on the in-patient status of the patient at each episode (see Table 22). Of those studies where
all-episodes, regardless of admission status of the patient, were recorded, there was
considerable variability in the proportion of episode of FN originating in in-patients and out-
patients.
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Table 22: Percentage of out-patient, unwell and cardiovascular/respiratory compromise episodes for
informative studies
Study ID % Out-patient % “Unwell”
patients
% Cardiovascular
compromise
% Respiratory
compromise
Alexander 100% 22%
BaselSPOG 11% 100% 0% 67%
BernSPOG 82% 14% 6% 42%
BonnSPOG 84% 5% 5% 5%
EORCT-XIV 15%
EORTC-IX 35%
EORTC-XI 37%
EORTC-XII 67%
Hakim 100% 25% 2% 5%
Kitanovski 65% 4% 1% 0%
Klaassen 100% 27% 4% 2%
Lehrnbecher 5%
PINE 14% 8% 9%
RetroBern 73% 2% 7%
Silva 96% 0%
Spassova 26% 24% 9% 14%
Styjewski 100% 20%
Sung 97% 41% 7%
Tezcan 5%
Tissing 100%
ZurichSPOG 79% 31% 5% 35%
Clinical impression of significantly unwell patient
The usefulness of the clinical impression of a child/young person presenting being “severely
unwell” has been debated[249], but in practice has been held as a firm and important factor.
A variable accounting for this gestalt impression was present in 15 of the 22 datasets. The
presence of such a feature was again quite variable, but was between 20% and 30% in most
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studies (see Table 22). The very small dataset of BaselSPOG is somewhat of an outlier in this
group, with all patients having “severe illness”, but this is a very small group of patients.
Vital signs
It is relevant to note again that the expected values for respiratory rate, pulse and blood
pressure vary with age, and that the simple values delivered are unhelpful. For example, a
one year old breathing at 30 breaths/minute is perfectly normal whereas an adult breathing
at the same rate would be panting. Transformations which can address this include z-score
(“centile”) modifications or dichotomising values into abnormal/normal, as in the case of
shock/respiratory compromise (as noted in Methods chapter 6). As data were provided in
raw form by relatively few studies, analysis was limited to the dichotomised versions of
cardiac or respiratory compromise.
Respiratory compromise was proposed as a practical way of combining datasets where this
dichotomised assessment of respiratory function had been supplied, and those few datasets
where respiratory rates had been supplied. The process of mapping from respiratory rate to
compromise was undertaken for the SPOG group datasets, and produced markedly higher
rates of respiratory compromise (see Appendix 22, Table 22) which makes the interpretation
of this “mapped” variable difficult to believe.
A similar mapping exercise was undertaken for blood pressure and cardiovascular
compromise. In this instance, a difference between mapped and directly reported data was
not noted (see Table 22), and around 1 in 20 episodes presented with cardiovascular
compromise.
Episode-specific laboratory factors
The use of laboratory-measured features to predict outcome is considered to be more
objective and consequently robust than subjective clinical assessments of mucositis,
respiratory compromise or gestalt “unwellness”. The features examined have focussed on
the cellular elements of the full blood count (haemoglobin, a reflection of red cell count,
platelets, total white cell count and particular sub-types, neutrophils and monocytes) and
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inflammatory biomarkers (particularly C-reactive protein, CRP; procalcitonin, PCT; and
interleukins 6 and 8, IL-6 and IL-8) measured in serum.
Full blood count
Of these features, all except for haemoglobin showed a log-normal distribution, and were
used after natural log transformation (see Figure 41).
Figure 41: Density of distribution of FBC parameters, by study, transformed where appropriate
Haemoglobin red, Platelets purple, White Cell Count green, Absolute Neutrophil Count blue, Absolute
Monocyte Count black
The study groups showed similarity across the range of haemoglobin values, which are to be
expected from clinical practice (for greater detail see
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Table 50).
Other parameters of the blood count were also as expected (for greater detail see Appenidx
22, Table 51- Table 54). The occasional very high values of white cells recorded are to be
sometimes found in patients presenting with a strong marrow response, often in the setting
of severe infection or occasionally as a complication of therapy, for example corticosteroids
or GCSF.
Different studies provided different elements of the blood count (as noted in earlier in the
chapter). The elements were only moderately correlated (calculated where pairs existed; see
Table 23).
Table 23: Spearman rank correlation coefficients
ln(white cell
count)
ln(absolute
neutrophil
count)
ln(absolute
monocyte
count)
ln(platelets) haemoglobin
ln(white cell count) 1
ln(absolute neutrophil
count)
0.468 1
ln(absolute monocyte
count)
0.43 0.369 1
ln(platelets) 0.33 0.271 0.408 1
haemoglobin 0.147 (*) 0.035 0.124 0.22 1
All p<0.001 except * (p=0.0357)
Biomarkers
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The serum biomarkers were far less frequently available. The number of studies providing
information is grossly variable; eleven with CRP, five with IL-8, four with IL-6 and only two
studies reporting on PCT (see Figure 42 and Appendix 22, Table 55 and Table 56).
Figure 42: Density plots of ln(biomarkers) per study
Blue – CRP, Red PCT, Green IL-6, Black IL-8
Examining these data for correlations between biomarkers values between studies are
suggestive of some inconsistency (see Table 24). For instance, whereas IL-6 and IL-8 are
strongly positively correlated, IL-8 is moderately correlated with PCT and IL-6 is
(insignificantly) negatively correlated with PCT. One of these three relationships appears
incongruent which may be in part due to different datasets providing information (IL-6/8:
Spassova, Styjewski, Lehrnbecher, IL-8/PCT: Styjewski, IL-6/PCT: Styjewski and Kitanovski)
Table 24: Correlation of ln(biomarkers)
ln(CRP) ln(PCT) ln(IL-6) ln(IL-8)
ln(CRP) 1
ln(biomarkers), by study
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ln(PCT) 0.302 1
ln(IL-6) 0.123 -0.12 1
ln(IL-8) 0.026 0.429 0.715 1
Normal: p>0.05, Bold: p 0.01 to 0.05, Bold Italic: p<0.01
Summary
The PICNICC collaboration collected data prior to the cut-off of November 2011 for
derivation in 22 datasets from 16 collaborative groups. These contained information from
5,127 episodes of FNP in 3,504 patients. The median age at first episode recorded was 6.5y
(mean 8.4y, range 50 days to 25 years, IQR 3.4y to 12.8y), and has a slight male
preponderance (56% male). A wide variety of malignancies were represented, in keeping
with the nature of diagnoses treated in paediatric oncology/haematology units.
A wide range of outcomes and potential predictor variables were provided in the PICNCC
dataset, all of which show marked differences in completeness and consistency. The issue of
missing data was more significant than originally envisaged. This was almost entirely at the
level of study, whereby predictor or outcome variables were “not recorded” rather than
“missing” for some patients or episodes. Some data items, such as the presence or absence
of shock, could be recoded to minimise inconsistencies. Others are inconsistent as reflected
in their original study designs (e.g. proportion of episodes commencing as out-patients).
Some variables (such as remission and time-from-chemotherapy) have been found to be
unusable in the analysis. The distribution of continuous variables followed a Normal or Log-
Normal pattern, as expected.
The assessment of these data for consistency and quality is an important first step in
preparing to undertake univariate analyses, which are important to clinicians who would
ideally wish a single feature to be powerfully predictive of the presence or absence of
adverse outcomes, and multivariable analyses from which the decision rule will be built in
subsequent chapters.
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Chapter 8: Results of the univariate analyses
In the examination of candidate predictors of outcome, a useful first step is a univariate
assessment of the association between each predictor and outcome. The term 'univariate'
means that each predictor is considered separately and so each association is not adjusted
for other variables. Multivariable analyses (which do adjust) are conducted in subsequent
chapters.
In this chapter univariate analyses are undertaken to create a list of potential predictors for
use in the multivariable analysis, and to inform clinicians of the association between single
factors and the risk of infection in their patients. Univariate associations are important to
obtain an initial overview of the associations and whether they appear consistent with
clinical expectations. Additionally, if a univariate association is extremely strong, it may
remove the need for any more complex examination of the data as a clinically effective
decision can be made from that one piece of information.
To assess the consistency of these features across the different component studies, the
univariate model has been fitted directly to each dataset. This chapter illustrates the general
approach using particular examples, both as exemplars and to illustrate specific problems.
Additionally, the data on inflammatory biomarkers, which were present in very few datasets
and could contribute little to the multivariable analyses, are also explored in depth.
Outcome examined
This thesis considers the outcome of microbiologically documented infection (MDI). This was
selected from the wider range of outcomes included in the initial protocol for the PICNICC
analysis because it is the most completely reported, is the most frequently concerning to
clinicians in paediatric FN, and has an uncomplicated definition.
Models fitted
Three logistic regression models were fitted to explore univariate associations for each of
the candidate predictors of microbiologically documented infection. The models were fitted
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using maximum likelihood estimation within the package lme4 in R (see Appendix 23 for
code).
These models are presented using the same notation as Chapter 5, briefly :
p – the probability of an outcome (in this case microbiologically defined infection,
MDI)
()
i
- i refers to the ‘i-th’ dataset
()
k
- k refers to the ‘k-th’ patient
()
ik
- ik refers to the ‘k-th’ patient of the ‘i-th’ study
beta
0
(β
0
) – the estimate of the ‘intercept’, that is, the log-odds of MDI when all the other
features have ‘zero’ value
t - the predictive feature under investigation (e.g. temperature)
beta1 (β
1
t) – the estimate of the log odds ratio of the probability of MDI in individuals who
vary by one unit of ‘t’
The first models is the “full hierarchical with individual effect” which fitted a hierarchical
model estimating independent intercepts by study, with random effect on predictor within
study (to allow for a separate predictor effect in each study), and random effect on
individuals (to allow for a separate intercept for individuals with multiple records within a
study),
[1] Logit(p
ik
) = β
0i
+ β
1i
t
ik
+ β
2k

1i
~ N(β
1
, τ
2
β1
)
β
2k
~ N(β
2
, 
2
β2
)
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This model, additionally, has
beta2 (β
2
) – the estimate of the log odds ratio of the probability of MDI in individuals who
vary by study
tau (τ) - an estimate of the variation of the predictive feature under investigation between
studies
sigma () - an estimate of the variation of the predictive feature under investigation
between individuals
The following model was the “reduced hierarchical with study effect” estimating
independent intercepts by study, with random effect on predictor within study alone,
[2] Logit(p
ik
) = β
0i
+ β
1i
t
ki

1i
~ N(β
1
, τ
2
β1
)
Finally, a “fixed effect model” allowing intercept to vary by study, with fixed effect on
predictor within study, was used
[3] Logit(p
ik
) = β
0i
+ β
1
t
ik
The previously described difficulties interpreting data on remission, time since
chemotherapy, pulse, blood pressure, respiratory rate and respiratory compromise meant
they were excluded from meaningful analysis (see Chapter 7). The effect of tumour type
could be examined using a fixed effects model only because the fitting of 528 random effect
estimates (22 studies * 24 tumour-types) was not feasible.
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Results of model comparisons
Full hierarchical model
Full hierarchical analyses with individual effects were undertaken with (a) all patient data
and (b) in the subset of patient data where multiple episodes were permitted. The latter
approach provides a fairer approximation of the effect of variation attributable to the
individual patient
The full comparison is provided in Appendix 24. In brief, estimates of the predictive value of
the candidate variables were largely unchanged when approached with either information
from every patient-episode, or only those patient-episodes from studies where multiple
episodes per patient were permitted, for example in temperature (beta-estimates of 0.81
will all data, 0.77 with multiple-entry-studies only data). Estimates of the individual variation
were also largely similar, with the ‘temperature’ data having individual level standard
deviation estimates of 1.1 for all data and 1.4 for multiple-entry-studies . Features where
differences in parameter estimates were shown included patient age (which had a very small
absolute change in the predictive estimate), chemotherapy intensity (where the estimate of
the predictive value of Haemopoetic Stem Cell Transplant, HSCT, varied markedly; see later
for discussion) and absolute neutrophil count. Differences in patient-related variability were
seen in central line type (where the use of multi-patient data to estimate the individual
effect showed reduced variation), out-patient status, and the presenting features of
temperature, shock, severe mucositis and clinical “unwellness” which demonstrated greater
variability when estimated from multi-episode samples.
Reduced hierarchical model
Comparing the reduced model (see equation [2] above) to the full model led to very little
difference in the association estimates for each candidate predictor. The differences
introduced by assessing multiple episodes within patients were assessed by comparing the
predictor estimates from the dataset with every patient-episode and a subset with just one
episode per patient (full data in Appendix 5). This showed only meaningful difference when
all episodes (examined as independent events) were compared with one-episode-per-
patient; IL-6 was significantly less predictive of MDI when only one episode per patient was
included.
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Fixed effects model
Given the limited benefits demonstrated from the full multilevel model, a further
assessment of the differences between the hierarchical and simple fixed effects model was
undertaken. This demonstrated no significant difference in predictive estimates for the
univariate predictors of MDI. (The results of this are shown in 26.)
Between-study consistency
As between-study consistency was considered important, an analysis of the predictors was
undertaken per-study to assess this.
Univariate predictors of MDI
The fixed effect model was used to examine twenty-six different candidate predictors of
MDI. Of these, twelve were significant at p<0.05, and six between p=0.05 to 0.15. The values
of the strength of association are considered in order of statistical significance (see Table
25). The assessment of the effect of tumour type relative to acute lymphoblastic leukaemia
(the most common diagnostic group) is shown in Figure 43.
Figure 43: Odds ratio of MDI by tumour type relative to ALL
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Table 25: Fixed-effect predictors arranged by order of statistical significance
Predictor name OR 95% CI p-value
% of episodes
with missing
data
Temperature 1.9 1.61 to 2.24 2.60E-14 72%
Log (white cell count) 0.72 0.66 to 0.78 1.40E-13 72%
Severely unwell 2.2 1.78 to 2.73 2.20E-13 72%
Log (IL-6) 2.1 1.71 to 2.63 4.40E-12 72%
Log (absolute monocyte
count) 0.8 0.75 to 0.86 4.50E-11 49%
Log (IL-8) 1.8 1.48 to 2.28 1.70E-08 38%
Log (platelets) 0.8 0.74 to 0.87 2.10E-08 45%
Log (absolute neutrophil
count) 0.92 0.9 to 0.95 1.20E-07 45%
Chemo.intensity - Low 1 45%
Chemo.intensity - Standard 2.2 1.56 to 3.04 4.00E-06 91%
Chemo.intensity - HSCT 1 0.83 to 1.22 0.96 45%
Shock 2.4 1.69 to 3.43 1.60E-06 98%
Log (PCT) 1.9 1.35 to 2.73 0.00033 91%
Out.patient 0.7 0.53 to 0.92 0.0078 79%
Cvl.type - None 1 53%
Cvl.type - Port 1.1 0.66 to 1.7 0.8 39%
Cvl.type - Hickman 1.4 0.87 to 2.32 0.17 69%
Cvl.type - Untunnelled 3.1 0.95 to 9.55 0.054 0%
Relapse 1.4 1.08 to 1.87 0.012 88%
Mucositis 0.89 0.8 to 1 0.052 48%
Severe.mucositis 0.76 0.55 to 1.03 0.078 10%
Marrow 1.5 0.92 to 2.46 0.095 10%
Haemoglobin 1 0.99 to 1.1 0.11 88%
Log (CRP) 1.1 0.96 to 1.19 0.25 63%
Age.days 1 1 to 1 0.38 13%
Central venous line 1.2 0.82 to 1.65 0.4 60%
Diastolic BP 0.99 0.97 to 1.02 0.47 47%
Sex - F 1 1 to 1 67%
Sex - M 0.96 0.84 to 1.1 0.56 43%
Remission 0.98 0.74 to 1.29 0.87 39%
Systolic BP 1 1 to 1 0.92 38%
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These results suggest the following clinically suspected covariates may be associated with
MDI: the presence of an untunnelled central line, the clinical appearance of significant
unwellness, of documented cardiovascular compromise (shock), a high temperature, raised
serum biomarkers, low white cell counts and platelets, a diagnosis of AML, and undergoing
treatment for relapsed disease. The following potential associations are more clinically
surprising; osteosarcoma/Ewings sarcoma patients, and patients with more severe
mucositis, are associated with a decreased risk of MDI.
Patient age has been shown to be associated with the risk of death from FN [250] with
teenagers at greater risk of dying. The reasons for this are unclear, and may relate to an
increased risk of MDI, delayed presentation to hospital, or a reduced physical reserve than in
younger children. Infants too (those less than 12 months old) are felt to be at greater risk,
potentially through a natural lack of immunity to disease or the subtlety of clinical signs of
severe illness. However, data from the IPD analysis suggest that there is no clear relationship
between age and rate of MDI (also see Appendix ).
The consistency of these features across studies can be examined graphically and by fitting
the model direct to each. The general approach is illustrated using temperature (showing
the approach to linearity and consistency), elements of the full blood count (where study-
level variation was hypothesised to be important), and the challenges of presenting large
amounts of data in the different tumour types. The issue of chemotherapy intensity is also
examined in detail, exploring the inconsistencies found. Finally, the data on inflammatory
biomarkers, which were present in very few datasets and could contribute little to the
multivariable analyses, are explored in depth.
Temperature
Figure 44 shows the association between probability of infection and temperature assessed
in each individual study. The dataset of Spassova shows a negative relation between
temperature and risk of MDI. This outlier may be partly explained by the inclusion of a
hypothermic (rather than febrile) patient with maximum measured temperature of 35
o
C.
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Figure 44: Relation of MDI and temperature by study. Data points indicated by rug plot.
This is demonstrated even more clearly by combining each study estimate onto a single
graph Figure 45, and in further analyses, removing the hypothermic outlier reduced the
inconsistency importantly.
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Figure 45: Relation of MDI and temperature by study
An alternative explanation for this finding is that temperature has a non-linear relationship
with the probability of infection, with both very low and very high readings being linked to
increased risk of MDI. Such a relationship was assessed by using fractional polynomials with
common transformations of [-2, -1, -0.5, log, 0.5, 1 or 2]. These did not improve AIC values.
A centralised transformation of the temperature covariate (taking 37
o
C, normal body
temperature, away from each reading) was then used to comparing the linear model fit
using quadratics. This led to statistically insignificant decrease in residual deviance and a
small decrease in AIC (2832 vs. 2827).
Using splines with df= 2 , 3 or 4 led to one transformation of the formula which showed a
statistically significant improvement in fit (placing a single knot at 38.3
o
C; improved residual
deviance p=0.008) but this benefit was of marginal benefit when assessed by AIC (2832 vs.
2828).
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A major challenge in assessing the possibility of non-linear associations between the
probability of infection and temperature comes from the inclusion criteria of the datasets.
Only a very few datasets have selected patients without fever (or with hypothermia) and
infection. As the data are sparse, the best fit can really only be based on when fever,
measured as >37.5
o
C in most of these data, is present.
Full blood count
Examining the relationships between the various subcomponents of the common blood test
“full blood count” is instructive in assessing the potential utility of this extremely simple and
widely available test, and examining for between-study effects. This test assesses aspects of
the bone marrow’s formation of the cellular components of blood, so may reflect the
amount of bone marrow suppression induced by treatment, or in the case of cancer
involving the bone marrow, disease.
There is evidence of the expected association (OR 0.8, 95% CI 0.75 to 0.86) between a lower
absolute monocyte count (AMC) and risk of MDI is consistent across all studies that report
this variable (see Figure 46). This is also seen – though less strongly (OR 0.92, 95% CI 0.9 to
0.95) with the absolute neutrophil count (ANC, Figure 62). This is of clinical importance as
the currently “valued” element of the differential white cell count is the ANC, rather than
the AMC.
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Figure 46: Relation of MDI and ln(AMC) by study.
Haemoglobin (Hb) and platelets are importantly distinct from differential white cell counts,
in that low levels may be supplemented by transfusion of blood components. As policies to
undertake such transfusions vary between clinical centres and have varied across time, it is
important to examine for study-level variation in the predictive power of these variables,
before accepting the overall estimate of association to be correct.
The relationship between Hb and risk of MDI appears less consistent than the white cell
subsets (see Table 26) with some datasets estimating a positive relationship between
increasing Hb values and risk of MDI, and the remainder a small negative relationship. No
individual dataset has a “conventionally statistically significant” estimate of association, and
no dataset has an estimate incompatible with the overall IPD estimate. The potential
explanation of transfusion policies varying does not seem to apply in this group; while there
is variation, it is generally in the trigger-level at which to transfuse, and aims to raise Hb to
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approximately 12 g/dL. If this was a strong effect we should see both a bimodal distribution
of Hb values and clear clustering of MDI cases around this value. The distributions of Hb
shown in the previous chapter do not support this, nor do the distribution of MDI cases. As
such, the most plausible explanation of these findings is chance variation.
Table 26: Per study estimates of haemoglobin (g/dL) in predicting MDI
Study OR 95% CI p-value
BaselSPOG 0.92 0.71 to 1.19 0.49
BernSPOG 3.6 0.53 to 25.53 0.2
BonnSPOG 1.1 0.9 to 1.27 0.48
EORCT-XIV 0.79 0.49 to 1.26 0.32
EORTC-IX 1.2 0.98 to 1.52 0.06
EORTC-XI 0.98 0.87 to 1.12 0.81
EORTC-XII 0.85 0.72 to 1.01 0.06
Hakim 0.88 0.48 to 1.62 0.68
Kitanovski 1.1 0.95 to 1.36 0.16
Klaassen 1.1 0.77 to 1.45 0.72
Sung 1.1 0.99 to 1.28 0.07
Tissing 1.2 0.8 to 1.75 0.39
ZurichSPOG 1.1 0.96 to 1.3 0.16
IPD Model 1 0.99 to 1.11 0.11
When examining the association between MDI and platelet levels, there is cross-study
consistency and the expected increased likelihood of MDI with low levels. This may be a
response to infection (with platelet consumption being a common finding in bacterial sepsis)
or part of the increased susceptibility one expects with marrow suppression.
Page 185 of 410
Tumour type
The strength of this IPD meta-analysis becomes apparent when the variable “tumour type”
was examined as an individual-study level predictor (see Figure 43).
Graphically demonstrating the strength of association in such large and complex datasets is
challenging. A traditional systematic review approach of forest plots would need to show 23
different plots. An alternative would be to display a heat map of the data points (see Figure
47). This can demonstrate that, for most tumour types, the point estimates (which are very
imprecise – see Appendix 27, Tumour type
Table 57) tend in the same direction (shaded greens indicating an association with reduced
risk of MDI, or orange/reds indicating an association with an increased risk). Blue represents
an estimate of about unity, and white an area with no data.
Figure 47: Heatmap of strength of association (OR) between tumour type and MDI
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While this graphical display does show concisely a great deal of information from varied
sources, it fails to illustrate the uncertainty around each odds ratio displayed, providing only
the point estimate, and should be an aid to interpretation alongside the numerical data.
Although the finding of an increased risk of MDI in AML is widely acknowledged, the
unexpected finding of an association between a reduced chance of infection in patients with
bone sarcomas and febrile neutropenia requires further examination in a multivariable
model, as it may affect the views of clinicians on implementing a reduced intensity therapy
for low-risk patients.
Chemotherapy intensity
As discussed in Chapter 6, the intensity of chemotherapy refers to a concept encompassing
the likely duration and severity of complications attributable to the cytotoxic agents used to
treat cancer. For the purposes of the PICNICC analysis, a three-level ordered categorical
approach was used: Low, Standard and HSCT; (commonly referred to as “bone marrow
transplant”), but only two studies provided data on HSCT.
Table 27: IPD analysis for chemotherapy intensity
Predictor name OR 95% CI p-value
chemo.intensity - Low 1
chemo.intensity - Standard 2.2 1.56 to 3.04 0.000004
chemo.intensity - HSCT 1.0 0.83 to 1.22 0.96
The IPD analysis (Table 27 ) contradicts the clinical experience that HSCT patients, who have
undergone an extremely intense and immunosuppressive treatment, have a higher rate of
documented MDI, than those undergoing standard or low-intensity therapy. This “expected”
view is supported by the Genoa dataset (
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Table 28 )
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Table 28: Observed association of chemotherapy intensity including HSCT from informative studies
Chemo intensity n Patients OR 95% CI p-value
Genoa Low 23 1
Standard 504 1.1 0.52 to 2.29 0.82
HSCT 176 1.5 0.96 to 2.46 0.08
PINE Low 218 1
Standard 577 2.5 1.21 to 4.98 0.01
HSCT 17 1.0 0.66 to 1.56 0.96
The Genoa dataset included patients currently undergoing HSCT treatment, and in the
immediate period after this, unlike the PINE data where the HSCT patients largely consists of
those who had recovered from the intensively treated phase and were recuperating with a
greatly improved immune response and fewer other toxicities. As such, the HSCT data from
the two groups appear to reflect different clinical phenotypes, and the clinical interpretation
is challenging.
The relationship between standard intensity and chemotherapy is less contradictory (Figure
48), although quite heterogeneous between groups:
Figure 48: Association of standard intensity vs. low intensity chemotherapy and MDI
The variation in estimates of increased risk of MDI with chemotherapy intensity may be due
to chance, to the changes in intensity of therapies across eras, or to different definitions of
intensity. There is little to support the latter two explanations in these datasets.
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Other clinical predictors
Many of the findings from the univariate analysis are as expected, and show consistency
across the datasets (for further details, see Appendix 27). These findings include the
associations of relapsed disease, out-patient status, severe cardiovascular compromise, the
gestalt appearance of a patient being unwell, and central line type or presence. The absence
of an association with patient age, gender and marrow involvement is also consistent.
The relatively surprising association suggested with increasingly severe mucositis decreasing
the risk of MDI was consistent across studies, though no single study would have detected
this association, and using the grossly categorical approach of “severe” vs. “non-severe” also
dilutes this association (see Table 29).
Table 29: Study level associations of mucositis with MDI
Predictor name OR 95% CI p-value
BaselSPOG Mucositis (per grade) 0 0 to infinite 1
Severe mucositis 0 0 to infinite 1
BernSPOG Mucositis (per grade) 0.78 0.57 to 1.07 0.1
Severe mucositis 0.51 0.18 to 1.45 0.21
BonnSPOG Mucositis (per grade) 0.66 0.19 to 2.3 0.51
Severe mucositis 0 0 to infinite 1
Hakim Mucositis (per grade) 1.1 0.78 to 1.51 0.66
Severe mucositis 1.3 0.45 to 3.74 0.64
Kitanovski Mucositis (per grade) 0.99 0.59 to 1.65 0.98
Severe mucositis 0.71 1.88 to 1.88 0.63
Klaassen Mucositis (per grade) 0.91 0.67 to 1.25 0.57
Severe mucositis 0.78 0.28 to 2.16 0.64
Lehrnbecher Mucositis (per grade) 0.75 0.55 to 1.02 0.07
Severe mucositis 0.41 0.12 to 1.38 0.15
Spassova Mucositis (per grade) 1 0.85 to 1.3 0.69
Severe mucositis 1.1 0.59 to 2.15 0.72
Sung Mucositis (per grade) 0.73 0.26 to 2.05 0.55
Severe mucositis 4.6 1.05 to 19.11 0.04
ZurichSPOG Mucositis (per grade) 0.8 0.54 to 1.19 0.26
Severe mucositis 0.5 0.11 to 2.29 0.37
PINE Severe mucositis 0.54 0.29 to 1.02 0.05
IPD
estimate
Mucositis (per grade) 0.89 0.80 to 1.00 0.05
Severe mucositis 0.76 0.55 to 1.03 0.16
Shaded row shows single dataset with only dichotomous mucositis
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Biomarkers
The datasets providing information on the four biomarkers studied in the PICNICC
collaboration (CRP, IL-8, IL-6 and PCT) were much smaller than for many of the other
potential predictor variables (1606 episodes with CRP, 485 with IL-8, 456 with IL-6, and 123
with PCT) and represents a smaller subgroup of the biomarkers studies. As explored
extensively in the systematic reviews (with update) the desire to find effective early serum
markers of infection is strong and an extension of the PICNICC project with further data
collection and synthesis may well be warranted.
CRP was assessed in the greatest number of datasets, and showed a repeatedly statistically
non-significant association with risk of MDI.
Table 30: Association of ln(CRP) with risk of MDI
Predictor
name
OR 95% CI p-value
BaselSPOG ln(CRP) 2.1 0.55 to 7.87 0.28
BernSPOG ln(CRP) 0.95 0.7 to 1.3 0.73
BonnSPOG ln(CRP) 1.2 0.44 to 3.25 0.72
Kitanovski ln(CRP) 1.9 0.99 to 3.77 0.05
Lehrnbecher ln(CRP) 0.91 0.74 to 1.13 0.42
Silva ln(CRP) 0.77 0.38 to 1.56 0.47
Spassova ln(CRP) 1.2 0.95 to 1.51 0.13
Tezcan ln(CRP) 1.1 0.8 to 1.44 0.66
Tissing ln(CRP) 0.94 0.72 to 1.24 0.67
ZurichSPOG ln(CRP) 1.5 0.99 to 2.25 0.06
IPD
estimate 1.1 0.95 to 1.18 0.25
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Figure 49: Studies with superimposed IPD estimate (black)
The data for IL-6 are more suggestive of a discriminatory value, with varying but consistent
associations. IL-6 values appear to be most strongly associated with gram-negative bacterial
infections; if a larger proportion of the 18 cases of MDI in the Kitanovski study were of this
type, it may explain the very strong association seen here. Removing this study led to a
smaller, but still significant, OR of 1.88 (95% CI 1.52 to 2.33).
Table 31: Association between ln(IL-6) and MDI
Predictor name OR 95% CI p-value
Kitanovski ln(IL-6) 7.1 2.61 to 20.88 0.00
Lehrnbecher ln(IL-6) 2.3 1.73 to 2.99 0.00
Spassova ln(IL-6) 1.4 0.65 to 3.23 0.37
Styjewski ln(IL-6) 1.1 0.74 to 1.75 0.54
IPD
estimate 2.10 1.71 to 2.61 4.4 x10
-12
IL-8 has been used in the definition of a group of individuals who have received no antibiotic
despite being febrile and neutropenic. In this IPD analysis, IL-8 was confirmed as being a
potentially very important biomarker. It is the very low estimated intercept values of IL-8
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which are of particular interest, giving the estimated proportion of MDI in patients with
undetectable IL-8 (see Table 32).
Table 32: Association between ln(IL-8) and risk of MDI
Predictor
name
OR 95% CI p-value Estimated
intercept
(proportion
MDI)
95% CI
BonnSPOG ln(IL-8) 3.6 0.71 to 19.04 0.12 0 0 to 0.51
Lehrnbecher ln(IL-8) 1.8 1.37 to 2.37 0.00 0.01 0 to 0.04
Spassova ln(IL-8) 1.7 0.96 to 3.12 0.06 0.07 0 to 0.51
Styjewski ln(IL-8) 1.9 1.1 to 3.28 0.02 0.04 0.01 to 0.22
Tissing ln(IL-8) 1.9 0.94 to 4 0.08 0.01 0 to 0.27
IPD estimate 1.8 1.48 to 2.28 1.7E-08
Figure 50: Association of ln(IL-8) with risk of MDI
The paucity of overall data limits the more extensive exploration of this biomarker.
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Procalcitonin had the fewest data of the biomarkers studied, despite being used widely in
adult respiratory medicine and critical care to help define when to refrain from commencing
or discontinuing antibiotics in patients with suspected significant infections. Data were only
available from two studies.
Predictor name OR 95% CI p-value
Kitanovski ln(PCT) 4.7 1.79 to 13.72 0.00
Styjewski ln(PCT) 1.6 1.12 to 2.28 0.01
IPD Estimate 1.9 1.34 to 2.72 0.00033
While these are both strongly suggestive that PCT is an effective marker of infection, there
are far fewer data on which to base this conclusion.
Conclusion
Analysis of the univariate relationships between the patient-specific background features,
episode-specific background factors, episode-specific clinical features and episode-specific
laboratory features has confirmed many of the previously suspected associations. It also
revealed some novel and challenging findings, which may be explained by confounding as
these are univariate associations. It has not revealed any single feature as being compellingly
associated with either the absence of, or presence of, microbiologically documented
infection. The proposed use of models assessing individual clustering through hierarchical
random effects assessments, although statistically appealing and theoretically advantageous
was not shown to meaningfully affect the association estimates for each predictor, and was
therefore not pursued as a technique.
The IPD analysis confirms existing beliefs that gender is unimportant in predicting the risk of
MDI, and suggested there is not an association between age and risk of MDI. Tumour type is,
as expected, related to the risk of MDI, but this very large data set has shown an unexpected
but consistent relationship between reduced risk of MDI and a bone tumour (Ewings /
osteosarcoma) diagnosis.
Examination of the episode-specific background factors of the type of CVL, and intensity of
chemotherapy highlighted challenging aspects of the dataset. The CVL data, providing both
dichotomised and type-specific data, has shown that granular categorical data is more
informative than lumped data where there are important differences between the
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categories. It has also shown that selective inclusion criteria when creating the datasets can
lead to paradoxical results, as demonstrated in the chemotherapy intensity variable.
Although patchy in coverage between datasets, there were sufficient numbers and broad
enough coverage of out-patient status at onset of the episode to suggest a small decrease in
the risk of MDI in patients presenting from home. The clinical impression of a severely
unwell child or young person was strongly associated with the risk of MDI, as was an
increasing maximum recorded temperature. Again, the power of such large numbers
suggests an unexpected negative association between the grade and severity of mucositis,
and risk of MDI.
The objective measures of blood tests for marrow function and inflammatory biomarkers
showed evidence of the increased risk of MDI with lower platelets and white cell subsets,
particularly AMC rather than ANC. Of the serum biomarkers, there were convincing data of
the poor discriminatory value of CRP and a suggestion that IL-8 may be a very effective
marker. PCT was insufficiently studied to be as convincing in value as the other markers.
The univariate associations described in this chapter are clinically interesting, in showing
which features may be key discriminators and which we should not rely too strongly on in
practice. If one, or more, predictors had shown very high odds ratios to “rule in” MDI, or
alternatively, had extremely low intercept values, where the absence of the feature could
“rule out” MDI, and that this feature was consistent and reproducible across data sets, then
there would be no need to develop this analysis further.
In the absence of such a feature, the exploration of ideas of how the variables are related to
each other, and where one variable provides information above and beyond that provided
by others, is needed for an efficient CDR to be produced. Multivariable approaches provide
this next step, and are described in the next chapter.
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Chapter 9: Results of the multivariable analyses
Introduction
The primary clinical aim of the IPD analysis was to quantify the risk of adverse clinical
outcomes; primarily microbiologically documented infection in children and young people
undergoing treatment for malignant disease presenting with febrile neutropenia.
To recap briefly, the previous chapter showed how univariable analysis did not indicate any
single feature was extremely strongly associated with MDI, or its absence, in this population.
A new multivariable risk prediction model was therefore required, and this chapter details
how the model was built and evaluated. The methods are fully discussed in Chapter 6.
Data selection
Data selection was very challenging, as there were a high proportion of studies with
uncollected variables which considerably reduced the number of patients, episodes and
studies available for a complete case analysis. Therefore, a decision was made to work with
a dataset containing 1,000 episodes, estimated to contain 200 events of MDI and produce a
20:1 ratio for the analysis of 10 separate predictor variables. The method used to derive this
dataset was based on taking the univariate predictors with greatest statistical significance
and removing incomplete cases until the limit of fewer than 1,000 episodes was reached.
The steps undertaken to reach this dataset are demonstrated in Table 33.
Table 33: Data available for complete case analysis
Constituents Episodes Patients Studies Proportion
of episodes
with MDI
Temp 2461 1798 15 28%
Temp + Severe Unwell 1486 925 10 27%
Temp + Severe Unwell + ANC 1348 849 9 27%
Temp + Severe Unwell + ANC + plts 1148 768 8 24%
Temp + Severe Unwell + ANC + plts + wcc 1101 742 7 24%
Temp + Severe Unwell + ANC + plts + wcc + tumour 1101 742 7 24%
Temp + Severe Unwell + ANC + plts + wcc + tumour + OP 1101 742 7 24%
Temp + Severe Unwell + ANC + plts + wcc + tumour + severe
mucositis
965 616 7 25%
Temp = temperature, ANC = absolute neutrophil count, plts= platelets, wcc = white cell count, tumour
= tumour type, OP = out-patient status
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Model selection
The model finally selected to produce the most accurate prediction of the risk of MDI
proceeded following the pre-specified method (See Chapter 6). This was by forward
selection including variables with p<0.15, commencing with the demographic details and
assessing model improvements using Akaike’s Information Criterion (AIC; a measure of the
goodness of fit of a model to the data). On the basis of this, variables were incorporated or
rejected as shown in Table 2.
Table 34: Selection of model prediction terms
Variable p-value for
parameter
Model
AIC
NRI (95% CI) AUC ROC Included or
rejected
Base case 1069 0.646
Age in days 0.689 1070 NA 0.645 Rejected
Tumour type 0.003 1076 0.012 (0.004 to 0.02) 0.644 Included
CVL 0.625 1076 0.001 (-0.001 to 0.004) 0.645 Rejected
Out patient 0.668 1076 0.008 (0.002 to 0.015) 0.644 Rejected
Temperature 0.00002 1058 0.015 (0.006 to 0.024) 0.671 Included
Shock 0.392 1032 NA 0.670 Rejected
Mucositis 0.295 1031 NA 0.672 Rejected
Severely unwell 0.000005 1039 0.01 (0.001 to 0.018) 0.697 Included
Haemoglobin 0.012 1035 NA 0.701 Included
log(Platelets) 0.028 1029 NA 0.703 Included
initially,
rejected when
WCC included
log(WCC) 0.00003 1021 0.018 (0.007 to 0.028) 0.723 Included,
Rejected plt
log(ANC) 0.585 1012 NA 0.723 Rejected
log(AMC) 0.0002 999 NA 0.736 Included
Antibiotics
(sensitivity)
0.989 1017 NA (Essentially
unchanged)
CVL – central venous line; WCC – white cell count; ANC – absolute neutrophil count; AMC - absolute
monocyte count. NRI – net reclassification improvement on previous model, in classification of low
risk (<5% MDI)
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The final model
The final model included:
Tumour type + Temperature + Severely unwell + Hb + log(WCC) + log (AMC)
Logit(pMDI
ik
) =  + β
0k
+ β
1
tumour type
i
+ β
2
temperature
i
+ β
3
unwell
i
+ β
4
Hb
i
+ β
5
log
e
(white cell count)
i
+ β
6
log
e
(absolute monocyte count)
i
The value of the model can be assessed by comparing it to simpler versions to evaluate if the
increase complexity can produce meaningful benefits. When the full model was compared
with the simplest model possible, using only study-ID to predict the risk of MDI, this
produced a net reclassification improvement (NRI; a measure of the clinically relevant
improvement of identifying children correctly as infected or non-infected) of 0.079, and AUC
ROC improved from 0.646 to 0.736. Using clinical variables only (tumour type, temperature,
severely unwell) gave an AUC ROC of 0.697. The addition of the simple full blood count
variables (haemoglobin, white count and monocyte count) improved the prediction further
with an NRI of 0.042, and AUC ROC improved to 0.736.
The predictive estimates of the variables were then revised using bootstrapping, as
described in Chapter 6, re-sampling 5,000 iterations with replacement. For most predictive
estimates, there appeared to be little bias (see Table 35). For those data items with sparse
data, for example, the tumour type GCT (n=7) the bootstrapped estimates were not
normally distributed and the median estimate is markedly different than that initially
derived (see Appendix 28. Detailed estimates from final multivariate model).
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Table 35: Selected parameter estimates and bootstrap values
AML GCT
Osteo-
sarcoma RMS
Temp-
erature
Severely
unwell
Haem-
oglobin log(WCC) log(AMC)
Original
estimates 0.655 -0.069 -1.193 -0.244 0.566 0.786 0.180 -0.299 -0.209
Bootstrap
Median 0.661 -0.148 -1.229 -0.253 0.588 0.809 0.182 -0.309 -0.215
Lower limit
95%ile 0.128 -16.046 -2.889 -0.952 0.296 0.400 0.081 -0.516 -0.332
Upper limit
95%ile 1.158 1.832 -0.288 0.393 0.905 1.203 0.292 -0.103 -0.099
Difference 0.006 -0.078 -0.036 -0.008 0.022 0.023 0.002 -0.010 -0.005
% variation 1% 113% 3% 3% 4% 3% 1% 3% 3%
The shrinkage estimate for the model [243] was calculated to be 0.97, in keeping with the
very small differences produced by the bootstrap values.
Validation
The new model was tested by assessing the calibration (comparing the actual proportions of
MDI in patients with the predicted proportion of MDI) and by assessing it’s discriminatory
value in classifying patients at very low risk (<5%) of MDI
Calibration
In order to test the model’s calibration, we extracted the predicted risk of MDI using the
derivation dataset, but using a generalised intercept based on a meta-analysis of the study-
variable intercepts from the model, rather than the study-specific intercept of the individual
patient, in an attempt to produce a result more likely to be applicable in future clinical
practice (as intercepts for each practice are unlikely to be available in reality). These were
then shown graphically by plotting the predicted result against actual outcomes, grouped by
either deciles of predicted risk (i.e. the predicted probability from those with <10%, 10% to
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<20%, etc.) or by deciles of population (i.e. the predicted probability from the first 10%, 20%,
etc.)
Figure 51 shows the actual average % of MDI per predicted MDI decile (0-10%, 10-20%, etc.),
comparing the actual rate of MDI in these patients with the value calculated from the model.
It also shows, on the categorical axis, the percentage of patients who fall into the risk
grouping.
Figure 51: Discriminatory performance of the new model
An alternative visualisation is to plot the grouped observations against each other, see
Figure 52.
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Figure 52: Calibration plot of the new model
This Figure shows the distribution of predicted probabilities as a rug plot, with the height of
the line showing the frequency of the predicted probability. The group estimates are shown
in deciles of the population, rather than deciles of the predicted values, as triangles. The
dashed line of “perfect fit” at 45
o
shows where predicted and actual probabilities would
perfectly intersect; the dotted line is a Lowess smoothed curve of the predictive versus
actual values.
These figures show that the predictive value of the model is very close to the actual
probability of MDI across the range of predictions, showing no major systematic bias, though
there is a slight underprediction of risk between approximately 0.2 and 0.4.
The use of bootstrapped median parameter estimates made no effective difference to the
model’s predictive ability (see Appendix 28. Detail, Figure 65).
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Discrimination
Assessments of discriminatory validity were based on a categorising the results to lower
than 5% chance of MDI or greater. This value was chosen as discussed in Chapter 6 by an
expert consensus with parent/carer involvement to reflect a very conservative estimate of
acceptable risk of MDI. This was the same cut-off as the NRI calculation for model derivation.
The results are shown in ROC space in Figure 53, demonstrating an AUC (also known as C-
index) of 0.723 (95% CI by bootstrapping 0.685 to 0.785).
Figure 53: Model discrimination at in ROC space
An alternative approach to this is to examine how many patients fall in the correct category,
and to how many this rule would apply. This is shown in Table 36 where the model places 57
patients (6% of the total) into a low risk category, of whom 2 (~4%) were misclassified and
have an MDI. This type of dichotomous “rule” use of the model can also be described by its
sensitivity (99.2%) and specificity (7.5%).
Table 36: Discrimination matrix (2x2 table) for 5% risk of MDI
MDI No MDI
High risk 234 676
Low risk 2 55
Sn= 99.2% Sp = 7.5%
(LR is 6% total patients and 4% LR patients are misclassified)
Specificity (%)
S
e
n
s
i
t
i
v
i
t
y
(
%
)
0
2
0
4
0
6
0
8
0
1
0
0
100 80 60 40 20 0
Page 202 of 410
Cross validation
Validation was undertaken by comparing the results of the initial analyses against the data
from all bar one of the studies in turn (cross validation of intrinsic prognostic performance),
without significant differences in calibration (see Appendix 28. Detail) or discrimination (see
Table 37).
Table 37: Calibration and discrimination values of all-bar-one analysis
Study removed AUC ROC Sensitivity Specificity Proportion in
LR group
Misclassified
BaselSPOG 0.724 99.2% 7.6% 5.9% 3.5%
BernSPOG 0.718 99.0% 8.1% 6.4% 3.8%
BonnSPOG 0.723 99.1% 7.9% 6.1% 3.5%
Hakim 0.710 100.0% 3.9% 2.9% 0.0%
Kitanovski 0.712 99.1% 7.2% 5.7% 3.9%
Klaassen 0.766 98.2% 11.7% 9.6% 3.8%
ZurichSPOG 0.720 99.1% 7.3% 5.7% 4.0%
The discrimination qualities were also tested by bootstrapping (2,000 samples, with
replacement, comparing predicted risk of MDI against actual risk) reporting the sensitivity,
specificity, percentage of patients classed as low risk and percentage of patients
“misclassified” – with an MDI in the low risk group.
Table 38: Bootstrapped estimates of discrimination
Median
Lower 95%
confidence
limit
Upper 95%
confidence
limit
Sensitivity 99.2% 97.8% 100.0%
Specificity 7.6% 5.6% 9.7%
Proportion in LR group 5.9% 4.3% 7.4%
Misclassified 3.2% 0.0% 8.4%
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Sensitivity analyses
The PICNICC model for the prediction of probability of MDI was robust to cross validation of
intrinsic prognostic performance and bootstrapping, and the heuristic estimate of uniform
shrinkage was also low (0.97), all congruent with a prediction model which was not
overfitted or overoptimistic.
A sensitivity analysis adding antibiotic type to the model was planned in the protocol. This
did not change the predictive value of the model (see Table 34). This is to be expected as a
standard set of antibiotics tends to be given in each hospital, without reference to any
variable which may be predictive of MDI.
A series of further sensitivity analyses were undertaken addressing other potential
challenges to validity. Examining the model for evidence of study-level variation is important
as only seven of the 22 datasets could contribute sufficient variables to provide information
for the model. If these studies were importantly different than those which could not be
included, the validation procedures undertaken could fail to give an accurate estimate of
how useful the model may be in practice.
This potential problem was addressed by undertaking a sensitivity analysis, where an
average value for each of the missing variables was used where it had been unrecorded. This
is a simple initial step in addressing missing data through imputation, and further research
could consider multiple imputation techniques. To fit this “average imputed” model, the
mean values of each continuous variable drawn from the entire dataset was placed where
an NA was recorded. The “severely unwell” variable was coded at 0.17; the proportion of
episodes where severely unwell had been recognised. The tumour type was coded as “ALL”;
this was the most common diagnosis, and also the reference diagnosis for tumour type.
Using these values, the model showed much worse discrimination, with an AUC ROC of
0.619 (see Figure 54), as expected with the insertion of large quantities (~50%) of
undiscriminating data.
Page 204 of 410
Figure 54: ROC curve for “average imputed” sensitivity model
The test accuracy values were similarly reduced (see Table 39) for a cut-off of 5% chance of
MDI for low-risk.
Table 39: Discrimination values for “average imputed” sensitivity model
Original
Sensitivity analysis
dataset
Sensitivity 99.2% 98.1%
Specificity 7.6% 4.0%
Proportion in LR group 5.9% 3.4%
Misclassified 3.2% 15.6%
The model also demonstrated worse calibration, as seen by the distribution of actual versus
predictive probabilities in Figure 55, particularly in the “bunching” of probabilities in the
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~20% range. The plot demonstrates that this sensitivity analysis data typically
underestimates probabilities, but follows a reasonably similar slope for most of the curve.
Again, this is highly likely to be due to the very large amount of non-discriminatory data.
Figure 55: Calibration plot for sensitivity analysis
Examining the parameter estimates obtained by fitting the model to this “average imputed”
data shows the predictive values of clinically recognised “unwellness”; temperature, WCC
and AMC remain similar. The point estimates of the predictive values of some tumour types
changes, and the value of haemoglobin as a predictor is also reduced, although remains
predictive (see
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Table 40).
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Table 40: Parameter estimates in model fitted to original and sensitivity analysis data
Original dataset
OR (95% CI)
Sensitivity analysis
OR (95% CI)
AML 1.92 1.17 to 3.17 1.15 0.91 to 1.45
Brain 0.63 0.3 to 1.35 1.39 0.79 to 2.43
Carcinoma NA NA 0.39 0.05 to 3.11
Ewings 0.53 0.14 to 1.93 0.50 0.3 to 0.83
GCT 0.93 0.17 to 5.2 0.91 0.3 to 2.76
Hepatoblastoma 1.61 0.53 to 4.91 0.13 0.02 to 0.98
High grade Brain 0.71 0.29 to 1.75 0.78 0.49 to 1.23
Hodgkins 0.67 0.17 to 2.63 0.97 0.55 to 1.73
HR-NBL 2.51 0.69 to 9.17 0.39 0.23 to 0.67
LCH NA NA 1.33 0.41 to 4.37
LGBrain NA NA 0.83 0.31 to 2.25
LR-NBL NA NA 0.41 0.09 to 1.93
Lymphoma NA NA 0.67 0.37 to 1.21
NBL 1.6 0.61 to 4.23 1.52 0.96 to 2.42
NHL 0.62 0.34 to 1.16 0.70 0.5 to 0.96
Nonmalignant NA NA 1.02 0.33 to 3.17
Osteosarcoma 0.30 0.1 to 0.92 0.36 0.21 to 0.6
Other 2.22 0.49 to 9.99 0.42 0.18 to 1
Retinoblastoma 1.73 0.32 to 9.26 0.17 0.02 to 1.4
RMS 0.78 0.42 to 1.46 0.76 0.5 to 1.17
Sarcoma 1.21 0.24 to 6.03 0.96 0.48 to 1.92
Solid NA NA 0.43 0.27 to 0.69
Wilms 0.61 0.17 to 2.24 0.78 0.47 to 1.29
Temperature 1.76 1.33 to 2.34 2.03 1.61 to 2.56
Severe unwell 2.20 1.5 to 3.21 2.20 1.63 to 2.98
Haemoglobin 1.20 1.09 to 1.32 1.06 0.99 to 1.15
ln(WCC) 0.74 0.61 to 0.9 0.75 0.67 to 0.84
ln(AMC) 0.81 0.72 to 0.91 0.87 0.79 to 0.96
In both models only the osteosarcoma has statistical significance as a predictor, AML losing
significance in the sensitivity analysis. Some of the tumour types reverse their direction of
association: brain, high-risk neuroblastoma, hepatoblastoma and retinoblastoma.
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Modified model
On the basis of the complexity of the tumour type classification and the huge uncertainty
associated with many of the subtypes, a pragmatic decision was made to simplify the values
with only AML (OR 1.5), Ewings sarcoma (OR 0.5) and Osteosarcoma (OR 0.3) being different
to ALL (OR 1, reference value). These were chosen because they were consistent in the data
sets (the sarcomas) and clinically recognised as being having a serious concern about
repeated severe infection (AML).
This model, when applied to the original derivation dataset, produced a marginally less
effective discrimination (ROC 0.709 cf 0.723) mainly through a loss in specificity (see Table
41). When used in the “average imputed” sensitivity analysis dataset it showed smoother
discrimination and calibration characteristics (ROC 0.629 cf 0.619), though remained far
worse than the original dataset (see Table 41 and Appendix 28. Detail).
Table 41: Discrimination characteristics of simplified model
Original Tumour simplified
model
Sensitivity analysis
dataset
Simplified model
in sensitivity
analysis
Sensitivity 99.2% 99.2% 98.1% 99.2%
Specificity 7.6% 5.3% 4.0% 2.6%
Proportion in LR group 5.9% 4.2% 3.4% 2.1%
Misclassified 3.2% 4.9% 15.6% 10.5%
Comparison
The new PICNICC model was compared against previously proposed and evaluated risk
stratification rules identified in the systematic reviews. The rules were selected because they
had previously shown excellent properties (Santolya [22]), had been suggested in national or
international guidelines (Alexander [134]), were very recently published (Swiss Paediatric
Oncology Group, SPOG [144]) or were extremely simple (Rackoff [141]) (see Table 42). The
Page 209 of 410
rules were all designed to stratify the risk groups into low risk and high risk and so were
assessed for their discrimination rather than calibration, and were undertaken in the
PICNICC dataset when studies which had been used to derive the rules had been excluded.
Table 42: Previous Rules for comparison
The analyses show that the previous rules have worse discrimination as the rule derived
from the PICNICC model, as measured by the AUC ROC, and one rule (Santolaya) included a
greater proportion of patients with MDI in the low risk than the high risk group.
This illustrates the dilemma that is faced when choosing a rule to use, and which has been
explored initially in Chapter 1 and will be discussed at greater length in Chapter 10. Rules
Elements Rackoff Alexander Santolaya SPOG
Patient and
disease related
factors
None AML, Burkitt lymphoma,
induction ALL, progressive
disease, relapsed with
marrow involvement
Relapsed leukemia,
chemotherapy within 7
days of episode
4 points for
chemotherapy more
intensive than ALL
maintenance
Episode specific
factors
Absolute
monocyte count
Hypotension,
tachypnea/hypoxia <94%,
new CXR changes, altered
mental status, severe
mucositis, vomiting or
abdominal pain, focal
infection, other clinical
reason for in-patient
treatment
CRP ≥90 mg/L,
hypotension, platelets
≤50,000/uL
5 points for
hemoglobin > 9 g/dL, 3
points each for white
blood cell count
<300/uL, platelet <
50,000/uL
Rule formulation Absolute
monocyte count
> 100/uL= low-
risk of
bacteremia
Absence of any risk factor =
low-risk of serious medical
complication
Zero risk factors or only
low platelets or only <7
days from
chemotherapy = low-
risk of invasive
bacterial infection
Total score <9 = low-
risk of adverse FN
outcome
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which have a high sensitivity have a low specificity, and while very “safe” apply to very few
patients. If “safety” was the greatest concern then the Rackoff rule may be considered
better than the PICNICC rule because the misclassification rate is 0% (but applies only to 3%
of episodes). If a greater misclassification rate is acceptable, with lower sensitivity but
greater specificity, then the SPOG rule could be considered a better rule as it applies to a
much greater proportion of patients (43% cf. 6%) but at the “cost” of an increased
misclassification rate (10% vs. 3.5%).
Conclusions
The PICNICC dataset allowed the development of a new clinical prediction rule to determine
the risk of microbiologically documented infection consisting of a combination of three
clinical features (tumour type, maximum temperature and the clinical appearance of being
significantly unwell) and three elements of the full blood count (haemoglobin, white cell
count and absolute monocyte count). This model was developed without including
biomarkers due to limited quantities of data. This clinical model had moderate
discrimination and calibration, with fair agreement between the predicted probabilities and
actual rates of MDI. These results were then dichotomised at a predicted value of 5% or less
to produce a low risk group. This produced a highly sensitive, through poorly specific, rule
which applied to ~6% of the population.
The model and resultant rule appeared to be robust to internal validation techniques, but
exploratory sensitivity analyses examining the model performance across the non-included
studies offer a suggestion that the inclusion of haemoglobin may not prove to be efficient
when the model is used in future populations, and that a simpler approach to tumour type
inclusion may be warranted.
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Chapter 10: Discussion
Introduction
Children with cancer in Europe now have an 80% chance of cure[2]; this has been possible
through meticulous attention to treatments directed at their cancer and supporting them
through the side effects of these therapies. The cost of this cure, in terms of intensity of
therapy and recurrent admissions with toxic effects, is considerable and a burden upon
children, young people and their families [58]. One such toxicity, fever with neutropenia
(FN), also known as “febrile neutropenia” or “neutropenic sepsis”, has been the focus of this
thesis, which has addressed the issues of balancing risks and personalising care in FN by
undertaking risk stratification at each episode to differentiate who was at higher or lower
risk of significant infection, and who was potentially eligible for alternative treatment
approaches.
What was already known
Cancer in children is curable in an increasingly large proportion of cases
Emergency readmission in patients with fever and neutropenia (FN) is the second
largest reason for hospitalisation (after chemotherapy delivery)
Risk stratification had been proposed using a number of different approaches
What this thesis adds
The range and heterogeneity of studies exploring risk prediction in paediatric FN was
captured in five systematic reviews
The reviews influenced national and international guidelines in FN
An international collaboration of 22 groups over 15 countries formed to share
information from previously undertaken studies and explore clinical and
methodological problems
A robust prediction rule was developed to predict the risk of microbiologically
documented infection
Methodological and graphical refinements of the approaches undertaken were
developed and disseminated
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Background
At the onset of this programme of study, it was clear that current practice in managing
febrile neutropenia in paediatric oncology was variable, both nationally [53] and
internationally[51, 54-55]. Some centres used a risk-stratified, reduced intensity approach,
directed by clinical decision rules (CDR) whereas others treated all children with aggressive
antibiotic therapy.
An ideal system for FN management would predict the risk of adverse outcomes, classically
the occurrence of a microbiologically documented infection, using clinical data collected at
or soon after presentation. These data can be clinically derived from the simple act of
reviewing and examining a patient, performing basic bedside tests, such as measuring pulse
rate or blood pressure. They can also be obtained from routine laboratory investigations
such as the measurement of full blood count, or from more specialised tests, including the
measurement of serum biomarkers of inflammation.
Information from these data sources would then be used in a simple system (a predictive
model) to determine the risk of a microbiologically documented infection for each episode.
The output of such a predictive model could then be used in two different ways: to decide if
the risk was low enough to allow out-patient management; and at the opposite end of the
risk scale, to consider the need for increasingly close observation and more aggressive
management. Developing predictive models needs to be done in a robust manner to reduce
the effects of chance, confounding and bias obscuring the true relationships between
proposed predictor variables and the outcome of each episode of febrile neutropenia.
Furthermore, a rule needs to be tested, to make sure it works effectively and is practically
useful.
Building a robust and reliable model required obtaining large numbers of well-collected data
from FN episodes that had occurred in different places and at different times. As with much
paediatric research, it was noted that essential problems of research in this area were linked
to the condition’s rarity and small numbers of cases, and limited collaboration in primary
studies.
The first step in addressing this issue was to systematically review existing studies to assess
published CDR and the value of serum biomarkers in performing risk stratification, to
determine whether an individual patient data (IPD) meta-analysis was necessary; to identify
suitable data sets; and to guide the development of such a study. These reviews were
Page 213 of 410
subsequently updated [115-116] to inform the development of national [128] and
international [129] guidelines in this area.
The results of the systematic reviews of CDR in the prediction of adverse outcomes from
episodes of FN included a total of 10,431 patients from thirty-four studies developing
twenty-one different CDR. Four of these rules stood out for their simplicity (using just
temperature and absolute monocyte count: Rackoff[141] rule), their predictive ability
(Santolaya [22] and SPOG [144] rules) or their current use in some areas of the UK
(Alexander [154] rule). The serum biomarkers reviews included over 5,100 episodes
assessing twenty-four different markers of inflammation or infection. Those markers with
fewer studies appeared to have better characteristics but much greater uncertainties.
Taken together, these reviews suggested a CDR for the prediction of poor outcomes during
episodes of febrile neutropenia could be effective, and that there was potential additional
value from the incorporation of serum biomarkers. None of the rules had been subject to
extensive geographical and temporal discriminatory validity assessments, and many
potential difficulties with the studies were identified.
To maximise the value of the information already collected by these and other cohorts of
children with febrile neutropenia, an international collaboration was established to facilitate
an individual-patient-data (IPD) meta-analysis to develop and test a new prediction
model[231].
Collaboration
The “Predicting Infectious ComplicatioNs In Children with Cancer” (PICNICC) collaboration
was formed by engaging international clinical and methodological experts, authors of studies
identified in the systematic reviews, parent representatives and healthcare researchers. The
PICNICC collaboration consists of twenty-two different study groups from fifteen countries.
Although PICNICC was created via (and provided the data and drive for) this PhD, the
collaboration will continue to develop and progress research into infection in children and
young people with cancer beyond this thesis.
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Aims and Data collected
A protocol for the PICNICC IPD study was developed, registered and published prior to
commencement of the analysis.[231]
The primary aim of the IPD analysis was to quantify the risk of adverse clinical outcomes
according to clinical variables in children and young people undergoing treatment for
malignant disease who present with an episode of febrile neutropenia; and to develop a new
risk prediction model. A further aim was to develop methodological approaches to IPD
analysis in the development of predictive models, including the graphical display and
communication of such information. This thesis focused on the outcome of microbiologically
documented infection (MDI) because it was the most completely reported and most
objective and frequently occurring significant complication of paediatric FN.
IPD information from 5,127 episodes of FN in 3,504 patients was provided for analysis. A
wide variety of malignancies were represented, in keeping with the disparate nature of
diagnoses treated in paediatric oncology/haematology units. The median age of the patients
was 6.8 years, with a range of 50 days to 25 years old; 56% of the patients were male.
Assessment of the IPD collected showed a wide range of outcomes and potential predictor
variables demonstrating marked differences in completeness, interpretation and
consistency. No dataset completely reported every item. Tumour type was the most fully
collected data item, with only four episodes having missing data; procalcitonin was only
reported in 93 episodes, and missing in 5,034 Data were largely absent because individual
studies did not record variables. The nature of the unrecorded data effectively reduced the
dataset available to undertake multivariate analysis to around 1,000 episodes in 600
patients over seven studies, still greater than the previous largest study of 447 episodes in
227 patients. [139]
The small quantity of information available on biomarkers in comparison to the clinical data
meant that they were assessed only in their univariate relationship with MDI and not as part
of a multivariable model.
Results - Associations with microbiologically documented infection
The results of univariate analyses showed expected associations between potentially
predictive covariates and MDI including the presence of an untunnelled central line, the
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clinical appearance of significant unwellness, of documented cardiovascular compromise
(shock), a high temperature, raised serum biomarkers, low white cell counts and platelets, a
diagnosis of AML, and undergoing treatment for relapsed disease. There was no clear
relationship demonstrated between age and risk of MDI. Two surprising potential
associations were found: osteosarcoma/Ewings sarcoma patients and patients with more
severe mucositis were associated with a decreased risk of MDI.
The biomarkers studied were C-reactive protein, procalcitonin, interleukins 6 and 8. Of note,
CRP was not significantly associated with MDI, and while only studied in five datasets, IL-8
was interesting in both the strength of association (OR 1.8, 95% CI 1.48 to 2.28) and very low
intercept implying that very low levels were potentially able to rule out MDI.
Mucositis was reported differently in the different study sets. More data were present on
the presence/absence of severe mucositis than a graded response. Contrary to popular
belief, the presence of increasingly severe mucositis was associated in univariate analysis
with a decreased risk of MDI, and the relationship was consistent across studies. No single
study would have detected this association. However, when subject to multivariable
analysis, mucositis no longer provided any information above the tumour type and
maximum temperature. This may be explained by the strong association between mucositis
and type of chemotherapy delivered, and the malignant diagnosis of the patient.
Multivariable model building
The multivariable predictive model derived had six components: Tumour type, temperature,
clinical description of being “severely unwell”, and the results of measurements of
haemoglobin concentration, total white cell count and absolute monocyte count. The model
is:
Logit(p(MDI)
ik
) =  + β
0k
+ β
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ik
+ β
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log
e
(absolute monocyte count)
ik
(where the subscript i refers to the i’th patient, and k the k’th data set )
This predictive model showed moderate discrimination (AUC ROC 0.736) and good
calibration between predicted and actual estimates of the risk of MDI when assessed across
the range of predictive values. The rule was robust to bootstrap and cross-validation
sensitivity analyses.
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This model produced predicted probabilities of MDI. A clinically useful dichotomy was then
introduced by creating a ‘rule’ stating episodes with a predicted risk of MDI <5% were ‘low
risk’ episodes and all others ‘not-low-risk’ episodes.
This clinical decision rule was highly sensitive, which means that those patients classified as
low risk are extremely unlikely to have a microbiologically documented infection (~3%).
However, the rule was very poorly specific, which means that many of the patients classed
as “high risk” do not have a documented infection, and also that the rule only classified a
very small proportion (between 4% and 7%) of the episodes of patients presenting with FN
as low risk.
Comparison with other low risk rules
The full PICNICC prediction model had better discrimination (based on the AUC ROC) than
the other four published models selected for comparison (Rackoff[141] rule, Santolaya [22],
SPOG [144] and Alexander [154] rule).
When the PICNICC model was converted into a dichotomous rule by using a threshold of 5%
predicted risk of MDI, the PICNICC model had equivalent sensitivity (99.2% vs. 100%) to the
Rackoff rule but better specificity (7.5% vs. 3.7%). It was more sensitive than the SPOG rule
(99.2% vs. 80.8%) but at the expense of specificity (7.5% vs. 50%), which led to a much
smaller proportion of the population being classified as low risk (6% vs. 43%). The Santolaya
and Alexander rules performed poorly.
The appropriate choice of a low risk rule to use in clinical practice requires a discussion of:
the acceptable threshold value, which influences the proportion of patients who are
classified as low risk and the proportion who will have a microbiologically documented
infection in this group; the ease of implementation; and the reproducibility and reliability of
the rule across different locations.
Threshold choice
The threshold of 5% was based on a consensus of the collaborating members who met at
the Congress held to discuss the initial analyses and report the IPD findings. This included a
series of clinically active research physicians, a parent whose child had undergone treatment
for malignancy and who had experienced FN, and statisticians. If this very strict definition of
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low risk is used to decide who may be eligible for out-patient antibiotic therapy, then there
will be limited chance to markedly decrease the proportion of patients who are hospitalised
for treatment of FN. However, if the threshold value had been set at a 10% risk of MDI, the
derived rule would have applied to approximately 20% of patients, which would have an
important impact on the application of the rule.
The clinical implications of a choice of threshold are extremely important. “Too low” a
threshold will be exceptionally safe. It will not risk sending a child or young person out of
hospital that may have a microbiologically documented infection developing. However, it
will severely limit the size of the group for whom out-patient therapy will be judged possible,
and will result in a large number of children and young adults being hospitalised
unnecessarily. A higher threshold may increase the number of patients who will need to be
readmitted after an MDI is identified, but will allow a greater number of patients to receive
out-patient care. Identifying how this threshold should be set requires a balance of the
costs, risks, and benefits of the different thresholds. Such an investigation requires a specific
research project to identify the key factors involved and assess the opinions of the various
stakeholders: children and young people; parents or carers; and health professionals.
Clinical implementation
The clinical implementation of prediction model or rule will require it to be believed by the
clinical teams, based on sound data, and easily usable in practice. The full PICNICC model has
complexity (with the series of different predictors for tumour type, and the use of log-
transformed data) which makes it likely to be unwieldy unless made easily applicable.
A basic implementation of the predictive model has been made ‘live’ on a shared google-
drive spreadsheet: http://tinyurl.com/PICNICC1. This could be easily adapted to work off a
standard (or smartphone) web page or ‘app’. An alternative formulation for a dichotomous
‘rule’ based on the model could be created as a nomogram.
Limitations of this study
The lack of commonly agreed clear definitions has restricted what can sensibly be analysed
to generate a predictive model for microbiologically defined infection. A further analysis
could be undertaken using a definition of “significant adverse outcome” concluded upon by
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the Thesis Advisory Panel, or a group of the PICNICC collaborators. This would have some
benefits; it would produce a further model, and allow investigations as to the similarities and
differences between the models and CDRs produced. The disadvantage of producing a
further CDR which would again use an outcome without wide agreement of its utility by
clinicians and the families to whom it would be applied, and this may importantly reduce its
chance of being taken up and used in practice, and this is felt to outweigh any potential
benefits.
The issue of missing data was more significant than originally envisaged, as data were found
to be missing almost entirely at the level of study, whereby predictor or outcome variables
were “not recorded” rather than “missing”. This has led to a much smaller dataset being
available for the development of the multivariable analyses, and so reduced precision. In
particular, the pattern of data collected has meant that the recipients of bone marrow
transplant/autologous stem-cell rescue chemotherapy are not adequately represented in
the dataset.
Strengths
Robust systematic reviews of published studies underpinned the development of
the IPD analysis
Geographically and temporally varied datasets included in the IPD data
Clinically sensible analyses conducted to derive a meaningful prediction model
Robust to most sensitivity analyses
Limitations
Missing data a larger and more comprehensive problem then initially foreseen
Heterogeneity of definitions for some clinically important outcomes limited analyses
to be undertaken
Lack of collaboration with groups collecting quantities of biomarkers data limited
the analyses addressing their predictive ability
The related issue of limited biomarker data also restricted analyses. It is not known exactly
why some groups did, and others did not agree to collaborate in this project, despite
requesting feedback, and so considerations of why this is the case are tentative. It appears
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that fewer infectious disease led groups who have explored biomarkers have taken part
compared to the oncology led groups. It may be that those groups, working primarily on the
laboratory evaluation of such markers may not have collected sufficient patient-level clinical
information to be eligible for inclusion. It may be that an oncology-led group failed to
generate sufficient peer-recognition to encourage the clinicians to become involved. The
lack of sufficient data provides an opportunity to develop this research further.
The prediction model developed contained five items which were relatively consistent
across the different study groups (tumour type, temperature, unwellness, absolute
monocyte count and total white cell count) and one item (Hb) which was heterogeneous
across studies when assessed in univariate analyses. The limitations in the unreported data
meant it was not possible to tell accurately if the heterogeneity found in the univariate
analysis would also be present when assessed in a multivariable model. Therefore, it is
difficult to tell if the inclusion of haemoglobin would be applicable in alternative datasets
and subsequently in clinical practice.
Further research
This thesis has completed an analysis of the PICNICC dataset focusing on the prediction of
microbiologically documented infection. There remain a number of research opportunities
available from the current PICNICC dataset, and also developments which the Collaboration
will drive further.
Further research opportunities
 International collaborative to harmonise endpoint definitions and define a core
dataset
 Develop prediction model based on this harmonised endpoint definition, potentially
using advanced approaches to missing data handling
 Evaluate model performance on new datasets
 Continue to build the PICNICC group and incorporate more information on
biomarkers
 Work with children, young people, their families and clinicians to define a ‘low
enough’ level of risk to make decisions about therapeutic management
 Undertake a RCT of risk adapted management of FN
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The multiple definitions of “adverse events” from FN episodes led to complications in
synthesising data in the systematic reviews. The problem of inconsistency in trial definitions
has become prominent recently with the formation of the international Core Outcome
Measures in Effectiveness Trials (COMET) initiative. Through the development of agreed
core outcome measures, this initiative aims to promote awareness of the problems of
inconsistent data collection and enhance the collection of identical core outcomes for
specific clinical questions.[251] In achieving this goal, it will allow greater comparability and
synthesis of data to maximise the value of both individual studies and meta-analysis and
allow these to influence practice more strongly. Such an approach, though not strictly
relevant as these are not “effectiveness trials”, is required in this area of research and it
would be sensible to build on the PICNICC Collaboration to achieve a committed consensus.
Following on from such a consensus, further analysis of the PICNICC dataset to produce a
CDR addressing the prediction of ‘any adverse event’ will be necessary. This may well be
subtly different than the CDR predicting microbiologically documented infection, as has
been shown in the systematic reviews of previous CDR.
Developments in the handling of missing data using simulation have produced guidelines
using imputation techniques to maximise the value of the IPD data collected[252-254]. The
application of such methods in the particular situation of large quantities of unreported data
has yet to be fully explored, and provides an opportunity for further study exploiting the
PICNICC dataset further.
The model produced as part of this thesis and its consequent CDR, and any future predictive
models and CDR addressing a consensus definition of “adverse event”, will require
evaluation in clinical practice from alternative datasets collected in different geographical
locations. The PICNICC Collaboration will undertake this by continuing the collection of
existing datasets in which to evaluate the rules, but the collection of new data from other
areas will also be necessary. Such investigations will provide both specifically collected
information to analyse, and allow the uptake of a risk stratified approach to treating FN and
dissemination of the PICNICC CDR in settings where this has not previously been undertaken.
The small amount of data reporting on the value of serum biomarkers, particularly when
taken with the systematic reviews on this subject, suggest that more information and
different analyses of the data are required. We need to collect greater quantities of
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information on the additional benefit of particular biomarkers and good quality data on their
comparative efficacy in initial risk stratification. Moving beyond the initial treatment of FN,
and focusing on how we should treat patients with either a defined MDI or those without a
clear cause, the patterns of how biomarkers change over time which reflect response to
treatment will require evaluation, and also how these patterns may vary both between
individuals and within individuals after different elements of their cancer treatment.
Undertaking such research will move closer to an ideal of ‘personalised medicine’, and is
part of the continued efforts of the PICNICC team to undertake and combine such studies.
It is clear that the description and decision of what constitutes a ‘low enough’ risk to draw a
threshold at remains a matter of debate. The choice of threshold reflects both a need to
predict if a patient has a significant infection requiring specific therapy to avert a poor
outcome, and an understanding of the likelihood of a fatal or near-fatal outcome given the
particular infection and physiological response to it. The setting of this threshold of ‘low
enough’ risk appears to vary between healthcare professionals and families, and between
healthcare professionals themselves [38] , and requires further study. Such a project is under
development, with a PhD candidate at the University of York preparing a Thesis including
these stakeholders and supported by a local Children’s Cancer charity. With this information,
combined with solid evaluations of an effective CDR, a randomised non-inferiority trial of
discharge of children and young people with low-risk FN within 24 hours of presentation to
hospital should be achievable to prove or disprove the utility of this approach to
management[255].
Innovations and Impact
The work undertaken during the completion of this thesis has extended methods of
undertaking diagnostic meta-analysis (multinomial approaches to multi-level diagnostic
tests[113]), and promoted alternative graphical methods of presenting diagnostic test
information (cross-hairs plots[126]) which have already been incorporated into computer
software for undertaking such analyses (the ‘mada’ package in R[256]). It has also adapted
display techniques from other areas, such as the ‘heat maps’ of social science research, to
display the rich information found in IPD datasets in an accessible way. The practical and
ethical framework for sharing such information has been delineated and a better
understanding of the different barriers involved has been achieved [246].
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The systematic reviews [113-116, 257] forming the basis of the IPD have been cited in
national [128] and international guidelines [129] on the management of FN and have been
key in forming some of their recommendations. These have influenced changes in clinical
practice and as such instituted improvements for people with cancer presenting with FN
[246].
Finally, the formation of the PICNICC collaborative has brought together an international
core of researchers who remain committed to improving the management of FN and
advancing our understanding of how treatments for infection in children and young people
with cancer should be trialled and implemented.
Conclusions
The aim of this thesis was to describe the clinical problem of the initial management of
febrile neutropenia in children and young people undergoing treatment for malignant
disease, to thoroughly examine the existing research, and to seek to synthesise this to
quantify the risk of adverse clinical outcomes and develop a new risk prediction model. This
was undertaken to inform everyday clinical decisions and future research. A further aim was
to develop methodological approaches to IPD analysis in the development of predictive
models, including the graphical display and communication of such information. This thesis
focused on the outcome of microbiologically documented infection (MDI) because it was the
most completely reported and most objective, and frequently occurring, significant
complication of paediatric FN.
The work undertaken has formed a global collaboration which has shared thousands of
items of data, developed a new predictive model for MDI, and from this derived a CDR which
is robust to internal validation techniques. We have demonstrated that such a project is
feasible across many different jurisdictions and eras of study, and should provide the
impetus for a series of projects which will evaluate and improve the management of FN
across the world.
Page 223 of 410
Appendices
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Appendix 1. CDR Search Strategy
Example based on OVID-Medline: (this was adapted for other databases)
FNP identification
1 Neutropenia/
2 (neutropenia or neutropenic).ti,ab.
3 1 or 2
4 Fever/
5 (fever$ or febril$).ti,ab.
6 4 or 5
7 3 and 6
Child identification
8 adolescent/ or child/ or child, preschool/ or infant/ or infant, newborn/ or Puberty/
9 schools/ or schools, nursery/
10 (infan$ or newborn$ or new born$ or baby$ or babies or neonat$ or neonat$ or child$
or schoolchild$ or kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$ or minor$ or
underage$ or under age$ or juvenil$ or youth$ or kindergar$ or nursery or puber$ or
prepuber$ or pre puber$ or pubescen$ or prepubescen$ or pre pubescen$ or pediatric$ or
paediatric$ or peadiatric$ or school or schools or preschool$ or pre school$ or
schoolage$).ti,ab.
11 8 or 9 or 10
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Cancer identification
12 exp Neoplasms/
13 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or sarcoma$
or leukaemi$ or leukemi$ or chemotherap$).ti,ab.
14 12 or 13
Consolidation
15 11 and 14
16 7 and 15
CDR Hedge
17 (predict$ or clinical$ or outcome$ or risk$).mp.
Final search
18 16 and 17
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Appendix 2. Biomarkers Search Strategy
Example based on OVID-Medline: was adapted for other databases
FNP identification
1 Neutropenia/
2 (neutropenia or neutropenic).ti,ab.
3 1 or 2
4 Fever/
5 (fever$ or febril$).ti,ab.
6 4 or 5
7 3 and 6
Child identification
8 adolescent/ or child/ or child, preschool/ or infant/ or infant, newborn/ or Puberty/
9 schools/ or schools, nursery/
10 (infan$ or newborn$ or new born$ or baby$ or babies or neonat$ or neonat$ or child$
or schoolchild$ or kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$ or minor$ or
underage$ or under age$ or juvenil$ or youth$ or kindergar$ or nursery or puber$ or
prepuber$ or pre puber$ or pubescen$ or prepubescen$ or pre pubescen$ or pediatric$ or
paediatric$ or peadiatric$ or school or schools or preschool$ or pre school$ or
schoolage$).ti,ab.
11 8 or 9 or 10
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Cancer identification
12 exp Neoplasms/
13 (cancer$ or neoplas$ or oncolog$ or malignan$ or tumo?r$ or sarcoma$
or leukaemi$ or leukemi$ or chemotherap$).ti,ab.
14 12 or 13
15 14 and 11 and 7
Markers identification
16. Biological Markers/
17. (marker$ or serum).ti,ab.
18. (biomarker$ or bio-marker$).ti,ab.
19. or/18-20
20. Cytokines/
21. cytokine$.ti,ab.
22. 22 or 23
23. Interleukin-1/
24. (interleukin-1 or interleukin-i or il-1 or il1).ti,ab.
25. t-helper factor.ti,ab.
26. lymphocyte-activating factor.ti,ab.
27. macrophage cell factor.ti,ab.
28. epidermal cell derived thymocyte-activating factor.ti,ab.
29. or/25-30
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30. Interleukin-5/
31. (interleukin-5 or il-5 or il5).ti,ab.
32. eosinophil differentiation factor.ti,ab.
33. t-cell replacing factor.ti,ab.
34. (b-cell growth factor-ii or b-cell growth factor-2).ti,ab.
35. (bcgf-ii or bcgfii or bcgf-2 or bcgf2).ti,ab.
36. or/32-37
37. Interleukin-6/
38. (interleukin-6 or il-6 or il6).ti,ab.
39. plasmacytoma growth factor.ti,ab.
40. b-cell differentiation factor.ti,ab.
41. (b-cell stimulat$ factor-2 or b-cell stimulat$ factor-ii).ti,ab.
42. (bsf-2 or bsf2 or bsf-ii or bsfii).ti,ab.
43. hepatocyte-stimulating factor.ti,ab.
44. hybridoma growth factor.ti,ab.
45. (interferon beta 2 or interferon beta2 or ifn-beta 2 or ifn-beta2).ti,ab.
46. mgi-2.ti,ab.
47. myeloid differentiation-inducing protein.ti,ab.
48. or/39-49
49. Interleukin-8/
50. (interleukin-8 or il-8 or il8).ti,ab.
51. monocyte-derived neutrophil chemotactic factor.ti,ab.
52. neutrophil activation factor.ti,ab.
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53. lymphocyte-derived neutrophil-activating peptide.ti,ab.
54. monocyte-derived neutrophil-activating peptide.ti,ab.
55. (alveolar macrophage chemotactic factor-i or amcf-i).ti,ab.
56. anionic neutrophil-activating peptide.ti,ab.
57. cxcl8.ti,ab.
58. macrophage-derived chemotactic factor.ti,ab.
59. neutrophil chemotactic factor.ti,ab.
60. or/51-61
61. Interleukin-10/
62. (interleukin-10 or il-10 or il10).ti,ab.
63. csif-10.ti,ab.
64. or/63-65
65. Interferon-gamma/
66. (interferon-gamma or gamma-interferon or IFN-gamma or IFNgamma).ti,ab.
67. (interferon ii or interferon 2).ti,ab.
68. (type ii interferon or interferon type ii).ti,ab.
69. immune interferon.ti,ab.
70. or/67-71
71. Interferon-beta/
72. (interferon-beta or beta-interferon or IFN-beta or IFNbeta).ti,ab.
73. fibroblast interferon.ti,ab.
74. (interferon-beta1 or beta1 interferon or beta-1 interferon or IFN-beta1 or
IFNbeta1).ti,ab.
75. Fiblaferon.ti,ab.
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76. or/73-77
77. transforming growth factor beta/
78. (beta transforming growth factor or transforming growth factor beta or tgf-beta or
tgfbeta).ti,ab.
79. milk growth factor.ti,ab.
80. platelet transforming growth factor.ti,ab.
81. bone-derived transforming growth factor.ti,ab.
82. or/79-83
83. Antigens, CD70/
84. (CD70 or cd27l or cd27 ligand).ti,ab.
85. 85 or 86
86. Tumor Necrosis Factor-alpha/
87. (tumour necrosis factor or tumor necrosis factor).ti,ab.
88. (tnf or tnfalpha).ti,ab.
89. Cachectin.ti,ab.
90. or/88-91
91. Receptors, Tumor Necrosis Factor, Type II/
92. (tnfrii or tnfr-ii or tnfr2 or tnfr-2).ti,ab.
93. (stnf-ii or stnfrii or stnfr2 or stnfr-2).ti,ab.
94. (tnfr p75 or tnfr p80 or tnf-sr75).ti,ab.
95. (cd-120b or cd120b).ti,ab.
96. tnfrsf1b receptor$.ti,ab.
97. or/93-98
98. C-Reactive Protein/
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99. (c-reactive protein or Creactive protein or c-reaction protein or Creaction
protein).ti,ab.
100. 100 or 101
101. Receptors, Interleukin-2/
102. (interleukin-2 receptor$ or interleukin-ii receptor$).ti,ab.
103. (il-2 receptor$ or il-ii receptor$ or il2 receptor$).ti,ab.
104. (sil-2 or sil-2r or sil2 or sil-ii or sil-iir).ti,ab.
105. (t-cell growth factor receptor$ or tcgf receptor$).ti,ab.
106. or/103-107
107. (procalcitonin or pro-calcitonin).ti,ab.
108. calcitonin precursor.ti,ab.
109. 109 or 110
110. Receptors, IgG/
111. igg receptor$.ti,ab.
112. (gamma fc receptor$ or fc gamma receptor$).ti,ab.
113. immunoglobulin g receptor.ti,ab.
114. (leu-11 or leu11).ti,ab.
115. (cdw32 or cd-32 or cd32 or cd-64 or cd64 or cd-16 or cd16).ti,ab.
116. (fc gamma ri or fc gammari or fc gamma rii or fc gammarii or fc gamma riii or fc
gammariii).ti,ab.
117. (sfc gamma riii or sfc gammariii).ti,ab.
118. or/112-119
119. Adenosine Deaminase/
120. adenosine deaminase.ti,ab.
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121. (ada-1 or ada1 or ada-2 or ada2).ti,ab.
122. (adenosine aminohydrolase or adenosine amino hydrolase).ti,ab.
123. or/121-124
124. Blood Sedimentation/
125. ((erythrocyte or blood) adj sedimentation).ti,ab.
126. 126 or 127
127. Serum Amyloid A Protein/
128. (serum amyloid A or serum amyloid protein a).ti,ab.
129. serum a related protein.ti,ab.
130. amyloid serum protein saa.ti,ab.
131. amyloid-related serum protein.ti,ab.
132. (amyloid a adj (precursor or protein)).ti,ab.
133. (amyloid protein adj (saa or aa)).ti,ab.
134. amyloid fibril protein aa.ti,ab.
135. or/129-136
136. Chemokine CCL2/
137. (monocyte chemotactic protein-1 or monocyte chemoattractant protein-1 or mcp-
1).ti,ab.
138. ccl2.ti,ab.
139. or/138-140
140. Neopterin/
141. (neopterin or neopterine).ti,ab.
142. (umanopterin or monapterin).ti,ab.
143. or/142-144
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144. lipopolysaccharide-binding protein.ti,ab.
145. lps binding protein.ti,ab.
146. 146 or 147
147. 21 or 24 or 31 or 38 or 50 or 62 or 66 or 72 or 78 or 84 or 87 or 92 or 99 or 102 or
108 or 111 or 120 or 125 or 128 or 137 or 141 or 145 or 148
148. 15 and 147
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Appendix 3. Modified QUADAS Criteria for Quality Assessment
Item Yes No Unclear
1.
Was the spectrum of patients representative of
the patients who will receive the test in
practice?
( ) ( ) ( )
2. Were selection criteria clearly described? ( ) ( ) ( )
3.
Is the reference standard likely to correctly
classify the target condition?
( ) ( ) ( )
4.
Is the time period between reference standard
and index test short enough to be reasonably
sure that the target condition did not change
between the two tests?
( ) ( ) ( )
5.
Did the whole sample or a random selection of
the sample, receive verification using a
reference standard of diagnosis?
( ) ( ) ( )
6.
Did patients receive the same reference
standard regardless of the index test result?
( ) ( ) ( )
7.
Was the reference standard independent of
the index test (i.e. the index test did not form
part of the reference standard)?
( ) ( ) ( )
8.
Was the execution of the index test described
in sufficient detail to permit replication of the
test?
( ) ( ) ( )
9.
Was the execution of the reference standard
described in sufficient detail to permit its
replication?
( ) ( ) ( )
10.
Were the index test results interpreted without
( ) ( ) ( )
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knowledge of the results of the reference
standard?
11.
Were the reference standard results
interpreted without knowledge of the results
of the index test?
( ) ( ) ( )
12.
Were the same clinical data available when test
results were interpreted as would be available
when the test is used in practice?
( ) ( ) ( )
13.
Were uninterpretable/ intermediate test
results reported?
( ) ( ) ( )
14. Were withdrawals from the study explained? ( ) ( ) ( )
QUADAS criteria which are struck through were not used in the assessment
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Appendix 4. Key Data Extraction Fields
Quality of the study
 Was the study retrospective or prospective?
 Were selection criteria clearly described?
o No
o Yes – Consecutive
o Yes – Random
o Yes – Other
 Was the study population appropriate to clinical practice?
 Did the whole sample or a random selection of the sample, receive adequate
outcome assessment?
 Did patients receive the same outcome assessment regardless of the serum marker
test result?
 Was the outcome assessment independent of the serum marker test (i.e. the serum
marker test did not form part of the outcome assessment)?
 Was the execution of the serum marker test described in sufficient detail to permit
replication of the test?
 Was the execution of the outcome assessment described in sufficient detail to
permit its replication?
 Were the serum marker test results interpreted without knowledge of the results of
the outcome assessment?
 Were the outcome assessment results interpreted without knowledge of the results
of the serum marker test?
 Were the same clinical data available when the serum marker test was interpreted
as would be available when the serum marker test is used in practice?
Comments
Study & Patient Background
 Where did the study take place (country/continent)?
 What years were the patients studied in?
 What are the inclusion criteria?
 What are the exclusion criteria?
 What number of patients were included?
 What number of episodes were included?
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 What was the average age (& range or SD) of the patients?
 What number of the patients/episodes were male?
 What number of the patients/episodes had missing values?
Comments
Results
 Serum marker test assessed:
o Marker #1
o Marker #2
o Marker #3
 List all clinical end points (outcomes) examined.
o Death
o Intensive care admission
o Medical complications (eg need for O2, renal failure)
o Bacteraemia
o Significant bacterial infection
o Absence of adverse sequelae
o Other
Marker #1 Cutpoint used: Cutpoint used: Cutpoint used:
No. true positive
No. false positive
No. true negative
No. false negative
Marker #2 Cutpoint used: Cutpoint used: Cutpoint used:
No. true positive
No. false positive
No. true negative
No. false negative
Marker #3 Cutpoint used: Cutpoint used: Cutpoint used:
No. true positive
No. false positive
No. true negative
No. false negative
 Other indicator #1 (e.g. correlation or HR) with SE or CI
o Marker #1
o Marker #2
o Marker #3
 Other indicator #2 (e.g. correlation or HR)
o Marker #1
o Marker #2
o Marker #3
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 How were continuous variables handled in the analyses?
o As continuous values
o Made ordinal (e.g. high/mid/low)
 If relevant, describe methods used for cutpoint determination?
 How were categorical variables handled in the analyses?
o Grouped (e.g. high/mid/low)
o Other
 If relevant, describe methods used for cutpoint determination?
 How was missing data handled?
o Not applicable
o Not specified
o Completed data only used
o Imputation method
 How were multiple episodes in individual patients handled?
o No discrimination
o First-last comparison
o Generalised equivalence equation (GEE)
o Other
Comments
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Appendix 5. Example ‘Stata’ Code for Cross-Hairs Plots
/* Using cxr2.dta for CROSS-HAIRS*/
/* uses llsn = lower limit of sn for individual study (and similar) with other 5 params */
/* uses exbisn = lower limit of sn for summary estimate study ... etc ... */
set scheme s2color
twoway (rcap llsn ulsn sp, msize(large) lwidth(medthin) lcol(eltblue)) (rcap llsp ulsp sn, hor
msize(large) lcol(eltblue) lwidth(medthin)) (sc sn sp [w=d+nd] , msize(*.6) msymbol(oh)
mcol(eltblue) yscale(range(1 0)) ylabel(1(0.2)0, format(%03.1f)) ytitle("Sensitivity")
xscale(rev range(1 0)) xlabel(1(0.2)0 , format(%03.1f)) xtitle("Specificity") aspectratio(1)
legend(off)) (rcap exbisnll exbisnul exbisp, msize(large) lcol(navy)) (rcap exbispll exbispul
exbisn, hor msize(large) lcol(navy)) (sc exbisn exbisp, msymbol(O) mcol(navy))
/* USING SM-CRP.DTA: cross-hairs with weighted marker sizes, >50mg only */
twoway (rcap snll snul sp if marker==1 & group==2 & val==50, msize(large) lwidth(medthin)
lcol(eltblue)) /*
*/ (rcap spll spul sn if marker==1 & group==2 & val==50, hor msize(large) lcol(eltblue)
lwidth(medthin)) /*
*/ (sc sn sp [w=d+nd] if marker==1 & group==2 & val==50, msize(*.4) msymbol(oh)
mcol(eltblue) yscale(range(1 0)) ylabel(1(0.2)0, format(%03.1f) angle(360)) /*
*/ ytitle("Sensitivity") xscale(rev range(1 0)) xlabel(1(0.2)0 , format(%03.1f) alt)
xtitle("Specificity") aspectratio(1) /*
*/ legend(off))
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/* USING SM-CRP.DTA: cross-hairs with weighted marker sizes, any CRP results */
twoway (rcap snll snul sp if marker==1 & group==2 , msize(large) lwidth(medthin)
lcol(eltblue) lp(solid)) /*
*/ (rcap spll spul sn if marker==1 & group==2 , hor msize(large) lcol(eltblue) lwidth(medthin)
lp(solid)) /*
*/ (sc sn sp [w=d+nd] if marker==1 & group==2 , msize(*.4) msymbol(oh) mcol(eltblue)
yscale(range(1 0)) ylabel(1(0.2)0, format(%03.1f) angle(360)) /*
*/ ytitle("Sensitivity") xscale(rev range(1 0)) xlabel(1(0.2)0 , format(%03.1f) alt)
xtitle("Specificity") aspectratio(1) /*
*/ legend(off))
/* USING SM-CRP.DTA: cross-hairs with weighted marker sizes split across two graphs, any
CRP results */
twoway (rcap snll snul sp if marker==1 & group==2 , msize(large) lwidth(medthin)
lcol(eltblue) lp(solid)) /*
*/ (sc sn sp [w=d+nd] if marker==1 & group==2 , msize(*.4) msymbol(oh) mcol(eltblue)
yscale(range(1 0)) ylabel(1(0.2)0, format(%03.1f) angle(360)) /*
*/ ytitle("Sensitivity") xscale(rev range(1 0)) xlabel(1(0.2)0 , format(%03.1f) alt)
xtitle("Specificity") aspectratio(1) /*
*/ saving(CRPsn, replace) legend(off))
twoway (rcap spll spul sn if marker==1 & group==2 , hor msize(large) lcol(eltblue)
lwidth(medthin) lp(solid)) /*
*/ (sc sn sp [w=d+nd] if marker==1 & group==2 , msize(*.4) msymbol(oh) mcol(eltblue)
yscale(range(1 0)) ylabel(1(0.2)0, format(%03.1f) angle(360)) /*
*/ ytitle("Sensitivity") xscale(rev range(1 0)) xlabel(1(0.2)0 , format(%03.1f) alt)
xtitle("Specificity") aspectratio(1) /*
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*/ saving(CRPsp, replace) legend(off))
graph combine CRPsn.gph CRPsp.gph
/* USING CROSS HAIRS WITH BIVARIATE OVERALL SUMMARY */
/* Cheating, sort of, by running this after a 'metandi' command */
/* code for the dotty elipse of the summary confidence interval taken directly from it */
tempname covmuAB sAB rconfAB sepredA sepredB rpredAB
matrix V = e(V)
scalar `covmuAB' = V[1,2]
scalar `sAB' = _b[sAB]
/* derived params */
scalar `rconfAB' = `covmuAB'/(_se[muA]*_se[muB])
scalar `sepredA' = sqrt(_b[s2A]+_se[muA]^2)
scalar `sepredB' = sqrt(_b[s2B]+_se[muB]^2)
scalar `rpredAB' = (`sAB'+`covmuAB')/(`sepredA'*`sepredB')
tempname croot phi confB confA confspec confsens
scalar `croot' = sqrt(2*invF(2,e(N)-2,95/100))
range `phi' 0 `=2*c(pi)' 500
gen `confB' = _b[muB] + _se[muB] * `croot' * cos(`phi')
gen `confA' = _b[muA] + _se[muA] * `croot' * cos(`phi' +
acos(`rconfAB'))
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gen `confsens' = invlogit(`confA')
gen `confspec' = invlogit(`confB')
twoway (rcap llsn ulsn sp, msize(large) lwidth(medthin) lcol(eltblue)) (rcap llsp ulsp sn, hor
msize(large) lcol(eltblue) lwidth(medthin)) (sc sn sp, msymbol(oh) mcol(eltblue)
yscale(range(1 0)) ylabel(1(0.2)0, format(%03.1f)) ytitle("Sensitivity") xscale(rev range(1 0))
xlabel(1(0.2)0 , format(%03.1f)) xtitle("Specificity") aspectratio(1) legend(off) title("Summary
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Appendix 6. Numerical aspects of derivation studies
Citation
n
patient
s
n
episodes
n
events of
1
0
outcome
n
variables
examined
events
per var
All candidate variables initially examined
How were
candidate
variables
selected?
Adcock, 1999 33 88 16 14 1.14
Demographics, primary diagnosis, history of present illness,
vital signs, and physical examination. Recent chemotherapy
regimen, prophylactic (antibiotic) therapy, leukocyte count
and ANC, maximum daily temperature, age, and condition of
central line
Not stated
Alexander,
2002
104 104 13 2 6.5
Anticipated neutropenia <7 days, no significant comorbidity
at presentation (defined later).
Literature review
Ammann,
2003
111 285 90 39 2.31
39 variables: age, gender, pre-B-cell leukaemia or other
diagnosis, first or later malignancy, relapsed or unrelapsed
malignancy, history of episodes of FN without significant
Covariates with
possible relevance
to severe bacterial
(models #1 -
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#3)
bacterial infection, history of episodes of FN with significant
bacterial infection, history of episodes of FN with
bacteraemia, remission status of malignancy, bone marrow
involvement, maintenance therapy or more intensive
chemotherapy, delay since last chemotherapy, time since
diagnosis, year of previous episode(s) of FN, season of
previous episode(s) of FN, preventive application of G-CSF,
central venous catheter present, hospitalisation history
before FN, presence of comorbidity requiring hospitalisation,
iatrogenic reason for fever, fever rule (≥38.5°C persisting for
at least two hours or once ≥39°C), weight loss since last
chemotherapy, BMI, maximal fever at presentation, general
appearance, presence of chills at presentation, lowest
systolic BP, lowest diastolic BP, presence of oral mucositis,
presence of clinical signs of viral infection, haemoglobin
level, leukocyte count, neutrophil count, monocyte count,
phagocyte count, thrombocyte count, serum CRP level,
serum creatinine level, and serum ASAT level.
infections and
accessible to the
treating physicians
within the first
two hours after
fulfilment of the
criteria of FN
Ammann,
2004
132 364 85 39 2.18
Amman, 2010 206 423 62 33 1.88
Age, gender, past-FN, past-bacteraemia, relapse, AML, any
haematological, BM involvement, CR, >1y since diagnosis,
Not stated
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interval from chemo <7d, intensiveness of therapy, GCSF,
inpatient status, ‘unwell’, mucositis (oral & any), CVL, URTI,
temp >39.5, raised HR, RR, low BP or sats, Hb, WCC, ANC,
AMC, APC, plts, CRP … plus at reassessment: low, Bp or sats,
chills, T-max, CXR needed, focal infection, other need for IP
care
Ayegman,
2011
206 423 67 33 2.03
Age, gender, past-FN, past-bacteramia, relapse, AML, any
haematological, BM involvement, CR, >1y since diagnosis,
interval from chemo <7d, intensiveness of therapy, GCSF,
inpatient status, ‘unwell’, mucositis (oral & any), CVL, URTI,
temp >39.5, raised HR, RR, low BP or sats, Hb, WCC, ANC,
AMC, APC, plts, CRP … plus at reassessment: low, Bp or sats,
chills, T-max, CXR needed, focal infection, other need for IP
care
Not stated
Badeiei, 2011 68 120 35 18 1.94
At least Sex, Age, tumour type (solid vs non-solid), relapse,
time from chemo (grouped), temp (grouped), duration of
fever before admission, URTI symptoms, mucositis, WBC
(grouped), ANC(grouped), Hb(grouped), Plt(grouped), CXR
finding
Not stated
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Delebarre,
2010
146 316 70 N/A N/A Not stated Not stated
Hann, 1997 759 759 165 13 12.69
Gender, underlying disease (AML, ALL, BMT, HD/NHL, CML-
aplasia-blast-crisis-other, Solid tumour), disease status
(induction, relapse, maintenance), IV line in situ, defined site
of infection, shock, granulocyte count, period of
granulocytopenia, antifungal prophylaxis, antibacterial
prophylaxis, age, temperature, (log) creatinine
Not stated
Hakim, 2010 332 332 41 22 1.86
Age, gender, race, cancer diagnosis, Prior relapse, time-
since-relapse, CVL, steroid use, GCSF use, recent antifungal
therapy, colonisation (VRE, MRSA, pseudo), tmax>39, clinical
appearance, comorbidity at presentation, URI symptoms,
Hb, ANC, Plts, anticipated neutropenia <7d, antifungal
prophylaxis, time-since-chemo, duration of preceding
neutropenia
Literature review
and medical
expertise
Jones, 1996 127 276 68 5 13.6
Underlying disease and status (i.e. induction therapy,
remission or relapse). Age at time of fever episode. ANC at
time of onset of fever. Inpatient versus outpatient status
Not stated
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Klaassen, 2000 140 227 28 13 2.15
13 variables assessed: age, presence of bone marrow
disease, central venous catheter type, general appearance
on initial examination, previous granulocyte colony-
stimulating factor (G-CSF) therapy, initial ANC, initial
lymphocyte count, initial monocyte count, initial platelet
count, presence of localized bacterial infection on initial
examination, peak temperature, tumour type, and sex.
Systematic review
to identify risk
factors for
significant
bacterial infection
and expert
opinion.
Lucas, 1996 161 509 82 8 10.25
Chills, hypotension, poor perfusion, the need for fluid
resuscitation, time from cytotoxic chemotherapy, diagnosis,
disease status, and the presence of a focus of infection
Not stated
Mian, 2010 29 51 8 N/A N/A Not stated Not stated
Paganini, 2007 458 714 18 17 1.06
Age, days since chemotherapy, ‘advanced stage of disease’
(= bone marrow involvement, relapse, second tumour, high-
dose therapy, genetic disease), previous antibiotic or CSF
use, ANC <100, clinical infection, pneumonia, mucositis,
bacteraemia <24h, comorbidity (=incoercible bleeding,
refractory hypoglycaemia and hypocalcaemia, hypotension,
altered mental status, renal insufficiency, hepatic
dysfunction, and respiratory failure). They also state that the
Unclear
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following variables were collected and registered for
analysis: facial, anal, oral or catheter-associated cellulitis,
sepsis, necrotising gingivitis, sex, underlying disease and
staging, predicted period of neutropenia, presence of
intravenous device.
Rackoff, 1996 72 115 24 9 2.67
State of disease (remission vs. not), degree of mucositis, ill
appearance, presence of GI symptoms, cellulitis, use of GCSF,
admission ANC, admission AMC, maximum admission
temperature
Unclear
Rackoff, 1996
revised model
102
(see
note)
57 10 7 1.43
AMC, Temperature (39.5C cutoff), ANC, APC, Platelets, age,
WBC
By reference to
previously
published
literature
Riikonen 1993 46 91 17 16 0.94
Duration of fever, duration of neutropenia, central line
present, prophylaxis with Septrin, general clinical
examination, HR, signs of bleeding, BP, temperature, chills,
Hb, Plt, prolonged PTT, sodium & potassium ESR, CRP
Unclear
Rojo, 2008 33 47 4 6 0.67
Sex, age, type of malignancy (leukaemia vs. solid), focus of
Unclear
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infection, duration of hospitalisation, microbiologically
proven infection
Rondinelli,
2006
283 283 93 17 5.47
Significantly on univariate: Age, gender, disease type (AML,
ALL, Others), disease status (remission/other), CVC,
temperature, Hb, WCC, AGC, Plt, AMC, URTI, time from
chemotherapy, pneumonia, clinical site of infection,
mucositis plus others not reported
Unclear
Santolaya,
2001
257 447 179 17 10.5
(1) demographic variables, i.e., age, sex, and maternal
educational level; (2) cancer-related variables, i.e., cancer
type, intensity of chemotherapy, use of granulocyte colony-
stimulating factors since last administration of
chemotherapy, and use of an indwelling catheter; (3)
variables related to the febrile episode, i.e., hours of fever
before admission, days since last administration of
chemotherapy, and use of prophylactic antimicrobial agents;
(4) admission clinical and laboratory variables, i.e., axillary
temperature, blood pressure, ANC, AMC, quantitative serum
CRP level, haemoglobin level, and platelet count
Not stated
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Tezcan, 2006 240 621 143 11 13
Age, sex, ANC, AMC, CRP, duration of neutropenia, duration
of fever, presence of previous FN, presence of hypotension,
uncontrolled malignancy, cancer type.
Unclear
West, 2004 143 303 36 18 2
Age, type of cancer, chills, temperature, HR, RR, SBP, DBP,
mucositis, Hb, Plts, WCC, differential WCC, ANC, AMC,
monocytes <10%, perirectal abscess, capillary refill time >3s.
Review of
literature +
medical opinion
Note: 102 minus participants excluded for meeting exclusion criteria
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Appendix 7. Variable and missing data handling techniques in derivation studies
Citation Statistical
technique to build
the model
Management
of multiple
episodes.
Management of
continuous
variables…
… and cutpoint
determination
Management
of categorical
variables.
and cutpoint
determinatio
n
n patients
or episodes
with
missing
values
Management
of missing
data.
Adcock,
1999
Univariate analysis No
discrimination
Made ordinal (BP
described as
‘hypotension’ or
not)
Not stated Grouped (Ara-C
vs. Other
chemotherapy)
Based on
“trend to
significance”
from
univariate
analysis
Not stated Not stated
Alexander
, 2002
Univariate analysis First episode
only used
Made ordinal
(hypotension and
hypoxia)
Not stated Grouped
(‘anticipated
neutropenia’
group by
cancer type –
AML/Burkitts/I
nduction
Not stated Two
patients
excluded
due to
missing
data
Completed
data only
used
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ALL/Progressiv
e-relapsed with
marrow
involvement vs
not)
Ammann,
2003
Decision tree,
regression type
First-last
comparison
Made ordinal, with
up to three
categories
Not stated Grouped Not stated One patient
(two
episodes)
excluded
due to
missing
data
exclusion of
41 episodes
where
>10% of
covariates
were
missing
Completed
data only
used.
Covariates
with more
than 10%
missing
values were
discarded
from the
prediction
model
Ammann, Stepwise First-last Made ordinal, with
up to three
Not stated Grouped Not stated One patient
(two
Completed
data only
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2004 backward comparison categories episodes)
excluded
due to
missing
data.
exclusion of
16 episodes
where
>10%
covariates
were
missing
used.
Covariates
with more
than 10%
missing
values were
discarded
from the
prediction
model
Amman,
2010 (and
Ayegman,
2011)
Forwards stepwise
logistic regression,
with random
effect per patient,
and with 100-fold
cross-validation to
protect against
overfitting
Generalised
equivalence
equation (GEE)
Made ordinal (e.g.
high/mid/low)
Split using
recursive
partitioning
before
introduction as
dichotomous
variables.
Grouped (e.g.
high/mid/low)
Not stated Unclear Imputation
method
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Badeiei,
2011
C4.5 decision tree
system in SPSS
No
discrimination
As continuous
values or as
categorical
variables
Not stated Grouped (e.g.
high/mid/low)
Not stated Not stated Not stated
Delebarre,
2010
Univariate and
multivariable
analysis – no
further detail
Not specified Some continuous,
some as ordinals
Not stated Not stated Not stated Not stated
(multivariat
e analysis
was based
on 678
children.
For one of
the
included
trials data
were
available
for 145/220
children)
Not stated
Hann,
1997
Stepwise
backward
First episode
only used
As continuous
values, or if skewed
distribution,
According to
clinical
Grouped According to
clinical
Not stated
(multivariat
e analysis
Not stated
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categorised
according to
clinical judgement
judgement judgement was based
on 678
children.
For one of
the
included
trials data
were
available
for 145/220
children)
Hakim,
2010
Stepwise multiple
logistic regression
with
bootstrapping
Only one
episode per
patient
selected
As continuous
values then Made
ordinal (e.g.
high/mid/low)
ROC-based
efficiency
methods:
Minimising
sn/sp
differences,
more efficient
ROC placement
and maximising
distance from
chance. All
Grouped (e.g.
high/mid/low)
According to
clinical
judgement
43% of
episodes
had missing
data for
absolute
monocyte
and
lymphocyte
counts
Completed
data only
used
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methods agreed
Jones,
1996
Logistic regression
- unclear
No
discrimination
Made ordinal (e.g.
age <2, 2-5, 6-12,
13+, ANC <200,
≥200).
Not stated Grouped (e.g.
solid tumour,
leukaemia,
other).
Not stated. Not stated Not stated
Klaassen,
2000
Forward logistic
regression
Generalized
linear mixed
model
All continuous
variables except
age were
dichotomised.
Using
predefined
thresholds
taken from the
literature, or
recursive
partitioning for
monocyte count
and peak
temperature
Dichotomised
(tumour type –
AML/NHL
versus others).
According to
clinical
judgement
Derivative
set – 1.
When
monocyte
count was not
available the
patient was
excluded
(n=1), for
other
variables it
was unclear
(all 13
variables
were
prospectively
collected in
98% of the
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episodes).
Lucas,
1996
Logistic regression
- unclear
GEE Made ordinal (time
from chemo:
><10d, ANC
><100/mm)
Not stated. Grouped Not stated Unclear Not specified
Mian,
2010
Stepwise
multivariable
logistic regression,
cut-off p<0.05
Not specified As continuous
values or as
categorical
variables
Based on
published
‘normal
range’cut-offs
(HR & Sys BP)
Not stated N/A Not stated Not stated
Paganini,
2007
Forward logistic
regression
No
discrimination
Made ordinal (e.g.
ANC <100) or used
as continuous (e.g.
age & days since
chemo)
Not stated. Not used Not stated Not stated
Rackoff,
1996
Backwards logistic
regression
GEE Initially continuous, then recursive
partitioning
analysis
Grouped –
disease state
into remission
vs.
relapse/progres
Not stated D: One
patient had
missing diff
WBC for
one
Completed
data only
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sive episode –
excluded
leaving 115
episodes
Rackoff,
1996
revised
model
Logistic regression
- unclear
No
discrimination
Made ordinal
(dichotomous)
The AMC, APC
and ANC cut-off
values of
250/mm3 and
temperature of
39.5C were
selected
arbitrarily. AMC
cut off of
100/mm3 was
used due to
previous study
findings
(Rackoff, 1996).
Serial NLR
determined at
intervals of 5
units/mm3
Not applicable Validation
set – 82
(60%)
episodes
Not stated
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across the range
of AMC, ANC
and APC values.
Platelet count
values
>25,000/mm3
were tested at
intervals of
25,000/mm3
Riikonen,
1993
Univariable
analysis
No
discrimination
Made ordinal: Hb
<100g/l, Plts <10,
10-30, 30-100), PT
‘prolonged’, Na &
K: less than normal
limits. Kept
continuous: ESR &
CRP
Not stated Not applicable Unclear Not stated
Rojo, 2008 Univariable
analysis
No
discrimination
Not applicable Grouping (solid
vs.
haematological
Not stated Not stated Not stated
Page 260 of 410
malignancy)
Rondinelli
, 2006
Forward logistic
regression
First episode
only used
Made ordinal Not stated, but
use previously
defined cut-offs
Grouped Not stated Not stated Completed
data only
Santolaya,
2001
Forward logistic
regression
Secondary
analysis
undertaken
with first
episode only
As continuous
values initially
Then cutpoints
determined
with ROC (for
CRP and
platelets)
Grouped (ALL,
AML,
lymphoma,
sarcoma,
relapsed
leukaemia,
other solid)
Not stated Not stated Not stated
Tezcan,
2006
Logistic regression
- unclear
No
discrimination
Some kept
continuous (e.g.
age, CRP, duration
of fever, duration
of neutropenia),
some made ordinal
(e.g. ANC <100,
AMC <100).
Not stated Grouped (e.g.
cancer type:
leukaemia and
lymphoma vs.
solid tumours
Not stated Not stated
– different
outcome
categories
have
different
total values
Not stated
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West,
2004
Stepwise
backward &
bootstrapping
Multivariate
analysis
"adjusted for
clustering at
patient level"
Some continuous
(temp, age, heart
rate z-score) some
categorised (BP
dichotomised to -
2SD, monocytes
<10% and ANC=0)
Not clearly
described
Categorised:
type of cancer
–
leukaemia/lym
phoma,
sarcoma/neuro
blastoma,
other
Not stated Not stated Not stated
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Appendix 8. Performance of CDR
Citation Clinical prediction rule
Number
of
episodes
Outcome
Number
with
Outcome
Predictive accuracy
% Low LR Low LR High
Models with one supporting data set
Adcock, 1999
High risk = hypotension/septic shock, inflamed central line
site, recent high dose Ara-C
88 Gram positive bacteraemia 26
Refers
to G+ve
Data
not
given
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Ammann,
2003
Final decision tree model: four covariates were used to
classify low risk; bone marrow involvement, leukocyte
count >0.5 x 10
9
/L, with clinical signs of a viral infection,
and aged up to six years at presentation. For those with a
leukocyte count ≤0.5 x 10
9
/L, they were further classified
according to CRP level (≤ or >50mg/L).
111
Severe bacterial infection,
(death from bacterial
infection, a positive culture
of normally sterile body
fluids, radiologically proven
pneumonia, clinically
unequivocal diagnosis of a
bacterial infection, or
CRP>150 mg/L)
90 10% 0 1.18
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(model #1:
bootstrapped)
(model #3)
Low risk ≤4 factors. Risk factors = bone marrow
involvement, absence of clinical signs of viral infection,
high serum CRP level, low leukocyte count, presence of a
central venous catheter, high haemoglobin level, and Pre-
B-cell leukaemia.
-111 As above -90 20% 0.07 1.39
Agyman 2011
(Same
population as
Amman 2010)
Applied after 24 hours: shaking chills ever observed,
haemoglobin >90 g/L, platelet <50 G/L, any other need
for IP treatment. No risk factors = low risk
423 Late bacteraemia 67 36% 0.17 1.58
Badiei
11
,
Threshold
value:
Platelets <20 g/dL, temperature ≥39ºC, ANC <100/mm3,
mucositis, abnormal CXR on presentation. Risk of
infection greater with more risk factors: for 0 factors:
120 Life threatening infection 35 29.20% 0.07 1.62
For 1 risk factor 64% 0.36 3.37
For 2 risk factors 75% 0.41 6.69
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For 3 risk factors 85% 0.63 8.51
For 4 risk factors 98% 0.94 Infinite
Gala-Peralta,
2005
Low risk ≤2 of: <1yr, poor bone marrow response (plt <75,
ANC <100),uncontrolled solid tumour or relapsed
leukaemia, chemotherapy <10d earlier, rapid
neutropenia, cardiac & renal dysfunction
60 Positive blood culture 16 27% 0.18 1.44
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Hakim
8
Score from cancer diagnosis: AML = 20, ALL/lymphoma =
7, Solids = 0 Clinical presentation of serious unwell or
toxic = 14, fever at presentation: ≥39ºC = 11, ANC
<100/mm3 = 10 points, Total score <24 = low risk of
serious infection or sepsis
332 Serious infection or sepsis 47 69% 0.33 3.16
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Score from cancer diagnosis: AML = 11, others = 0.
Relapsed disease = 11. Non-white patient = 8, Clinical
presentation of serious unwell or toxic = 20. Total score
<20 = low risk of any medical complication
332 Medical complications 40 63.00% 0.32 2.54
Jones 1996 Low risk = ANC ≥200, outpatient at onset, in remission 127 Bacteraemia 68 17% 0.71 1.07
Lucas, 1996
Low risk = no chills, hypotension, or a requirement for
fluid resuscitation at admission
509 Positive blood culture 82 87% 0.72 4.05
Petrelli, 1991
Low Risk: patients with solid tumors and lymphomas
stage I-II.High Risk: patients with leukemias and
lymphomas stage III-IV,
146 Positive blood culture 35 45% 0.58 1.42
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Rondinelli,
2006
Low risk = 2.5 to 5 points: Intermediate risk = 5.5 to 9
points: High risk = Greater than 9 points. 4.5 points for:
clinical site of infection; 2.5 points for: no URTI; 2 points
for: CVC; 1 point for: aged ≤5y, fever >38.5°C, Hb ≤7g/dL
283
‘Serious infectious
complication’ – sepsis, shock,
+ve blood cultures, infection-
related death
93
Odds
ratio
only:
Low 1.0
Mid 13
High 50
West, 2004
(bootstrapped)
High risk = temp >39.5C and CRT >3s; Mid risk = temp
>39.5C or CRT >3s; Low risk = neither
143
Requirement for critical care
within 24 hours of
presentation (fluid boluses
≥60ml/kg, inotropes or
ventilation)
36
Low
89%
0.73 Infinite
Mid
10%
2.7
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ALL = acute lymphoblastic leukaemia. AML = acute myeloid leukaemia. AMC = absolute monocyte count. CoNS = Coagulase-negative Staphylococcus CRP =
C-reactive protein. CRT = capillary refill time. CXR = chest X-ray. Hb = haemoglobin. Plt = platelets.
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Performance of CDR with more than one supportive data set
Clinical
prediction rule
Number
of
episodes
Outcome
Number
with
Outcome
% Low LR Low LR High
Santolaya,
2001
Low risk = 0
factors or
isolated low
plts or <7 days
from
chemotherapy.
High risk = >1
risk factor, or
isolated high
CRP,
hypotension or
relapsed
leukaemia.
Risk factors:
CRP ≥90,
hypotension,
relapsed
leukaemia, plts
≤50,
chemotherapy
within seven
days
407
Invasive
bacterial
infection =
positive blood
culture (2 for
Coagulase-
negative
Staphylococcus
spp), positive
bacterial
culture from
usually sterile
site, or sepsis
syndrome
and/or focal
organ
involvement
and
haemodynamic
instability and
severe malaise
178 42% 0.22 2.41
Santolaya,
As above 263 As above 140 40% 0.11 3.91
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2002
Amman,
2010
As above 423 As above 122 15% 0.35 1.15
Macher,
2010
As above 249 As above 46% 0.8 1.1
Clinical
prediction
rule
Number
of
episodes
Outcome
Number
with
Outcome
% Low LR Low LR High
Rackoff,
1996
Low risk =
AMC
>100;
High-risk
=
AMC<100
57 Bacteraemia 10 23% 0 1.45
(proposed
from
validation
set)
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Baorto,
2001
As above 1171 Bacteraemia 189 21% 0.45 1.45
Madsen
16
As above 157
Microbiologically documented
infection
12 39% 0.21 1.55
Klassen As above 227 Significant bacterial infection 43 37% 0.30 1.48
Amman
13
As above 423 Serious adverse medical outcome 67 38% 0.26 1.72
Macher
14
As above 377 Significant bacterial infection 70 40% 0.46 1.44
Tezcan,
2006
As above 621
Microbiological documented
infection
225 60% 0.74 1.59
Clinical
prediction
rule
Number
in study
Outcome
Number
with
Outcome
% Low
% Mid
LR Low LR Mid LR High
Paganini, Low risk <4.
714 Death 18 82% 0 2.38 12
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2007
Mid-risk = 4.
High risk =
>4.
Advanced
stage of
disease = 3
points,
Comorbidity
= 2 points,
Bacteraemia
= 1 point
10%
(validation
set)
As above 806 Death 19 82% 0.12 2.76 9.86
12%
Clinical
prediction
rule
Number
in study
Outcome
Number
with
Outcome
% Low
% Mid
LR Low LR Mid LR High
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Rackoff,
1996
Low risk =
AMC
>100;
Mid-risk=
AMC
<100, and
temp <39;
High-risk
=
AMC<100,
but temp
≥39
115 Bacteraemia 24 17% 0 0.87 3.44
(derivation
set)
65%
(validation
set)
As above 57 Bacteraemia 10 23% 0 0.21 3.52
40%
Klaassen,
2000
As above 227 Bacteraemia 28 37% 0.35 0.75 2.57
37%
Significant
43 0.39 0.94 2.29
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bacterial
infection
(validation
set)
As above 136 Bacteraemia 19 42% 0.21 3.93 2.8
24%
Significant
bacterial
infection
27 0.59 1.59 1.22
Madsen,
2002
As above 157
Positive
blood
culture
12 25% 0.31 0.91 3.72
64%
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Clinical
prediction
rule
Number
of
episodes
Outcome
Number
with
Outcome
% Low LR Low LR High
Amman,
2004
Low risk ≤3
factors. Risk
factors =
bone
marrow
involvement,
absence of
clinical signs
of viral
infection,
high serum
CRP level,
low
leukocyte
count,
presence of
a central
venous
catheter,
high
haemoglobin
level, and
Pre-B-cell
leukaemia.
364
Severe
bacterial
infection
(death from
bacterial
infection, a
positive
culture of
normally
sterile body
fluids,
radiologically
proven
pneumonia,
clinically
unequivocal
diagnosis of
a bacterial
infection, or
CRP>150
mg/L)
132 14% 0.00 1.29
Amman,
As above 423 122 10% 0.27 1.10
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2010
Macher,
2010
As above 377 122 8% 2.29 0.97
Clinical prediction rule
Number
of
episodes
Outcome
Number
with
Outcome
% Low LR Low LR High
Alexander,
2002
Low risk = Not
AML/Burkitts/Induction
ALL/Progressive-
relapsed with marrow
involvement and no
significant comorbidity
104 Bacteraemia 13 58% 0.24 2.39
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Amman,
2010
304 Bacteraemia 122 8% 0.66 1.03
Domment,
2009
762 Bacteraemia 122 53% 0.72 1.38
Clinical
prediction rule
Number
of
episodes
Outcome
Number
with
Outcome
% Low LR Low LR High
Amman,
2010
Applied after
24 hours: 4
points for
chemotherapy
more
intensive than
ALL
423
Serious adverse medical
outcome
122 35% 0.18 1.67
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maintenance,5
points for
hemoglobin
>90 g/L, 3
points each
for white
blood cell
count <0.3
G/L, platelet
<50 G/L, any
adverse event
occurred in
preceding 24h.
Scores ≤9 are
low risk.
Miedema,
2011
210 57 50% 0.31 1.55
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Appendix 9. Individual factors used in clinical prediction rules
Overview
Variable Citations
Pt related
Age
<6yr
Amman
2003
(Madsen) (Tezcan)
<5yr Rondinelli
<4, 4-8, >8yr
(Amman
2010)
Disease
AML/Burkitts/Induction
ALL/Relapse-
progressive/BM
involvement
Alexander
Page 281 of 410
AML or ALL/Lymph or
Other
Hakim Amman 2010
Leuk/Lymph or BMT vs
Other
Hann (Lucas) (Badei) Delabarre
BM involved
Amman
2003
Amman 2004 (Klassen)
(Amman
2010)
Pre-B Leukemia
Amman
2003
In PR/CR
Amman
2004
(Rondinelli) (Tezcan)
(Amman
2010)
Induction/relapse vs.
remission
Jones (Amman 2010)
Advanced disease Paganini
Relapsed leuk Santolaya Hakim
Rx related
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Type of Rx
Ara-C <7d Adcock
Low intensity
(anticptaed neutropenia
<7d)
Alexander Amman 2010 (Hakim) Delabarre
Chemo <7d Santolaya (Amman 2010) (Badei)
Others
CVC present
Amman
2003
Hann Rondinelli
(Amman
2010)
Episode related
Airway/Breathing
Tachypnoea/hypoxia Alexander (Amman 2010)
Circulation
Tachycardia (Mian) (Amman 2010)
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Hypotension Adcock Santolaya (Tezcan) (Mian)
(Amman
2010)
Chills/hypotension/fluid
bolus composite
Lucas
Shock/Severe sepsis Hann Delabarre
CRT >3 West
Neurology
Altered mental status Alexander
Source
Inflammed CVC site Adcock
CXR +ve / pneumonia Alexander Badei (Rondinelli)
Mucositis Alexander (Rondinelli)
(Amman
2010)
(Badei)
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Vomiting/diarrhoea Alexander
Viral infection
Amman
2003
Rondinelli (no
URTI)
Clincally unwell
(Amman
2010)
Hakim
Known bactermia Paganini Amman 2010 Mian
Clincal site Rondinelli Delabarre (Madsen)
Temperature
Cont variable Hann Rackoff Madsen West
<38.5 Rondinelli (Badei)
<39.7 C
Amman
2004
<39 (also 39.5 used) Klassen Hakim Delabarre Badei (Mian)
(Amman
2010)
(Santollaya)
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Others
Other comorbidity Alexander Amman 2004 Paganini
(Amman
2010)
Abdominal pain Alexander
OP at start Jones
Blood work
FBC
WCC >0.5
Amman
2003
Amman 2004 Amman 2010 Delabarre (Madsen) (Rondinelli)
Hb <7 Rondinelli Amman 2003 (Badei)
Han >10
Amman
2010
Granulocytopenia >15d Hann
ANC Jones Hakim (Rackoff) (Lucas) (Madsen) (Tezcan) (West)
(Amman
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2010)
AMC Klassen Rackoff (Paganini Madsen Delabarre (Santolaya) (Baorto) (Tezcan)
(Amman
2010)
Plts Santolaya Amman 2010 Badei (Madsen) (Rondinelli) (Hakim)
Biochemistry
PCT >0.3 Delabarre
CRP (continuous) Mian
CRP >50
Amman
2003
CRP >90 Santolaya
CRP >150
Amman
2010
Study citations in (brackets) refer to those assessed but not included in models.
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Appendix 10. Factors predictive of adverse outcome, by study
Table a – Assessments of individual factors predicting bacteraemia
Variabl
e
Citati
on
Univariate
p-value or
OR 95% CI
Adjusted p-
value or
95% CI
Citati
on
Univariate
p-value or
OR 95% CI
Adjusted
p-value or
95% CI
Cit
ati
on
Univariate
p-value or
OR 95% CI
Adjusted p-
value or 95%
CI
Cit
ati
on
Univariate
p-value or
OR 95% CI
Adjusted
p-value or
95% CI
Pt
relate
d
Age
<6yr (Mad
sen
0.447 (cont n/s)
Diseas
e
AML/Burkitts/Induction
ALL/Relapse-
progressive/BM
involvement
Alex
ande
r
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Leuk/Lymph or BMT vs
Other
Hann n/a p<0.0001
(0.23 to
0.77)
(Luca
s
0.041 n/a)
BM involved Amm
an
2004
1.3 to 1.46 n/a Agye
man
n/a 1.2 to 8.6 (Kl
ass
en
0.002, 0.008 on fixed
and 0.014 on
random)
AML Agye
man
n/a 1.3 to 5.1 Haki
m
2.77 to
17.24
2.76 to
20.14
ALL/Lymphoma vs. solid Haki
m
0.83 to 4.51 0.84 to
5.02
In PR/CR Amm
an
2004
n/a n/a
Induction/relapse vs.
remission
Jone
s
1.23 to
10.95
n/a (Haki
m
0.9 to 3.74 n/a)
Rx
relate
d
Type
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of Rx
Low intensity (anticptaed
neutropenia <7d)
Alex
ande
r
(Haki
m
0.23 to 0.83 n/a)
Others
CVC present Hann n/a 0.03 (1.06
to 3.31)
Episod
e
relate
d
Airway
/Breat
hing
Tachypnoea/hypoxia Alex
ande
r
Circula
tion
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Chills/hypotension/fluid
bolus composite
Luca
s
<0.0001 n/a
Shock Hann n/a 0.003 (1.80
to 17.3)
Neurol
ogy
Altered mental status Alex
ande
r
Source
Inflammed CVC site Adco
ck
p>0.05 n/a
CXR +ve / pneumonia Alex
ande
r
Mucositis Alex
ande
r
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Vomiting/diarrhoea Alex
ande
r
Clincal site (Mad
sen
0.044 (cont) n/s)
Tempe
rature
Cont variable Hann n/a <0.0001 Rack
off
0.002 n/a Ma
dse
n
0.012 0.031
<38.5
<39.7 C Amm
an
2004
1.5 to 7.1 n/a
<39 (also 39.5 used) Klass
en
0.023 0.033
(Fixed)
0.049
(Random)
Agye
man
n/a 1.2 to 7.2 Ha
ki
m
1.0 to 2.4 1.3 to 6.5
Others
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Other comorbidity Alex
ande
r
Amm
an
2004
1.3 to 4.2 n/a
Abdominal pain Alex
ande
r
OP at start Jone
s
1.36 to 5.71 n/a
Blood
work
FBC
WCC >0.5 Amm
an
2004
1.4 to 4.1 n/a (Mad
sen
0.321 (cont) n/s)
WCC <0.3 Agye
man
n/a 2.3 to 7.0
Hb <7
Granulocytopenia >15d Hann n/a 0.01 (1.5 to
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37.9)
ANC >200 Jone
s
0.63 to 2.43 n/a (Rac
koff
>0.5 n/a, as
cont var)
(Lu
cas
>0.05 n/a, for >100) (M
ads
en
0.227 (cont) n/s)
ANC <100 Agye
man
n/a 2.9 to 17.4 Haki
m
1.4 to 5.7 1.2 to 5.7
AMC (<100, 10 or 115) Klass
en
0.002 0.031
(Fixed)
0.046
(Random)
Rack
off
0.08 (by
partitonin
g)
(Ba
ort
o
0.28 to 0.72 n/a) Ma
dse
n
0.004 (cont) 0.016
(cont)
Plts <50 Agye
man
n/a 1.1 to 4.3 Haki
m
1.25 to 4.34 n/a (M
ads
en
0.036 (cont) n/s)
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Table b – Assessments of individual factors predicting significant/documented infection and/or complications
Variable Citation Univariate
p-value or
OR 95% CI
Adjusted
p-value or
95% CI
Citation Univariate
p-value or
OR 95% CI
Adjusted
p-value or
95% CI
Citation Univariate
p-value or
OR 95% CI
Adjusted
p-value or
95% CI
Citation Univariate
p-value or
OR 95% CI
Adjusted
p-value or
95% CI
Pt related
Age
<6yr Amman
2003
0.67 to
3.41 (to
12) or 0.60
to 3.05
(older than
12y)
(Tezcan 0.01 n/s)
<5yr Rondinelli 1.37 to
3.37,
<0.001
1.0 to 3.4,
0.049
<4, 4-8, >8yr (Amman
2010)
0.9 to 2.8
(middle
group)
n/a
Disease
Page 295 of 410
AML Amman
2010
1.7 to 6.1 1.5 to 6.3
Leuk/Lymph or
BMT vs Other
Delabarre n/a n/a
BM involved Amman
2003
1.47 to
8.87
n/a (Amman
2010
0.7 to 6.2 n/s)
Pre-B Leukemia Amman
2003
0.38 to
1.54
n/a
In PR/CR (Rondinelli 1.3 to 4.0,
0.001
n/s) (Tezcan
docum inf
n/s n/s) (Amman
2010
0.9 to 2.5 n/s)
Relapsed leuk Santolaya n/a 1.7 to 2.3
Rx related
Type of Rx
Low intensity
(anticptaed
neutropenia <7d)
Amman
2010
1.1 to 7.1 n/s
Chemo <7d Santolaya n/a 1.1 to 1.6 Delabarre n/a n/a (Amman
2010
0.4 to 1.6 n/s)
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Others
CVC present Amman
2003
0.79 to
2.98
Rondinelli 2.0 to 6.3,
0.001
1.5 to 5.5,
0.001
(Amman
2010
0.3 to 1.1 n/s)
Episode
related
Circulation
Hypotension Santolaya n/a 2.3 to 3.2 (Tezcan n/s n/s)
Severe sepsis Delabarre n/a n/a
Source
Inflammed CVC
site
CXR +ve /
pneumonia
Badei n/a n/a (Rondinelli 2.3 to 9.9,
0.001
n/s)
Mucositis (Rondinelli 1.8 to 5.4,
0.001
n/s) (Amman
2010
0.4 to 1.0 n/s)
Viral infection Amman
2003
0.96 to
4.57
n/a Rondinelli
(no URTI)
2.2 to 5.5,
p=0.045
1.7 to 15.1,
p=0.001
Badei (no
URTI)
n/a n/a
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Clincal site Rondinelli 1.2 to 21,
0.001
7.0 to 39.5,
0.001
Delabarre n/a n/a
Temperature
Cont variable
<38.5 Rondinelli 1.0 to 3.6,
p 0.033
1.0 to 3.6,
p 0.033
<39 (also 39.5
used)
Badei n/a n/a Delabarre n/a n/a (Santollaya 0.19 n/a)
Blood work
FBC
WCC >0.5 Amman
2003
1.20 to
7.14 (cf >1)
(Rondinelli 0.97 to 2.7,
0.053
n/s)
WCC <0.3 Amman
2010
0.4 to 2.1 2.5 to 6.8
Hb <7 Rondinelli 1.1 to 3.5,
0.021
1.2 to 3.6,
0.021
Amman
2003
0.26 to
2.04
n/a
Hb >9 Amman 1.1 to 1.8 1.5 to 4.3
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2010
ANC <500 Delabarre n/a n/a
ANC >200 (Tezcan
<100
n/s n/s)
AMC (<100, 10
or 115)
(Santolaya 0.04 0.236) (Tezcan 0.01 n/s)
Plts <50 Santolaya n/a 1.4 to 2.2 Badei n/a n/a Delabarre n/a n/a (Amman
2010
1.2 to 3.2 n/s)
Biochemistry
CRP >50 Amman
2003
1.21 to
62.9
n/a
CRP >90 Santolaya n/a 3.6 to 4.8
PCT >0.3 Delabarre n/a n/a
Table c – Assessments of individual factors predicting outcomes including ICU & death
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Variable Citation
Univariate
p-value or
OR 95% CI
Adjusted
p-value
or 95%
CI
Citation
Univariate
p-value or
OR 95% CI
Adjusted
p-value
or 95%
CI
Pt related
Age
<5yr Rondinelli
1.37 to
3.37,
<0.001
1.0 to
3.4,
0.049
Disease
In PR/CR (Rondinelli
1.3 to 4.0,
0.001
n/s)
Advanced disease Paganini
0.01 (1.02
to 1.06)
0.001
Rx related
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CVC present Rondinelli
2.0 to 6.3,
0.001
1.5 to
5.5,
0.001
Episode
related
Circulation
Tachycardia (Mian p=0.27 n/s)
Hypotension (Mian p=0.34 n/s)
CRT >3 West 0.01
1.88 to
16.84,
0.002
Source
CXR +ve / pneumonia (Rondinelli
2.3 to 9.9,
0.001
n/s)
Mucositis (Rondinelli
1.8 to 5.4,
n/s)
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0.001
Viral infection
Rondinelli
(no URTI)
2.2 to 5.5,
p=0.045
1.7 to
15.1,
p=0.001
Known bacteraemia Paganini
<0.0001
(5.2 to 39)
0.001 Mian 0.031
1.8 to
240,
p=0.015
Clinical site Rondinelli
1.2 to 21,
0.001
7.0 to
39.5,
0.001
Temperature
Cont variable West
0.002
(cont)
1.25 to
2.43.
p0.001
<38.5 Rondinelli
1.0 to 3.6,
p 0.033
1.0 to
3.6, p
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0.033
>39 (Mian p=0.21 n/s)
Others
Other comorbidity Paganini
0.001
(10.5 to
102)
0.0001
Blood work
FBC
WCC >0.5 (Rondinelli
0.97 to
2.7, 0.053
n/s)
Hb <7 Rondinelli
1.1 to 3.5,
0.021
1.2 to
3.6,
0.021
ANC >200 (West 0.69 n/s)
AMC (<100, 10 or 115) (Paganini
0.03 (0.9
n/a)
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to 12)
Plts <50
(Rondinelli
<20
1.2 to 3.9,
0.007
n/s)
Plts <20 (Mian p=0.05 n/s)
Biochem
CRP Mian 0.029
1.0 to
1.03,
p=0.021
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Appendix 11. Full list of QUADAS criteria for included biomarkers studies
Author 1 2 3 4 5 6 7 8 9 10 11
Ammann, 2003 Yes Yes Yes Yes No Yes Yes Unclear Unclear Yes Yes
Asturias, 2010 Yes Yes Yes Yes Unclear No No Unclear Unclear Yes Yes
Avabratha, 2009 Yes Yes Yes Yes Unclear Yes No Unclear Unclear Yes Yes
Barnes, 2002 Yes No Yes Yes Yes Yes Yes Unclear Unclear No Yes
Cost, 2011 Yes Yes Unclear Unclear Unclear No No Unclear Unclear Unclear Yes
de Bont, 1999 Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Diepold, 2008 Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Dylewska, 2005 a&b Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
El-Maghraby, 2007 Unclear Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Hatzistilianou, 2007 Unclear No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Hatzistilianou, 2010 Yes No Yes Unclear Unclear Yes Yes Unclear Unclear Yes Yes
Heney, 1992 Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
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Hitoglou-Hatzi, 2005 Unclear No Yes Yes Yes Yes Yes Unclear Unclear Unclear Yes
Hodge, 2006 Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Hodge, 2011 Yes No Yes Yes Yes Yes No Unclear Unclear Unclear Yes
Kharya, 2010 Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Katz, 1992 Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Kitanovski, 2006 Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Lehrnbecher, 1999 Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Unclear
Lehrnbecher, 2004 Yes No Yes Yes Yes Yes No Unclear Unclear Yes Yes
Lodahl, 2011 Yes Yes Yes Unclear Yes Yes No Unclear Unclear Yes Yes
Mian, 2009 Yes No Yes Yes Unclear No No Unclear Unclear Unclear Yes
Miedema, 2011 Yes Yes Yes Unclear Unclear Yes Yes Unclear Unclear Yes Yes
Nishikawa, 2010 Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Reitman, 2010 Yes No Unclear Unclear Yes No No Unclear Unclear Unclear Yes
Richardson, 2009 Yes Yes Yes Yes Yes Yes No Unclear Unclear Yes Yes
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Riikonen, 1992 Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Riikonen, 1993 Unclear No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Santolaya, 1994 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Santolaya, 2007 Yes Yes Yes Yes Yes Yes Yes Yes Unclear Yes Yes
Santolaya, 2008 Yes Yes Yes Yes Yes Yes Yes Unclear Yes Yes Yes
Secmeer, 2007 Unclear No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Soker, 2001 Unclear No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Spasova, 2005 Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Stryjewski, 2005 Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes Yes
Santolaya, 2001 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Santolaya, 2002 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
1 = representative patients, 2 = clearly described selection criteria, 3 = whole sample, or a random selection of sample, received reference standard, 4 = all patients
received same reference standard, 5 = index test not part of reference standard, 6 = index test described adequately, 7 = reference standard described adequately, 8 =
blinded interpretation of index test results, 9 = blinded interpretation of reference standard results, 10 = same clinical data available as in clinical practice, 11 = adequate
reference standard
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Appendix 12. Handling continuous and categorical variables in biomarkers studies.
Citation
How were continuous
variables handled in the
analyses?
If relevant, describe methods used for
cutpoint determination
How were categorical variables
handled in the analyses?
If relevant, describe
methods used for cutpoint
determination
Ammann, 2003
Made ordinal, with up
to three categories
Not stated Grouped Not stated
Asturias, 2010 Grouped Not described
Avabratha,
2009
Grouped Not described
Barnes, 2002
Continuous and
dichotomised
Not stated. Appears to be maximal diagnostic
efficiency (based on study Figure)
Cost, 2011 Continuous
de Bont, 1999
Continuous (markers),
grouped (age)
Age split into <16, 16-50, and >50. Implied
that a level was chosen 'that identified 28%
patients as low risk with 100% sensitivity'
Sex and type of malignancy
used ungrouped
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Diepold, 2008
Continuous and
dichotomised
Based on ROC curve to maximise diagnostic
utility
Dylewska, 2005
a & b
Continuous
El-Maghraby,
2007
Continuous and
dichotomised
Taken from (CRP) literature or cytokines local
control upper limit of normal
Hatzistilianou,
2007
Continuous and
dichotomised
Not stated. Appears to be based on ROC
analysis.
Hatzistilianou,
2010
Continuous
Heney, 1992 Continuous
Hitoglou-Hatzi,
2005
Continuous
Hodge, 2006
Continuous and
dichotomised
Upper limit of normal defined as Mean + 2SD
in control population
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Hodge, 2011 Continuous
Kharya, 2010
Continuous then
grouped
ROC curves
Katz, 1992
Continuous and
dichotomised
Not stated. Appear arbitrary. Dichotomised
Haematological vs. solid
tumours
Kitanovski,
2006
Continuous and
dichotomised
'Best predictive value' by ROC analysis
Lehrnbecher,
1999
Continuous and
explored with cutoffs
IL6 & 8 cut at two levels: to maximise
sensitivity and median values.
Lehrnbecher,
2004
Continuous and
dichotomised
Based on previous threshold values (not this
dataset)
Lodahl, 2011
Continuous and
grouped (alternative
models)
Grouped: PCT - PCT cut-off levels from
literature, CRP- cutoff levels chosen to give
identical sensitivities
Mian, 2009 Continuous
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Miedema, 2011 Continuous
Nishikawa,
2010
Continuous
Reitman, 2010 Continuous
Richardson,
2009
Grouped
Results from another study suggesting that
CRP >/=4 was predictive of bacteraemia
Riikonen, 1992
Continuous and
explored with cutoffs
Not stated Unclear
Riikonen, 1993
Continuous and
explored with cutoffs
Not stated. Appears to be based on previously
defined values
Santolaya, 1994
Continous and
dichotomised
From literature reflecting CRP in non-
immunosuppressed patients
Santolaya, 2001
Continuous and
dichotomised
By ROC analysis Grouped Not stated
Santolaya, 2002
Continuous and States cutoffs were determined using ROC
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dichotomised analysis
Santolaya, 2007
Continuous and
dichotomised
States cutoffs were determined using ROC
analysis
Grouped Not stated
Santolaya, 2008
Continuous and
dichotomised
"best discriminative cutoff value"
Secmeer, 2007
Continuous and
dichotomised
Not stated. Appears to be based on previously
defined values
Grouped (e.g. duration of
neutropenia was defined as
prolonged if more than 72
hours)
Not stated
Soker, 2001 Continuous
Spasova, 2005
Continuous and
dichotomised
Not stated
Stryjewski,
2005
Continuous and
dichotomised
Data derived (maximal efficiency, and to
ensure 100% Sn)
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Appendix 13. Further data on infrequently or partially reported markers
and outcomes
Citation
Marker and
Cutpoint
Outcome
Sensitivity
(95% CI)
Or measure in
‘infected’
Specificity (95%
CI)
Or measure in
‘non-infected’ Method of derivation
De Bont, 1999 CRP Bacteraemia Not significantly associated
De Bont, 1999 IL6
Bacteraemia
Beta value ln(IL6) = 0.658 (se
0.31)
De Bont, 1999 IL8
Bacteraemia
Beta value ln(IL8) = 0.551 (se
0.28)
Delebarre,
2010
PCT
0.3ng/ml
Significant
infection
‘Significantly associated in
multivariate analysis’
El-Maghraby,
2007
MCP
350
Documented
infection
0.644 (95% CI
0.517 to 0.754)
0.923 (95% CI
0.759 to 0.979)
2*2 extracted from
text/graph
Hitoglou-
Hatzi, 2005
tADA
35U/l
Significant
bacterial
infection
1 (95% CI
0.883 to 1)
1 (95% CI 0.908
to 1)
2*2 extracted from
text/graph
Cost, 2011
IL8 and IL5
(no cutoff)
Bacteraemia
or clinical
sepsis 0.88 0.48
Kharaya, 2010
PCT
3.3ng/ml Bacteraemia
Sn 66%
(derivation),
80%
(validation)
Sp 85%
(derivation),
80% (validation
No absolute numbers of
bacteraemia to use in
calculating appropriate
CI
Kharaya, 2010 IL6 Bacteraemia
Sn 67% Sp 75% No absolute numbers of
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137pg/ml
(derivation),
60%
(validation)
(derivation),
77% (validation
bacteraemia to use in
calculating appropriate
CI
Riikonen,
1992
TNF
40
Bacteraemia
or focal
infection
1 (95% CI
0.879 to 1)
0.065 (95% CI
0.025 to 0.154)
2*2 extracted from
text/graph
Hodge, 2006
IL5
17
Positive
blood culture
0.5 (95% CI
0.215 to 0.785)
Could not
calculate
2*2 extracted from
text/graph
Hodge, 2006
IL5 & 8
combined
>17 and >220
Positive
blood culture
1 (95% CI
0.676 to 1)
0.87 (95% CI
0.679 to 0.955)
2*2 extracted from
text/graph
Riikonen,
1992
IL1
SAA
Bacteraemia
or focal
infection
Could not
calculate
Could not
calculate
Soker, 2001 IL2R
Bacteraemia
Median
(range)
5230U/mL
(1120 to 7600)
1190 (724 to
5400)
Medians/range only
reported
Soker, 2001 TNF-alpha
Bacteraemia
8.4 (4.0 to
68.2) 7.8 (3.0 to 37.2)
Medians/range only
reported
Soker, 2001 IL1
Bacteraemia
Could not
calculate
Could not
calculate
Soker, 2001 IL8
Bacteraemia
305pg/ml (16
to 4838)
23pg/ml (5 to
184)
Medians/range only
reported
Santolaya,
2008 PCT (ng/ml)
Severe
infectious
complications
Mean (+/-
reported SD)
Admission
Mean (+/-
reported SD)
Admission 6 5.5
Only in patients in the
non-low risk group.
Clearly non-Normal
data reported as
Page 314 of 410
13.6 +/- 63.6
24h 14.5 +/-
54.5
+/-30.7
24hrs 8.8 +/-
40.2
mean/SD.
Santolaya,
2008 IL8 (ng/ml)
Severe
infectious
complications
Mean (+/-
reported SD)
444.9 (623)
Mean (+/-
reported SD)
232.9 (445.6)
Only in patients in the
non-low risk group.
Clearly non-Normal
data reported as
mean/SD.
Secmeer,
2007 ESR
Bacteraemia
“not statistically significantly
different between patients with
and without documented
infection” Figures not shown
Stryjewski,
2005 PCT
Sepsis or
septic shock
502pg/ml (39
to 54774)
201pg/ml (47 to
9862)
Median values (range)
for admission
comparing non-septic
with septic
Stryjewski,
2005 IL6
Sepsis or
septic shock
10pg/ml (0 to
597)
11pg/ml (0 to
105)
Median values (range)
for admission
comparing non-septic
with septic
Stryjewski,
2005 IL8
Sepsis or
septic shock
45pg/ml (7 to
278)
15.5pg/ml (0 to
219)
Median values (range)
for admission
comparing non-septic
with septic
Mian, 2011 IL6
Admission to
PICU 5594(+/-4337) 981 (+/-2252) Mean +/- SD
Mian, 2011 IL8
Admission to
PICU 2465 (+/-2504) 419 (+/-921) Mean +/- SD
Mian, 2011 IL10
Admission to
3971
322 (+/11819) Mean +/- SD
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PICU (+/15251)
Mian, 2011 TNF-alpha
Admission to
PICU 61 (+/-56) 11 (+/-22)
Mean +/- SD
Mian, 2011 CRP
Admission to
PICU 243 (+/-112) 130 (+/-91)
Mean +/- SD
IL6 cutoff 137pg/ml - 67% sensitive and 75% specific in predicting bacteraemia in test group IL6
cutoff 137pg/ml - 60% sensitive and 77% specific in predicting bacteraemia in validation group
Figure 56: Diagnostic value of exploratory biomarkers for documented infection
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Appendix 14. Study inclusion flow diagram
Study groups identified through
database searching in SRs
n = 28
Additional groups identified
through other sources
n = 9
Total study groups approached
(n = 36)
Responses received
(n = 19: 53%)
Groups not interested
(n = 2)
Groups with studies
assessed for eligibility
n = 17
Full-data studies excluded,
with reasons
(n = 4; never returned
data)
Studies included in
qualitative synthesis
(n = 22)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 22)
Groups returning extra
studies
(n = 4)
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ppendix 15. The PICNI
The PICNICC (Predicting Infectio
Children with Cancer) Collabora
Optimizing risk predictive strate
undergoing treatment for malig
Dr. Michaela Semeraro
Department of Paediatric Oncol
39 Rue Camille Desmoulins
94805 Villejuif
France
3 December 2010
Dr Bob Phillips
PICNICC Collaborative
Centre for Reviews and Dissemi
Alcuin College
University of York
York
UK
YO10 5DD
Dear Dr Semeraro,
We are writing to you on behalf
academics who are undertaking
studies evaluating risk stratifica
Through our systematic searche
author of “Semeraro M, Thomé
neutropenic paediatric patients
2010;54(2):284-290.” and woul
Systematic reviews and meta-a
of research by drawing togethe
study could achieve. When publ
conclusions they reach because
varied assessments of differenc
patient data techniques preserv
limitations of reporting within p
C Invite Letter
us Complications of Neutropenic sepsis In
ive
ies in febrile neutropenic episodes in children a
ant disease
gy
ation
of an emerging collaboration of paediatric onco
a systematic review and individual patient data
ion of febrile neutropenic episodes in children a
s of the published literature in this field, we hav
C, Rolland E, et al. A predictor of unfavourable
presenting with fever of unknown origin. Pediat
like to invite you to join the collaboration.
alyses provide an opportunity to improve our k
multiple studies to produce a more precise con
ished summary results alone are used, reviews c
of the challenges of reporting data in published
s between important sub-groups of patients. T
es the benefits of traditional systematic reviews
ublished papers and allows more powerful sub-
nd young people
ogists and
meta-analysis of
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We would like to invite you to become a collaborator: to be involved in the refinement of the
protocol, and provide your dataset for the central collaborative. The collaborative already includes
clinicians from the UK, USA, Switzerland, Germany, Mexico, India and Italy, and we would greatly
value the input of your group. We intend the results of this review be submitted to a peer-reviewed
journal regardless of its findings, under the collaborative group name, of which you would be a
member.
To be a member of the PICNICC collaborative, you would need to supply individual patient data from
cohort studies of in children and young people, including randomised trial data, who presented with
febrile neutropenia. This could be with either prospective or retrospective data collection, but needs
to provide data for all ‘essential’ predictive variables in >50% of included episodes and two or more
of the study defined outcomes for >90% of the included episodes of FNP. We will exclude studies
which are case-series (for example, of only ‘gram negative bacteraemias’).
The ‘essential’ predictive variables are proposed to be age, underlying tumour type, and remission
status; chemotherapy type and time elapsed since last cycle; in-patient or out-patient at onset of
episode; maximum temperature; antibiotic therapy used; white cell count; neutrophil count and at
least one of the following four assessments: respiratory rate (or compromise), circulatory status (or
compromise), presence of severe mucositis, or a global assessment of illness severity. The core
outcome variables are: death; intensive care admission; need for moderate organ support (fluid
bolus, oxygen); clinically documented infections and microbiologically documented infections. These
are subject to discussion in the refinement of the study protocol.
We would be delighted hear from you, and happy to answer any questions that you may have about
becoming involved in this project.
Dr Bob Phillips
MRC Research Fellow, Centre for Reviews and Dissemination, University of York and Consultant in
Paediatric Oncology, Leeds Teaching Hospitals Trust, Leeds
Prof Alex Sutton, Professor of Medical Statistics, University of Leicester
Dr Richard Riley, Senior Lecturer in Medical Statistics, University of Birmingham
Dr Julia Chisholm, Consultant in Paediatric Oncology, Royal Marsden NHS Foundation Trust, Surrey
Dr Susan Picton, Consultant Paediatric Oncologist, Leeds Teaching Hospitals Trust, Leeds
Prof Lesley Stewart, Director, Centre for Reviews and Dissemination, University of York
e: crd-picnicc@york.ac.uk
t: +44 1904 321099
f: +44 1904 321041
w: http://bit.ly/PICNICC
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Appendix 16. Parental Advisory Request
The PICNICC (Predicting Infectious Complications of Neutropenic sepsis In
Children with Cancer) Study
Optimizing risk predictive strategies in febrile neutropenic episodes in children
and young people undergoing treatment for malignant disease
This project will use an individual patient data meta-analysis approach to develop and
evaluate a risk stratification model to predict which children and young people have a
low risk of adverse outcomes during an episode of febrile neutropenia. This will define a
group of individuals who may be treated with reduced intensity or duration of antibiotic
therapy, and so reduce the inconvenience and cost of these episodes. The project will
also explore specific issues around adapting established techniques of IPD meta-analysis
of interventions for use the method of prognostic evidence synthesis and predictive
modeling.
Febrile neutropenia (FNP) is a complication of cancer therapy. It is the occurrence of a
fever in the context of immunosuppression which may lead to death from overwhelming
sepsis. It is the second commonest reason for hospital admission among children &
young adults with cancer, with approximately 4000 episodes of FNP occurring annually in
the UK. In adopting a policy of aggressive in-patient intravenous antibiotic use in such
episodes, the mortality rate related to these episodes has improved dramatically (from
30% in the 1970s to 1% in the late 1990’s). However, there remain many episodes of
FNP, possibly two-thirds or more, in whom no significant infection is identified, and in
whom this aggressive management strategy is likely to be excessive.
The National Institute for Clinical Excellence (NICE) guidance document “Improving
outcomes with children and young people with cancer” called for "the development of
robust methods of risk stratification in the management of FNP". At present there are
many differing policies for the management of FNP in the UK with lack of agreement
about how risk stratification, if any, is used. Such models of risk stratification are based
on small data sets with relatively few events.
Individual patient data pooled analysis for the synthesis of prognostic information has
only recently been begun to be applied to real world clinical data sets where they have
clarified existing understanding of particular prognostic variables. It has been suggested
that the use of IPD will provide a more accurate and robust assessment of the value of
potential risk factors. Systematic review and use of summary prognostic data may be
unreliable as the published data may be incomplete (missing vital information for
meaningful meta-analysis), often relies on categorization of continuous outcome
variables (which themselves may be biased), are susceptible to significant publication
bias (with prognostic markers showing ‘highly significant’ responses being more likely to
be published) and may have many simple methodological flaws (such as inconsistent
reporting of ostensibly similar outcomes).
Methodological exploration, development and adaptation to the prognostic setting of the
techniques of IPD pooled analysis will also be undertaken (the exact analyses will be
subject to the data sets obtained). The analyses may address issues regarding the
development of clinical decision rules in a meta-analytic setting, the analysis of missing
data using different imputation models, the relative merits of prospective and
retrospectively collected information, the comparison between episodic and patient-
centred analyses and the use of categorical outcome variables.
It is for these reasons that this project was conceived, and awarded funding as part of
an MRC Research Training Fellowship. The Fellowship will be undertaken in the Centre
for Reviews and Dissemination (University of York) under the supervision of Prof Lesley
Stewart, Dr Alex Sutton and Dr Dawn Dowding. The Fellowship has been awarded on a
part-time basis, to complement a part-time post as Consultant in Paediatric Oncology in
St James’s Hospital, Leeds. The two aspects will complement and support both the
project and clinical practice, while being separated by being undertaken on different sites
on different days in the week.
PICNICC
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The PICNICC (Predicting Infectious Complications of Neutropenic sepsis In
Children with Cancer) Study Clinical Advisory Group
This group will be include clinicians and methodologists and will provide advice
throughout the project. This group will help:
ground decisions on data in clinical practice
explore the opportunities for family/patient centered analyses
advise on methodological issues
provide advice as to likely clinical uptake and implementation
encourage networking and data sharing for success of the project
Members of the group will ideally attend the international collaborative group meetings,
when this is formed.
The currently proposed structure of this group is:
Lesley Stewart, CRD, York (expert in IPD methodologies & reviews)
Sue Picton, Paediatric Oncology, Leeds (interest in FNP, great experience in field)
Julia Chisholm, Paediatric Oncology, London (interest in FNP, Chair of CCLG supportive
care group)
Alex Sutton, Medical Statistics, Leicester (expert in meta-analytic techniques, including
Baysian approaches)
This group may be usefully strengthened by the addition of two patient or family
representative members, and a statistician with expertise in prognostic models and/or
clinical decision rule building.
The group is expected to meet between one and two times per year, with occasional
contact by telephone call or email in between the meetings. Such meetings would be
unlikely to be more than half-a-day in length. The offer of pre-meeting and post-
discussions with one of the PICNICC team would be offered to patient or family
representative members in order to discuss any issues that arise during the meetings.
Expenses to cover travel and associated expenses have been awarded.
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draft)
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and the use of categorical rather than dichotomous outcome variables (for example
“Needed ICU”, “Needed oxygen”, “Identified infection” and “Well - no complications”
compared with “Well” vs. “Not well”).
It is to develop a clinically useful decision rule and to advance our understanding of the
statistical techniques used that this project was conceived, and awarded funding as part
of a Medical Research Council (MRC) Research Training Fellowship. The Fellowship will be
undertaken in the Centre for Reviews and Dissemination (University of York) under the
supervision of Prof Lesley Stewart, Dr Alex Sutton and Dr Dawn Dowding. The Fellowship
has been awarded on a part-time basis, to complement a part-time post as Consultant in
Paediatric Oncology in St James’s Hospital, Leeds. The two aspects will complement and
support both the project and clinical practice.
The PICNICC (Predicting Infectious Complications of Neutropenic sepsis In
Children with Cancer) Study Clinical Advisory Group
This group will provide advice throughout the project. This group will help:
ground decisions on data in clinical practice
explore the opportunities for family/patient centered analyses
advise on methodological issues
provide advice as to likely clinical uptake and implementation
encourage networking and data sharing for success of the project
This group will benefit from the involvement of two patient or family representative
members, and a statistician with expertise in prognostic models and/or clinical decision
rule building.
The group is expected to meet between one and two times per year, with occasional
contact by telephone call or email in between the meetings. Such meetings would be
unlikely to be more than half-a-day in length. Pre-meeting and post- discussions with
one of the PICNICC team will be offered to patient or family representative members in
order to discuss any issues that arise during the meetings. Expenses to cover travel and
associated expenses have been awarded. Members of the group will ideally attend the
international collaborative group meetings, when this is formed. These may occur only 2-
3 times over 5 years.
The currently proposed structure of this group is:
Prof. Lesley Stewart, CRD, York (Expert in IPD methodologies & reviews)
Dr. Sue Picton, Paediatric Oncology, Leeds (Extensive experience in FNP)
Dr. Julia Chisholm, Paediatric Oncology, London (Chair of CCLG supportive care group)
Dr. Alex Sutton, Medical Statistics, Leicester (Expert in meta-analytic techniques)
Should you wish to find out more to consider becoming involved, please contact Dr Bob
Phillips at picnicc@gmail.com or phone (10904) 321099.
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Appendix 17. Protocol
PROTOCOL Open Access
Predicting infectious complications in
neutropenic children and young people with
cancer (IPD protocol)
Robert S Phillips1,5*, Alex J Sutton2, Richard D Riley3, Julia C Chisholm4, Susan V Picton5 and Lesley A Stewart1, for
the PICNICC Collaboration
Abstract
Background: A common and potentially life-threatening complication of the treatment of childhood cancer is
infection, which frequently presents as fever with neutropenia. The standard management of such episodes is the
extensive use of intravenous antibiotics, and though it produces excellent survival rates of over 95%, it greatly
inconveniences the three-fourths of patients who do not require such aggressive treatment. There have been a
number of studies which have aimed to develop risk prediction models to stratify treatment. Individual participant
data (IPD) meta-analysis in therapeutic studies has been developed to improve the precision and reliability of
answers to questions of treatment effect and recently have been suggested to be used to answer questions
regarding prognosis and diagnosis to gain greater power from the frequently small individual studies.
Design: In the IPD protocol, we will collect and synthesise IPD from multiple studies and examine the outcomes
of episodes of febrile neutropenia as a consequence of their treatment for malignant disease. We will develop and
evaluate a risk stratification model using hierarchical regression models to stratify patients by their risk of
experiencing adverse outcomes during an episode. We will also explore specific practical and methodological
issues regarding adaptation of established techniques of IPD meta-analysis of interventions for use in synthesising
evidence derived from IPD from multiple studies for use in predictive modelling contexts.
Discussion: Our aim in using this model is to define a group of individuals at low risk for febrile neutropenia who
might be treated with reduced intensity or duration of antibiotic therapy and so reduce the inconvenience and
cost of these episodes, as well as to define a group of patients at very high risk of complications who could be
subject to more intensive therapies. The project will also help develop methods of IPD predictive modelling for use
in future studies of risk prediction.
Keywords: individual participant data meta-analysis, predictive modelling, paediatric oncology, febrile neutropenia,
collaborative studies
Background
Children undergoing treatment for malignancy have an
excellent chance of survival, with overall rates approach-
ing 75% [1]. In most cases, children who die following
treatment for cancer do so as a result of their disease,
but despite huge improvements in supportive care,
around 16% of deaths within 5 years of diagnosis are
due to the complications of therapy [2,3]. One such life-
threatening complication in immunocompromised chil-
dren remains infection, which frequently manifests as
the occurrence of fever with neutropenia [4].
In adopting a policy of aggressive inpatient intravenous
antibiotic use in such episodes, the mortality rate related
to these episodes has improved dramatically (from 30%
in the 1970s to 1% in the late 1990s) [4]. Intensive care
management is required in less than 5% of cases [5-7],
although a substantial proportion of children have com-
plications which require specialised care [7]. There
* Correspondence: bob.phillips@york.ac.uk
1Centre for Reviews and Dissemination, Alcuin College, University of York,
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remain many episodes of febrile neutropenia (FNP), pos-
sibly two-thirds or more, among patients in whom no
significant infection is identified and in whom this
aggressive management strategy is likely to be excessive
[7].
To better inform the clinical management of children
with cancer and FNP, there is increasing interest in
using risk prediction models (also known as ‘prognostic
models’) and clinical decision rules (CDRs) [8-10]. Risk
prediction models utilise multiple prognostic factors in
combination to predict the risk of a future health out-
come for an individual on the basis of their set of prog-
nostic factor values. A CDR recommends a particular
clinical action (or inaction) for an individual on the
basis of the prediction (for example, the predicted prob-
ability, or ‘risk score’) derived from the model.
A robust risk prediction model which identifies those
children at very low risk of having a significant infection
could result in reduced intensity and/or duration of anti-
biotic therapy in the hospital. It could also form the basis
of a randomised controlled trial (RCT) of alternative
management approaches (for example, ambulatory oral
antibiotics vs inpatient intravenous antibiotics) and
would be the ideal way of informing the sample size
required by reliably predicting the proportion of events
expected in a low-risk group. This would lead to reduced
costs for the healthcare system and the patient and family
[11], as well as potentially a better quality of life for all
affected. At present, there are many differing policies for
the management of FNP in practice [12,13] but a lack of
agreement about how and which CDRs, if any, are used.
Assessment of the risk of adverse outcome of each epi-
sode of FNP has been undertaken by many different
groups, with many of them creating a CDR which aims to
allow clinicians to accurately judge risk and treat patients
appropriately. However, none of these analyses have
resulted in a widely used risk stratification model, and cur-
rent practice is variable, both in the United Kingdom [12]
and internationally [13-15]. Some centres use a risk-strati-
fied, reduced-intensity approach, and others treat all chil-
dren aggressively. The essential problems with research in
this area are common across much of paediatric practice:
those of rare conditions with small numbers of cases and
limited collaboration in primary studies. The modelling
studies that have been done have incorporated different
clinical features and outcomes and have used different
methodologies, and it is therefore difficult to draw mean-
ingful conclusions from this body of evidence. Calls for
collaborative trials [16-18] have led to little progress.
This setting provides an ideal opportunity to under-
take a collaborative, pooled analysis of the existing data
sets in the form of an individual participant data (IPD)
meta-analysis. In this effort, we will collect and reanalyse
the original study data, which will permit reanalysis of
the same clinical features across studies using a consis-
tent approach and provide sufficient numbers to draw
more robust and reliable conclusions. The findings of
this work should therefore more robustly inform prac-
tice and future therapeutic RCTs. The analysis can be
approached from three methodological directions: test-
ing existing CDRs for their ability to ‘diagnose’ adverse
outcomes, assessing the added value of individual prog-
nostic factors and building a more accurate predictive
rule containing a parsimonious set of prognostic factors.
Systematic reviews of existing knowledge
In preparation for this project, two systematic reviews
were undertaken to assess the prior knowledge of the
discriminatory ability of CDRs [19] and inflammatory
serum markers (R Phillips, R Wade, T Lehrnbecher, LS
Stewart, A Sutton) in children and young people with
FNP. The systematic review of CDRs initially identified
2,057 potential studies and finally included 24, of which
21 had data in a usable format. It showed that two
groups of studies have been undertaken to risk-stratify
children who present with FNP. Researchers in the first
group of studies examined the use of clinical examina-
tions to predict radiographic pneumonia (4 studies) [20],
and investigators in the second group examined more
general infectious complications (20 studies) [19].
Among the studies in which general infectious compli-
cations were examined, 16 separate models were pro-
duced and contained 9 data sets used to validate
previously derived models. The researchers studied a
variety of outcomes with individual differences in defini-
tions, but covered five main categories: death, critical
care requirement, serious medical complications, signifi-
cant bacterial infections and bacteraemia.
Only one rule could reasonably be assessed across
multiple data sets: that of absolute monocyte count and
temperature criteria proposed by Rackoff et al. [21] to
exclude bacteraemia. The most appropriate meta-analy-
sis of the rule’s effectiveness led to estimates of moder-
ate discriminatory ability, with the average probability of
bacteraemia in the groups being low risk = 6% (95% CrI
= 1% to 34%), middle-level risk = 18% (CrI = 3% to
37%) and high risk = 49% (95% CrI = 6 to 84%).
Of the other rules, the model of Santolaya et al. [22]
showed a good ability to differentiate between low- and
high-risk groups when a wider definition of ‘serious
infection’ was used, with average predictive ability esti-
mated as low risk = 13% (95% CI = 9% to 18%) and
high risk = 72% (95% CI = 68% to 75%). The rule has
been developed and tested in Chile and may be of lim-
ited applicability in Western Europe and North America
[23]. Other rules show promise and have clinical physio-
logical similarities, but have not undergone extensive
testing.
Phillips et al. Systematic Reviews 2012, 1:8
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The systematic review of the predictive value of serum
markers of inflammation and infection in children pre-
senting with FNP included 27 studies reporting over 13
different markers derived from an initial screen of 375
studies. The studies included had similar methodological
challenges as well as problems with reporting and analy-
sis. Many failed to assess whether the marker had any
supplementary value over and above the simple admis-
sion data collected by the clinicians at every encounter:
age, malignancy, temperature, age-corrected vital statis-
tics and blood count.
To interpret the information on serum markers in a
clinically meaningful way, we had to allow for the
marked heterogeneity of the results. The quantitative
pooling and a qualitative summary of the results sug-
gested that procalcitonin might be a better discrimina-
tory marker than C-reactive protein (CRP) and that IL-6
had a very good ability to predict documented infection.
Overall the findings were uncertain and unstable, and
only small amounts of new data may alter them sub-
stantially. Data for the other markers were too sparse to
reasonably be interpreted, although IL-8 had significant
potential value.
These reviews have a wide range of rules for the pre-
diction of poor outcomes during episodes of FNP in
children and the use of a variety of individual serum
markers to predict outcome. None of the rules found
has yet been subjected to the extensive geographical and
temporal discriminatory validity assessments that mark
the highest quality CDR. Many potential difficulties with
different outcomes, variable selection and model-build-
ing have been identified. The data on serum markers
were extremely heterogeneous, and only tentative con-
clusions could be drawn.
The problems identified are inherent in the attempt to
undertake meta-analyses of aggregate data. The limita-
tions of the reporting in published studies mean we do
not have access to the exact data distribution or the full
range of univariable estimates of predictive power.
These issues could be addressed by attempting to collect
more detailed summary data from the authors of the
original studies, but this would not allow cross-study
validation of different rules or attempts at alternative
rule-building. To meet these challenges and to maximise
the value of the information already collected by these
groups and in other cohorts of children with FNP, an
IPD meta-analysis will enable us to develop and test
new and existing prediction models. This will provide a
firmer basis for stratified treatment trials in this com-
mon and occasionally fatal complication of therapy.
Rationale for an individual participant data analysis
Individual patient data pooled analysis in therapeutic
studies have been developed for two decades to improve
the precision and reliability of answers to questions
regarding treatment [24,25]. It has more recently been
promoted for the synthesis of diagnostic data [26] and
prognostic information [27] to improve the quality of
answers to important prognostic questions [28] and
matters of diagnostic accuracy [29]. These techniques
have been applied to real-world clinical data sets
[30,31], in which they have clarified existing understand-
ing of particular prognostic variables and enhanced
understanding of how different diagnostic tests can be
used [32].
The key benefits of prognostic IPD analysis generally
can be summarised as follows: (1) Analyses are not
restricted to those of the published results or subgroups;
(2) analytical techniques, inclusion criteria and outcome
definitions can be standardised across studies; (3) larger
numbers of data points allow more powerful statistical
conclusions to be drawn, including checking modelling
assumptions and accounting for missing data at the
individual level; (4) IPD can model data more appropri-
ately, such as by analysing continuous variables on con-
tinuous scales (unlike in many prognostic studies in
which data are reported as categorical variables); (5)
analysis can account for clustering (for example, of
patients within studies) and correlated information (for
example, multiple events per individual); (6) multivariate
models can be created across different healthcare set-
tings; (7) data can be reviewed for completeness and
accuracy; and (8) the analysis can provide extensive
internal cross-validation to guard against data-driven
exaggerations of predictive power.
In the Predicting Infectious Complications of Neutro-
penic sepsis In Children with Cancer (PICNICC) study,
the collection and analysis of IPD will provide specific
benefits that overcome many of the problems found in
the aggregate data meta-analysis. Many of the benefits
of IPD analysis are technical, being related to the statis-
tical methods underlying the meta-analysis and the
building of predictive models. Although at first sight the
failure to address the problems inherent in statistical
interpretation may seem to be clinically irrelevant, it has
clear and real clinical implications [33]. Other benefits
are more obviously clinical; for example, the collection
of the different data sets will enable us to clarify and
harmonise the different outcomes collected.
One of the primary ‘statistical’ benefits will be the use
of firmly prespecified potential predictor variables built
upon the experience of the PICNICC Collaborative and
the systematic reviews. This will guard against the devel-
opment of purely data-driven analyses, which have a
tendency to overestimate any predictive value [28].
In the reviews, we found the studies designed to build
a CDR used a large number of variables (median = 13,
range = 2 to 39) and had a small number of events
Phillips et al. Systematic Reviews 2012, 1:8
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(median = 36, range = 4 to 178) with 70% (12 of 16)
studies having fewer than 10 events per variable under
consideration and no study having more than 14 events
per variable. These low event-per-variable ratios render
predictive conclusions drawn from the studies unstable
and estimates of predictive power overly optimistic [34].
IPD will allow us to consolidate the information and
increase greatly the number of events studied from the
same number of predictive variables.
The raw data will also allow a detailed analysis of the
clustering of events (multiple episodes per patient) and
variation at the level of the individual patient. This issue
is significant when assessing the problems identified in
the aggregate data reviews. Multiple episodes in indivi-
dual patients were treated primarily as if they came
from dissimilar individuals in the 20 CDR and 24 serum
marker studies. Four papers explicitly described no
adjustment [22,35-37], with 12 undertaking some
attempt at assessment. Secondary analysis was per-
formed to assess ‘first included case’ versus ‘all episodes’
and ‘no significant differences’ in three studies
[22,38,39] and in nine others in which more advanced
statistical modelling was used [6,21,40-46]. In 28 studies,
the assessment was unclear.
The functional form of the data regarding a priori
nonlinear fractional polynomial relationships can be
assessed in detail. In no study assessed were clear
attempts made to fit nonlinear forms to the data. This is
unsurprising, as the development of practical techniques
to undertake this effort is very recent [47].
Modern statistical developments in the handling of
missing data may enhance the information already
acquired. Again, very little information on the assess-
ment and management of missing data was available
from the reviews (five CDR studies [21,38,39,42,44] and
two serum marker studies [48,49]). Very recent publica-
tions of studies in which simulation [50] and surveying
practice [51] were used produced workable guidelines
for the use of imputation techniques to maximise the
value of the data collected. IPD will allow us not only to
test existing rules and combine data derived from
attempts to examine the rules but also, potentially, to
develop a more robust rule for future use worldwide.
Parent and/or caregiver involvement
The development of shared research initiatives involving
patients, clinicians and researchers has been a notable
change in the practice of clinical research over the past
decade [52]. It remains surprising to many researchers,
clinicians and patients when they learn that their views
are often strikingly different from each others’ [53]. A
systematic review of studies of the process of research
planning and priority setting undertaken by the James
Lind Alliance [52] demonstrated that the involvement of
patients and parents as well as other caregivers was
extremely infrequent.
The PICNICC group has sought to involve parents
early in the treatment process. Discussions of the nature
of their engagement in the process have so far high-
lighted that the representatives involved have not wished
to be actively involved in the process of reviewing, but
to be included in discussions about the nature of, the
adverse effects of FNP and that they have been willing
to provide their own nonmedical expertise in advancing
the project.
The discussion of the nature and extent of patient and
caregiver involvement in the PICNICC group will con-
tinue as the project develops. Possible opportunities for
further involvement include writing commentaries on
the study for patients and their families, providing
alterative views on ethical questions, making choices
regarding risk thresholds and considering how uncer-
tainty and imprecision should be managed.
Methods
Aims
Primary
A primary aim of the project is to undertake an IPD
pooled analysis to quantify the risk of adverse clinical
outcomes according to clinical variables in children and
young people undergoing treatment for malignant dis-
ease who present with an episode of FNP; that is, to
identify which variables are prognostic and which have
the most independent prognostic importance. Another
primary aim is to develop and validate a new risk pre-
diction model containing multiple prognostic factors in
combination.
Secondary
The secondary aim of this project is to develop and
explore practical and methodological issues surrounding
the use of pooled IPD analysis in the development of
predictive models.
Inclusion and exclusion criteria
Studies will be considered for inclusion in the IPD
meta-analysis if they are cohort studies of children and
young people presenting with FNP and/or with either
prospective or retrospective data collection, including
RCT data; if they provide data for all ‘essential’ predic-
tive variables in more than 50% of included episodes
(see ‘Core data set and variables’ section); and if they
provide details of two or more study-defined outcomes
in more than 90% of individual episodes of FNP.
Studies will be excluded if they are case series (for
example, studies of only ‘Gram-negative bacteraemias’)
and if they did not record data on all ‘essential’ predic-
tive variables or cannot provide sufficient outcome data.
Studies will be included if they focus on the collection
of data from children and young people (between 0 and
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24 years old). The purpose of the inclusion criterion of
studies of young people up to the age of 24 years is to
address a paucity of research on individuals in the
‘young adult’ age range [54]. Data from individual
patients ages 25 years and older will be excluded from
this analysis. The median age of inclusion in the ‘chil-
dren’s’ cohorts examined in our reviews was about 7
years old (ranging from 1 month to 23 years), and the
‘adult’ study from the Multinational Association for Sup-
portive Care in Cancer group [55,56] has a median age
of 52 years (range, 16 to 91 years old).
Identification of potential studies
The initial identification of studies has been through
extensive literature searches undertaken as part of the
systematic reviews reported briefly in the Additional
material at the end of the protocol (see Appendix 1 in
Additional file 1 for a list of studies).
The following databases were searched by two inde-
pendent reviewers to identify potential collaborators:
MEDLINE, MEDLINE in-process and other nonindexed
citations, Embase, Cumulative Index to Nursing and
Allied Health Literature, Cochrane Database of Systema-
tic Reviews, Database of Abstracts of Reviews of Effects,
Health Technology Assessment Database, Cochrane
Central Register of Controlled Trials, Thomson Reuters
Conference Proceedings Citation Index-Science and Lit-
eratura Latinoamericana y del Caribe en Ciencias de la
Salud. The reference lists of relevant systematic reviews
and included articles were reviewed for further relevant
studies. Published and unpublished studies were sought,
and no language restrictions were applied. Non-English-
language studies were translated into English. (See
Appendix 2 in Additional file 2 for a sample search that
we conducted.)
Further analysis of the initial literature searches will be
undertaken to identify any published cohorts of FNP
patients that may have been excluded from the reviews
because a CDR or serum marker was not tested, yet
could provide the information essential to being
included in the IPD study. In addition to this, open calls
for participation have been made via the International
Society for Paediatric Oncology Supportive Care Group,
the University of York Centre for Reviews and Dissemi-
nation website (http://www.york.ac.uk/inst/crd/projects/
picnicc_patient.htm), presentations at relevant UK and
international conferences, and via the Oncopedia web
community of paediatric oncologists (https://www.cur-
e4kids.org/ums/home/index.php?location=%2Fums%
2Foncopedia%2F).
Core data set and variables
This IPD meta-analysis will develop a risk stratification
model to predict which children and young people have
a low risk of adverse outcomes during an episode of
FNP. The predictor variables and adverse outcomes
sought have been based on our systematic reviews of
aggregate data, in which exploratory analysis showed
that age, malignant disease state, clinical assessment of
circulatory and respiratory compromise, higher body
temperatures and bone marrow suppression had expla-
natory value and reflected clinical experience of the pae-
diatric oncologists.
The following predictor variables are divided into
‘essential’ and ‘desirable’ items and can be categorised as
(1) patient-related, episode-related clinical variables and
(2) patient-related, episode-related laboratory variables:
1. Age
2. Underlying tumour type
3. Marrow involvement and/or remission status
4. Chemotherapy type and time elapsed since last
cycle
5. Presence of central venous line
6. Inpatient or outpatient at onset of episode
7. Maximum temperature
8. Antibiotic therapy used
9. Respiratory rate (or compromise)
10. Circulatory parameters (or compromise)
11. Severe mucositis
12. Global assessment of illness severity
13. Haemoglobin
14. Platelet count
15. White blood cell count
16. Neutrophil count
17. Monocyte count
18. CRP
19. Procalcitonin
20. IL-6
21. IL-8
The following are outcomes of primary interest from
each episode:
1. Death
2. ICU admission
3. Need for moderate organ support (fluid bolus,
oxygen)
4. Clinically documented infections
5. Microbiologically documented infections
Two or more of these outcome measures should be
provided for more than 90% of episodes.
If available, we will also collect data on the following:
1. Duration of fever
2. Duration of admission
An example of the initial survey of data available from
collaborators is provided in Appendix 3 in Additional
file 3. An a priori mapping schema linking microbiologi-
cal and clinical outcome variables into a unified descrip-
tion of ‘severe’ and ‘nonsevere’ infections has been
developed to assist with unifying outcome definitions.
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Providing data
Anonymised deidentified data
Data sets should be anonymised (that is, have all directly
identifiable material removed, such as name, address,
postal code, record number). A patient identification
number should be provided to facilitate communication
and data queries. For the purposes of this report, the
age of the patient (an indirect identifier) is essential and
should be provided [57].
Data format
The data will be accepted by the PICNICC Collaborative
in any electronic format, but ideally a ‘flat’ spreadsheet
format (such as Microsoft Excel; Microsoft Corp, Red-
mond, WA, USA) will be most useful, with one episode
per row and variables listed in columns. Each patient
should be assigned an in-cohort unique identifier (such
as a simple number 1, 2 ... n) to highlight repeated epi-
sodes in the same patient. A suggestion for coding the
variables is provided in Appendix 4 in Additional file 4
and a sample flat file is available on request.
Transfer of data
The data should be transferred to a secure password-
protected web server or by pretty good privacy-
encrypted email. This permits a secure and identifiable
connection to the University of York servers and mini-
mises the possibility of data loss.
Data checking
Simple checks of data integrity will be undertaken prior
to analysis. These checks will include sense checking of
data (for example, impossibly low presenting tempera-
tures, such as less than 30°C or for second episodes of
FNP where the outcome of the first was death), clarify-
ing missing data (that is, ensuring missing data is
recorded as ‘missing’ rather than ‘zero’) and calculating
simple descriptive statistics of ‘essential’ elements to
assess for ‘outlier’ studies (for example, age, sex, number
of episodes per person). Any problems or inconsisten-
cies flagged during these procedures will be discussed
with the individual responsible for each study and
amended as appropriate by consensus.
Ethical and regulatory considerations
This IPD protocol has been approved in the United
Kingdom by the University of York Health Services
Research Ethics and Research Governance Committee.
Each clinician member of the PICNICC Collaborative is
advised to seek country-specific advice regarding the
regulations which apply to data shared in this study.
Plan of investigation
Method of analysis
The primary method of analysis for the PICNICC study
will be the use of multivariable logistic regression mod-
elling. There are a series of different analytical
techniques that can be used to produce rules, including
multivariable regression analysis, classification and
regression tree (CART) models, discriminant analysis
and neural networks. There is no clear evidence that
one method is superior to any other [58], and, as multi-
variable logistic models have the widest clinical under-
standing and applicability, this method has been
selected.
In the primary analysis, data used will be from the
first recorded episode for each patient to predict an
absence of adverse outcomes due to the individual epi-
sode (that is, death, intensive care requirement, medical
complication, bacteraemia or other significant bacterial
infection). Following the primary analysis, outcome data
and predictor variables from subsequent episodes will be
analysed to assess the independence or otherwise of
these data, and this information will also be included
using an appropriate model.
Prospective and retrospective cohorts will be consid-
ered separately in the initial analyses on the basis of the
hypothesis that there will be a clinically important dif-
ference between the two types of studies. If no differ-
ence is found, then the data set will be examined as a
whole. The prognostic importance of individual vari-
ables, both unadjusted and adjusted for other variables
(the latter to summarise independent prognostic value),
will be summarised for each study.
Assessment of study and data quality
There is very little advice in the literature for assessing
the quality of prognostic studies. Altman and Lyman
presented suitable criteria that those initiating a primary
prognostic study should consider [59], and they sug-
gested that every effort should be made to limit poten-
tial biases and to emulate the design standards of a
clinical trial. Ideally, the data should be collected pro-
spectively, with little missing data for predictors or out-
comes and with predefined hypothesises. We will use
these guidelines and those published by Hayden et al.
[60] to help inform the quality of the IPD obtained. For
example, an assessment will be made of the proportion
of missing data and the completeness of follow-up. The
influence of any studies considered problematic (for
example, those with large amounts of missing data or a
great deal of incomplete follow-up) on the prediction
model will then be considered, resulting in either their
exclusion or in sensitivity analyses comparing model
estimates when they are included or excluded.
Model development
The model will initially incorporate the simplest predic-
tor variables (malignant diagnosis, age, time since che-
motherapy, and maximum recorded temperature) before
standard additional variables (such as clinical
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assessments of compromise, inpatient or outpatient sta-
tus, white blood cell counts or other haematological
parameters) are added. Further specialist tests (for
example, CRP and IL-6 levels) will be added. The type
of antibiotic therapy used will always be incorporated
into the model as a categorical variable. Potential
sources of heterogeneity (for example, in effects of parti-
cular variables across studies) will be incorporated as
random effects as appropriate. The models will be
assessed for improvement in fit by using an information
criterion (for example, Akaike’s information criterion)
with a P-value of < 0.15 used for inclusion. We will use
a 15% rather than a 5% level, as we feel this is more
conservative and will limit the chance of missing impor-
tant covariates. At the stage of deciding our final model,
however, we will check that the model’s predictive accu-
racy (discriminatory ability) is improved by the inclusion
of variables whose significance is between 5% and 15%.
If predictive accuracy is not improved, then these vari-
ables will be removed.
This approach (of adding specialist tests only after
considering the simpler tests) maximises the utility of a
model by ensuring that, if extra tests with their addi-
tional costs are required, they will add considerable pre-
dictive power to existing simpler variables [61]. We will
use bootstrapping and shrinkage to adjust for potential
overoptimism (bias) in parametric estimates and trends.
Continuous candidate variables will be assessed using
the best fitting functional form considering appropriate
transformations or fractional polynomials (also assessed
using an information criterion) as suggested by previous
evidence. Missing data will be examined to define the
nature of the ‘missingness’. If they are missing at ran-
dom, then multiple imputation techniques will be used
to address these gaps utilising all the other available
data [50,51]. The results of these analyses will be com-
pared with a complete case analysis. We will conduct an
analysis comparing the new model that we develop with
other validated models, for example, that of Santolaya et
al. [62]. This will provide an opportunity to test these
CDRs against data from other geographical areas.
We acknowledge that there may be unforeseen chal-
lenges caused by the variations in the data formats avail-
able from the different studies. Therefore, we
acknowledge that establishing the definitive analysis
plan will be an iterative process and may even demand
novel methodological developments (see ‘Further
research opportunities arising from PICNICC’ section).
Assessing model performance
An important goal of a prediction model is to classify
patients into risk groups. The developed model will pro-
duce a risk score for each individual that is based on
the patient’s own predictor values. We will then use a
cutoff value to decide when a risk score is high (such
that we predict an adverse outcome) and when it is low
(such that we predict a good outcome); this will be our
CDR. The calibration of the model will be assessed by
classifying children into deciles ordered by predicted
risk and considering the agreement between the mean
predicted risk and the observed events in each decile.
The derived CDR will be cross-validated by comparing
the classification of each patient with his or her actual
outcome, thus allowing an estimate of the sensitivity
and specificity of the prediction model. Next, by varying
the chosen cutoff level, we will be able to produce a
receiver operating characteristic curve (ROC) summaris-
ing the sensitivity and specificity of the predictive rule
across the range of cutoffs. The overall discriminatory
ability will be summarised as the area under the ROC
(AUC ROC) with the 95% confidence interval. The most
suitable cutoff level can then also be detected.
Each predictive model will be tested by checking how
it performs against the data from all but one of the stu-
dies in turn (cross-validation of intrinsic prognostic per-
formance) [63] and by using the bootstrap procedure
[64]. This will adjust for overoptimism in the estimation
of model performance due to validation in the same
data set that was used to develop the model itself.
The improvement in model performance by adding
prognostic factors will be assessed by net reclassification
improvement. By analysing the difference among the
prognostic factors, a shrinkage factor will be calculated
and the model will be corrected by this shrinkage factor.
Note also that clustering of patients within studies will
be accounted for in the model framework.
Validation in new data
We will compare the predicted and observed event rates
to assess calibration (as described above) and the AUC
ROC to assess discriminatory ability. If new data
become available after the formation of the PICNICC
Collaborative, they will provide an excellent test bed for
the newly proposed model. Such an analysis is outside
the initial scope of this project. We will update the
model if it shows poor performance to adjust it to the
new situation by recalibration or revision methods,
depending on discrimination performance. Simple diag-
nostic test accuracy measures (such as positive and
negative predictive values) will be computed for a
hypothetical population (with its particular incidence
rates) to aid clinical interpretation of the study results
that define a low-risk group.
Assessment of publication bias
We do not believe that publication bias will affect the
data we obtain. We have sought to retrieve full data
from the studies and so have sidestepped many of the
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problems of reporting bias. There may remain issues of
different outcome collection and different outcome
assessment methods, but these will not have been biased
by collection and analysis of the predictive data. We
have tried to avoid publication bias by making open
calls for data which has been collected but not yet pub-
lished, and we have probably secured three such data
sets for analysis. This may be too few to undertake a
formal assessment of the difference between the pub-
lished and unpublished sources. We are also using the
data for a purpose different from that used by the origi-
nal data collectors. We are developing a prediction
model, whereas the original researchers are interested
only in the prognostic effect of particular variables.
Furthermore, by obtaining the IPD, we have obtained
outcomes and variables not reported by the original
data collectors in any publication. However, to check
whether our collection of studies may be affected by
publication bias, we will display a funnel plot for each of
the variables included in the final model to see whether
there is asymmetry (that is, potential publication bias).
We will use guidelines for assessing asymmetry recently
published in BMJ [65].
Publication policy
The main results of the meta-analysis will be published
and presented under the PICNICC name, with PIC-
NICC comprising groups supplying data for analysis as
well as its advisory group. Any subsequent technical
papers which describe innovations in the methodologies
used in the meta-analysis will acknowledge the PIC-
NICC Collaborative as the source of the data. The PIC-
NICC Collaborative will disseminate the findings of its
research widely at academic conferences and in journal
publications, on the University of York website and in
lay summaries of the research.
Discussion
Status of the project
Currently, the PICNICC Collaborative has completed
study identification and invitation and has collected data
derived from 23 data sets from 12 countries, including
the Europe-wide European Organisation for Research
and Treatment of Cancer studies. No data analyses have
yet been undertaken. The opportunity to include data
sets for the derivation of a new PICNICC CDR have
now closed, but approaches may be made to the authors
for consideration of inclusion of further data sets in sub-
sequent validation testing or further refinements of the
initiative.
Further research opportunities arising from PICNICC
It is hoped that collaborations developed through the
PICNICC project may also lead to a series of
international studies to improve patients’ experiences
and outcomes with regard to infectious complications in
cancer. One obvious follow-up study might be the use
of the newly derived model in a RCT of alternative
management approaches (for example, ambulatory oral
antibiotics vs inpatient intravenous antibiotics). Other
studies may include the investigation of genetic poly-
morphisms in determining the outcomes of infectious
episodes; the prediction of specific infections which may
require different management approaches, such as anti-
biotic-resistant bacteraemia; or the prediction of the risk
of an episode of FNP.
The PICNICC Collaborative will provide data that will
prove invaluable in the development of the methodology
of IPD meta-analysis for risk prediction. This develop-
mental work, which will be essential to developing the
best possible model in PICNICC, is outside the core
clinical questions set for the PICNICC Collaborative and
will be undertaken as a series of linked projects. The
problems to be addressed in developing the methodolo-
gies will depend on the nature of the data sets obtained.
They may address issues regarding the analysis of miss-
ing data, the use of different imputation models, the
modelling of multiple-episode data, the relative merits
of prospective and retrospectively collected information,
the use of alternative modelling techniques (such as
CART, structured equation modelling, Bayesian techni-
ques or neural networks), the comparison of episodic
and patient-centred analyses and the use of categorical
outcome variables. A short methodological protocol will
be developed for each methodological investigation prior
to commencement.
Additional material
Additional file 1: Appendix 1: Potential IPD Datasets.
Additional file 2: Appendix 2: Search Strategy.
Additional file 3: Data collection survey.
Additional file 4: Suggested coding structure.
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Appendix 18. Mapping for severe infection
Severe infections:
 Isolation in the blood of any gram-negative organism
 Isolation in the blood of selected gram-positive infections (eg Staph. Aureus, Strep viridans)
 Any significant bacterial isolate from CSF
 Any significant bacterial isolate from lower respiratory tract secretions
 Probable / proven invasive fungal infection according to EORTC definitions Isolation of
bacteria from a deep soft-tissue or bone infection
 Mycobacteria
 Malarial parasites
 Serum isolation of significant quantities of adenovirus,VZV, HSV or CMV (as determined by
PCR copy number)
 Respiratory virus isolation in the setting of stem cell procedures
 Additionally, clinical site information without definite microbiological confirmation may also
indicate:
 Cellulitis or CVC tunnel infection
 Bone / deep soft tissue infection
 Finally, any admission to a critical care facility is considered to be related to severe infection,
unless designated clearly as for an alternative cause.
Non-severe infections:
 Isolation of most gram-positive organisms, for example coagulase negative staphylococci, or
diptheroids
 Isolated bacterial growth in urine, or scanty yeast
 Respiratory viruses from respiratory secretions without hypoxia
 Superficial skin infections (eg exit site infection without significant cellulitis)
 Viral gastroenteritis
 Additionally, clinical site information without definite microbiological confirmation may also
indicate:
 Otitis media
 Tonsillitis
 Superficial skin infection
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Checklist of potential data item
Centre Name/Location
Principle clinician
Contact for data
queries (if known)
Please tick (√) each item as to if your database could or could not provide the informaƟon.
Item
Predictors
Age
Underlying tumour type
Marrow involvement/remis
Chemotherapy type and da
cycle
Presence of central venous l
In-patient or out-patient at
episode
Maximum temperature
Respiratory rate (or compro
Circulatory (or compromise)
Severe mucositis
Global assessment of illness
Antibiotic therapy used
data screening questionnaire
ctious Complications of Neutropenic
r) Collaborative
ate ies in febrile neutropenic episodes in
nder oin treatment for mali nant disease
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Can provide Cannot provide
ion status
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severity
Unsure
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Item Can provide Cannot provide Unsure
Haemoglobin
Platelet count
White cell count
Neutrophil count
Monocyte count
CRP
PCT
IL6
IL8
Outcome
Death
Duration of intensive care admission
Need for moderate organ support
(fluid bolus, oxygen)
Clinically documented infections
Microbiologically documented
infections
Duration of fever
Duration of admission
Other
Date of episode of FNP
Age at episode of FNP
Please return completed form to crd-picnicc@york.ac.uk
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ppendix 20. Coding str
Age
Actual age at start of episode, i
999 = unknown
Tumour type
(Diagnosis under treatment, co
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Other leukaemia
Hodgkins lymphoma
Non-Hodgkins lymphoma
Low-grade brain tumour (I-II)
High-grade brain tumour (III-IV)
‘High risk’ neuroblastoma
Other neuroblastoma
Retinoblastoma
Wilm’s tumour
Other renal tumour
Hepatoblastoma
Other liver tumor
Osteosarcoma
Ewing’s sarcoma
Rhabdomyosarcoma
Other sarcoma
Germ cell/gonadal neoplasm
Carcinoma/melanoma
LCH
Other Please provide separate
99 Unknown
Relapsed/progressive disease
Is this a relapsed/progressive m
0 = no
1 = yes
9 = unknown
Marrow involvement
Bone marrow involvement at di
0 = no
1 = yes
9 = unknown
cture.
months
ed as:)
details of any ‘other’ diagnoses
lignancy:
gnosis:
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Remission status
In remission (leukaemia only) or on-treatment or post-treatment (solid tumours)
0 = no
1 = yes
9 = unknown
Chemotherapy type
Specify the most recent chemotherapy cycle (in words/by acronym or explicit numerical coding)
This will require a description of each chemotherapy protocol included from each study.
Specify ‘Unknown’ if unknown
Time from last chemotherapy cycle
Time (in days) since the start of most recent cycle of chemotherapy. For maintenance/prolonged
chemotherapy courses, code as ‘ongoing’ even if temporarily discontinued.
0 = ongoing
1 ….k = time in days
999 = unknown
Presence of central venous line
0 = no
1 = fully implanted (e.g. Port-a-cath)
2 = external tunnelled (e.g. Hickman)
3 = non-tunnelled line (e.g. PICC line or Vascath)
4 = line present, type unknown
9 = unknown if line present or not
In-patient or out-patient at onset of episode
0 = in-patient
1 = out-patient
9 = unknown
Maximum temperature
Maximum recorded temperature at admission. May be parent-reported or clinician-measured.
To be recorded as an absolute value in
0
C to one decimal place.
99.9 = unknown
Respiratory assessment
At initial assessment. To be recorded as an absolute value in breaths/min where given.
1 ….k = respiratory rate (breaths/min)
If data are only available on the presence/absence of respiratory compromise:
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777 = no compromise
888 = compromised
999 = unknown
Circulatory assessment - HR
At initial assessment. To be recorded as an absolute value of heart rate in beats/min.
1 ….k = pulse rate (beats/min)
999 = unknown/not recorded
Circulatory assessment – BP systolic
At initial assessment. To be recorded as an absolute value mmHg.
1 ….k = systolic blood pressure (mmHg)
999 = unknown/not recorded
Circulatory assessment – BP diastolic
At initial assessment. To be recorded as an absolute value mmHg.
1 ….k = diastolic blood pressure (mmHg)
If data are only available on the presence/absence of circulatory compromise, code here:
777 = no compromise
888 = compromised
999 = unknown
Mucositis
At initial assessment. To be recorded as
0 = none
1 = mild
2 = severe
9 = unknown
Global assessment of illness severity
At initial assessment. To be recorded as
0 = well
1 = mildly unwell
2 = severely unwell
9 = unknown
(If an alternative study-specific system is available, please report and specify coding separately.)
Page 340 of 410
Initial antibiotic therapy
The initial antibiotic therapy used should be reported. This can be done by specify the treatment
used (in words/by acronym).
(Will require a description of each chemotherapy protocol included from each study)
Specify ‘Unknown’ if unknown
The PICNICC Secretariat will recode such information as below:
Initial antibiotic therapy coded as the PRODUCT of individual codes
0 = none
2 = oral antibiotics; quinilone
3 = oral antibiotics; penicillin
5 = oral antibiotics; macrolide
7 = IV antibiotics; cephalosporin
11 = IV antibiotics; carbapenem
13 = IV antibiotics; aminoglycoside
17 = IV antibiotics; piperacillin/tazobactam
19 = IV antibiotics; glycopeptide
(as a series of prime numbers, any number which is coded from them will be unique)
Modification of antibiotic therapy
Modification of antibiotic therapy required
0 = no
1 = yes
9 = unknown
Haemoglobin
At initial assessment. In mg/dL
9999 = unknown
Platelet count
At initial assessment. As count *10
9
9999 = unknown
White cell count
At initial assessment. As count *10
6
9999 = unknown
Neutrophil count
At initial assessment. As count *10
6
9999 = unknown
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Monocyte count
At initial assessment. As count *10
6
9999 = unknown
CRP
At initial assessment. In mg/dL
9999 = unknown
PCT
At initial assessment. In mg/mL
9999 = unknown
IL6
At initial assessment. In pg/mL
9999 = unknown
IL8
At initial assessment. In pg/mL
9999 = unknown
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Appendix 21. Data manipulation SOPs
Data collection & file naming convention
Individuals responsible for the storage of data will send the files in electronic format to the
University of York via ‘Dropbox’.
This is a secure, personalised web-based system where documents can be shared with specific
individuals via any web browser (www.dropbox.com).
Each contact will be emailed a ‘share’ request to use for this data-drop
Files will be removed from the ‘Dropbox’ when received
The data file when retrieved will be stored in the \\projectfs\CRDdata\PICNICC\received filestore
For those persons having difficulty with the Dropbox.com system, a secure email service (using PGP
key) is also offered.
The file will be converted to a flat spreadsheet format and renamed according to the convention
“GroupAcronym-raw” (e.g. SPROG-raw)
Should two different data sources be supplied by the group, they will be suffixed according to the
starting year of the data (e.g. SPROG1999-raw and SPROG2008-raw)
This file will be stored in the \\projectfs\CRDdata\PICNICC\raw filestore
The working copy of the file will be named “GroupAcronym-working-yyy-mm-dd” while being
cleaned, recoded and tidied up to fit into the standard format
The final version of the data will be named “GroupAcronym-final”
This file will be stored in the \\projectfs\CRDdata\PICNICC\final filestore
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The data will be incorporated into the master data file, named “PICNICC-yyyy-mm-dd”
Log files should be named “GroupAcronym-log”
R-logs should be named “GroupAcronym-Rlog-yyy-mm-dd”
This file will be stored in the \\projectfs\CRDdata\PICNICC\logs filestore
Nature of the data supplied
The files containing data should have:
One row of data per episode
One variable per column, first row a header
Linked with a patient identification number, but anonymised (i.e. have all directly identifiable
material removed, such as name, address, postcode, medical number).
A coding sheet, detailing the different columns and codes used in the data file should be provided
Any uncertainties will be resolved, in the first instance, by email communication.
Logging interventions upon data supplied
Log files – plain text record of actions – should be opened and retained for each received data file.
It should record any actions (such as renaming) in the following structure, with the oldest records at
the top (head) of the document
DATE: Action
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e.g. 14-02-2011: Copy saved ‘Valentine-raw’
14-02-2011: Copy saved ‘Valentine-working-2011-02-14’
14-02-2011: Understood code sheet and data file
It should include emails & phone calls sent & received in order to clarify any data queries.
Any actions within the ‘R’ programme will be recorded in its own log, so all that needs to be
recorded is that R was used, and a brief note of what was done (for ease of finding again)
Sense checking and resolution of queries
The first action on opening the raw data file should be to rename the file and save as ‘raw’,
according to the naming convention.
A copy should then be opened and renamed ‘working’
The first review should be to confirm that the supplied coding sheet and data file correspond, and
that any uncertainties are logged.
If uncertainties exist, then a contact (email) should be undertaken with the data supplier clarifying
the nature of the problem and requesting a response to the uncertainty.
This should be undertaken by using a common identifier and pointing out clearly the area of
uncertainty
A copy of the isolated lines of queried data may be placed as an XLS worksheet in the ‘dropbox’ if
further clarification is needed: this should have the initial datafile’s row/column identified, and the
queried calls should be highlighted
The columns should be reordered in line with the PICNICC master data file structure
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Presence of the essential variables and outcomes should be verified at the ‘column’ level
The variable names should be altered according to the conventions of the PICNICC master data file
structure
The file should be examined for missing data and recoded as NA (in accordance with R data
structures)
When any uncertainties at this level are resolved, it should be still saved as a ‘working copy’
The data checks which are simplest to be undertaken in Excel (as it’s prettier) seem to be
age checking (negative, zero and not older than 9125 days (25yr), consistency of patient DOBs, and
sensible diagnosis & age relationships)
episodic checking – listing by age and DOB and then admission date and looking for odd/inconsistent
elements (>6m in between FNP episodes)
time-since-chemo checking (negative and >42 days), and looking for consistency with other episodes
white cell indices (making sure not ‘zero’, and that components eg ANC and AMC are not greater
than the total WCC)
The data should be imported into R and the data checking procedures run upon the data as an
independent data file, unconnected to the rest of the PICNICC dataset. See section ‘R-data-checking’
Subsequent queries and their resolutions should be recorded in the ‘flat’ & updated working copy
file
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When all queries have been adequately resolved, the data should be saved as a final form. This is the
data which will be imported into the master R data file.
R data checking
All actions in R should be logged and the file saved according to the convention on a sessional basis
As data manipulation in R is difficult, data have been exported as CSV files and undergone checking
as per non-R files
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Appendix 22. Further detailed information on the IPD data
Table 43: Summary of relevant QUADAS criteria for included studies
Author Data
collection
1 2 3 4 6 7 8 9 11
Alexander [134] Retrospective Yes Yes Yes Yes No Yes Yes Yes Yes
EORTC Studies[5] Prospective Yes Yes Yes Yes Yes Yes Yes Unclear Yes
Genoa[258] Prospective Yes Yes Yes Yes Yes Yes No No Yes
Hakim [129] Retrospective Yes Yes Yes Yes Yes Yes No Yes Yes
Kitanovski [163] Prospective Yes No Yes Yes Yes Yes Unclear Unclear Yes
Klaassen [26] Prospective Yes Yes Yes Yes Yes Yes Yes Yes Yes
Lehrnbecher [259] Prospective Yes No Yes Yes Yes Yes No No Yes
PINE [154] Prospective Yes Yes Yes Yes Yes Yes Yes No Yes
RetroBern [79] Retrospective Yes Yes Yes Yes Yes Yes No No Yes
Silva[260] Prospective Yes Yes Yes Yes Yes Yes Yes Yes Unclear
Spasova [160, 261] Prospective Yes No Yes Yes Yes Yes Unclear Unclear Yes
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SPOG groups [144] Prospective Yes Yes Yes Yes Yes Yes No No Yes
Stryjewski [262] Prospective Yes Yes Yes Yes Yes Yes Unclear Unclear Yes
Sung [263] Prospective Yes Yes Yes Yes Yes Yes No No Yes
Tezcan [69] Retrospective Yes No Yes Yes Yes Yes Yes Unclear Unclear
Tissing [148, 158] Prospective Yes Yes Yes Unclear Yes Yes Unclear Unclear Yes
1 = representative patients, 2 = clearly described selection criteria, 3 = whole sample, or a random selection of sample, received reference standard,
4 = all patients received same reference standard, 6 = index test described adequately, 7 = reference standard described adequately, 8 = blinded
interpretation of index test results, 9 = blinded interpretation of reference standard results, 11 = adequate reference standard.
(5 = index test not part of reference standard: omitted as data permitted unpicking of these, 10 = same clinical data available as in clinical practice:
omitted as all data selected were available in clinical practice)
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Table 44: Age distribution (in years) across derivation studies
Study ID Min Median Mean Max
Alexander 1.4 7.3 8.8 25
BaselSPOG 4.1 5.4 6 9.7
BernSPOG 1 6.8 7.6 16
BonnSPOG 1.3 8.1 8.6 18
EORCT-XIV 2.1 19 18 25
EORTC-IX 1 8 9.9 24
EORTC-XI 0.65 13 13 25
EORTC-XII 5.2 21 19 25
Genoa 0.14 5.7 7 20
Hakim 0.2 6 7.8 22
Kitanovski 0.92 6.7 8.5 18
Klaassen 0.48 6.4 7.4 18
Lehrnbecher 0.36 7.5 9 29
PINE 0.15 5.5 6.7 18
RetroBern 0.63 6.8 8 17
Silva 1.2 7.5 7.6 29
Spassova 0.2 7.8 8.5 19
Styjewski 0.42 5 6.8 17
Sung 0.81 6.2 7.9 18
Tezcan 0.25 4.57 6.7 17.65
Tissing 0.52 5.9 7.2 19
ZurichSPOG 1.2 6.8 7.9 17
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Figure 57: Proportions of diagnoses per episode per study
Proportion
Alexander
BaselSPOG
BernSPOG
BonnSPOG
EORCT-XIV
EORTC-IX
EORTC-XI
EORTC-XII
Genoa
Hakim
Kitanovski
Klaassen
Lehrnbecher
PINE
RetroBern
Silva
Spassova
Styjewski
Sung
Tezcan
Tissing
ZurichSPOG
0.0 0.2 0.4 0.6 0.8 1.0
ALL
AML
Brain
Carcinoma
Ewings
GCT
Hepato
HGBrain
Hodgkins
HR.NBL
LCH
LGBrain
LR.NBL
Lymphoma
NBL
NHL
Nonmalignant
Osteo
Other
Retino
RMS
Sarcoma
Solid
Wilms
Page 351 of 410
Figure 58: Distribution of tumour type by age
Table 45: Gender distribution per study
Study Female Male NA.s Proportion
Male
M:F
Ratio
Alexander 90 97 0 0.52 1.08
BaselSPOG 3 6 0 0.67 2
BernSPOG 100 71 0 0.42 0.71
BonnSPOG 18 26 0 0.59 1.44
EORTC-IX 136 179 0 0.57 1.32
EORTC-XI 127 174 0 0.58 1.37
EORTC-XII 10 11 0 0.52 1.1
Genoa 271 432 0 0.61 1.59
Kitanovski 25 43 0 0.63 1.72
Klaassen 198 233 0 0.54 1.18
Lehrnbecher 124 186 1 0.6 1.5
PINE 374 438 0 0.54 1.17
RetroBern 143 221 0 0.61 1.55
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Silva 26 26 0 0.5 1
Spassova 82 117 0 0.59 1.43
Styjewski 27 29 0 0.52 1.07
Sung 29 46 0 0.61 1.59
Tezcan 68 77 0 0.53 1.13
Tissing 127 123 8 0.49 0.97
ZurichSPOG 63 91 0 0.59 1.44
Table 46: Episodes per patient in non-unique-entry studies
Study ID Min Median Mean Max
Alexander 1 2 2.3 8
BaselSPOG 1 1.5 1.5 2
BernSPOG 1 2 2.7 10
BonnSPOG 1 2 1.9 4
Genoa 1 1 1.6 7
Kitanovski 1 2 2.6 6
Klaassen 1 2 2.4 9
Lehrnbecher 1 2 2.4 10
PINE 1 1 1.5 2
RetroBern 1 2 2.8 12
Silva 1 2 2.5 6
Spassova 1 2 2.5 7
Tezcan 1 2 2.6 10
Tissing 1 2 2.6 14
ZurichSPOG 1 2 2.1 6
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Table 47: Proportion of patients who experienced the dichotomous outcomes
Death ICU
admission
Organ
support
Severe
infection
Clinically
documented
infection
Microbiologically
documented
infection
Blood
stream
infection
Alexander 1.1% NA 8.0% 16.6% NA 14.4% 8.6%
BaselSPOG 0.0% 0.0% NA 44.4% NA 44.4% 44.4%
BernSPOG 1.2% 51.5% NA NA NA 32.2% 19.9%
BonnSPOG 0.0% 0.0% NA NA NA 13.6% 13.6%
EORCT-XIV 0.0% NA NA 36.9% 10.1% 26.8% 22.1%
EORTC-IX 1.9% NA NA 46.7% 16.8% 29.8% 24.4%
EORTC-XI 1.3% NA NA 45.8% 19.3% 26.6% 20.6%
EORTC-XII 0.0% NA NA 42.9% 23.8% 19.0% 19.0%
Genoa 2.4% NA NA 21.5% 6.4% 17.4% 11.2%
Hakim 1.5% 35.7% 11.7% 35.5% 21.4% 23.2% 12.3%
Kitanovski 0.0% 39.7% 11.8% 44.1% 32.4% 26.5% 24.6%
Klaassen 0.7% 6.0% NA 23.4% 28.3% 28.3% 12.5%
Lehrnbecher NA NA NA 33.1% 22.5% 17.4% 10.6%
PINE 0.4% 19.0% NA 33.3% 12.1% 39.2% 32.8%
RetroBern 0.5% NA NA 50.3% 41.2% NA 23.9%
Silva 0.0% 9.9% 1.9% 17.3% 67.3% 17.3% 11.5%
Spassova 3.5% 15.6% NA 56.3% 0.0% 42.7% 42.7%
Styjewski 5.4% NA NA 30.4% NA 28.6% 19.6%
Sung 0.0% NA NA NA NA 12.0% 9.3%
Tezcan 2.1% 7.2% NA 63.4% 40.0% 53.1% 39.3%
Tissing 0.8% 32.0% 8.8% NA NA 34.4% 23.7%
ZurichSPOG 0.6% 7.1% NA 17.5% NA 14.9% 11.7%
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Figure 59: Duration of admission (per study)
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Figure 60: Duration of fever (per study)
Duration of fever, by study
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Table 48: Days since chemotherapy (by study)
Study ID Min Median Mean Max
BaselSPOG 12 16 20 40
BernSPOG 2 11 13 66
BonnSPOG 3 14 16 44
Hakim 0 5.1 7.3 510
Kitanovski 1 11 10 24
Lehrnbecher 1 6.9 8 77
RetroBern 2 11 12 44
Silva 0 8 7.3 23
Spassova 1 17 30 310
Sung 2 6.9 14 360
Tezcan 1 1 1.4 3
Tissing 0 5.8 6.6 40
ZurichSPOG 1 12 25 310
Table 49: Temperature (
o
C) per study
Study ID Min Median Mean Max
BaselSPOG 37.9 39 38.76 39.4
BernSPOG 36.3 39 38.88 40.6
BonnSPOG 38.1 38.8 38.85 39.8
EORCT-XIV 38 38.6 38.66 40
EORTC-IX 38 38.6 38.71 40.9
EORTC-XI 38 38.6 38.73 40.5
EORTC-XII 38 38.7 38.82 39.5
Hakim 36.1 38.4 38.5 41
Kitanovski 38 38.8 38.8 41
Klaassen 37.9 39 39.07 41.8
RetroBern 36.3 39.1 39.03 41.3
Silva 38 38.5 38.63 40
Spassova 35 38.4 38.5 40.4
Styjewski 37.2 38.3 38.51 40.2
Tissing 37.8 39.5 39.48 41
ZurichSPOG 37 38.6 38.62 40.5
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Table 50: Distribution of Hb (g/dL) by study
Study ID Min Median Mean Max
BaselSPOG 5 6.2 6.3 8.1
BernSPOG 4.4 9.5 9.4 15
BonnSPOG 6.6 10 10 15
EORCT-XIV 4.3 8.7 8.9 15
EORTC-IX 3.5 9.4 9.5 17
EORTC-XI 5.6 9.6 9.7 16
EORTC-XII 4.7 9.1 8.9 13
Hakim 5 8.8 8.9 13
Kitanovski 5.6 9.3 9.3 14
Klaassen 4.6 8.6 8.6 15
RetroBern 3.4 8.8 8.9 14
Sung 5.4 8.9 9 14
Tissing 3.9 8.3 8.4 17
ZurichSPOG 4.7 7.6 7.9 13
Table 51: Distribution of platelet count (x10
9
) per study
Study ID Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
BaselSPOG 1.792 2.996 3.324 5.112 6 20 49.22 166
BernSPOG 0 3.296 3.261 5.927 1 27 56.19 375
BonnSPOG 0 3.433 3.589 5.561 1 31 60 260
EORCT-XIV 0 3.258 3.263 6.073 1 26 40.91 434
EORTC-IX 0 3.466 3.474 6.021 1 32 51.12 412
EORTC-XI 0.6931 3.511 3.526 6.461 2 33.5 57.83 640
EORTC-XII 2.303 4.137 4.202 5.905 10 63 107.8 367
Hakim 0 4.016 4.022 6.422 1 55.5 98.19 615
Kitanovski 0 3.636 3.464 6.215 1 38 74.99 500
Klaassen 0 4.111 3.93 6.477 1 61 93.79 650
RetroBern 0 2.89 3.032 6.447 1 18 56.1 631
Silva 0.6931 4.483 4.376 5.875 2 88.5 120.3 356
Styjewski 0.6931 4.007 3.877 6.438 2 55 91.22 625
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Sung 1.099 4.443 4.246 6.227 3 85 117 506
Tissing 0 3.761 3.375 6.709 1 43 66.97 820
ZurichSPOG 0 3.892 3.796 6.524 1 49 76.05 681
Table 52: Distribution of white cell counts (WCC x10
6
) per study
Study ID Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
Alexander -2.813 -0.6162 -0.5945 2.917 0.06 0.54 0.9297 18.48
BaselSPOG -2.12 -1.238 -0.9462 0.1398 0.12 0.29 0.5022 1.15
BernSPOG -3.507 -0.9163 -1.077 1.308 0.03 0.4 0.5411 3.7
BonnSPOG -2.303 -0.1054 -0.2515 1.03 0.1 0.9 0.937 2.8
EORCT-XIV -4.605 -1.204 -1.073 5.226 0.01 0.3 2.581 186
EORTC-IX -2.303 -0.9163 -0.8323 3.493 0.1 0.4 1.023 32.9
EORTC-XI -2.303 -0.6931 -0.8024 3.699 0.1 0.5 1.163 40.4
EORTC-XII -2.303 -0.734 -0.6643 0.7885 0.1 0.48 0.8038 2.2
Hakim -2.303 -0.5108 -0.6391 2.617 0.1 0.6 0.8421 13.7
Kitanovski -2.303 -0.5108 -0.5823 2.14 0.1 0.6 0.9912 8.5
Klaassen -2.303 -0.5108 -0.581 2.639 0.1 0.6 0.8494 14
Lehrnbecher -3.219 -0.1054 -0.32 2.934 0.04 0.9 1.22 18.8
RetroBern -2.303 -0.6931 -0.7393 1.482 0.1 0.5 0.7344 4.4
Silva -1.609 -0.0526 -0.1379 1.335 0.2 0.95 1.076 3.8
Tissing -2.996 -0.9163 -1.197 1.065 0.05 0.4 0.5677 2.9
ZurichSPOG -4.605 -1.036 -1.011 1.411 0.01 0.355 0.5777 4.1
Table 53: Distribution of absolute neutrophil counts (ANC; cells/cubic mm), by study
Study ID Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
Alexander 0 3.689 3.195 6.209 1 40 95.78 497
BaselSPOG 4.382 4.382 4.811 5.67 80 80 150 290
BernSPOG 0 2.303 2.363 6.215 1 10 82.68 500
BonnSPOG 0 3.589 3.343 3.912 1 36.2 33.46 50
EORCT-XIV 0 2.996 2.723 6.685 1 20 81.46 800
EORTC-IX 0 0 1.776 6.888 1 1 87.79 980
EORTC-XI 0 3.401 2.821 6.894 1 30 114.6 986
EORTC-XII 0 3.916 3.364 6.729 1 51.5 187.6 836
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Genoa 0 3.912 3.264 8.716 1 50 172.4 6100
Hakim 0 0 2.256 6.215 1 1 85.33 500
Kitanovski 0 1.589 1.993 6.867 1 5 69.6 960
Klaassen 0 3.689 3.108 6.856 1 40 119.9 950
Lehrnbecher 0 5.58 5.053 9.035 1 265 497.9 8390
PINE 0 4.605 4.083 9.036 1 100 326.4 8400
RetroBern 0 4.094 3.553 6.824 1 60 178 920
Silva 0 2.996 2.782 7.601 1 20 184.9 2000
Spassova 0 4.605 3.659 6.908 1 100 161.1 1000
Sung 0 4.552 4.194 6.856 1 95 203 950
Tezcan 0 4.277 4.419 6.908 1 72 222.9 1000
Tissing 0 4.605 4.891 10.31 1 100 489.6 30000
ZurichSPOG 0 1.151 2.327 6.215 1 5.5 83.61 500
Table 54: Distribution of absolute monocyte count (AMC; cells / cubic mm) per study
Study ID Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
Alexander 0 3.718 3.477 7.652 1 41.2 125.2 2105
BaselSPOG 0 1.099 1.134 2.303 1 3 4.667 10
BernSPOG 0 0.6931 1.042 4.394 1 2 7.223 81
BonnSPOG 0 1.609 1.702 3.912 1 5 9.608 50
Hakim 0 4.357 3.568 7.473 1 78 141 1760
Kitanovski 0 1.946 2.286 7.153 1 7 98.28 1278
Klaassen 0 1.386 1.58 5.517 1 4 15.92 249
RetroBern 0 2.079 1.976 5.159 1 8 20.63 174
Spassova 0 2.303 2.26 5.704 1 10 53.34 300
Styjewski 0 3.515 2.786 6.109 1 33.6 67.04 450
Tezcan 0 3.219 3.361 8.208 1 25 179 3672
ZurichSPOG 0 0 1.146 5.635 1 1 13.52 280
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Table 55: C-reactive protein (CRP) values (mg/dL) per study
Study ID Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
BaselSPOG 1.099 2.835 2.884 5.081 3 19.5 38.63 161
BernSPOG 1.099 3.829 3.744 5.849 3 46 66.05 347
BonnSPOG 0.6931 3.497 3.408 5.124 2 33 42.36 168
Kitanovski 1.856 3.892 3.783 5.568 6.4 49 64.06 262
Lehrnbecher 0 3.198 2.972 5.659 1 24.5 42.84 287
RetroBern 0 3.871 3.617 5.771 1 48 64.04 321
Silva 0 3.02 2.87 4.394 1 20.5 25.77 81
Spassova 0 3.258 3.139 5.932 1 26 46.54 377
Tezcan 0 3.848 3.797 6.064 1 46.9 80.15 430
Tissing 0.8329 3.807 3.646 6.023 2.3 45 63.42 413
ZurichSPOG 1.386 3.638 3.553 6.246 4 38 61.97 516
Table 56: Further biomarker distributions
PCT (ng/ml) Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
Kitanovski -1.273 -0.5978 -0.3852 2.351 0.28 0.55 1.036 10.5
Styjewski -0.9416 0.9126 1.437 6.306 0.39 2.495 32.93 547.7
IL-6 (pg/ml) Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
Kitanovski 1.504 4.508 4.511 5.991 4.5 90.75 167.4 400
Lehrnbecher 0 3.978 4.059 9.418 1 53.4 216.1 12310
Spassova 1.131 3.761 3.676 4.605 3.1 43 55.98 100
Styjewski 0 2.35 2.372 6.392 1 10.5 40.68 597
IL-8 (pg/ml) Log-Min Log-
Median
Log-
Mean
Log-Max Natural
min
Natural
median
Natural
mean
Natural
max
BonnSPOG 2.175 4.58 4.435 6.418 8.8 97.55 110.1 613
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Lehrnbecher -1.386 5.178 4.87 8.567 0.25 177.4 306.5 5256
Spassova 2.398 4.035 4.324 6.892 11 56.65 184.9 984.5
Styjewski 0 2.944 2.925 5.628 1 19 46.61 278
Tissing 2.197 4.525 4.59 7.703 9 92.5 212.9 2214
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Appendix 23. R-code for IPD models
Full hierarchical model
glmer(data[,outcome] ~ factor(study.id) + data[,predictor] + (data[,predictor]-1|study.id) +
(1|picnicc.id), data=data, na.action(na.exclude), family=binomial)
Reduced hierarchical model
glmer(data[,outcome] ~ factor(study.id) + data[,predictor] + (data[,predictor]-1|study.id), data=data,
na.action(na.exclude), family=binomial)
Fixed effects model
glm(data[,outcome] ~ factor(study.id) + data[,predictor], data=data, na.action(na.exclude),
family=binomial)
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Appendix 24. Hierarchical model comparing estimates with all vs. multi-episode data
All episodes with clustering Multi-episodes only with clustering Variation
Predictor name OR beta SE-beta
Individual-
level SD
Study-
level SD
p-value
(beta) OR beta SE-beta
Individual-
level SD
Study-
level SD
p-value
(beta)
beta
variation
relative
to s.err
p-
value
for
beta
diff *
ind SD
variation
glass'
effect
size
sex - F 1 0 1 0 0
sex - M 0.98 -0.022 0.084 0.87 1.70E-05 0.8 0.92 -0.08 0.15 1 0 0.59 0.058 0.690 0.490 - -0.130 -0.149 -
age.days 1 2.60E-05 2.00E-05 0.85 0 0.19 1 -5.90E-05 4.00E-05 0.99 0 0.14 0.000085 4.250 0.000 * -0.140 -0.165 -
marrow 1.4 0.34 0.38 2.1 0 0.37 1.1 0.14 0.42 2.1 5.60E-07 0.75 0.2 0.526 0.599 - 0.000 0.000 -
relapse 1.5 0.39 0.19 1.2 0 0.038 1.8 0.59 0.24 1.2 0 0.015 -0.2 1.053 0.293 - 0.000 0.000 -
chemo.intensity - Low 1 0 1 0 0 0
chemo.intensity - Standard 2.5 0.93 0.2 1.1 0 3.30E-06 3.5 1.3 0.63 1.3 0.05 0.045 -0.37 1.850 0.064 -0.200 -0.182 -
chemo.intensity - HSCT 0.99 -0.0062 0.12 1.1 0 0.96 0.72 -0.33 0.37 1.3 0.043 0.37 0.3238 2.698 0.007 * -0.200 -0.182 -
cvl 1.4 0.37 0.28 1.1 0.027 0.19 1.1 0.06 0.29 1.1 2.60E-06 0.83 0.31 1.107 0.268 - 0.000 0.000 -
cvl.type - None 1 0 1 0 0 0
cvl.type - Port 0.98 -0.021 0.85 4.7 0.26 0.98 0.96 -0.04 0.49 2 0.00012 0.94 0.019 0.022 0.982 - 2.700 0.574 +
cvl.type - Hickman 1.8 0.6 0.76 4.7 0.061 0.43 1.9 0.63 0.52 2 6.60E-06 0.23 -0.03 0.039 0.969 2.700 0.574 +
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cvl.type - Untunnelled 12 2.5 1.9 4.7 0.68 0.2 14 2.6 2.7 2 8.10E-06 0.33 -0.1 0.053 0.958 - 2.700 0.574 +
out.patient 0.62 -0.48 0.16 1.1 2.00E-07 0.0028 1.1 0.11 0.3 1.2 0 0.71 -0.59 3.688 0.000 * -0.100 -0.091 -
temp 2.2 0.81 0.098 1.1 0 2.50E-16 2.2 0.77 0.15 1.4 0 2.00E-07 0.04 0.408 0.683 - -0.300 -0.273 +
shock 3.5 1.2 0.37 1 0.77 0.00093 2.7 1 0.69 1.4 1.5 0.15 0.2 0.541 0.589 - -0.400 -0.400 +
sys 1 -0.0013 0.011 0.25 0 0.91 1 0.0018 0.012 0.21 0 0.89 -0.0031 0.282 0.778 - 0.040 0.160 -
dia 0.99 -0.0095 0.013 0.28 0 0.46 0.99 -0.0078 0.014 0.26 0 0.58 -0.0017 0.131 0.896 - 0.020 0.071 -
mucositis 0.83 -0.18 0.076 1.3 0 0.017 0.81 -0.21 0.089 1.4 2.80E-07 0.018 0.03 0.395 0.693 - -0.100 -0.077 -
severe.mucositis 0.68 -0.38 0.19 1.1 2.60E-05 0.045 0.62 -0.48 0.28 1.4 3.20E-06 0.085 0.1 0.526 0.599 - -0.300 -0.273 +
severe.unwell 2.5 0.91 0.12 1 0 1.50E-13 1.9 0.65 0.2 1.3 0 0.0012 0.26 2.167 0.030 * -0.300 -0.300 +
hb 1 0.047 0.029 0.45 0 0.1 1.1 0.061 0.047 0.5 0 0.2 -0.014 0.483 0.629 - -0.050 -0.111 -
ln.plt 0.82 -0.19 0.038 0.41 0 3.00E-07 0.82 -0.2 0.06 0.45 0 0.00091 0.01 0.263 0.792 - -0.040 -0.098 -
ln.wcc 0.76 -0.27 0.076 0.51 0.22 0.00032 0.7 -0.36 0.11 0.6 0.22 0.00067 0.09 1.184 0.236 - -0.090 -0.176 -
ln.anc 0.97 -0.033 0.0054 0.92 0 1.40E-09 0.95 -0.048 0.011 1.1 0.013 4.50E-06 0.015 2.778 0.005 * -0.180 -0.196 -
ln.amc 0.95 -0.053 0.0097 1.3 0.01 4.60E-08 0.95 -0.053 0.012 1.3 0.0097 1.00E-05 0 0.000 1.000 - 0.000 0.000 -
ln.crp 1 0.024 0.034 1.3 0 0.48 1.1 0.07 0.048 1.3 0 0.14 -0.046 1.353 0.176 - 0.000 0.000 -
ln.pct 1.9 0.65 0.18 6.20E-06 0 0.00033
ln.IL-6 2.4 0.87 0.12 1.1 0 2.80E-12 2.9 1.1 0.18 1.1 0 1.10E-09 -0.23 1.917 0.055 - 0.000 0.000 -
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ln.IL-8 2 0.7 0.13 1 0 2.50E-08 2 0.67 0.16 1 0 1.60E-05 0.03 0.231 0.817 - 0.000 0.000 -
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Appendix 25. Reduced hierarchical model comparing all vs. single-episode estimates
All episodes, no clustering 1 episode per patient Variation
Predictor name OR beta SE-beta
Study-
level SD p-value OR beta SE-beta
Study-level
SD p-value
beta
variation
relative to
s.error p-value
sex - F 1 0 1 0 0
sex - M 0.97 -0.029 0.071 0 0.68 0.95 -0.05 8.30E-02 7.70E-07 0.54 0.021 0.296 0.767 -
age.days 1 2.20E-05 1.70E-05 1.20E-13 0.21 1 2.50E-05 1.90E-05 0 0.19 -3E-06 0.176 0.860 -
marrow 1.5 0.41 0.25 4.70E-06 0.095 1.1 0.11 3.40E-01 4.90E-06 0.73 0.3 1.200 0.230 -
relapse 1.4 0.36 0.18 0.27 0.042 1.3 0.27 1.90E-01 3.50E-08 0.15 0.09 0.500 0.617 -
chemo.intensity - Low 1 0 1 0 0
chemo.intensity - Standard 2 0.7 0.23 0.033 0.002 1.5 0.43 0.27 0.058 0.12 0.27 1.174 0.240 -
chemo.intensity - HSCT 1.1 0.059 0.14 0.021 0.67 1.3 0.27 0.17 0.028 0.11 -0.211 1.507 0.132 -
cvl 1.3 0.28 0.24 0.021 0.25 1.3 0.23 2.30E-01 2.70E-08 0.32 0.05 0.208 0.835 -
cvl.type - None 1 0 1 0 0
cvl.type - Port 1.1 0.061 0.24 0 0.8 1.6 0.46 0.35 0 0.19 -0.399 1.663 0.096 -
cvl.type - Hickman 1.4 0.35 0.25 0 0.17 2.2 0.77 0.37 0 0.037 -0.42 1.680 0.093 -
cvl.type - Untunnelled 3.1 1.1 0.59 0 0.054 5.1 1.6 0.65 0 0.013 -0.5 0.847 0.397 -
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out.patient 0.7 -0.36 0.14 9.10E-08 0.0078 0.62 -0.48 1.60E-01 3.20E-08 0.0024 0.12 0.857 0.391 -
temp 1.9 0.64 0.084 0 2.60E-14 2 0.7 0.1 0.00E+00 3.70E-12 -0.06 0.714 0.475 -
shock 2.8 1 0.32 0.63 0.0013 1.9 0.63 0.34 0.47 0.066 0.37 1.156 0.248 -
sys 1 -0.0011 0.011 0 0.92 1 0.019 0.016 0 0.24 -0.0201 1.827 0.068 -
dia 0.99 -0.0092 0.013 0 0.47 1 0.012 0.018 0 0.5 -0.0212 1.631 0.103 -
mucositis 0.89 -0.11 0.058 0 0.052 0.85 -0.17 8.80E-02 6.60E-07 0.057 0.06 1.034 0.301 -
severe.mucositis 0.76 -0.28 0.16 3.50E-07 0.078 0.71 -0.35 2.00E-01 1.30E-06 0.091 0.07 0.438 0.662 -
severe.unwell 2.2 0.79 0.11 0 2.20E-13 2.3 0.84 0.13 0.00E+00 4.00E-11 -0.05 0.455 0.649 -
hb 1 0.044 0.028 0 0.11 1 0.047 0.033 0 0.15 -0.003 0.107 0.915 -
ln.plt 0.83 -0.19 0.037 0 3.00E-07 0.81 -0.21 0.045 0.00E+00 4.50E-06 0.02 0.541 0.589 -
ln.wcc 0.78 -0.25 0.072 0.21 0.00041 0.84 -0.17 0.053 0.12 0.001 -0.08 1.111 0.267 -
ln.anc 0.97 -0.027 0.0048 4.10E-07 9.90E-09 0.97 -0.027 0.0055 0.00E+00 6.60E-07 0
ln.amc 0.96 -0.045 0.0098 0.018 4.40E-06 0.96 -0.046 9.30E-03 2.20E-07 8.60E-07 0.001 0.102 0.919 -
ln.crp 1 0.017 0.028 0 0.54 1 0.00016 0.038 0 1 0.01684 0.601 0.548 -
ln.pct 1.9 0.65 0.18 0 0.00033 1.8 0.58 0.18 0 0.0017 0.07 0.389 0.697 -
ln.IL-6 2.1 0.75 0.11 0 4.40E-12 1.7 0.51 0.13 0 0.00011 0.24 2.182 0.029 *
ln.IL-8 1.8 0.61 0.11 0 1.70E-08 1.7 0.54 0.14 0 0.00018 0.07 0.636 0.525 -
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Appendix 26. Comparing full hierarchical model vs. fixed effects model estimates
Full heirarchical Fixed effect Full vs Fixed
Predictor name beta SE-beta beta SE-beta diff beta as prop se diff p-val p<0.05
sex - F 0 0
sex - M -0.022 0.084 -0.041 0.07 0.019 0.22619 0.821 -
age.days 0.000026 0.00002 0.000015 0.000017 0.000011 0.55 0.582 -
marrow 0.34 0.38 0.41 0.25 -0.07 0.184211 0.854 -
remission 0.086 0.25 -0.023 0.14 0.109 0.436 0.663 -
relapse 0.39 0.19 0.35 0.14 0.04 0.210526 0.833 -
chemo.intensity - Low 0 0 0 -
chemo.intensity - Standard 0.93 0.2 0.78 0.17 0.15 0.75 0.453 -
chemo.intensity - HSCT -0.0062 0.12 0.0055 0.1 -0.0117 0.0975 0.922 -
chemo.time -0.0035 0.0039 -0.0019 0.0029 -0.0016 0.410256 0.682 -
cvl 0.37 0.28 0.15 0.18 0.22 0.785714 0.432 -
cvl.type - None 0 0 0 -
cvl.type - Port -0.021 0.85 0.061 0.24 -0.082 0.096471 0.923 -
Page 369 of 410
cvl.type - Hickman 0.6 0.76 0.35 0.25 0.25 0.328947 0.742 -
cvl.type - Untunnelled 2.5 1.9 1.1 0.59 1.4 0.736842 0.461 -
out.patient -0.48 0.16 -0.36 0.14 -0.12 0.75 0.453 -
temp 0.81 0.098 0.64 0.084 0.17 1.734694 0.083 -
resp.rate -0.038 0.026 -0.031 0.022 -0.007 0.269231 0.788 -
resp.compromise 0.22 0.32 0.028 0.17 0.192 0.6 0.549 -
pulse.rate 0.002 0.0055 0.0015 0.0054 0.0005 0.090909 0.928 -
shock 1.2 0.37 0.88 0.18 0.32 0.864865 0.387 -
sys -0.0013 0.011 -0.0011 0.011 -0.0002 0.018182 0.985 -
dia -0.0095 0.013 -0.0092 0.013 -0.0003 0.023077 0.982 -
mucositis -0.18 0.076 -0.11 0.058 -0.07 0.921053 0.357 -
severe.mucositis -0.38 0.19 -0.28 0.16 -0.1 0.526316 0.599 -
severe.unwell 0.91 0.12 0.79 0.11 0.12 1 0.317 -
hb 0.047 0.029 0.044 0.028 0.003 0.103448 0.918 -
ln.plt -0.22 0.04 -0.22 0.039 0 -
ln.wcc -0.37 0.057 -0.33 0.044 -0.04 0.701754 0.483 -
ln.anc -0.095 0.017 -0.08 0.015 -0.015 0.882353 0.378 -
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ln.amc -0.28 0.042 -0.22 0.034 -0.06 1.428571 0.153 -
ln.crp 0.064 0.067 0.063 0.055 0.001 0.014925 0.988 -
ln.pct 0.65 0.18 0.65 0.18 0 -
ln.IL-6 0.87 0.12 0.75 0.11 0.12 1 0.317 -
ln.IL-8 0.7 0.13 0.61 0.11 0.09 0.692308 0.489 -
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Appendix 27. Further within and between study results for univariate
predictors
Gender
Predictor
name
OR beta SE-beta p-value
Alexander Male 0.84 -0.17 0.42 0.68
BaselSPOG Male 2 0.69 1.5 0.64
BernSPOG Male 1.6 0.46 0.33 0.17
BonnSPOG Male 0.1 -2.3 1.1 0.049
EORTC-IX Male 0.92 -0.087 0.25 0.72
EORTC-XI Male 1.9 0.63 0.28 0.022
EORTC-XII Male 0.89 -0.12 1.1 0.92
Genoa Male 0.75 -0.29 0.2 0.15
Kitanovski Male 0.64 -0.44 0.56 0.43
Klaassen Male 1.2 0.14 0.22 0.51
Lehrnbecher Male 0.96 -0.037 0.3 0.9
PINE Male 0.95 -0.053 0.14 0.71
Silva Male 2.3 0.83 0.77 0.28
Spassova Male 0.78 -0.25 0.29 0.39
Styjewski Male 0.9 -0.1 0.59 0.87
Sung Male 0.76 -0.27 0.72 0.7
Tezcan Male 0.91 -0.099 0.33 0.77
Tissing Male 0.72 -0.33 0.27 0.22
ZurichSPOG Male 0.88 -0.12 0.46 0.79
IPD estimate Male 0.96 -0.041 0.07 0.56
Marrow involvement
Predictor name OR beta SE-beta p-value
BaselSPOG Marrow
Involved
2.40E-08 -18 4000 1
BernSPOG Marrow
Involved
2 0.7 0.52 0.17
Kitanovski Marrow
Involved
2.3 0.85 0.57 0.14
Spassova Marrow
Involved
1.5 0.37 0.35 0.28
ZurichSPOG Marrow
Involved
1.20E-07 -16 1400 0.99
IPD
estimate
Marrow
Involved 1.5 0.41 0.25 0.095
Page 372 of 410
Out patient status
Predictor name OR beta SE-beta p-value
BaselSPOG Out-patient 71000000.00 18 4000 1
BernSPOG Out-patient 0.43 -0.85 0.41 0.036
BonnSPOG Out-patient 22000000.00 17 2500 0.99
EORCT-XIV Out-patient 0.10 -2.3 1 0.028
EORTC-IX Out-patient 0.45 -0.79 0.28 0.0046
EORTC-XI Out-patient 0.71 -0.34 0.28 0.22
EORTC-XII Out-patient 0.42 -0.88 1.1 0.44
Kitanovski Out-patient 2.3 0.85 0.64 0.18
Silva Out-patient 0.19 -1.7 1.5 0.26
Spassova Out-patient 1.30 0.24 0.33 0.47
Sung Out-patient 2200000 15 1700 0.99
ZurichSPOG Out-patient 1.4 0.3 0.59 0.61
IPD estimate
0.7 (0.53 to
0.91) -0.36 0.14 0.0078
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Figure 61: Association between probability of MDI and ln(WCC) by study
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Figure 62: Association between probability of MDI and ln(ANC) by study
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Tumour type
Table 57: Individual study p-values for parameter estimates of tumour type
Genoa
Alex
ander
Basel
SPOG
Bern
SPOG
Bonn
SPOG
EORTC
XIV
EORTC
XI
EORTC
IX
EORTC
XII Hakim
Kitan
ovski
Klaas
sen
Lehrn
becher PINE Silva
Spass
ova
Styjew
ski Sung
Tez
can
Tiss
ing
Zurich
SPOG
ALL
(referent) . . . . . . . . . . . . . . . . . . . . .
AML 0.57 0.0056 1 0.034 0.31 0.83 0.41 0.026 . 0.00096 0.11 0.93 0.09 0.037 . 0.019 1 1 0.98 0.99 0.049
Brain 0.28 0.88 . . . . . . . . . 0.42 0.64 . . 0.99 . . 0.035 . .
Carcinoma 0.23 . . . . . . . . . . . . . . . . . . . 0.18
Ewings 0.99 0.55 . 0.55 1 . . . . 0.82 1 . 0.028 0.43 0.99 0.2 1 1 0.9 0.99 0.99
GCT 1 . . . . . . . 1 . . 1 0.62 0.73 . . . . . . .
Hepato 0.99 . . . . . . . . 0.36 1 0.57 0.99 0.98 1 . . . . 0.85 .
HGBrain 0.014 . . 0.63 0.21 . . . 1 0.99 0.2 . 0.81 0.046 . . 1 1 . 0.31 0.88
Hodgkins 0.051 0.99 . . . 0.93 . . 1 0.8 . 0.39 0.62 0.2 . 0.99 . . . . 1
HR-NBL 0.00011 . . . . . . . . 0.91 0.88 . . . 1 0.99 . 1 . 0.99 .
LCH 0.92 . . . . . . . . 1 1 . 1 0.99 . . . . . 1 .
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LGBrain . . . 0.99 . . . . . 0.99 . . 0.86 0.98 . . . 1 . . .
LR-NBL 0.99 . . . . . . . . . . . . . . 0.99 . . . . .
NBL . 0.72 1 0.6 1 . . . . . . 0.69 0.68 0.038 . . 0.51 0.77 0.078 . 0.6
NHL 0.0081 0.2 1 0.71 1 0.99 . . 1 0.82 0.43 0.95 0.19 0.65 1 0.092 . 0.7 0.2 0.27 1
Nonmalig.nt 0.66 . . . . . . . . . . . . . 1 . . . . . .
Osteo 0.0018 0.87 . 0.089 1 . . . 1 0.66 . 0.35 0.99 0.31 . 0.084 0.98 . . 0.23 1
Other 0.87 0.8 . . . 0.99 0.99 0.56 . 0.4 . 0.37 . 0.49 . . . 1 0.23 . .
Retino . . . 0.6 . . . . . 1 . 0.85 . 0.17 . . . 1 . . 1
RMS 0.08 0.34 . 0.46 0.31 . . . 1 0.62 0.99 0.55 0.81 0.14 0.9 . . 0.88 0.36 0.39 0.32
Solid . . . . . 0.45 0.37 0.37 . . . . . . . . . . . . .
Sarcoma 0.37 . . . . . . . . 0.36 . 0.88 1 0.11 1 0.28 1 1 . 0.73 0.32
Wilms 0.4 0.99 . 0.99 . . . . 1 0.99 1 0.58 0.99 0.48 . 0.99 1 . 0.79 0.23 0.26
Highlighted cells are significant (p<0.05)
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Relapsed disease
Table 58: Association between probability of MDI and relapsed disease
Predictor
name
OR beta SE-beta p-value
BaselSPOG Relapse 5.00E-01 -0.69 1.5 0.64
BernSPOG Relapse 0.94 -0.066 0.37 0.86
BonnSPOG Relapse 1.40E-07 -16 2800 1
Genoa Relapse 1.4 0.3 0.23 0.18
Kitanovski Relapse 2.50E+00 0.91 0.6 0.13
Lehrnbecher Relapse 4.3 1.5 0.38 0.00012
Spassova Relapse 1.6 0.48 0.58 0.4
Sung Relapse 0.7 -0.36 1.1 0.75
Tissing Relapse 0.91 -0.098 0.34 0.77
ZurichSPOG Relapse 1.6 0.49 0.56 0.38
IPD
estimate Relapse
1.4
(1.07 to 1.86) 0.35 0.14 0.012
Cardiovascular compromise
Table 59: Association of shock with MDI
Predictor
name
OR beta SE-beta p-value
BernSPOG Shock 1.40 0.36 0.76 0.63
BonnSPOG Shock 0.00 -16 2800 1
Hakim Shock 3.50 1.2 0.83 0.13
Kitanovski Shock 1.70E+07 17 1500 0.99
Klaassen Shock 0.84 -0.18 0.59 0.77
PINE Shock 2.4 0.88 0.26 0.00074
Spassova Shock 1.8 0.57 0.5 0.25
Sung Shock 6 1.8 1 0.072
Tezcan Shock 4.5 1.5 1.1 0.18
IPD
estimate
2.4
(1.69 to 3.43) 0.88 0.18 1.6E-06
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Outpatient status
Presenting from outside the hospital was associated with a reduced chance on MDI in the IPD
analysis, with an estimated OR 0.7 (95% CI 0.53 to 0.91).
Figure 63: OR of MDI by hospitalisation status
Clinical recognition of ‘severely unwell’
Table 60: Association of 'severely unwell' appearance with MDI
Predictor name OR beta SE-beta p-value Prevalence
of ‘unwell’
Alexander Severely unwell 1.60 0.48 0.46 0.3 0.22
BernSPOG Severely unwell 2.40 0.87 0.45 0.051 0.14
BonnSPOG Severely unwell 7.40 2 1.5 0.18 0.05
Hakim Severely unwell 1.90 0.65 0.28 0.022 0.25
Kitanovski Severely unwell 52000000.00 18 1400 0.99 0.04
Klaassen Severely unwell 2 0.71 0.23 0.0022 0.27
Lehrnbecher Severely unwell 4.1 1.4 0.53 0.0079 0.05
PINE Severely unwell 1.8 0.6 0.2 0.0033 0.14
Spassova Severely unwell 2.5 0.9 0.34 0.0084 0.23
Styjewski Severely unwell 2500000000.00 22 3200 0.99 0.20
Sung Severely unwell 1.2 0.14 0.72 0.84 0.41
ZurichSPOG Severely unwell 1.6 0.45 0.47 0.33 0.30
IPD estimate
2.2
(1.77 to 2.33) 0.79 0.11 2.2E-13 0.16
0.1 0.5 2.0 10.0
OR of MDI in out-patients compared with in-patients
ZurichSPOG
Spassova
Silva
Kitanovski
EORTC-XII
EORTC-XI
EORTC-IX
EORCT-XIV
BernSPOG
1.3 [ 0.4 , 4.3 ]
1.3 [ 0.7 , 2.4 ]
0.2 [ 0.0 , 3.5 ]
2.3 [ 0.7 , 8.2 ]
0.4 [ 0.0 , 3.6 ]
0.7 [ 0.4 , 1.2 ]
0.5 [ 0.3 , 0.8 ]
0.1 [ 0.0 , 0.7 ]
0.4 [ 0.2 , 1.0 ]
0.70 [ 0.53 , 0.91 ]IPD estimate
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Age
Figure 64: Age (years) and probability of MDI, relationships superimposed
Table 61: Age (in years) and risk of MDI
Predictor
name
OR 95% CI Beta
(age.days)
SE-beta p-value
Alexander Age
(years)
1.02 0.95 to
1.09
0.000045 0.0001 0.66
BaselSPOG Age
(years)
0.65 0.27 to
1.52
-0.0012 0.0012 0.29
BernSPOG Age
(years)
1.00 0.94 to
1.07
5.4E-06 0.000095 0.95
BonnSPOG Age
(years)
0.91 0.75 to
1.12
-0.00025 0.00028 0.38
EORCT-XIV Age
(years)
1.02 0.96 to
1.09
0.00006 0.000085 0.48
EORTC-IX Age
(years)
1.02 0.99 to
1.06
0.000059 0.000045 0.19
EORTC-XI Age
(years)
1.02 0.99 to
1.06
0.000057 0.000049 0.25
age.days
P
r
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m
d
i
)
0.0
0.2
0.4
0.6
0.8
1.0
2000 4000 6000 8000 10000
EORTC-XI
EORTC-XII
Genoa
Hakim
Kitanovski
Klaassen
Lehrnbecher
PINE
Silva
380 of 410
EORTC-XII Age
(years)
1.05 0.85 to 1.3 0.00013 0.0003 0.67
Genoa Age
(years)
1.03 0.99 to
1.07
0.000086 0.000054 0.11
Hakim Age
(years)
0.99 0.94 to
1.03
-3.2E-05 0.000064 0.62
Kitanovski Age
(years)
1.10 0.98 to
1.22
0.00025 0.00015 0.087
Klaassen Age
(years)
1.01 0.96 to
1.05
0.000018 0.000063 0.77
Lehrnbecher Age
(years)
1.01 0.97 to
1.06
0.00003 0.000064 0.64
PINE Age
(years)
0.99 0.96 to
1.02
-2.9E-05 0.000045 0.52
Silva Age
(years)
1.07 0.96 to
1.19
0.00018 0.00015 0.24
Spassova Age
(years)
0.93 0.88 to
0.99
-0.00019 0.000076 0.014
Styjewski Age
(years)
1.11 0.99 to
1.24
0.00028 0.00016 0.088
Sung Age
(years)
0.99 0.86 to
1.13
-0.00004 0.00019 0.83
Tezcan Age
(years)
0.92 0.86 to
0.99
-0.00023 0.0001 0.024
Tissing Age
(years)
0.99 0.94 to
1.04
-3.4E-05 0.000075 0.65
ZurichSPOG Age
(years)
1.03 0.94 to
1.13
0.000089 0.00013 0.51
IPD
estimate 1.01
0.99 to
1.02 0.000015 0.000017 0.38
As with temperature, an analysis was undertaken to compare the common Box-Tidwell
transformations of [-2, -1, -0.5, log, 0.5, 1 and 2]. These worsened the AIC values. Splines with
df=2,3,4 were also assessed. A single knot (at 6.8yrs) produced a statistically significant (p=0.0018)
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small decrease in AIC (5449 cf 5442), two knots at 4.4y and 10.8y had borderline significance
(p=0.05) and a very small further decrease in AIC (5440).
Mucositis
Table 62: Study level association of graded mucositis with MDI
Predictor name OR beta SE-beta p-value
BaselSPOG Mucositis (per grade) 0.00 -18.00 5200.00 1.00
BernSPOG Mucositis (per grade) 0.78 -0.25 0.16 0.10
BonnSPOG Mucositis (per grade) 0.66 -0.42 0.64 0.51
Hakim Mucositis (per grade) 1.10 0.08 0.17 0.66
Kitanovski Mucositis (per grade) 0.99 -0.01 0.26 0.98
Klaassen Mucositis (per grade) 0.91 -0.09 0.16 0.57
Lehrnbecher Mucositis (per grade) 0.75 -0.29 0.16 0.07
Spassova Mucositis (per grade) 1.00 0.05 0.11 0.69
Sung Mucositis (per grade) 0.73 -0.32 0.53 0.55
ZurichSPOG Mucositis (per grade) 0.80 -0.22 0.20 0.26
IPD estimate
0.89
(0.80 to 1.00) -0.11 0.058 0.052
Table 63: Study level associations of severe mucositis with MDI
Predictor name OR beta SE-beta p-value
BaselSPOG Severe mucositis 0.00 -18.00 4000.00 1.00
BernSPOG Severe mucositis 0.51 -0.67 0.53 0.21
BonnSPOG Severe mucositis 0.00 -15.00 2400.00 1.00
Hakim Severe mucositis 1.30 0.26 0.54 0.64
Kitanovski Severe mucositis 0.71 -0.34 0.72 0.63
Klaassen Severe mucositis 0.78 -0.25 0.52 0.64
Lehrnbecher Severe mucositis 0.41 -0.89 0.62 0.15
Spassova Severe mucositis 1.10 0.12 0.33 0.72
Sung Severe mucositis 4.60 1.50 0.74 0.04
ZurichSPOG Severe mucositis 0.50 -0.70 0.78 0.37
PINE Severe mucositis 0.54 -0.61 0.32 0.05
IPD estimate
0.76
(0.55 to 1.03) -0.28 0.16 0.078
Shaded row shows single added dataset beyond Table 62
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Appendix 28. Detail of final multivariate model
Final model beta-estimates and standard errors
Item Estimate Std.
Error
(Intercept) -3.996 816.492
tumourAM 0.655 0.255
tumourBrain -0.457 0.385
tumourCarcinoma 16.668 1455.398
tumourEwings -0.642 0.662
tumourGCT -0.069 0.876
tumourHepato 0.475 0.57
tumourHGBrain -0.345 0.462
tumourHodgkins -0.408 0.701
tumourHR-NB 0.921 0.661
tumourLCH -14.096 1025.44
tumourLGBrain -14.157 677.944
tumourNB 0.472 0.495
tumourNH -0.471 0.317
tumourOsteo -1.193 0.566
tumourOther 0.797 0.768
tumourRetino 0.547 0.856
tumourRMS -0.244 0.319
tumourSarcoma 0.188 0.821
tumourWilms -0.491 0.663
ctemp (temperature - 37°C) 0.566 0.144
severe.unwell (TRUE) 0.786 0.193
hb (g/dL) 0.18 0.05
ln (wcc x10
6
) -0.299 0.101
ln (amc /mm
3
) -0.209 0.057
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QQ quantile plots for selected bootstrap estimates
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Bootstrapped calibration plot
Figure 65: Calibration plot using bootstrapped estimates
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QQ quantile plots for discrimination bootstrap
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Leave on out calibration plots
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Comparison of included and excluded studies univariate estimates
Figure 66: Comparison of included and excluded studies univariate estimates of tumour-type predictive value
Per study OR association between tumour type and MDI
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Table 64: Comparison of included and excluded studies estimates of predictive value of Hb
Study OR (Hb) 95% CI p-value
BaselSPOG 0.92 0.71 to 1.19 0.49
BernSPOG 3.6 0.53 to 25.53 0.2
BonnSPOG 1.1 0.9 to 1.27 0.48
Hakim 0.88 0.48 to 1.62 0.68
Kitanovski 1.1 0.95 to 1.36 0.16
Klaassen 1.1 0.77 to 1.45 0.72
ZurichSPOG 1.1 0.96 to 1.3 0.16
EORCT-XIV 0.79 0.49 to 1.26 0.32
EORTC-IX 1.2 0.98 to 1.52 0.06
EORTC-XI 0.98 0.87 to 1.12 0.81
EORTC-XII 0.85 0.72 to 1.01 0.06
Sung 1.1 0.99 to 1.28 0.07
Tissing 1.2 0.8 to 1.75 0.39
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Calibration and discrimination plots for tumour simplified model
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Glossary
Adverse event
Detrimental change in health, or side effect, occurring in a patient receiving the
treatment.
Afebrile No fever, normal body temperature.
Aggregate data
Data collected relating to the average values of episodes or events in clinical research
studies, sometimes arranged in subgroups, but not referring to individual participants
Anti microbial
Therapy
Treatment of infectious disease using agents that either kill microbes or otherwise
interfere with microbial growth
Antibiotic
resistance
Resistance of a microorganism to an antimicrobial medicine to which it was previously
sensitive.
Bacterial
infection
Occurs when harmful bacteria enters the body and multiply, causing unpleasant
symptoms and/or an adverse event.
Bias Deviation from the truth
Biomarkers In this setting, serum (blood-derived) markers of inflammation and infection
Bivariate Using two variables (cf multivariate)
Bootstrapping
A mathematical technique where a repeated set of analyses are performed on a new
collection of data, which have been created by radomly choosing items of the original
data, including the posibilty of selecting one item more than once. An internal
validation technique.
Calibration
The extent to which the numerical risk predictions from a model agree with the
observed (actual) outcomes
Cart
Classification and regression tree - a different approach to discriminatory reasoning
than regression analysis
Clinical decision
rule (CDR) A clinical tool designed to be used at the bedside to assist clinical decision making
Clinically
documented
infection
An infection which has been diagnosed by the use of careful observation and physical
examination of a patient.
Clinically
relevant
An outcome or event which has a direct relevance to a patient’s health status, or which
is important in modifying which treatment is received or how it is delivered.
Clostridium
difficile
A type of bacteria that lives within the gut which can produce toxins (poisons), which
cause illness such as diarrhoea and fever
Co-efficient The amount of predictive power a covariate has in a predictive model
Covariate
A variable in a prediction model which may be useful in making a prediction more
accurate
Crd Centre for Reviews and Dissemination
C-reactive
protein (crp)
A protein that is produced by the liver and found in the blood. May be raised by a
variety of problems, including infection.
Critical care
Facilities within a hospital to look after patients whose conditions are life-threatening
and need constant close monitoring and support from equipment and medication to
keep normal body functions.
Ctc
Common Toxicity Criteria - well documented grading system for adverse effects used in
many cancer studies
Discrimination
The ability of a predictive model to separate patients at lower and higher risk of an
outcome
Documented
infection
An infection which has been diagnosed by clinical examination, or by the detection of
pathogenic organisms.
Domain
validation
Checking the CDR works when undertaken in a different location, but different clinical
setting such as secondary rather than tertiary care
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Eortc European Organisation for Research and Treatment in Cancer
Extrapolation
In data analysis, predicting the value of a parameter outside the range of observed
values.
False negative A result that appears negative but should have been positive, i.e. A test failure
False positive A result that appears positive but should have been negative, i.e. A test failure.
Febrile
neutropenia (fn)
The development of fever, often with other signs of infection, in a patient with
neutropenia,
Fever A raise in body temperature above normal range.
Fixed effect
covariate
The same effect is present across each study, and any differences are due to chance
sampling
Geographical
validation
Checking the CDR works when undertaken in a different location, but similar clinical
setting
Granulocyte
colony
stimulating
factor
A type of protein that stimulates the bone marrow to make white blood cells
(granulocytes).
Granulocyte
macrophage
colony
stimulating
factor
A type of protein that stimulates the bone marrow to make white blood cells
(granulocytes and monocytes)
Heterogeneity A term used to describe the amount of difference of results or effects.
Heuristics
Shortcuts or rules-of-thumb, applied in a variety of situations, for example diagnostic
thinking or in shrinkage techniques in statistics
Hierarchical
logistic
regression
A type of logistic regression technique where the structure of the data (for example,
episodes occuring in patients in studies) is explicitly considered to assess if the
'structure' (for example, patient or study) affects how effective the predictor is
Hierarchical
summary
receiver
operator curve
(HSROC)
The average ROC curve derived from the individual curves produced from multiple
studies in a diagnostic meta-analysis
Homogeneity A term used to describe the amount of similarity of results or effects
Imputation
Mathematical approach to use values which have been derived from some other source
(e.g. Group averages)
Individual
participant data
(IPD).
Data collected relating to individual episodes or events in clinical research studies (cf.
Aggregate data)
Infection The growth of a pathological organism within the body.
Inflammatory
markers
Proteins or other molecules which are raised by inflammatory processes in the body
and can be measured, usually by blood tests
Information
criterion
A value representing how poorly the data fit a statistical model, with lower numbers
indicating a better fit, e.g. Deviance Information Criterion (DIC) or Akaike’s Information
Criterion (AIC)
Internal
validation
techniques
Mathematical techniques to test for the likely truth of models (e.g. Predictive models)
using the same set of data
Leave-one-out
cross-validation
A mathematical technique where a repeated set of analyses are performed on a new
collection of data, created by using teh original data set but removing the items
contributed by each of the studies in turn, to assess if the results are similar across each
grouping. An interval validation technique.
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Life threatening
infection An infection which may cause death.
Linear
relationship.
(Within regression) The relationship between predictor and outcome variable is a
staight line; doubling one quantity doubles the other
Logistic
regression A type of regression techique where the outcome is binary (yes/no)
Low risk To be safe or without problems.
Meta-analysis
A method of summarising previous research by reviewing and combining the results of
a number of different clinical studies
Microbiologically
documented
infection (mdi) An infection which has been diagnosed by the detection of pathogenic organisms.
Missing at
random (MAR) Data are missing but related to other known and measured factors
Missing
completely at
random (MCAR) Data are missing for no reason but random chance
Missing not at
random (MNAR) Data are missing but related to unknown and unmeasured factors
Monocyte count The amount of monocytes in blood. Monocytes are a type of white blood cell
Morbidity A diseased condition or state.
Mortality Death
Multicollinearity
A mathematical description of the close relationship between quantities which may
lead to inaccurate conclusions if not accounted for
Multivariable Using more than one predictive variable (cf multivariate), usually more than two
Mutivariate Predicting more than one outcome variable (cf multivariable)
Negative
predictive value Proportion of people with a negative test result who truly didn’t have disease
Net
reclassification
improvement
(NRI) Measure of the overall ‘benefit’ of a new classification model
Neutropenia
An abnormally low number of neutrophils, the most important type of white blood cell
to fight off bacterial infections.
Neutropenic
sepsis
An abnormal decrease in the number of neutrophils in the blood together with
infection.
Neutrophil A type of white blood cell, important in fighting off particularly bacterial infections.
Neutrophil
count
This test measures the number of neutrophils in blood. Neutrophils are a type of white
blood cell
Non-linear form
(Within regression) The relationship between predictor and outcome variable is not
staight line; doubling one quantity does not double the other
Odds ratio
A measure of treatment effectiveness. The odds of an event happening in the
intervention group, divided by the odds of it happening in the control group. The ‘odds’
is the ratio of non-events to events.
Outcome An end result; a consequence.
PGP-encrypted Electronic communication using a highly secure shared-passkey encryption
Picnicc Predicting Infectious complications In Children with Cancer
Positive
predictive value Proportion of people with a postive test result who did have disease
Predictive Mathematical models using data to estaime a probability (chance) of a specific outcome
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models or outcomes
Primary
prophylaxis A preventative intervention administered in all cycles of chemotherapy.
Prognostic study
A study that examines selected predictive variables, or risk factors, and assesses their
influence on the outcome of a disease.
Prospective
study
A study in which people are entered into research and then followed up over a period
of time with future events recorded as they happen.
Publication bias
Also known as reporting bias. A bias caused by only a subset of all the relevant data
being available. The publication of research can depend on the nature and direction of
the study results. Studies in which an intervention is not found to be effective are
sometimes not published. Because of this, systematic reviews that fail to include
unpublished studies may overestimate the true effect of an intervention. In addition, a
published report might present a biased set of results (e.g. Only outcomes or sub-
groups where a statistically significant difference was found.
Qualitative study
A study used to explore and understand peoples' beliefs, experiences, attitudes,
behaviour and interactions.
Quality adjusted
life years (qalys)
A measure of health outcome which looks at both length of life and quality of life.
QALYS are calculated by estimating the years of life remaining for a patient following a
particular care pathway and weighting each year with a quality of life score (on a 0 to 1
scale). One QALY is equal to 1 year of life in perfect health, or 2 years at 50% health,
and so on
Quality of life An overall appraisal of well being.
Radiotherapy A treatment for cancer that uses high energy ionising radiation to kill cells.
Random effect
covariate
The effects come from a normal distribution of true effects; the estimates are both
different by chance and real differences in true effect between studies
Randomised
controlled trials
(rcts)
A clinical trial in which subjects are randomised to different groups for the purpose of
studying the effect of a new intervention, for example a drug or other therapy.
Rcpch Royal College of Paediatrics and Child Health
Receiver
operator curve
(ROC) A curve describing the relationship between the sensitivity and specificity of a test
Regression
A mathematical technique which relates one (or more) measured variables to an
outcome variable
Relative risk
(also known as
risk ratio)
The ratio of risk in the intervention group to the risk in the control group. The risk
(proportion, probability or rate) is the ratio of people with an event in a group to the
total in the group. A relative risk (RR) of 1 indicates no difference between comparison
groups. For undesirable outcomes, an RR that is less than 1 indicates that the
intervention was effective in reducing the risk of that outcome
Retrospective
data Data that deals with the present/past and does not involve studying future events.
Risk The chance of an adverse outcome happening.
Risk assessment
tool
A tool, usually a score from pieces of information given by patients, blood tests and
examination finding, which is used to assess a patient's risk of a particular outcome.
Risk
stratification
The process of grouping people into categories with different probabilities of a specific,
usually adverse, outcome
Sensitivity The proportion of individuals who have disease correctly identified by the study test
Sepsis The body's response to an infection
Septic shock
Septic shock is a medical emergency caused by decreased tissue perfusion and oxygen
delivery as a result of severe infection and sepsis,
Serious bacterial A bacterial infection with a high chance of causing siginifcant morbidity or death
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infection
Severe sepsis A life-threatening form of sepsis
Short-term
mortality Death within a short period of time, for instance 30 days from onset of fever.
Shrinkage
A mathematical technique used to improve the chances of a predictive model being
accurate in practice, related to internal validation techniques
Siop International Society of Paediatric Oncology
Specificity
The proportion of individuals who do not have a disease and who are correctly
identified by the study test.
Statistical
significance A mathematical concept, to be understood as 'unlikely to be due to chance'
Stem cell
transplant
A procedure that replaces the cells in a patient which make blood. (Haemopoietic stem
cell transplant.)
Step down Decrease or reduction in treatment or medication.
Systematic
review
A review of the literature done to answer a defined question often using quantitative
methods to summarise the results.
Temporal
validation Checking the CDR works when undertaken at a different point in time
Transformation
A mathematical technique of consistently modifiying varaibels, for example taking the
logarithm or square-root of a quantity
Treatment
failure Unsuccessful results or consequences of treatments used in combating disease.
True negative
When testing for a condition or disease, this result confirms the absence of the
condition in an individual who genuinely does not have the condition in question.
(Contrast with false negative (see above) where the test may incorrectly indicate that
the individual is free from the condition being investigated. The condition is present
but not detected by the test.).
True positive
When testing for a condition or disease, this result confirms the presence of the
condition in question in individuals who have it. (Compare with false positive where
the test may incorrectly indicate that the individual has a condition, but in fact they do
not.)
Tunnel infection
A device-related infection seen in central venous access devices, related to the tube as
it passes beneath the skin.
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